University of Missouri, St. Louis

IRL @ UMSL

Dissertations

UMSL Graduate Works

11-22-2019

Towards Completely Automated Glycan Synthesis

Matteo Panza University of Missouri-St. Louis, mp887@mail.umsl.edu

Follow this and additional works at: https://irl.umsl.edu/dissertation

Part of the Organic Chemistry Commons, Polymer and Organic Materials Commons, and the Polymer Chemistry Commons

Recommended Citation

Panza, Matteo, "Towards Completely Automated Glycan Synthesis" (2019). *Dissertations*. 907. https://irl.umsl.edu/dissertation/907

This Dissertation is brought to you for free and open access by the UMSL Graduate Works at IRL @ UMSL. It has been accepted for inclusion in Dissertations by an authorized administrator of IRL @ UMSL. For more information, please contact marvinh@umsl.edu.

Towards completely automated glycan synthesis

By

Matteo Panza

Master of Science (Chemistry), University of Missouri-St. Louis, May 2017Master of Science (Chemistry), University of Milan, Italy, October 2014Bachelor of Science (Chemistry), University of Milan, Italy, October 2012

A Dissertation Submitted to the Graduate School of the UNIVERSITY OF MISSOURI – ST. LOUIS in Partial Fulfillment of the Requirements for the Degree of

DOCTOR OF PHILOSOPHY

in

CHEMISTRY

December 2019

Dissertation Committee

Prof. Alexei V. Demchenko, Ph.D. (Chair)

Prof. Eike Bauer, Ph.D.

Prof. Keith J. Stine, Ph.D.

Prof. Chung F. Wong, Ph.D.

ABSTRACT

Towards completely automated glycan synthesis

Matteo Panza

Doctor of Philosophy, University of Missouri – St. Louis Prof. Alexei V. Demchenko, Advisor

Carbohydrates are ubiquitous both in nature as biologically active compounds and in medicine as pharmaceuticals. Although there has been continued interest in the synthesis of carbohydrates, chemical methods require specialized knowledge and hence remain cumbersome. The need for development of rapid, efficient and operationally simple procedures has come to the fore. This dissertation focuses on the development of a fully automated platform that will enable both experts and non-specialists to perform the synthesis of glycans. Existing automated methods for the synthesis of oligosaccharides are highly sophisticated, operationally complex, and require significant user know-how. By contrast, high performance liquid chromatography (HPLC) equipment-based automation introduced by our lab represents a highly accessible method of synthesis. This approach offers operational simplicity by delivering all reagents using standard liquid handling components and convenient real-time reaction monitoring of every step using detectors and standard computer software and interface. Many operations still require the operator intervention, and the entire technology remains semi-manual.

Building upon promising preliminary results, this dissertation aimed to generate a universal platform for the fully automated synthesis of glycans. To achieve the complete automation of the solid phase synthesis that has the potential to revolutionize glycan synthesis, this dissertation focuses on the following aspects: 1) the development of new concepts for chemical glycosylation applicable to stereoselective formation of challenging 1,2-cis glycosidic bonds; 2) implementation of autosamplers and switch valves as new components to achieve operator-less automation; and 3) the development of new chemically stable resins for solid phase synthesis. With these key developments, we have acquired a reliable and simple platform for fully-automated oligosaccharide synthesis. The proof of concept was assessed by the synthesis of a number of target glycans. Synthesis of

carbohydrates and other classes of biomolecules using this user-friendly and fullyautomated platform will accelerate discovery in many scientific disciplines, most prominently chemistry, automation, and therapeutic-agents development.

ACKNOWLEDGEMENTS

I have a long list of acknowledgments and I would like to begin thanking Prof. Alexei Demchenko. In these years he has been more than an advisor, he has been a mentor and a friend, guiding me through science and life decisions. His passion and enthusiasm for science and his curiosity have set an example for my future career. He has always devoted his time to make me feel welcomed in his lab and to my research to be productive. I would like to thank my committee members, Prof. Eike Bauer, Prof. Keith J. Stine and Prof. Chung F. Wong for their encouragement and their patience all throughout my PhD. I am thankful to Dr. Jagodige P. Yasomanee for training me during my first year in Glycoworld. I would like to especially thank Dr. Rensheng Luo for the help with NMR and low temperature experiments.

Also, I am very thankful to the funding received towards my PhD from the National Institute of Health (NIH) and University of Missouri- St. Louis. I would like to thank all faculty and staff from the Department of Chemistry and Biochemistry at UMSL for all the knowledge I have gained and support throughout my studies at UMSL.

My thanks and affection will always be to my second family, my Glycoworld present and former lab members, Dr. Salvo Pistorio, Dr. Xiao Jia, Dr. Satsawat Visansirikul (First), Dr. Michael Mannino, Dr. Tinghua Wang, Dr. Mithila Bandara, Scott Geringer, Catherine Alex, Samira Escopy, Ganesh Shrestha, Melanie Shadrick, Dr Crystal O'Neil and Dr. Yashapal Singh for the good time together and for making me feel welcomed in St. Louis.

Last, I am grateful to my wife, Myriam, for all the patience, the support, the encouragement and the motivation. Thanks to my daughter for always making my days plenty of fun. I want to thank my parents, my brother, my sister and my relatives for always believing in me and helping me in this American adventure. Thank you to my close friends Marta, Andrea, Manu, Nene and many others who have always been here for me and my family.

LIST	OF	ABBREVIATIONS
------	----	----------------------

Å	Ångström
Ac	Acetyl
Ac ₂ O	Acetic anhydride
AcOH	Acetic acid
AgOTf	Silver(I) trifluoromethanesulfonate
Ag ₂ CO ₃	Silver carbonate
BF ₃ •OEt ₂	Boron trifluoride etherate
BH3•THF	Borane tetrahydrofuran complex
Bn	Benzyl
BnBr	Benzyl bromide
Br ₂	Bromine
Bz	Benzoyl
BzCl	Benzoyl chloride
BzCN	Benzoyl cyanide
CaH ₂	Calcium hydride
CBn	2-Cyanobenzyl
CCl ₃ CN	Trichloroacetonitrile
CDCl ₃	Deuterated chloroform
CD ₃ COCD ₃	Deuterated acetone
CH ₂ Cl ₂	Dichloromethane
CH ₃ CN	Acetonitrile
ClCH ₂ CH ₂ Cl	1,2-Dichloroethane

Cu(OTf) ₂	Copper(II) trifluoromethanesulfonate
δ	Chemical shift
d	Doublet
DBU	
DFT	Density functional theory
dd	
DIPEA	
DMAP	4-Dimethylaminopyridine
DMF	N,N-Dimethylformamide
DMTST	Dimethyl(methylthio)sulfonium trifluoromethanesulfonate
D ₂ O	Deuterium oxide
Et	Ethyl
Et ₂ O	Diethyl ether
EtOAc	Ethyl acetate
EtOH	Ethanol
EtSH	Ethane thiol
Fmoc	Fluorenylmethoxycarbonyl
Gal	Galactose
Glc	Glucose
GlcNAc	N-Acetylglucosamine
h	
HAD	H-Bond-mediated aglycone delivery
HCl	Hydrogen chloride

H ₂ O	Water
НМО	Human Milk Oligosaccharides
HOPO(OBu) ₂	
H2NNH2.H2O	
HPLC	High performance liquid chromatography
HR-ESI MS	High Resolution Electrospray Ionization mass spectrometry
HR-FAB MS	High Resolution Fast Atom Bombardment mass spectrometry
Hz	
IDCP	Iodonium(di-γ-collidine) perchlorate
LG	Leaving group
М	Molar
MeOTf	
m	
Me	
MeCN	Acetonitrile
MeOH	
MgSO ₄	
min	
MS	
MW	
<i>m/z</i>	
Na	Sodium
NaCNBH3	Sodium cyanoborohydride

NaH	Sodium hydride
NaHCO3	Sodium bicarbonate
NaOH	Sodium hydroxide
NaOMe	
NBn	
NIS	N-Iodosuccinimide
Na ₂ S ₂ O ₃	Sodium thiosulfate
NMR	Nuclear magnetic resonance
NPhth	Phthalimido
Pd/C	Palladium on carbon
PFBz	Pentafluorobenzoyl
Ph	Phenyl
Pico	Picoloyl
ppm	Parts per million
Ру	Pyridine
RDS	Rate determining step
Rf	Retention factor
rt	Room temperature
s	Singlet
SBox	S-Benzoxazolyl
SBiz	
SEt	
S _N 1	-

S _N 2	Nucleophilic substitution bimolecular
SPh	S-Phenyl
STaz	
STol	
t	Triplet
TBDMS	<i>tert</i> -Butyldimethylsilyl
TBDMSOTf	tert-Butyldimethylsilyl trifluoromethanesulfonate
TBS	<i>tert</i> -Butyldimethylsilyl
TBAI	<i>tert</i> -Butylammonium iodide
TFA	Trifluoroacetic acid
Tf ₂ O	Trifluoromethanesulfonic anhydride
TfOH	Trifluoromethanesulfonic (triflic) acid
THF	Tetrahydrofuran
TIPS	Triisopropylsilyl
TLC	Thin layer chromatography
TMS	Trimethylsilyl
TMSCl	Trimethylsilyl chloride
TMSOTf	Trimethylsilyl trifluoromethanesulfonate
TolSCl	Toluenesulfonyl chloride
TOF	Time of flight
TsOH	
TTBP	2,4,6-Tri- <i>tert</i> -butylpyrimidine

TABLE OF CONTENTS

CHAPTER 1

Automated chemical oligosaccharide synthesis: a novel approach to traditional challenges

1.1.	Introdu	action:	carbohydrates,	oligosaccharides,	biological	roles	and	medical
	implica	ations						2
1.2.	Trad	itional 1	manual synthesis	of oligosaccharides			•••••	7
	1.2.1.	Chemi	ical glycosylatior	1		•••••		8
	1.2.2.	Oligos	saccharide synthe	sis				23
	1.2.3.	Suppo	orted and tagged of	ligosaccharide synt	hesis		•••••	37
1.3.	Auton	nated sy	ynthesis of oligos	accharides		•••••		53
	1.3.1.	Early	developments					56
	1.3.2.	Peptid	le synthesizer-bas	ed automation				58
	1.3.3.	Fluoro	ous-tag assisted a	utomated synthesis		•••••	•••••	63
	1.3.4.	Glyco	oneer 2.1 as a dedi	cated oligosacchari	de synthesiz	er	•••••	72
	1.3.5.	HPLC	C-assisted oligosa	ccharide synthesis				93
	1.3.6.	Electro	ochemical activat	ion platform for aut	omation			97
1.4.	Concl	usions a	and outlook					101
1.5.	Refere	ences						102

Bromine-promoted glycosidation of conformationally superarmed thioglycosides

2.1	2.1. Introduction140		
2.2	. Result	ts and discussion	142
2.3	. Concl	usions	152
2.4	.Experi	mental	155
	2.4.1.	General experimental	155
	2.4.2.	Synthesis of glycosyl donors and acceptors	155
	2.4.3.	Synthesis of glycosides	161
	2.4.4.	NMR studies of reaction intermediates	167
	2.4.5.	Computational studies	167
2.5	Refere	nces	169

CHAPTER 3

HPLC-assisted automated oligosaccharide synthesis: the implementation of the two-way split valve as a mode of complete automation

3.1.	Introdu	action	178
3.2.	Result	s and discussion	178
3.3.	Conclu	sions	184
3.4.	Experi	mental	185
	3.4.1.	General methods	185
	3.4.2.	Set up of the HPLC-A synthesizer	.186
	3.4.3.	Synthesis of glycosyl donors and acceptors	.187

3.4.4.	Preparation of the reagent vials	
3.4.5.	The automated assembly of oligosaccharides	189
3.4.6.	Synthesis of oligosaccharides	195
3.5. Refer	ences	201

The development of a dedicated polymer support for the solid-phase oligosaccharide

synthesis

4.1.	Introdu	uction	210
4.2.	Result	s and discussion	211
4.3.	Conclu	usions	217
4.4.	Experi	imental	218
	4.4.1.	General methods	218
	4.4.2.	Set up of the HPLC-A synthesizer	219
	4.4.3.	Synthesis of Panzagel crosslinker and Panzagel resin	220
	4.4.4.	Synthesis of glycosyl donors and glycosyl acceptors	221
	4.4.5.	Preparation of the reagent vials	222
	4.4.6.	The automated assembly of oligosaccharides	222
	4.4.7.	Synthesis of oligosaccharides	229
4.5.	Refere	nces	232

APPENDIX (selected spectral and computational data)

LIST OF SCHEMES

Scheme 1.1.	General outline of the chemical glycosylation reaction10
Scheme 1.2.	Examples of urea and thiourea-based organocatalytic reactions19
Scheme 1.3.	Synthesis of β -mannosides via intramolecular aglycone delivery22
Scheme 1.4.	Conventional linear oligosaccharide synthesis with alternating
	glycosylation and deprotection steps24
Scheme 1.5.	Convergent block synthesis of ganglioside GP325
Scheme 1.6.	Chemoselective (A) and selective (B) activation approaches to expeditious
	oligosaccharide synthesis
Scheme 1.7.	Hexasaccharide synthesis in five selective activation steps
Scheme 1.8.	Orthogonal activation of phenylthio glycosides and fluorides31
Scheme 1.9.	Glycal-epoxide method for iterative oligosaccharide synthesis
Scheme 1.10.	Two-directional approach for the synthesis of pentasaccharide 1.54 34
Scheme 1.11.	One-pot synthesis of tetrasaccharide 1.59 via chemoselective
	activation35
Scheme 1.12.	One-pot synthesis of tetrasaccharide 1.62 via sequential selective
	activation of building blocks equipped with different leaving groups36
Scheme 1.13.	Pre-activation-based one-pot synthesis of Globo-H hexasaccharide
	1.67
Scheme 1.14.	Glycosylation on polymer support
Scheme 1.15.	Acceptor-bound approach to the synthesis of oligosaccharide 1.73 43

Scheme 1.16.	Chiral auxiliary-assisted synthesis of 1,2-cis-linked oligosaccharide
	1.79
Scheme 1.17.	Donor-bound synthesis of pentasaccharide 1.82 45
Scheme 1.18.	Orthogonal synthesis of a combinatorial library on solid phase46
Scheme 1.19.	Peptide-templated oligosaccharide synthesis on polymer support47
Scheme 1.20.	STICS: Surface-Tethered Iterative Carbohydrate Synthesis48
Scheme 1.21.	Synthesis of dimeric Le ^x hexasaccharide using soluble polymer
	support
Scheme 1.22.	A fluorous tag-assisted synthesis of pentasaccharide 1.10 51
Scheme 1.23.	Convergent/orthogonal ionic liquid-tagged synthesis of mannans53
Scheme 1.24.	Solution phase automation of the oligosaccharide synthesis in one pot
	using parallel synthesizer Quest 21057
Scheme 1.25.	The synthesis of oligosaccharides 1.122a-c using a modified peptide
	synthesizer
Scheme 1.26.	Automated synthesis of Globo H hexasaccharide61
Scheme 1.27.	Automated synthesis of β-mannosides62
Scheme 1.28.	Fluorous tag supported synthesis of a tetrasaccharide 1.136 in a
	microreactor64
Scheme 1.29.	Automated synthesis of pentamannose 1.140 using fluorous support65
Scheme 1.30.	The automated synthesis of β -mannuronan and β -mannan70
Scheme 1.31.	Automated sequence to obtain a branched oligomannan fragment from N-
	glycans71
Scheme 1.32.	Automated synthesis of N-glycan core using the dedicated synthesizer73

Scheme 1.33.	Automated synthesis of manno triantamer 1.160 7	5
Scheme 1.34.	Automated synthesis of the 50-mer 1.162 using Glyconeer 2.1	'8
Scheme 1.35.	Automation of the sialylation reaction	79
Scheme 1.36.	Automation of 1,2-cis glycosylation	30
Scheme 1.37.	Automated synthesis of β -manno-linked dodecasaccharide 1.179	\$2
Scheme 1.38.	Synthesis of the branched hexasaccharide composed of multiple	
	arabinofuranosyl residues	35
Scheme 1.39.	Synthesis of a chondroitin sulfate	36
Scheme 1.40.	The synthesis of hyaluronic acid fragments8	8
Scheme 1.41.	Glycopeptide synthetic sequence	90
Scheme 1.42.	The synthesis of a representative galactosylated xyloglucan for generatir	ıg
	of oligosaccharide libraries9	2
Scheme 1.43.	HPLC-assisted automated oligosaccharide synthesis9	94
Scheme 1.44.	The use of an autosampler as the mode for reagent delivery for the	
	HPLC-based automation9	5
Scheme 1.45.	HPLC-assisted surface-tethered synthesis of disaccharides 1.209 9	17
Scheme 1.46.	Automated solution phase synthesis using electrochemical activation9	8
Scheme 1.47.	Electrochemical approach to GPI anchor's core trisaccharide10	0

Scheme 2.1.	Previous glycosidations of thioglycosides with Br ₂	141
Scheme 2.2.	Conversion of 3,4-di-O-TBS β -SEt glucoside β - 2.2 into α , β -bromides	
	2.4	.149

Scheme 3.1. Automated synthesis of glycan 3.1	34
---	----

CHAPTER 4

Scheme 4.1.	Synthesis of Panzage	el 4.7	213
-------------	----------------------	---------------	-----

LIST OF FIGURES

Figure 1.1.	Representative structures of common linear and branched oligosaccharide	
	motifs	5
Figure 1.2.	Directing neighboring participating groups at C-21	2
Figure 1.3.	Solid supports for oligosaccharide synthesis: Merrifield's resin (A),	
	Tentagel (B) and JandaJel (C)4	0
Figure 1.4.	Recently introduced linkers for polymer-supported oligosaccharide	
	synthesis	2
Figure 1.5.	The split-valve set-up for the alternate-pump system	7
Figure 1.6.	Representative 1,2-cis-linked oligosaccharides synthesized using Glyconee	r
	2.1	1

Figure 2.1. DFT-optimized 3S1 skew-boat conformation of the 3,4-O-TIPS

thioglucoside β -2.3 (hydrogens and phenyl groups have been omitted for clarity in the

ball and stick 3D-representation......146

Figure 2.2. Conformation and stereoselectivity of β-bromides......147

CHAPTER 3

Figure 3.1.	Modified HPLC-A set-up to achieve complete automation180	
Figure 3.2.	Glycan sequences 3.1-3.3 obtained in the fully automated mode and	
	building blocks 3.4-3.7 needed for all syntheses	181
Figure 3.3.	The synthesizer set up with the two channels of the valve	186
Figure 3.4.	Settings of the components of the HPLC synthesizer during	
	glycosylation	190
Figure 3.5.	Settings of the components of the HPLC synthesizer during Fmoc	
	removal	192
Figure 3.6.	Settings of the components of the HPLC synthesizer during the final	
	cleavage	193
Figure 3.7.	UV traces for the synthetic steps	194

Figure 4.1. Selection of the attachment strategies and cross-linkers	212
Figure 4.2. Thermogravimetric analysis (TGA) plots (black line) and Weigh	t derivatives
curves (red line) of Panzagel	

Figure 4.3. SEM images of Panzagel polymer at 100x (a) and 150x magnification	
(b)	216
Figure 4.4. Target compounds as showcase of the new resin	217
Figure 4.5. The synthesizer set up	220
Figure 4.6. Settings of the components of the HPLC synthesizer during	
glycosylation	224
Figure 4.7. Settings of the components of the HPLC synthesizer during Fmoc	
removal	225
Figure 4.8. Settings of the components of the HPLC synthesizer during the final	
cleavage	226
Figure 4.9. UV traces for the synthetic steps	228

LIST OF TABLES

CHAPTER 2

Table 2.1.	NMR data for thioglycosides β -2.1-2.3	144
Table 2.2.	DFT B3LYP/6-31G* minimum energy structures of thioglycosides β -2.2	
	and β -2.3 with relative Gibbs free energies	145
Table 2.3.	NMR data for thioglycosides α-2.1-2.3	151
Table 2.4.	Glycosidation of 3,4- <i>O</i> -TBS donor α- 2.2	153
Table 2.5.	Reactions of 3,4-O-TIPS donor	154

CHAPTER 4

 Table 4.1. Comparison of swelled JandaJel and Panzagel.....

Automated chemical oligosaccharide

synthesis: a novel approach to

traditional challenges

Panza, M.; Pistorio, S. G.; Stine, K. J., Demchenko, A. V., Automated chemical oligosaccharide synthesis: a novel approach to traditional challenges. *Chem. Rev.*, **2018**, 118, 8105-8150

1.1. Introduction: carbohydrates, oligosaccharides, biological roles and medical implications

Carbohydrates, the "essential molecules of life," play key roles in various biological processes. Carbohydrates are involved from the very beginning of life: fertilization occurs through carbohydrate-protein interaction.² Carbohydrates contribute to human health by facilitating joint lubrication, cell growth, and the inflammatory and immune responses.³ The exponential increase in interest in sugars and the notable growth of all areas of glycosciences also reveals the involvement of carbohydrates in processes detrimental for human health. Viral infections, bacterial- and parasite-related diseases, metastasis, and rejection of transplanted tissues are only a few of these processes that can be mentioned.⁴ The pathogenesis of diabetes, septicemia, cancer, pneumonia, malaria, AIDS, and hepatitis are all carbohydrate-mediated processes. Understanding the roles of carbohydrates in these processes has stimulated many biomedical discoveries glycosciences.⁵⁻⁷ Investigation of composition.⁸ involving carbohydrate conformation,⁹ interaction with other molecules and with themselves^{10,11} are some other areas of inquiry in the field. Isolation of carbohydrates from natural sources represents a viable approach to providing samples for the biological testing of these molecules. However, it is chemical synthesis that allows access to both natural carbohydrates and their mimetics, which are often of interest due to their therapeutic^{4,12} or diagnostic¹³⁻¹⁵ potential. Challenges related to the synthesis and purification of carbohydrates and the lack of universal methods applicable to all

systems is the key bottleneck of glycosciences. As a result, examples of large-scale development of carbohydrate-based pharmaceuticals including heparin and its analogs,^{16,17} antibiotics,^{18,19} glycoconjugate-based vaccines,²⁰⁻²⁴ and other applications^{6,7,25} are still rare.

Oligosaccharide sequences are found in numerous natural compounds and constitute the core of many therapeutics. The presence of glycans in glycoproteins, glycolipids, glycosaminoglycans and in other conjugates presents a treasure of potential information on cellular differentiation and condition. Over half of all proteins in the human body are N- or O-glycosylated³ and cell surfaces present a rich multitude of glycolipids and glycosaminoglycans, in addition to the presence of a variety of free oligosaccharides.²⁶ Glycans carrying information of biological significance are found in every body fluid, on cell surfaces, and within cells.

Glycan biomarker discovery is accelerating aided by advances in separation, mass spectrometric analysis,²⁷⁻²⁹ and in glycan-lectin array technologies.³⁰ Efforts to map the entire glycome of a cell have recently been reported.³¹ Glycans have been identified as markers for many different forms of cancer including breast, colon, lung, etc.³²⁻³⁴ Increases or decreases in the levels of certain glycans and changes in branching patterns can indicate the presence and progression of disease.³⁵ For example, one study showed that prostate cancer can be distinguished from benign prostatic hypertrophy via distinction of a specific glycoform by lectin binding.³⁶ In cerebrospinal fluid, the presence of a unique Nlinked glycan on transferrin has been used to distinguish Alzheimer's disease from a condition arising from abnormal metabolism.³⁷ Profiling of N-glycans on IgG has been found useful for following the metabolic disorder of galactosaemia.³⁸

Many families of glycoconjugates represent important therapeutic targets. High mannose, hybrid, and complex N-glycan families (Figure 1.1A) that are involved in many fundamental processes,³⁹⁻⁴¹ as well as in mediation of the pathogenesis of cancers,⁴² AIDS,⁴³ Alzheimer's disease,³⁷ etc.³⁸ have stimulated many synthetic developments.^{41,44-51} Another representative example is the globoside family of glycosphingolipids (Figure 1.1B, Neu –N-acetylneuraminic acid, Fuc - fucose) whose members present a broad range of significant biological roles as glycan biomarkers. For example, Gb3 is overexpressed in colorectal adenoma cells,⁵² in Burkitt's lymphoma cells,⁵³ and in breast and ovarian cancer.⁵⁴ Gb3 is found on the glycolipid that accumulates in the lysosomes of individuals suffering from Fabry disease.⁵⁵ Iso-Gb3 is found on natural killer T cells.⁵⁶ Gb4 has been found to be enhanced and attached to longer fatty acid chains in vascular endothelial cells undergoing an inflammatory response.⁵⁷ Stage-specific embryonic antigens SSEA-3 and SSEA-4 are glycosphingolipids found on the surface of human embryonic stem cells but not on differentiated cells.⁵⁸ SSEA-4 was found expressed in a variant of non-small cell lung cancer cells,⁵⁹ and on embryonal carcinoma cells in the ovaries.⁶⁰ Globo-H is a target antigen for the development of vaccines against prostate and breast cancer,⁶¹ for which clinical trials are underway. Globo-H and SSEA-3 have been found expressed on breast cancer stem cells.⁶² Many synthetic developments have been applied to the synthesis of globosides, and Globo-H in particular.⁶³⁻⁶⁸ More examples of the value of glycans and glycoconjugates as biomarkers are steadily emerging.




Figure 1.1. Representative structures of common linear and branched oligosaccharide motifs

Oligosaccharides or glycans can be obtained by isolation from natural sources or prepared enzymatically and/or chemically. All three major approaches are viable, but none yet can significantly outperform the others. This chapter is dedicated to chemical synthesis, which, in spite of recent progress, remains challenging. As a result, synthesis of even moderately complex glycans and their conjugates still require significant resources. This limits accessibility of these essential targets to only a small circle of glycoscientists and inhibits their industrial production and application. Recent development of dependable techniques for oligosaccharide synthesis using traditional manual synthesis are introduced in Section 1.2 of this chapter. An overview of very attractive and potentially transformative automated technologies that are expected to facilitate access to oligosaccharides is presented in Section 1.3.

A majority of complex sugars are oligomers in which monomeric units (monosaccharides) are connected via glycosidic bonds. The latter are obtained by glycosylation, a reaction discussed in section 1.2.1. Certain mechanistic conventions discussed in section 1.2.1. have been established and many factors that affect the outcome of glycosylations discussed in sections 1.2.1. are known. Nevertheless, chemical glycosylation remains challenging. Oligosaccharide synthesis brings about further challenges. Both traditional and expeditious strategies are known. Various one-pot strategies that offer a streamlined access to oligosaccharides have been developed. Supported and tagged synthesis has also been investigated. In particular, solid-phase synthesis, widely used in the preparation of oligopeptides and oligonucleotides, has also been applied to the preparation of oligosaccharides. This approach can streamline synthesis by eliminating the need to purify reaction intermediates and by simplifying the removal of excess reagents. Similar advantages are seen in the tagged synthesis wherein soluble polymer supports, ionic liquids and fluorous-based protecting groups have successfully been used to expedite oligosaccharide assembly.

Dedicated attempts to automate oligosaccharide synthesis resulted in the development of a number of platforms and technologies for their automated chemical synthesis. These developments are reviewed in section 3. Early attempts by Takahashi and Wong to develop the automated chemical syntheses in solution set the benchmark in the fiel. Those early attempts have also shown difficulties associated with the automation. To expedite polymer supported oligosaccharide synthesis, Seeberger introduced an automated approach. The automation was initially based on a modified peptide synthesize. In 2012, Seeberger et al. reported the "first fully automated solid-phase oligosaccharide synthesizer". Around the same time Pohl, Demchenko-Stine, and Nokami have developed alternative automation platforms discussed in sections 1.3.3, 1.3.5, and 1.3.6. Operation of all automated synthesizers is controlled by a computer. The greatest advantage of employing the computer interface along with liquid handling hardware and software is to allow recording successful automated sequences that can be then repeated over and over with an expected high degree of reproducibility.

1.2. Traditional manual synthesis of oligosaccharides

Glycosidic linkages are obtained by glycosylation, a reaction of the nucleophilic displacement of an anomeric leaving group (LG) on the glycosyl donor by a hydroxyl group of the glycosyl acceptor.⁶⁹ The remaining functional groups of both reaction counterparts (hydroxyl groups, amines, and carboxylic acid groups) are masked with respective temporary protective groups. A detailed mechanism of chemical glycosylation is unknown, but certain aspects, factors, and pathways have been established.⁷⁰⁻⁹³ With a notable progress in the field of chemical glycosylation,^{83,86-88,94} this reaction remains challenging. Beyond that, traditional stepwise oligosaccharide synthesis requires careful strategic planning to achieve protecting and/or leaving group introduction/removal between glycosylation steps. In addition, purification and reagent separation become difficult with large oligosaccharide sequences. Many selective, chemoselective, and regioselective strategies have been developed to streamline oligosaccharide

synthesis by reducing the number of additional steps.⁹⁵ Other advanced techniques, such as solid-phase synthesis,^{96,97} have been developed to streamline oligosaccharide synthesis. These approaches reduce the need to purify reaction intermediates and simplify the excess reagents removal.


1.2.1. Chemical glycosylation

The glycosylation reaction is the central reaction in glycochemistry. (Scheme 1.1) The glycosylation involves a promoter or activator-assisted reaction between a glycosyl donor and glycosyl acceptor. Along with the formation of a glycosidic bond, a new chirality center is produced. Therefore, particular care should be taken of stereocontrol. Discussed below are basic principles of chemical glycosylation and factors that have an effect on the reaction outcome. In addition to the glycosylation reaction, there are many competing processes that may simultaneously occur. Side reactions that often complicate stereocontrol of glycosylation and may have a profound effect on yields include, but are not limited to, migration, elimination, cyclization substitution, and redox reactions.

Reaction mechanism

The promoter-assisted departure of the leaving group leads to the formation of a glycosyl cation that is stabilized via an oxacarbenium ion intermediate (Scheme 1.1). The acceptor attack on the flattened oxacarbenium intermediate can take place either from the top or the bottom face of the sugar ring. As a result, uncontrolled glycosylations may lead to the formation of mixtures of 1,2-*trans* and 1,2-*cis* glycosides. Typical glycosylation conditions favor a unimolecular S_N1 mechanism, or may proceed at the S_N1 - S_N2 interface,⁹⁹ and the reaction involves four major steps.¹⁰⁰

Step 1. Formation of the activated donor as a result of the interaction of the LG and the promoter (Scheme 1.1 A-B). This step can be either reversible or irreversible depending on the type of the leaving group used and the method of activation.⁹³ There are a few reports indicating that the glycosyl acceptor attack may be directed to the activated donor.¹⁰¹⁻¹⁰⁶ This S_N2-like displacement pathway is desirable because it would allow for the stereospecific inversion of the stereochemistry at the anomeric carbon. Step 2. Dissociation of the LG, a typically irreversible expulsion of the activated leaving group (LGA), is the ratedetermining step (RDS). It leads to the formation of a glycosyl carbocation and/or its stabilized resonance form, an oxacarbenium ion. The latter is often responsible for scrambling the stereoselectivity of the reaction. Other intermediates, the existence of which is often ignored, or whose impact on the reaction is underestimated, may also form at this stage with or without counteranion B. Step **3.** As a consequence of the sp^2 -hybridization of the anomeric (C-1) carbon and the existence of the oxacarbenium ion in a flattened half-chair conformation the subsequent attack of the glycosyl acceptor is possible from both the bottom face of the ring (pathway a) and the top face (pathway b). As a result, "uncontrolled" glycosylation often leads to the formation of a mixture of products. Step 4. Upon the proton transfer the formation of the glycosidic bond becomes irreversible (the termination step).⁸⁰



Scheme 1.1. General outline of the chemical glycosylation reaction

The earliest reactions performed by Michael,¹⁰⁷ Fischer,¹⁰⁸ and Koenigs/Knorr¹⁰⁹ at the turn of the 20th century showcased the complexity of the glycosylation reaction. At that stage, glycosylations of sugar acceptors were quite inefficient and even the synthesis of disaccharides represented a challenge. The first attempts to solve this problem gave rise to the development of new activators.¹¹⁰⁻¹¹² The early attempts to improve the glycosylation reaction have also revealed the necessity to find a delicate balance between the reactivity and stereoselectivity.^{113,114}

Building blocks: glycosyl donors and acceptors

One of the main directions has been the investigation of leaving groups beyond the original halides, hemiacetals, and peracetates introduced by Helferich in 1933.¹¹⁵ Thus, in the 1970s - early 1980s a few new classes of glycosyl donors were developed.^{116,117} This first wave introduced thioglycosides,¹¹⁸⁻¹²¹ 1,2-orthoesters,^{122,123} Oimidates,^{124,125} thioimidates,¹²⁶⁻¹²⁸ and glycosyl fluorides¹²⁹ as alternative leaving groups. Many glycosyl donors introduced during that period have become common even to this day. The next wave of new methods arrived in the late 1980's. Among the new leaving groups introduced were glycosyl esters/carbonates,¹³⁰⁻¹³² thiocyanates,¹³³ diazirines,¹³⁴ xanthates,¹³⁵ glycals,^{136,137} phosphites,^{138,139} sulfoxides,¹⁴⁰ sulfones,¹⁴¹ selenium glycosides,¹⁴² alkenyl glycosides,¹⁴³⁻¹⁴⁵ and heteroaryl glycosides.¹⁴⁶ These developments were followed by a variety of more recent methodologies and improvements. These include glycosyl iodides,¹⁴⁷ phosphates,¹⁴⁸ Te-glycosides,¹⁴⁹ sulfonylcarbamates,¹⁵⁰ disulfides,¹⁵¹ 2-(hydroxycarbonyl)benzyl glycosides,¹⁵² novel thio-^{153,154} and Oimidates^{155,156} as well as alkynyl-based leaving groups.¹⁵⁷⁻¹⁶⁶ In addition, a variety of very recent methodologies¹⁶⁷⁻¹⁶⁹ have brought the use of classic glycosyl donors, such as glycals,^{170,171} hemiacetals,^{105,172,173} or halides^{174,175} to an entirely different level of flexibility and versatility.

Beyond studying the anomeric leaving group, protecting group effects have been investigated. Seminal work of Lemieux⁷⁰ and Fletcher,^{176,177} has led to appreciation that the reactivity of glycosyl halides and the stereoselectivity of glycosylation is directly correlated to the nature of the protecting groups, especially at the neighboring C-2 position. The participation of the neighboring 2-O-acyl substituent typically leads to the formation of 1,2-*trans* linkages.^{73,178} In this case, the oxacarbenium ion can be further stabilized via an acyloxonium (dioxalenium) intermediate. Since the bottom face of the sugar ring in the acyloxonium intermediate is blocked, the glycosyl acceptor will approach from the top face (Figure 1.2A). Following this method, a 1,2-*trans* linkage is typically produced with high stereoselectivity, however, sometimes 1,2-orthoesters or 1,2-*cis*-linked glycosides are formed.

Demchenko and co-workers introduced glycosyl donors equipped with a 2-Opicolinyl ether participating group that provides entire 1,2-*trans* stereoselectivity in glycosylations (Figure 1.2B).^{179,180} Mlynarski and co-workers investigated orthonitrobenzyl (NBn) as a participating group.¹⁸¹ Liu and co-workers investigated another alkyl participating group, o-cyanobenzyl (CBn) at the C-2 position of a glycosyl donor.¹⁰⁴ An interesting feature of this glycosylation method is that a single glycosyl donor can yield either α - or β -linked products depending on the nature of the glycosyl acceptor.




Figure 1.2. Directing neighboring participating groups at C-2

The presence of a non-participating group at C-2 such as benzyl is typically necessary for the synthesis of 1,2-*cis* glycosides. However, the non-participating substituent alone cannot provide stereocontrol, which makes the synthesis of 1,2-

cis glycosides much more challenging. Although the anomeric effect favours the formation of the α -product,¹⁸² the stereoselectivity of uncontrolled glycosylations can be low. In these cases, other factors for controlling stereoselectivity such as structural features of the reactants and reaction conditions become increasingly important. For example, Boons et al introduced chiral auxiliaries capable of producing trans-decalin-like intermediates depicted in Figure 2C.¹⁸³⁻¹⁸⁷ This opposite face of the ring type of participation helps to obtain 1,2-*cis* linked glycosides with very high stereoselectivity.¹⁸⁸ Turnbull and co-workers designed a similar concept showing that an oxathiane donor is also capable of highly α -selective glycosylations.^{189,190} Fairbanks showed the versatility of 2-(thiophen-2-yl)methyl derivatives for stereoselective 1,2-cis glycosylation.¹⁹¹

The effects of remote substituents, particularly those capable of steric hindrance, powerful electron-withdrawal, or long-range participation, have been known for some time.¹⁹²⁻¹⁹⁶ Observed for a variety of sugar series including D-galacto,^{197,198} L-fuco,^{199,200} L-rhamno,²⁰¹ D-manno,²⁰² and D-gluco²⁰³ the remote effects can be weaker than those by the C-2 substituent. More recent studies, by Kim et al,²⁰⁴ Nifantiev et al,²⁰⁵ Crich et al,^{206,207} Hung et al,²⁰⁸ and others^{209,210} showed how important the remote effects can be. A somewhat unexpected effect was noted for remote picolinyl ethers (Pic) and picoloyl esters (Pico). While 2-picolinyl participates at the anomeric center via the six-membered ring intermediate (see Figure 1.2B)¹⁸⁰ the action of the remote groups is different. It has been demonstrated that the nitrogen atom of the remote picolinyl/picoloyl groups is able to form a hydrogen bonding with the hydroxyl group of the glycosyl

acceptor. This leads to high *syn*-selectivity with respect to the picolinyl/picoloyl substituent.²¹¹ This reaction named H-bond-mediated aglycone delivery or HAD gave high α -gluco²¹² and β -manno²¹³ selectivity even at room temperature. As an extension to this study, the synthesis of β -mannan²¹³ and α -glucans²¹⁴ has been reported. Mong and co-workers applied 6-O-picoloyl-2-deoxy glycosyl donors to stereoselective synthesis of β -glycosides.²¹⁵ Very recently, De Meo²¹⁶ and Tsai²¹⁷ investigated the effect of picoloyl substituents on sialylations. Yang et al employed a similar 2-quinolinecarbonyl group to stereoselective synthesis of β -D- and β -L-arabinofuranosides.²¹⁸

Torsional effects induced by the cyclic protecting groups may also affect both the reactivity of glycosyl donors and/or the stereoselectivity of glycosylations. The work by Crich et al. on the synthesis of β -mannosides^{76,87,219-221} is the best known example of the deactivating (and stereodirecting) effect of the 4,6-Obenzylidene substituent. Benzylidene effect is due torsional strain²²² that restricts the conformational flexibility of the pyranose ring and also enhanced electronwithdrawal.²²³ A variety of other cyclic groups have been investigated. In particular, studies of 2-amino glycosyl donor protected with 2,3-transoxazolidinone by Kerns et al,²²⁴⁻²²⁷ Oscarson et al,²²⁸ Ye et al,²²⁹⁻²³² and Ito et al,^{233,234} yielded useful techniques for the synthesis 1,2-cis glycosides and glycosyl donors with switchable selectivity. Crich et al. demonstrated the utility of the 2,3-O-carbonate protection α -selective mannosylation for for and rhamnosylation, 206,235 as well as β -glucosylation. 236 The effect of 3,4-O-carbonate protection is weaker and it shows a slight bias toward β -selectivity.²³⁷ The 4,5O,N-oxazolidinone protection of sialyl donors often provides high yields and α stereoselectivities in sialylations and helps to suppress competing elimination.²³⁸⁻
²⁴⁰

The effect of the glycosyl acceptor on the stereoselectivity of glycosylation has also been investigated. The mechanistic outline of the glycosylation reaction (*vide supra*) implies that the RDS is unimolecular and should not be affected by the nature of the glycosyl acceptor (Scheme 1.1). However, the donor-acceptor mismatch concept of Paulsen²⁴¹ and Fraser-Reid/Lopez²⁴²⁻²⁴⁶ as well as the double stereo-differentiation phenomenon²⁴⁷ present a strong counterargument. In fact, different selectivities are often obtained for different glycosyl acceptors. Typically, the alcohol reactivity is inversely correlated with the stereoselectivity whereas the most reactive hydroxyls give the lowest α/β -ratios. For instance, glycosylation of axial 4-OH of galactose often gives excellent 1,2-*cis* stereoselectivity. Occasionally, primary hydroxyl groups can lead to higher selectivity than their secondary counterparts, particularly for reactions partially proceeding via the bimolecular mechanism. Toshima et al introduced a new technique that is based on the chiral recognition of aglycones.²⁴⁸

Reaction conditions

Several other factors including temperature, solvent, amount and type of promoter used can influence the outcome of chemical glycosylation by affecting its stereoselectivity and yield. Kinetically controlled reactions at low temperatures favor the formation of β -linked products,^{249,250} although opposite results have also been obtained.^{251,252} The solvent effect on the stereoselectivity of glycosylation

reactions has been widely studied.^{256,258-263} In general, polar reaction solvents increase the rate of the β-glycoside formation via charge separation between O-5 and β-O-1. If the synthesis of α-glycosides is desired, CH₂Cl₂, ClCH₂CH₂Cl₂Cl or toluene would be suitable candidates as the reaction solvents. However, there are more powerful forces than simple solvation. Thus, ethereal solvents are beneficial for α-selective glycosylation because diethyl ether,²⁵³ tetrahydrofuran,²⁵³ and dioxane²⁵⁴ have a tendency to form the equatorial O-linked intermediate. Conversely, nitrile solvents help the formation of β-glycosides because there reactions were thought to proceed via the axial glycosyl nitrilium cation intermediate.^{195,255} More recently, the Mong group suggested that in addition to the anomeric effect the formation of 1,2-*cis* nitrilium species is further reinforced by the participation of the oxygen atom at C-2.²⁵⁶ This would results in the formation of the glycosyl oxazolinium intermediate that is leading to the β-product as a result of the top-face nucleophilic attack.^{255,257-262}

Many decades ago, glycosylations of unreactive acceptors were very inefficient.^{109,110} Initial attempts to improve the glycosylation reaction by Zemplen¹¹¹ and Helferich¹¹² have also showed that faster reactions may result in lower stereoselectivity.^{113,114} Some reactive glycosyl donors can be activated under Lewis acid catalysis. The best-known examples of these leaving groups include trichloroacetimidoyl (TCAI),^{263,264} N-phenyl trifluoroacetimidoyl (PTFAI),²⁶⁵ and phosphites/phosphates.²⁶⁶ The use of transition metal catalysts based on palladium^{267,268} and nickel^{270,271} developed by Nguyen et al for TCAI donors offers new opportunities for stereocontrol.¹⁶⁷ Many other current methodologies for


glycosylation, such as glycosylation with S-aryl/alkyl thioglycosides, use stoichiometric promoters. $Bi(V)^{269,270}$ and $Au(III)^{191}$ catalyzed activations of thioglycosides represent other new promising directions in glycosylation chemistry.^{169,269} Recently there has been an explosion in the study of gold-catalyzed activation of alkynes to exploit the low oxophilic character of gold and the excellent functional group compatibilities these catalysts exhibit.^{159,162,271-274}

Another emerging approach is the use of (thio)ureas as organocatalysts for glycosylations with glycosyl chlorides.^{170,174,175,275,276} The underpinning idea for developing alternative methodologies for the promotion of glycosyl chlorides is to avoid the heavy metal catalyst utilized in traditional Koenigs-Knorr reactions.^{109,110} Ye and co-workers developed a catalytic system that makes advantage of the hydrogen-bond donor ability of urea.¹⁷⁴ These activation conditions allowed for smooth glycosidation of per-benzylated galactosyl, mannosyl and rhamnosyl chlorides. The glycosides were achieved in high yields and excellent α -stereoselectivities, but these reactions required the use of benzene as a solvent, high temperature, and long reaction times. For example, as depicted in Scheme 1.2A, activation of donor **1.1** with the urea-derived catalyst **1.3** for the reaction with glycosyl acceptor **1.2** in the presence of K₂CO₃ afforded disaccharide **1.4** in excellent stereoselectivity and yield. A phosphine additive, TTMPP, was found advantageous in achieving good selectivity with glucosyl donors.

Very recently, Jacobsen and co-workers studied a series of chiral thiourea catalysts for the activation of glycosyl chlorides.¹⁷⁵ In contrast to the previous example, the reaction affords disaccharides with high β -stereoselectivity, even in

the absence of the neighboring participating group. The direct access to the formation of β -mannosides is another advantageous application of this reaction. For example, as depicted in Scheme 1.2B, activation of donor **1.5** with the chiral thiourea-derived catalyst **1.7** for reaction with glycosyl acceptor **1.6** in the presence of isobutylene oxide (IBO) afforded disaccharide **1.8** in high β -stereoselectivity and yield. IBO is used as an electrophilic trap to scavenge HCl produced in these reactions. The reaction mechanism has been studied and some features, such as stereospecific inversion, in combination with the independence from the stereochemical relationship between electrophile and nucleophile suggest the S_N2-like nature of the displacement.

In addition, over the recent years there has been a noticeable shift in focus of the mechanistic glycosylation chemistry field towards studying stereoelectronics and conformation of material key reaction the starting and intermediates.^{74,75,77,79,80,82,84,91,100,172,223,277-290} While the stereoelectronic and conformational effects on reactivity have been studied extensively, the impact of these effects on stereoselectivity remains elusive. Although some model studies helped to establish general trends,^{75,82,277-280,290,291} practical application of the conformational factors to stereocontrol of glycosylation is still limited. Reagent- or additive-controlled glycosylations and reactions with reagent-dependent switchable selectivity are becoming active areas of research.^{105,292-299}



Scheme 1.2. Examples of urea and thiourea-based organocatalytic reactions Special cases and indirect methods

While some sugar series follow general trends, there are classes of compounds and linkages that require special methods. These special cases of glycosylation include the following major classes of compounds. 2-Deoxysugars,^{300,301} that are discussed in a separate review in this special issue.³⁰² 2-Amino-2-deoxy sugars,³⁰³ require additional steps and a careful selection of suitable protecting groups at C-2, most commonly 2,2,2-trichloroethoxycarbonyl


(Troc) or phthaloyl (Phth) for the synthesis of 1,2-trans and azide for the synthesis of 1,2-cis linked glycosides. The difficulty of the direct β -mannosylation³⁰⁴ was addressed by developing a variety of indirect approaches such as C-2 oxidation-reduction, C-2 inversion, anomeric alkylation, and intramolecular aglycone delivery (*vide infra*).^{305,306} Crich and co-workers discovered that 4,6-*O*-benzylidene protected donors provide excellent β -manno stereoselectivity.^{76,87,219-221} The HAD method developed by Demchenko provides nearly complete β -selectivity in mannosylation at room temperature.²¹³ Other useful approaches to the synthesis of β -mannosides include Kim's *o*-carboxybenzyl leaving group approach¹⁵² and van der Marel's C-5 carboxylate approach.³⁰⁷⁻³¹⁰

An area of intramolecular glycosylation has also been developed to enhance the production of difficult glycosidic linkages. A better stereocontrol is achieved by tethering the reaction counterparts and restricting the glycosyl acceptor attack.³¹¹⁻³¹⁸ The best known example, intramolecular aglycone delivery (IAD), was introduced by Barresi and Hindsgaul.³¹⁹ Over the years, IAD has evolved into a powerful means to perform glycosylations of complex targets with high efficiency and yields.³²⁰⁻³²³ The major improvement of this approach has emerged with the implementation of a 2-napthylmethyl group (Nap) as a tether group.³²³ A representative example is depicted in Scheme 1.3. The treatment of a mixture of donor **1.9** and acceptor **1.10** with 2,3-dichloro-5,6-dicyano-*p*-benzoquinone (DDQ) produces a mixed acetal that can be directly glycosidated in the presence of MeOTf and 2,6-di-*tert*butyl-4-methylpyridine (DTBMP) followed by acetylation to give disaccharide **1.11** in an excellent yield of 90% and complete β -selectivity.³²³ Initially investigated for the synthesis of β -mannosides, α -glucosides, and β -arabinofuranosides,³²³ this approach was extended to the synthesis of β -rhamnosides³²⁴ and other challenging targets.^{315,325-331}

The synthesis of 1,2-*trans* furanosides can be achieved with 2-O-acylated glycosyl donors.^{332,333} The synthesis of 1,2-*cis* furanosides is more difficult due to high conformational flexibility of the five-membered ring and lack of the anomeric effect. Recent advancements make use of glycosyl donors with the furanose ring locked into a single conformation This was achieved with 2,3-anhydro,^{334,335} 3,5-O-(di-*tert*-butylsilylene),^{336,337} or 3,5-O-tetraisopropyldisiloxanylidene³³⁸ protection. Young and co-workers successfully applied the HAD approach to 1,2-*cis* glycofuranosylation.²¹⁸

In spite of extensive efforts and notable progress, the chemical synthesis of α -sialosides also remains challenging.³³⁹⁻³⁴⁴ Destabilizing electron-withdrawing carboxylate and the lack of a substituent at C-3 often drive sialylation reactions toward competitive elimination. This side-reaction leads to the formation of a 2,3-dehydro derivative. In addition, the lack of a participating group means that stereoselectivity of sialylations can be low. To overcome these problems, a variety of leaving groups, participating auxiliaries, and activation conditions for sialylations have been developed. In recent years, it became evident that the remote N-substituent at C-5 may have a strong effect both on stereoselectivity of sialylations and the reactivity of sialyl donors.³⁴² A particular advance has been made with 4,5-*O*,*N*-oxazolidinone derivatives,²³⁸⁻²⁴⁰ and more recently with 5-isothiocyanate,³⁴⁵ that provide high yields and stereoselectivities in sialylations and

help to suppress the competing elimination. An investigation of the effect of remote picoloyl groups at C-4 in the presence of excess of triflic acid offered new mechanistic insights into the sialic acid chemistry.²¹⁶ This methodology has been extended in to the synthesis of 7,8-di-picoloylated donors bearing benzoyl protection at the other positions.²¹⁷



Scheme 1.3. Synthesis of β-mannosides via intramolecular aglycone delivery

A number of methods that do not include a formal glycosylation step have been developed.^{346,347} Since these indirect procedures include multistep syntheses practical application of these techniques is envisaged for the synthesis of glycosidic linkages that cannot be easily accessed by conventional technologies. O'Doherty developed a well-rounded methodology for Pd(0)-catalyzed glycosylations, wherein carbohydrate chirality centers are installed postglycosylationally. The *de novo* asymmetric synthesis methodology was instrumental for obtaining many mono-, di-, and oligosaccharide derivatives by means of palladium-catalyzed reactions.³⁴⁸⁻³⁵¹


1.2.2. Oligosaccharide synthesis

Glycosylation is only part of the challenge synthetic chemists confront during the synthesis of oligomeric sequences. A traditional stepwise approach requires additional manipulations after each glycosylation step. This multi-step reaction cycle is then repeated again until oligosaccharide of the desired chain length is obtained. This becomes increasingly inefficient at the advanced stages of the assembly,^{95,352} often leads to a dramatic drop in yield, and as a consequence, lesser availability of glycans. Many advanced strategies that streamline oligosaccharide assembly by minimizing or even eliminating leaving or protecting group manipulations between coupling steps are based either on chemoselective or on selective activation of leaving groups.⁹⁵ One-pot strategies help to expedite the oligosaccharide synthesis further. The one-pot sequences typically consist of the glycosylation steps only, but a minimal number of deprotection steps may also be included. Since all the sequential reactions are performed in a single flask (pot), the purification is only performed at the stage of the final product and purification of the intermediates is not required.

Conventional linear and convergent block synthesis

A traditional stepwise approach requires additional synthetic steps for the conversion of the disaccharide intermediate into the second-generation glycosyl donor or acceptor. Modified disaccharides are then coupled with a glycosyl donor (or acceptor) to


obtain a trisaccharide. This reaction sequence is then repeated again until oligosaccharide of the desired chain length is obtained. Despite the need for additional protecting group manipulations between the glycosylation steps the linear approach is still in common use and a relevant example, the synthesis of the blood-group determinant H-type II pentasaccharide **1.23** is depicted in Scheme 1.4.³⁵³



Scheme 1.4. Conventional linear oligosaccharide synthesis with alternating glycosylation and deprotection steps

Galactosyl phosphate **1.12** is glycosylated with acceptor **1.13** in the presence of trimethylsilyl trifluoromethanesulfonate (TMSOTf), followed by removal of the

temporary levulinoyl (Lev) protecting group. The sequence is repeated with TCAI and phosphate donors, as well as Lev and 2-azidomethylbenzoyl (AMB) removable protecting groups, to afford the target pentasaccharide in 60% overall yield. Numerous improvements of this basic concept include the use of solid-supported synthesis³⁵⁴ or fluorous protecting groups³⁵⁵ that significantly facilitate separation of products from the reactants (*vide infra*). The convergent building block approach is a faster way to obtain larger oligosaccharides.³⁵⁶⁻³⁵⁸ According to this strategy, oligosaccharide fragments are pre-synthesized and then converged by means of a glycosylation reaction.



Scheme 1.5. Convergent block synthesis of ganglioside GP3

Additional protection/deprotection steps may still be required but the over-all assembly is faster due to the use of oligomeric building blocks. The block synthesis is particularly

useful for the purpose of the introduction of a "difficult" linkage at an earlier stage of the saccharide assembly.³⁵⁹ Convergent block synthesis also streamlines the formation of oligosaccharide sequences containing two or more repeat units.

A relevant recent example, the synthesis of ganglioside GP3, developed by Kiso and co-workers is illustrated in Scheme 1.5.³⁶⁰ The synthesis of this complex structure was designed to avoid the introduction of "difficult" units including ceramide, α -galacto, and unusual internal α -sialo linkages. Tetrasaccharides **1.24** and **1.25**, both of which were obtained using a convergent [2+2] glycosylation strategy, were coupled in the presence of *N*-iodosuccinimide (NIS) and trifluoromethanesulfonic acid (TfOH) at 0 °C. As a result, an octasaccharide was obtained in 91% yield. The latter was reprotected and converted into TCAI donor **1.26** that was coupled with glycosyl ceramide acceptor **1.27** in the presence of TMSOTf affording the target ganglioside **1.28** in 77% yield. The recent synthetic effort in the area of convergent assembly field^{49,361-368} has culminated in the synthesis of a large mycobacterial arabinogalactan oligosaccharide containing 92 monosaccharide residues (92-mer) by Ye and co-workers.³⁶⁹

Expeditious strategies for oligosaccharide synthesis

Expeditious strategies streamline oligosaccharide assembly by minimizing or even completely eliminating manipulations between coupling steps.⁹⁵ All of these approaches can be classified into the following major categories. First, chemoselective approaches wherein the reactivity of building blocks is modulated by the protecting groups. Second, selective approaches that are based on selective activation of certain leaving groups. Third, preactivation-based approaches that can be used with any protecting and leaving groups. Fourth, regioselectivity-based approaches rely on the differential reactivity of different acceptor groups.


Fraser-Reid's seminal work on armed-disarmed approach showed that the building block reactivity can be modulated through the choice of protecting groups.^{370,371} Thus, benzylated (electronically activated, armed) building blocks are significantly more reactive than their acylated (Bz, disarmed) counterparts (Scheme 1.6A). Usually, protecting groups in both reaction components and careful selection of mild reaction conditions have to be taken into consideration to allow direct chemoselective activation of the armed glycosyl donor over the disarmed glycosyl acceptor. The convenience of this approach is that the same leaving group can be used for all building blocks in the sequence. However, "protecting groups do more than protect,"³⁷² and this can affect the stereochemical outcome and limit the scope of the method. For instance, the classical armed-disarmed approach can only lead to the formation of *cis-trans*-patterned oligosaccharide sequences.


In recent years, the scope of the original armed-disarmed concept has been expanded³⁷³ and a number of efforts to quantify or even predict the reactivity of building blocks have been reported by Fraser-Reid,^{222,374} Ley,³⁷⁵ Wong,³⁷⁶ and others.³⁷⁷ Wong's study also revealed a number of building blocks that extend beyond the traditional armed-disarmed boundary. Boons showed that 2,3-O-carbonate protected glycosyl donors are less reactive than disarmed acylated derivatives.³⁷⁸ Subsequently, Demchenko reported that 2-Bn-3,4,6-tri-Bz protected donors are even less reactive than their disarmed per-Bz counterparts (superdisarmed). This unexpected protecting group effect was explained by the existence of the O2/O5 cooperative effect that takes into consideration the

stabilization of reaction intermediates, rather than only the electronics of the starting material.³⁷⁹ In this case, the destabilization of the glycosyl cation is due to the electron poor environment of O-5 and the lack of anchimeric assistance.

Two concepts for superarming glycosyl donors have also emerged, further expanding the original scope of the armed-disarmed approach. First, Bols showed that superarming can be achieved by changing the equatorial-rich ${}^{4}C_{1}$ conformation to an axial-rich skew-boat conformation by creating steric congestion with TBDMS protecting groups at the C-2, 3 and 4 positions.^{84,285-288} These donors showed a hefty 20-fold increase in reactivity over the armed per-benzylated counterparts because the conformational change simplifies transition of the starting material into the oxacarbenium ion that is most stable in the all-axial half-chair arrangement.^{75,277,278,280,291} Second, Demchenko reported building blocks wherein the superarming was achieved via the O2/O5 cooperative effect. Glycosyl donors equipped with the superarming 2-Bz-3,4,6-tri-Bn pattern were 10-fold more reactive than their armed counterparts.³⁸⁰⁻³⁸² In this case, the stabilization of the glycosyl cation is possible both from the electron rich O-5 and from 2-Bz via the anchimeric assistance. With the two different approaches to superarm glycosyl donors, conformational and anchimeric, Bols and Demchenko jointly developed 2-Bz-3,4-di-TBS protected glycosyl donor. Glycosylations with the hybrid donors were swift, high yielding and β -selective.^{383,384}


This study showed that the conformational arming is a powerful tool to increase the reactivity and to achieve excellent yields. The anchimeric arming effects are weaker, but the participation ensures complete 1,2-*trans* selectivity.





Another general concept to expedite oligosaccharide synthesis is to achieve selective activation of different leaving groups, and it is practically independent of the nature of the protecting groups (Scheme 1.6B). One example presented below has a unique alignment of six different leaving groups, which were selectively activated affording hexasaccharide **1.39** in only five steps (Scheme 1.7).³⁸⁵ First, thiocyanate glycoside donor **1.29** was activated with Cu(OTf)₂ over S-thiazolinyl (STaz) acceptor **1.30** in 89% yield. Subsequently, disaccharide **1.31** was coupled with S-benzoxazolyl (SBox) glycosyl donor **1.32** in the presence of benzyl bromide to achieve the


trisaccharide **1.33** in 67% yield. The latter was coupled with fluoride acceptor **1.34** in the presence of MeOTf to produce tetrasaccharide **1.35** in 87% yield. Tetrasaccharide **1.35** was then reacted with SEt acceptor **1.36** in the presence of $AgClO_4/Cp_2ZrCl_2$ to afford the pentasaccharide **1.37** in 84% yield. Lastly, the coupling of *O*-pentenyl acceptor **1.38** with the pentasaccharide **1.37** using MeOTf as an activator produced hexasaccharide **1.39** in 72% yield.



Scheme 1.7. Hexasaccharide synthesis in five selective activation steps

Among all known selective activation strategies,⁹⁵ Ogawa's orthogonal concept is arguably the most advantageous.^{386,387} This technique used two chemically distinct glycosylation reactions and the selective activation of two orthogonal leaving groups is then reiterated (Scheme 1.6B).

The classic variation of the orthogonal activation involves building blocks bearing *S*-phenyl and fluoro leaving groups.³⁸⁸ As shown in Scheme 1.8, phenyl thioglycoside **1.40** is selectively activated over fluoride acceptor **1.41** in the presence of NIS/AgOTf. The fluoro leaving group of disaccharide **1.42** is then activated over thioglycoside acceptor **1.43** in the presence of Cp₂Hf₂Cl₂/AgOTf. This selective activation sequence is then reiterated to provide tetrasaccharide **1.44**. Ideally, the orthogonal approach allows for an unlimited number of reiterations of the two orthogonal leaving groups, which is conceptually very attractive.




Scheme 1.8. Orthogonal activation of phenylthio glycosides and fluorides

In practice, however, the yields, which are typically inversely correlated to the size of the glycosyl donor involved, decreased dramatically at the later stage of the assembly. A number of complementary combinations of orthogonal leaving groups and conceptual modifications have been implemented.^{385,387,389-399}

A number of concepts for selective activation have been introduced.^{145,398,400} For example, in the two-step activation approach both glycosyl donor and glycosyl acceptor initially bear the same type of a leaving group. In order to couple these two reactants, a different leaving group is introduced into the glycosyl donor. Upon the selective activation of the donor, this two-step activation sequence can be reiterated. Discovered for thioglycoside conversion into bromides³⁵⁶ this approach was extended to other systems.^{371,401-403} For example, Danishefsky's reiterative assembly approach involving glycal precursors that are converted into 1,2-anhydrosugars with dimethyldioxirane (DMDO)⁴⁰⁴ clearly illustrated the versatility of this strategy.^{137,405-407} Thus, 1,2-anhydrosugar **1.47** generated from glycal **1.46** could be activated over glycal acceptor **1.48** in the presence of ZnCl₂ to afford 1,2-*trans*-linked disaccharide **1.49** in 81% (Scheme 1.9). The epoxidation-glycosylation sequence can be then reiterated to yield larger oligosaccharides.

More recently, the versatility of the two-step activation was demonstrated by a one-pot pre-activation procedure,⁴⁰⁸⁻⁴¹⁰ according to which S-tolyl glycosides are converted *in situ* into a reactive intermediate. These pre-activation types of couplings cannot be formally classified as oligosaccharide synthesis via selective activations and it occupies its own niche.^{66,229,230,232,237,260,411-416} This strategy is particularly advantageous in conjunction with the one-pot oligosaccharide synthesis that will be discussed below.




Scheme 1.9. Glycal-epoxide method for iterative oligosaccharide synthesis

A number of useful expeditious approaches are based on regioselectivity of different acceptor groups. Thus, a two-directional strategy for glycan synthesis makes use of a building block capable of reacting first as a glycosyl donor and then as an acceptor. For example, building block **1.50** is first glycosidated with the reactive glycosyl acceptor **1.51** and then glycosylated directly at the deactivated position (synthesis of **1.54**, Scheme 1.10).⁴¹⁷ Hydroxyl deactivation can be achieved by introducing electron-withdrawing groups at surrounding positions. The use of temporary masking moieties (trityl, silyl) that can act as protecting groups in the first step and then be removed directly during glycosylation, has become a logical extension of this technique.^{418,419} The use of the glycosyl donor/acceptor unit on the solid support is another efficient way to "deactivate" the hydroxyl moiety in comparison to the solution-based acceptor (*vide infra*).⁴²⁰

Oligosaccharide synthesis in one pot

One-pot strategies allow to streamline glycan synthesis because all glycosylations are performed in a single flask (pot) and do not require purification of intermediates.⁴²¹⁻⁴²³ All one-pot strategies are based on the following five major concepts. The first approach discovered by Kahne and co-workers,⁴²⁴ remains the only pure one-pot concept because the synthesis is performed with all reaction components present in the reaction flask from the beginning. In all other approaches, the reactants are added sequentially, typically upon the consumption of the first batch of compounds.




Scheme 1.10. Two-directional approach for the synthesis of pentasaccharide 1.54

The fact that all reactants are present from the beginning implies that fine-tuning of all reaction components is required. According to this concept, the most reactive leaving group reacts with the most reactive hydroxyl first. Subsequent reaction between the second-ranked reactive leaving group and second-ranked hydroxyl takes place after the first step has been completed, etc. The concept of the conformational superarming developed by Bols et al.^{287,288} was also applied to a one-pot synthesis with all three reaction components present from the beginning.^{287,384}

The second approach is based on chemoselective activation wherein the reactivity of the glycosyl donor and acceptor is differentiated by varying the electronic properties of protecting groups.³⁷⁵⁻³⁷⁷ A relevant example is shown in Scheme 1.11 (synthesis of **1.59**) wherein the sequential activation of **1.55**, **1.56**, and **1.57** was based on their relative


reactivity, which was found to be 17000/162.8/13.1, respectively.³⁷⁶ In contrast to the first concept, building block **1.57** is added only after the reaction between **1.55** and **1.56** is completed, etc.



Scheme 1.11. One-pot synthesis of tetrasaccharide 1.59 via chemoselective


activation

The third approach is based on selective activation of one leaving group over another. Since the number of leaving groups that can be aligned for multi-step sequential activation is still limited only few examples are known. Highlighted herein is the synthesis of a linear tetrasaccharide derivative **1.62** that was accomplished in 73% yield over three sequential glycosylation steps.⁴²⁵ This was achieved by the stepwise activation of SBox donor **1.60** over S-ethyl glycoside **1.61**. The S-ethyl moiety of the disaccharide intermediate was then activated over STaz acceptor **1.30**. Finally, the STaz leaving group of the trisaccharide intermediate was activated for the reaction with glycosyl acceptor **1.2** (Scheme 1.12).



Scheme 1.12. One-pot synthesis of tetrasaccharide 1.62 via sequential selective activation of building blocks equipped with different leaving groups

The fourth approach is based on pre-activation and hence it is practically independent of the building block reactivity. A representative example illustrated in Scheme 1.13 deals with a straightforward synthesis of the tumor associated carbohydrate antigen Globo-H hexasaccharide.⁶⁶ Thus, preactivation of fucosyl donor **1.63** at -78 °C with p-TolSCl and AgOTf was followed by the addition of acceptor **1.64** along with a hindered base 2,4,6-tri-(t-butyl)-pyrimidine (TTBP). The temperature was then increased to -20 °C and the trisaccharide intermediate was formed. The reaction mixture was cooled again to -78 °C followed by the addition of AgOTf and p-TolSCl. After that, galactose acceptor **1.65** and TTBP were added and the reaction mixture was warmed to -20 °C. When acceptor **1.65** has disappeared, the temperature was lowered to -78 °C and the sequence was reiterated for glycosylation of lactose acceptor **1.66**. The resulting Globo H hexasaccharide α -**1.67** was formed in 47% yield based on the four-component reaction that required only 7 h to complete the assembly.



Scheme 1.13. Preactivation-based one-pot synthesis of Globo-H hexasaccharide 1.67

The fifth concept for one-pot oligosaccharide synthesis relies on the differentiation between various hydroxyl groups, such as primary vs. secondary or equatorial vs. axial, have been explored.⁴²⁶

1.2.3. Supported and tagged oligosaccharide synthesis

Further breakthroughs in the area of synthetic chemistry came with the development of supported or tagged organic synthesis techniques. As a consequence, the last two decades have also witnessed dramatic improvements in the area of supported oligosaccharide synthesis. Supported synthesis is very attractive as it allows for the rapid synthesis of oligosaccharide sequences without the necessity of purifying (and


characterizing) the intermediates. Another important advantage of supported oligosaccharide synthesis is that it simplifies reagent excess removal. It can be achieved either by filtration if insoluble polymer or other solid phase supports are used or, alternatively, by fractionation, extraction or precipitation if soluble polymer supports or other supports/tags are employed.

Synthesis on solid phases

Solid-phase synthesis using insoluble polymer supports (beads)^{96,97} has been widely used in the preparation of many classes of molecules of interest.^{96,97,427,428} Preparations of oligopeptides⁴²⁹ and oligonucleotides⁴³⁰ have been reported using insoluble supports. Merrifield⁴³¹ was the first to report the synthesis of peptide chains using polystyrene beads. The introduction of solid phases into the carbohydrate synthesis is credited to Fréchet and Schuerch who reported the first oligosaccharide synthesis on solid support.⁴³² Since those pioneering studies, the solid-phase synthesis has been widely utilized in a routine preparation of oligosaccharides and glycopeptides, and it is attracting renewed attention in connection with combinatorial chemistry⁴³³ and automation.^{354,434}

The two main strategies used for solid-phase synthesis of oligosaccharide are called donor-bound and acceptor-bound. In the first approach depicted in Scheme 1.14A, the acceptor is bound to the resin either through the anomeric position or one of positions away from the anomeric center. This approach has an important conceptual advantage by using highly reactive solution-based monosaccharide donor. As a result, the yields remain high, even at the advanced stages of the assembly. With the increasing size of the

oligosaccharide, the solid phase bound reaction sites extend further into solution phase, which also contributes to high yields that are achieved by means of this strategy.



Scheme 1.14. Glycosylation on polymer support

The second concept, the donor-based approach depicted in Scheme 1.14B, relies on the donor bound to the polymer support. After the glycosylation has occurred, the temporary protecting group on the acceptor is turned into a suitable leaving group and the chain elongation steps can be reiterated. In principle, the chain elongation can be continued directly, if a suitable set of orthogonal leaving groups is chosen. However, the main disadvantage of the donor-bound approach relates to the origins of the glycosylation mechanism. Glycosyl donors are much more prone to side reactions than are glycosyl acceptors. Donor that underwent a side reaction, or simply was hydrolyzed, cannot conduct further chain elongation and this will ultimately terminate the oligosaccharide sequencing.




Figure 1.3. Solid supports for oligosaccharide synthesis: Merrifield's resin (A), Tentagel (B) and JandaJel (C)

Also, the templated approach outlined in Scheme 1.13C, wherein both components are connected to the same polymer support has been investigated. Two-directional techniques, combining conventions of approaches A and B are also known.^{63,420}

Polymer beads or resins are the most commonly used supports for solid-phase synthesis. Polystyrene beads crosslinked with 1% divinylbenzene found broad acceptance in all fields since their introduction by Merrifield (Figure 1.3A).⁴³¹ Initially invented for peptide synthesis applications, the resin was successfully introduced into the solid phase

synthesis of oligosaccharides.⁴³² The high loading capacity and the compatibility with many reaction conditions have been crucial for the popularity of polystyrene-based resins. Since then, different solid supports with different swelling characteristics have been explored: polystyrene grafted with different lengths of polyethylene glycol (PEG) groups led to the development of Tentagel (Figure 1.3B), Hypogel and Argogel.

These resins are able to swell efficiently in both polar and non-polar solvents and are capable of higher loading capacity. Another approach made use of modifying the cross-linker by employing a tetrahydrofuran-derived bridge (Figure 1.3C).⁴³⁵ This resin has been commercialized with the tradename of JandaJel. Although polystyrene resins are fairly inert, it is noteworthy that some of these resins tend to partially decompose in the presence of large amounts of TMSOTf.⁴³⁵ To address possible instability of polymeric resins, non-swelling porous materials have been also been evaluated for solid-supported oligosaccharide synthesis, and controlled-pore glass⁴³⁶ and nanoporous gold^{437,438} are two of such materials to mention (*vide infra*).

The linker plays a central role in the synthesis of oligosaccharides using solidphases. Due to its labile nature, the linker itself has to be taken into account for orthogonality in respect to all protecting (or leaving) groups that will be manipulated during the various steps. For the same reason, various linkers stable under many different conditions have been developed for carbohydrate synthesis.^{354,439} In addition to known and widely used protecting group-derived linkers, such as succinoyl, alkoxybenzyl, and silyl-based linkers, a new wave of photoreactive, metathesis or hydrogenation-removable linkers had emerged.^{44,440-455} In the subsequent effort to develop new linkers with a versatile installation and/or removal profile, recent developments included Reichardt's spacer/linker,⁴⁵² as well as Seeberger's "Lenz linker,"⁴⁵⁶ safety catch linker,⁴⁵⁷ and photocleavable linker.⁴⁵⁸ Some examples of recently developed linkers are summarized in Figure 1.4.





Figure 1.4. Recently introduced linkers for polymer-supported oligosaccharide synthesis


More recently, Seeberger at al. developed a traceless photocleavable linker that is capable of producing oligosaccharides with the free reducing end.⁴⁵⁹ The linker offered stability and yields comparable to the parent structure, making it a suitable choice for future applications. The cleavage is achieved using a flow photoreactor, shown to be far more efficient than the classical batch reactors.⁴⁶⁰



Scheme 1.15. Acceptor-bound approach to the synthesis of oligosaccharide 1.73

As mentioned, most of the solid-phase syntheses involve glycosyl acceptor-bound approach. One of the classical examples of this approach involves Schmidt's synthesis of a branched saccharide **1.73** depicted in Scheme 1.15.⁴⁶¹ Lactose derivative **1.68** was attached glycosidically to the carboxypolystyrene resin support in the presence of TMSOTf. The chain was then extended by sequential removal of the orthogonal protecting groups fluorenylmethoxycarbonyl (Fmoc) with triethyl amine Et₃N and Lev with hydrazine acetate. Upon cleavage from the resin, achieved by the treatment with NaOMe/MeOH, and subsequent global acetylation with Ac₂O/pyridine hexasaccharide **1.73** was obtained in 43% overall yield.


Scheme 1.16. Chiral auxiliary-assisted synthesis of 1,2-cis-linked oligosaccharide



More recently, Boons et al. reported the synthesis of all- α -linked oligosaccharide **1.79** using chiral auxiliary mediated 1,2-cis glycosides on polymer support.¹⁸⁶ As depicted in Scheme 1.16, glucosyl donor **1.74** was attached glycosidically to the hydroxypolystyrene resin support in the presence of TMSOTf. The chain was then extended by sequential removal of the orthogonal protecting groups Fmoc (with


1.79

piperidine) and allyloxycarbonyl (Alloc) with Pd(PPh₃)₄. Upon cleavage from the resin and subsequent reprotection pentasaccharide **1.79** was obtained in 25% overall yield.




Scheme 1.17. Donor-bound synthesis of pentasaccharide 1.82

Most of the known syntheses involve a glycosyl acceptor-bound approach, but examples involving glycosyl donor bound have also emerged. As reported by Danishefsky et al,⁴⁶² glycal **1.80** was attached to a Merrifield resin via a silyl linkage in the presence of diisopropylethylamine (DIPEA, Scheme 1.17). The polymer-bound glycal was then epoxidized with DMDO and the resulting 1,2-anhydro sugar was glycosidated with acceptor **1.80** in the presence of ZnCl₂ to provide the immobilized disaccharide. This synthesis was reiterated until the desired oligosaccharide was obtained. The latter was then cleaved off by the treatment with Bu₄NF/AcOH to afford pentasaccharide **1.82** in 58% yield. Another similar examples of the donor-bound approach include the synthesis of the Le^b blood group antigen^{354,463} and selective activation of the SBox donor over solution phase thioglycoside acceptor.⁴⁶⁴




Scheme 1.18. Orthogonal synthesis of a combinatorial library on solid phase

The application of orthogonal strategy, which is another example of a donorbound approach in polymer supported synthesis, was introduced by Ogawa.⁴⁶⁵ A more recent example of this approach is illustrated in Scheme 1.18. As reported Kanie et al.,^{391,392} polymer-bound donor **1.83** was activated selectively over fluoride acceptor **1.84** in the presence of dimethyl(methylthio)sulfonium trifluoromethanesulfonate (DMTST). The immobilized glycosyl fluoride was then activated over *S*-phenyl acceptor **1.85** in the presence of Cp₂Hf(OTf)₂. Finally, the immobilized *S*-phenyl trisaccharide was glycosidated with octanol in the presence of DMTST. The resulting oligosaccharide was cleaved off and all eight diastereomers of **1.86** were separated by HPLC to provide a useful combinatorial library.



Scheme 1.19. Peptide-templated oligosaccharide synthesis on polymer support

³⁹¹Short peptide chains immobilized on the solid support have been investigated as templates for streamlining the oligosaccharide synthesis by Fairbanks et al.⁴⁶⁶⁻⁴⁶⁸ and Warriner.⁴⁶⁹ As shown by Warriner, conjugate **1.87** containing the hydroxyproline-linked glycosyl donor and acceptor pair with the glycine unit in between produced $(1\rightarrow 4)$ -linked disaccharide **1.89** in high yields (Scheme 1.19). A differential and highly substrate orientation-dependent stereoselectivity was observed by employing differently sequenced templates, such as **1.88**.



STICS 10-plate assembly

Scheme 1.20. STICS: Surface-Tethered Iterative Carbohydrate Synthesis


The application of emerging nanomaterials to organic synthesis has created the basis of the STICS (surface-tethered iterative carbohydrate synthesis) technology is a functionalized 'stick' made of chemically stable high surface area nanoporous gold that allows performance of cost efficient and simple synthesis of oligosaccharide chains.⁴³⁸ Nanoporous gold can be prepared by dealloying Ag from Au-Ag alloy or from Au-Ag alloy electrodeposited onto a gold surface in the presence of nitric acid.⁴⁷⁰⁻⁴⁷³ As depicted in Scheme 1.20, a stack on NPG plates, carrying acceptor **1.91** anchored to the gold surface with a thiolate linker, is assembled in a Teflon-shelved reactor. The oligosaccharide assembly is accomplished by alternating the glycosylation, deprotection, washing, and drying steps. Thus, 6-*O*-TBDPS protected S-benzoxazolyl (SBox) glycosyl

donor **1.90** was coupled to the immobilized acceptor **1.91** in the presence of MeOTf. Then, after a rinse, the tethered disaccharide intermediate was treated with Bu_4NF to remove the silyl group to afford the second generation glycosyl acceptor. After being dried in vacuum, the latter was reacted with SBox donor **1.60**. At the end of the synthesis, the oligosaccharide can be cleaved off from the gold surface offering a useful potential alternative both for directed and combinatorial synthesis.

Tagged synthesis (soluble polymer supports, ionic, fluorous)

Soluble polymer supports, many of which are based on a polyethyleneglycol core, have also found their application in oligosaccharide synthesis. This method has emerged to address problems of the resin-supported synthesis associated with slow reactions and reactivity mismatch between unreactive solid-phase based and highly reactive solution-based reactants.^{474,475} These supports, and everything attached to it, are freely soluble in the reaction media, but could be precipitated by the addition of diethyl ether or other suitable solvent and recovered by filtration.⁴⁷⁶⁻⁴⁷⁸ Alternatively, nanofiltration or a size-exclusion separation offer other possible alternatives for separation of polymer-bound molecules and the rest of the reaction components.⁴⁷⁹ An elegant synthesis that combines advantages of the soluble polymer-supported technology and convergent building block strategy was applied to the synthesis of hexasaccharide **1.100** (Scheme 1.21).⁴⁸⁰ In this application, fluorenylmethoxycarbonyl (Fmoc) and diethylisopropylsilyl (DEIPS) are used as temporary substituents that could be removed with Et₃N and TBAF, respectively, without affecting the linker. The


polymer-bound intermediates obtained, such as **1.98**, could be purified by recrystallization from absolute ethanol.



Scheme 1.21. Synthesis of dimeric Le^x hexasaccharide using soluble polymer support

Amongst other improvements of the supported oligosaccharide synthesis, fluorous tags incorporating a long per-fluorinated alkyl chain allow the separation of all

fluorinated from non-fluorinated species by partitioning between perfluorohexanes and methanol (or toluene). For the synthesis of oligosaccharide **1.105** shown in Scheme 1.22.³⁵⁵




Scheme 1.22. A fluorous tag-assisted synthesis of pentasaccharide 1.10

Triol **1.101** was protected at the O-2, O-3, and O-4 positions with fluorous protecting groups, using DCC/DMAP-mediated coupling with the fluorous acid **1.102**. The resulting "tagged" compound was detritylated with CSA (camphorsulfonic acid) and LiCl to provide acceptor **1.104**. The latter was glycosylated with glycosyl donor **1.103** in

the presence of TMSOTf in EtOC₄F₉-diethyl ether to provide the respective tagged disaccharide. Desilylation with HF in pyridine followed by glycosylation were reiterated until the desired pentasaccharide **1.105** was obtained. More recently, less heavily fluorinated tags and compounds have found a broad application in automated synthesis (*vide infra*).

Another promising technique for tagged oligosaccharide synthesis that makes use of an ionic-liquid support has recently emerged.^{481,482} Ionic liquid-supported assembly also expedites oligosaccharide synthesis by eliminating the need for chromatographic purification of the intermediates. After the desired reaction of the tagged compound has been completed, the reaction mixture is concentrated. The excess of organic reagents is removed by extraction with low polarity solvents in which the tagged compounds are insoluble. Using the same principle, the inorganic reagents are eliminated with aqueous washings to afford the pure target compound tagged with the ionic liquid. This approach is illustrated by a synthesis that incorporates elements of an orthogonal strategy making use of alternating activations of STol and F leaving groups and the convergent approach depicted in Scheme 1.23.483,484 (1-Methylimdazoliumhexafluorophospho) acetyl ionic liquid tag was introduced via the corresponding 6-chloroacetylated starting material by reaction with N-methylimidazole and potassium hexafluorophosphate. The tagged mannosyl fluoride donor 1.106 was glycosylated with thioglycoside acceptor 1.107 to afford the IL-tagged disaccharide 1.110. Meanwhile, the analogous disaccharide 1.111 was produced using thioglycoside 1.108 as the donor and fluoride 1.109 as acceptor. Each disaccharide was split into portions, and the tag was removed from one portion. This gave a library of two disaccharide donors (1.110 and 1.111) and two disaccharide

acceptors (**1.112** and **1.113**) that were converged to produce two tetrasaccharides. One of the tetrasaccharides was untagged to produce glycosyl acceptor **1.114**. Finally, the synthesis is concluded with a [4+4] glycosylation between the tagged tetrasaccharide fluoride donor and thioglycoside acceptor **1.114** to afford the final mannan octasaccharide **1.115**. Gouhier and co-workers⁴⁸⁵ reported efficient 1,2-cis glycosylations using ionic liquid-supported thioglycoside in a two-directional^{419,420} manner.



Scheme 1.23. Convergent/orthogonal ionic liquid-tagged synthesis of mannans

1.3. Automated synthesis of oligosaccharides

All traditional oligosaccharides contain multiple glycosidic linkages. This linkage is obtained by a glycosylation reaction, which, in spite of significant progress overviewed in Section 1.2.1 remains challenging due to the requirement to achieve stereocontrol and suppress side reactions. Beyond that, as overviewed in Section 1.2.2, oligosaccharide synthesis offers further challenges that may require further manipulations between each glycosylation step. Due to significant advances, the chemical synthesis of many glycans can now be streamlined by using various methods and strategies in solution. Solid-phase and tag-assisted syntheses, which were overviewed in Section 1.2.3, eliminate the need for purifying intermediates and simplify the removal of excess reagents. Following significant advancements in the preparation of peptides^{429,486} and oligonucleotides,⁴³⁰ since 1971 solid-phase synthesis has become a viable means for the preparation of oligosaccharides.

However, there are significant differences between glycosylations in solution and solid-phase synthesis that particularly affect glycosylation. Among a plethora of leaving groups developed, a vast majority of glycosylations in solution make use of thioglycosides⁴⁸⁷⁻⁴⁹⁰ and TCAI.^{125,263,264,491,492} Solid phase synthesis commonly demands highly reactive TCAI, PTFAI^{265,493,494} or phosphates.^{148,495-499} A series of novel S- and O- imidates have been tested in reactions on solid phases, but their comparison with more common donors showed no drastic difference.^{438,464,500-502} The use of thioglycosides as donors in solid phase has also been reported (*vide supra*), but their relatively low reactivity profile and the requirement for stoichiometric promoters limit their application. Only recently, the use of thioglycosides in solid phases has been brought to practical realization.⁵⁰³

The discoveries made over the course of traditional synthesis, wherein all manipulations are performed manually have laid the basis for considering their automation as an aid in synthesis manipulations. Automation introduces an idea of operational simplicity, attractive for transferable methods and the development of accessible methods for glycan production is essential for further innovations and practical applications in all areas of glycosciences. The development of automated oligosaccharides synthesizers offers a potential of revolutionizing the way oligosaccharides are produces. Hence, the development of a broadly useful technology for scalable and transformative automation has emerged as a timely and significant area of research.


Many automation platforms make use of a computer interface and liquid handling equipment. This helps to minimize the human error factor and improve the reproducibility of results and transferability to other platforms.^{504,505} The underpinning idea of automation is that a successful automated sequence is recorded as a computer program that can then be reproduced with a "press of a button". In addition, many automation platforms implement some tool for real-time reaction monitoring, which, in turn, helps reduce the reaction time and the amount of reagents and solvents needed. This section is dedicated to the overview of major research efforts dedicated to the refinement and implementation of various automated platforms that have emerged in the past decade following early efforts to automate solution-phase manual synthesis by Wong^{376,506,507} and Takahashi,⁵⁰⁸ and Seeberger's peptide synthesizer-based platform for automated synthesis on solid phase.^{509,510} Discussed below is the development of "the first fully automated solid-phase oligosaccharide synthesizer" by Seeberger et al., initially in its experimental form,⁴⁵⁶ that in 2014 was marketed as Glyconeer 2.1. Also discussed are other automation efforts, primarily by Takahashi,^{511,512} Pohl,⁵¹³ Demchenko/Stine,⁵¹⁴ and Nokami and co-workers⁵¹⁵ that have been also emerging during about the same timeperiod.

1.3.1. Early developments

As aforementioned, Wong et al. assigned relative reactivity values (RRVs) to a wide library of building blocks that were then used for oligosaccharide assembly in onepot.³⁷⁶ The determination of RRVs was made with tolylthio glycoside donors activated in the presence of an NIS/TfOH promoter system under standardized reaction conditions. The reactivity data was then compiled into a computer program named Optimer³⁷⁶ that was used to synthesize various oligosaccharides.⁵¹⁶⁻⁵¹⁸ Refer to Scheme 1.10 for a relevant example of a reactivity-based oligosaccharide synthesis in one pot. Not being strictly automated, this approach brought up an idea of standardizing the reactions and using computers in quantifying and even predicting the reactivity of different building blocks. Fraser-Reid,³⁷⁴ Ley,^{375,519,520} and others⁵²¹ also created relative reactivity scales for oligosaccharide synthesis.

Takahashi et al. investigated a number of platforms for the automation of solution-based oligosaccharide synthesis in one-pot. While the Wong approach was strictly chemoselective, in applications executed by Takahashi, selective activation of different leaving groups was employed. In 2000, they adapted a semi-automated parallel synthesis instrument Quest-210 by Argonaut Technologies, to the one-pot synthesis of linear and branched oligosaccharides.⁵⁰⁸Thus, for the synthesis of trisaccharide **1.119** shown in Scheme 1.24, bromide donor **1.116** was selectively activated over thioglycoside acceptor **1.117** in the presence of AgOTf. The anomeric thiophenyl leaving group of the resulting disaccharide intermediate was then activated by the addition of NIS, TfOH, and glycosyl acceptor **1.118** to afford trisaccharide **1.119** in 79% yield over two steps. Takahashi and co-workers further extended this effort to a number of automation

platforms, such as L-COS by Moritex, that allowed to automate temperature control, stirring, and rate of reagent addition for deprotection and glycosylation steps.^{511,522512,523} The synthesizer could be supplemented with Combi Flash automated chromatograph to purify the final products



MBz = *p*-methylbenzoyl



Image used with permission from Professor John Rimoldi


Scheme 1.24. Solution phase automation of the oligosaccharide synthesis in one pot

using parallel synthesizer Quest 210

1.3.2. Peptide synthesizer-based automation

The automated approach Seeberger and co-workers relied on is the acceptorbound one, where donor and promoter are in liquid phase.⁵⁰⁹ Since the early developments are already discussed in detail in other review articles,^{25,498,510,523-525} we will only briefly overview the key milestones and achievements. The main focus in this discussion will be placed on the dedicated effort and progress towards the synthesis of difficult glycosidic linkages. The instrument introduced by Seeberger and co-workers was derived from an Applied Biosystems Inc. Model 433A peptide synthesizer. It was modified to allow for performing reactions at low temperatures that were deemed necessary for the oligosaccharide assembly.⁵⁰⁹ The solid support chosen was Merrifield resin, well known in the peptide world, for its good chemical inertness and ideal swelling properties in solvents utilized in glycan assembly. As it has been discussed previously, the choice of the linker is critical since it should resist conditions required during the synthesis. An olefin-type linker was chosen, for its versatility and good behavior in both acidic and basic media, as well as the mild cleavage conditions. In the first synthesis depicted in Scheme 1.25, octenediol-functionalized resin 1.121 was glycosylated with TCAI donor **1.120** (10-fold excess) in the presence of TMSOTf. The ester group was then cleaved using Zemplen conditions to generate the disaccharide acceptor. The glycosylation and deprotection steps were repeated until the oligomers of the desired length, up to decasaccharide, had been achieved. Each step was performed in two iterations, to avoid the formation of deletion sequences, and hence maximize the yield and simplify the final purification. The linker was the removed using Grubbs' catalyst to afford penta-, hepta- and decasaccharides **1.122a-c** equipped with the anomeric pentenyl

moiety. The high promise of the automated approach was evident immediately. Thus, heptasaccharide **1.122b** was synthesized in 24 h in 42% over-all yield. In comparison, whereas their previous manual synthesis was less efficient (9% over-all yield in 14 days).⁴⁴³




Scheme 1.25. The synthesis of oligosaccharides 1.122a-c using a modified peptide

synthesizer

After this first milestone and with the intention of extending the scope of the new technology, the subsequent efforts performed by Seeberger et al. focused on the synthesis of oligosaccharides containing various challenging linkages.^{458,526-528} This included sialic furanosides,⁵³⁰ 1,2-cis glycosides,⁶⁷ glycopeptides,⁴⁶⁰ acids.⁵²⁹ and branched oligosaccharides.⁵⁰⁹ The expertise acquired in the development of this methodology for the synthesis of various glycosidic linkages and sequences led to an impressive synthesis of Globo-H hexasaccharide.⁶⁷ As shown in Scheme 1.26, phosphate donor 1.123, was used to glycosylate hydroxylated resin 1.121 using TMSOTf as a promoter. The temporary Fmoc substituent at C-4 was removed using piperidine leading to the formation of the polymer-bound disaccharide acceptor. Fmoc is commonly used in oligosaccharide synthesis because it is highly stable in acidic conditions common for glycosylation and it is easily removable in mildly basic conditions. In this particular application, The cleavage product of Fmoc, dibenzofluorene, is a convenient marker to monitor the progress of the reaction via colorimetric assay.⁵³¹ The synthetic sequence consists of glycosylation steps with two or three iterations, using either glycosyl phosphate (1.123-1.126) or glycosyl PTFAI donors (1.127 and 1.128) followed by the deprotection of the Fmoc group with piperidine.


The final product **1.129** was cleaved off the solid support using ethylene in the presence of Grubbs' catalyst⁵³² in 30% yield. The stereoselectivity of the 1,2-cis glycosylation step was enhanced by using diethyl ether, which is known to favor the formation of axial products (*vide supra*). As aforementioned, Globo H is an important synthetic target of high biomedical significance for the development of anti-cancer vaccines.^{22,25,533-537} The biological importance of the Globo-H antigen is so widespread

throughout the scientific community that many synthetic approaches have been developed.^{63-66,68}



Scheme 1.26. Automated synthesis of Globo H hexasaccharide

Seeberger and co-workers also developed reaction conditions to achieve β mannosylation on solid phase using an automated approach.⁵³⁸ They started from the methodology developed by Crich⁵³⁹ involving 4,6-O-benzylidene protected mannosyl donors bearing a sulfoxide leaving group. In the original procedure, the donor is preactivated with Tf₂O and then reacted with the nucleophile. To adjust the procedure to the automated synthesis, the solvent adopted was dichloromethane, and the pre-activation was abolished. Unfortunately, although the selectivity of the test reaction was high, the yields were only moderate at best. On this basis, the next method of interest was the o-carboxybenzyl donor developed by Kim.¹⁵² After the initial study in the solution phase that revealed high yields and selectivities, the selected donor was tested on solid phase to synthesize a series of di- and trisaccharides. The stereoselectivity fluctuated from 3.5:1 to 9:1 in favor of the desired diastereomer, showing a partial erosion of the selectivity compared to that achieved in reactions in solution.



Scheme 1.27. Automated synthesis of β-mannosides

Further, to facilitate the elongation of a sequence containing a β -mannosidic linkage, the donor was equipped with a triisopropylsilyloxymethyl ether (Tom) at C-3.⁵⁴⁰ This protecting group is removed under the same mild conditions as those that make the silyl protecting group ideal for synthetic application. The Tom substituent, however, is


much less bulky than conventional silyl protecting groups, which is strategically significant for β -mannosylation.⁵⁴¹ The donor was successfully used in the synthesis of a trisaccharide containing multiple β -linkages in excellent yield and good selectivity (Scheme 1.27). Mannose trisaccharide **1.133** was isolated in 50% yield as a mixture of anomers (8:1:1.3) and the pure β , β -linked product was isolated by HPLC. Van der Marel, Codee, and their co-workers have successfully applied a similar approach to the synthesis of ManA oligosaccharides.⁵⁴²

1.3.3. Fluorous-tag assisted automated synthesis

Fluorous tag-assisted technology has emerged as a new and attractive approach to oligosaccharide synthesis with good prospects for automation. As discussed previously, extensively fluorinated species and highly fluorinated protecting groups allow for the separation of the fluorine-containing components, typically glycosyl acceptors, from the non-fluorinated glycosyl donors, with the principle of different phase partitioning between per-fluoroalkenes and methanol.³⁵⁵ On the other hand, Seeberger showed that the chemistry of solution-based microreactors, developed in the late 1990's, could be applied to carbohydrate chemistry.⁵⁴³ The benefits of using a microreactor include: safety, a much greater control of the reaction temperature, and compatibility with various analytical techniques. Microreactors are amenable to automation and the syntheses can be scaled up by increasing the number of reactors.

By merging these two technologies, fluorous-tagged synthesis and chemistry in microreactors, the synthesis of a homotetramer **1.136** was accomplished as depicted in Scheme 1.28.⁴⁹⁷ Three different syringe pumps delivered the solutions through the inlets

into the mixing zone. The concentration can be controlled by the concentration of the original solution and the flow-rate at which each reagent is delivered into the system. The reaction occurs inside the reaction loop. Glycosyl phosphate donor **1.134** was first glycosidated with fluorous tag **1.135** in the presence of TMSOTF.



Scheme 1.28. Fluorous tag supported synthesis of a tetrasaccharide 1.136 in a microreactor

This was followed by the removal of the Fmoc group with piperidine and TBAF to afford the fluorous monosaccharide acceptor. Tetrabutylammonium fluoride proved necessary for removal of the 6-O-TMS by-products. The latter was glycosylated with donor **1.134** and the deprotection-glycosylation sequence was repeated until the desired

compound has been obtained. The product was then cleaved off from the fluorous support by the treatment with Grubbs' catalyst to provide tetrasaccharide **1.136**. The reaction can be followed by pairing the reactor with different detection systems including UV-vis detectors, IR or mass spectrometers.




Image used with permission from Victoria Kohout (Professor Nicola Pohl's group)

Scheme 1.29. Automated synthesis of pentamannose 1.140 using fluorous support

The reaction times for the glycosylations were 20 sec for the formation of the disaccharide, and 60 sec each for the tri- and tetrasaccharides. The yields for the reactions after purification were 97, 90, and 95% for the di-, tri-, and tetrasaccharides, respectively.

The Pohl group applied the fluorous tag-assisted glycosylation approach to developing an alternative automation technology. This was accomplished by using a commercially available automated liquid handler and the fluorous solid phase extraction (FSPE) technique (Scheme 1.29).⁵¹³ The handler was modified to accommodate cartridges for the FSPE. In this approach, the fluorous-tagged glycosyl acceptor **1.138** was glycosylated using an excess of TCAI donor **1.137** in the presence of TMSOTf as the promoter. The obtained tagged disaccharide was then separated using an automated three-step FSPE. This consists of loading into a separation column, and elution of all fluorine-free components using 20% solution of water in methanol. At last, the retained fluorinated molecules are released from the solid-phase using methanol or THF, which are fluorophilic solvents.

This procedure can be automated by using commercially available devices capable of applying a positive pressure at the top of the column or, alternatively, vacuum at the exit of the eluate. After purification, the disaccharide was treated sequentially with TBAF and hydrazine to remove TMS and Lev protecting groups, respectively. The resulting triol acceptor **1.139** was tri-glycosylated using TCAI donor **1.120**, to afford the desired pentasaccharide **1.140** in an excellent yield of 92%.




Figure 1.5. The split-valve set-up for the alternate-pump system

In an effort to pair an automated purification to the automated solution-phase synthesizer, Pohl's group worked on HPLC as the preferred instrument to accomplish this purpose. An alternate-pump system that differs from a direct-pump design because it is based on recycling the analyte through two identical columns using a 10-port switch valve was utilized.⁵⁴⁴ The advantage of this alternate-pump design is that peak broadening is avoided. The broadening is caused by the internal volume of the mobile-phase solvent pump the analyte goes through, when pumped back into systems with direct-pump design. The valve switches between two different positions, A and B, as shown in Figure 1.5. Starting from position A, the compound elutes through the first column and the UV detector. When the analyte reaches the half of the second column, the


system switches to position B, so that the second column is directly connected with the first one. When the compound travels back to column 1, halfway through column length, the system switches back to position A and the system is now back to the original set up, with the UV detector between column 1 and 2. Thus, the analyte passes through the detector every odd-numbered column, so after every run through column 1, for its purity to be assessed.

After choosing the purification set-up, the most suitable stationary phase was selected. Three different phases were considered: the commonly used C5, a phenyl hexyl, and a pentafluorophenyl (PFP) modified silica. The latter two were found superior in the separation of both monosaccharides and oligosaccharides with methanol as organic modifier. In particular, after numerous tests, the PFP-modified silica was found to be more suitable for the separation of acylated monosaccharides and aromatic group protected compounds, whereas the phenyl hexyl-modified silica worked better towards acyl protected oligosaccharides, respectively.⁵⁴⁵ This new methodology was used to purify the product of a reaction conducted in the automated synthesizer. The authors detected that sugars equipped with achiral linkers proved to be the most challenging compounds to purify through manual separation. In this case the product was successfully purified using a PFP-modified stationary phase and seven effective columns.

Over the recent years, the Pohl group has applied the fluorous tag assisted automated synthesis to the synthesis of a number of glycan sequences.⁵⁴⁶⁻⁵⁴⁹ Among this, is the synthesis of manno oligosaccharides connected via challenging β -linkages. This approach was based on the C-5 carboxylated mannosyl donor methodology developed by van der Marel for manual reactions.³⁰⁷ At first, the synthesis of 1,4-linked β -

oligomannosides was automated using alternative glycosylation, TBS-deprotection steps to achieve the mannuronic hexasaccharide **1.144** sequence (Scheme 1.30).⁵⁴⁷ After each glycosylation and deprotection step a FSPE is performed before reiterating the procedure to elongate the chain.

As shown in Scheme 1.30, mannuronic acid donor **1.141** was used to glycosylate fluorous-tagged glycosyl acceptor **1.142** in the presence of TMSOTf as the promoter. The resulting disaccharide was treated with TBAF and acetic acid to remove the TBS protecting group and was subsequently purified using the automated FSPE. The sequence was repeated three times with the automated purification. The fourth iteration, followed by the benchtop purification, afforded the tagged compound 1.142. The latter was reinjected into the synthesizer, the TBS group was removed using tetrabutylammonium fluoride, and the resulting compound 1.143 was purified using FSPE. At the end of the assembly, the carboxyl groups are reduced with DIBAL-H using the automated platform to afford the desired β -linked hexamannose **1.144**. More recently, Tang and Pohl applied a similar approach to the synthesis of other positional isomers of mannans.⁵⁴⁹ For the synthesis of 1,2- and 1,3 linked oligomers, glycosyl donors bearing an easily removable temporary PMB substituent at the respective positions were employed. At the end of the sequencing the mannuronates were reduced with lithium triethylborohydride before the final benzyl removal leading to excellent yields. In the case of the synthesis of 1,6-linked mannans, the reduction of the carboxylic group is performed before the subsequent glycosylation instead of the protecting group removal.⁵⁴⁹




Scheme 1.30. The automated synthesis of β -mannuronan and β -mannan

Excellent stereoselectivity for the glycosylation of all positions has been achieved; however, the elongation of the 1,2-, 1,3- and 1,6-linked oligomannans beyond trisaccharides proved to be difficult. The reasons for this are not clear, but it could relate to the increased steric demand as the size of the acceptor increases.

This approach was also applied to the synthesis of branched, all-mannosylated N-linked glycan structures.⁵⁴⁶ The core N-glycan structure is characterized by the presence

of a β -mannoside carrying two α -mannosides at O-3 and O-6 (refer to Figure 1.1). As shown in Scheme 1.31, the formation of the difficult linkage is addressed using the strategy of the C-5 carboxylate methodology (*vide supra*). The branching point has a PMB to mask O-3 and the carboxylic group working both as directing and protecting group.



Scheme 1.31. Automated sequence to obtain a branched oligomannan fragment

from N-glycans


The automated sequence consists of the glycosidation of donor **1.145** with the fluorous tag **1.146**. *p*-Methoxybenzyl group is removed in the presence of CAN, followed by the automatic purification of the tagged monosaccharide using the FSPE. Further benchtop purification to eliminate the undesired α -isomer afforded mannuronate **1.147** in

78% yield. The latter was reduced to obtain free hydroxyl at the C-6 position and the product was purified. The subsequent glycosylation performed with six equivalents of donor allowed for bis-mannosylation. Benchtop Zemplen reaction afforded trisaccharide **1.148** in 50% yield. The synthesis was completed by removing the benzyl group and the fluorous tag.

1.3.4 Glyconeer 2.1 as a dedicated oligosaccharide synthesizer

After proving that a peptide synthesizer-based apparatus may be a viable platform for oligosaccharide synthesis, Seeberger and co-workers took one step further. In 2012, they reported the "first fully automated solid-phase oligosaccharide synthesizer".⁴⁵⁶ This dedicated apparatus is a sophisticated system, consisting of a syringe pump-driven part and a solenoid valve-driven part. The reaction vessel is double-jacketed to allow for the circulation of the cryogenic fluid. It is connected to the inlet tubes to avoid splashing of the solution injected and to allow for washing the vessel walls. The bottom of the vessel is equipped with a porous glass filter and pipelines that can be directed to waste or to a fraction collector. An exhaust opens only if a positive pressure of argon is used. This also helps to assure the compete isolation from external atmosphere. The system is built with two syringe pumps, but only one is used.

It is filled exclusively with 1,2-dichloroethane to avoid solvent contamination. Four rotary valves are designated to regulate the delivery of building blocks and reagents for activation and deprotection. The solenoid valves are used to deliver solvents, mix reactions solutions, and manage the waste delivered from the reaction vessel.




Scheme 1.32. Automated synthesis of N-glycan core using the dedicated synthesizer

In addition to the parts already described, a cryostat operating between -50 °C and -90 °C and a fraction collector are important features of the synthesizer. The instrument is paired with a computer that helps to design, record and control glycosylation and deprotection protocols. This set-up provides complete automation for reactions, temperature control, cleavage, and collection of the final product. The complexity and the number of channels available, combined with the positive pressure of Argon throughout the whole system make the Glyconeer 2.1 the most complete and versatile synthesizer currently available, allowing for achieving a significant variety of reaction conditions. The versatility of the new system was tested by performing the synthesis of a range of oligomers, including a high mannose type branched glycan **1.153** as illustrated in Scheme 1.32. The new linker **1.150** was also developed for this purpose. This linker helps to assure better stability during the glycosylation conditions.

The chitobiose portion of the core pentasaccharide sequence was assembled first, using glycosyl donor **1.149** for both units. After the two glycosylation-deprotection cycles a challenging β -mannosyl residue was introduced by utilizing glycosyl donor **1.131** equipped with the 2-(hydroxycarbonyl)benzyl leaving group originally developed by Kim and co-workers. Subsequent treatment with TBAF to remove the silyl protecting group at C-3 and a selective opening of the benzylidene group afforded the desired 3,6-diol, which was subjected to bis-mannosylation using glycosyl donor **1.151** to afford a branched pentasaccharide. Cleavage from the solid support was performed using MeONa affording the precursor **1.152** as a mixture of two anomers ($\alpha/\beta = 1/3$) in 3.5% overall yield. Preparative HPLC separation was used to isolate the desired product, which

underwent global deprotection using hydrogenation to afford the final product in 78% yield.



Scheme 1.33. Automated synthesis of manno triantamer 1.160

Subsequently, relying on a similar technology, Seeberger et al obtained an α -(1 \rightarrow 6)-linked oligomannan sequence containing 30 monosaccharide residues (triantamer).⁵⁵⁰ To achieve this challenging target, a modified Merrifield resin **1.155** carrying a photocleavable linker was used. The solid support was repeatedly glycosylated using phosphate donor **1.154** in the presence of TMSOTf as a promoter (Scheme 1.33).

To avoid the formation of many deletion sequences and to make the final separation easier, the unreacted hydroxyls were capped with Ac₂O in pyridine. Piperidine in dimethylformamide was used for the cleavage of the Fmoc protecting group from C-6 to afford the next generation glycosyl acceptor. The presence of benzoyl esters on the other positions allowed for complete stereoselectivity of the glycosylation reactions and high yields. The 29-mer resulting from 28 iterations of the glycosylation-cappingdeprotection sequence, was then glycosylated with donor **1.156**, equipped with a spacer to perform a very effective cap-and-tag purification. Therefore, upon removal of the oligosaccharide 1.158 from the solid support, a conjugation step to magnetic beads through the *ɛ*-aminocaproic ester spacer was performed. The purification step consisted of a magnetic separation of the tagged 30-mer **1.159**, followed by release using Zemplen conditions also to remove benzoyl protecting groups. Finally, hydrogenation was performed to free the terminal amine of the linker from the Cbz group, resulting in the fully unprotected 30-mer **1.160**, obtained in 1% yield, which corresponds to 96% yield per synthetic step.

In the further development of the Glyconeer synthesizer, Seeberger et al successfully synthesized mannosyl 50-mer **1.162** (penindamer), the longest sequence ever obtained with a solid phase automated approach.⁵⁵¹ The approach is similar to the one

used for the synthesis of the 30-mer, although an important methodological advancement has emerged with the implementation of the ethylthio glycoside as glycosyl donor. In this application, the glycosyl donor 1.161 was activated with NIS in the presence of TfOH at -40 °C. The temperature was immediately ramped up to -20 °C and the reaction was completed in 20 min. The study of the most suitable building block brought highlight to a donor carrying a permanent benzoyl group at position 2, to assure neighboring group participation and therefore high selectivity. C3 and C4 are protected with arming benzyls³⁷⁰ and position C6 is carrying a temporary Fmoc group, removed with Et₃N in DMF every iteration. To facilitate the purification process, which revealed to be challenging for deletion sequences longer than n-5, a capping step was introduced after every glycosylation step. Furthermore, in the latest cycles, from 46 to 50, a second glycosylation was added to the sequence to ensure even better conversion during the elongation (Scheme 1.34). Since these additional steps are expensive in terms of time, a 25-mer was synthesized as a proof of concept, to show that the capping steps become necessary only in the latest stages of the sequence. The approach proved to be successful allowing an easy separation of the desired product from the shorter oligomers and a higher average yield for each step. The purification was achieved by HPLC before the deprotection steps and later on using dialysis and size exclusion chromatography.

For expanding the scope of the automated oligosaccharide synthesis, the Seeberger group also worked on refining reaction conditions for the formation of other challenging glycosidic linkages. For example, a number of efforts were dedicated to the formation of sialylated oligosaccharides. Previously, sialic acid containing disaccharides were pre-synthesized and then used as building blocks in the convergent solid phase synthesis.⁵²⁹





Image used with permission from Professor Todd Lowary

Scheme 1.34. Automated synthesis a 50-mer 1.162 using Glyconeer 2.1

More recently,⁴⁹⁹ the use of more sophisticated sialyl building blocks based on the 4,5-oxazolidinone chemistry²³⁸⁻²⁴⁰ allowed for direct sialylation in the synthesizer. These new sialyl donors were also equipped with chloroacetyl protecting groups at position C-7 and C-8 and position C-9 was protected with Fmoc. A similar protecting group pattern, along with the phosphate leaving group, showed good levels of reactivity in sialylation reactions in solution developed by Wong and Wu.⁵⁵² After optimizing the glycosylation conditions and reaction temperature this approach was successfully applied to the automated synthesis of α -(2,6)-linked sialosides.




Scheme 1.35. Automation of the sialylation reaction

A representative example is shown in Scheme 1.35 wherein the target disaccharide was synthesized from building blocks **1.161** and **1.162**. The immobilized disaccharide **1.165** was obtained from the reaction of the photocleavable linker **1.155** with donor **1.163** in the presence of TMSOTf.

Capping of the unreacted linker with acetic anhydride in pyridine, followed by removal of the Fmoc protecting group with triethylamine (TEA) in dichloromethane afforded the immobilized acceptor. Phosphate sialyl donor **1.164** was then activated in the presence of TMSOTf. Finally, the photocleavage provided the target compound **1.165** in 10% overall yield. The yields for the formation of α -(2,3)-linkages were lower. Another approach to sialooligosaccharides involved a chemoenzymatic synthesis.⁵⁵³

According to their strategy a desired oligosaccharide sequence was assembled using the synthesizer first. After the cleavage from the solid support, the target compound underwent the entire protecting group removal followed by enzymatic sialylation. This step was accomplished in the presence of α -(2,3)-sialyltransferase from *Pasturella Multocida* that was originally introduced by the Chen group.⁵⁵⁴ As a result, the desired α -(2,3)-linked products were isolated in in 78-89% yields.⁵⁵³



Scheme 1.36. Automation of 1,2-cis glycosylation

Seeberger and co-workers also studied the automated synthesis of 1,2-*cis*-linked residues that are abundant both in microbial glycans and in the mammalian glycome. In

particular, reactions assisted by the remote group participation were of particular interest to this application. An overview of compounds **1.170-1.176**, synthesized using the Glyconeer 2.1, is depicted in Figure 1.6.





Figure 1.6. Representative 1,2-cis-linked oligosaccharides synthesized using

Glyconeer 2.1

A systematic study of differently protected galactosyl and glucosyl donors was performed.⁵⁵⁵ The highest stereoselectivity was obtained with the galactosyl donor carrying acetates at the C-3 and C-4 positions. Glucosyl donor required esters at the C-3 or C-6, and depending on the desired propagation site, either a removable Fmoc carbonate or more permanent acetate were used. A representative example is the all α -linked oligomer **1.169** depicted in Scheme 1.36, achieved from glucosyl donors **1.166**, **1.167** and **1.168**. Thus, donor **1.166** was glycosylated in the presence of NIS and triflic acid to the photocleavable linker. The Fmoc protecting group was removed with triethylamine in DMF to obtain the immobilized monosaccharide acceptor.



Scheme 1.37. Automated synthesis of β-manno-linked dodecasaccharide 1.179

The sequence was repeated to obtain the disaccharide, then donor **1.167** was glycosylated in the previous conditions and Fmoc protecting group was removed, affording the immobilized trisaccharide. Finally, donor **1.168** was reacted with the

trisaccharide acceptor and photocleavage was performed to afford the final tetrasaccharide **1.169** in 20% overall yield and with excellent α selectivity.


Among other useful methodologies for the synthesis of 1,2-*cis*-linked oligosaccharides is the solid-phase synthesis of β -mannosides developed by Codee and co-workers.⁵⁴² Glyconeer 2.1 was used as a platform for automation of glycosidation of mannuronic acid donor **1.177** equipped with a *N*-phenyltriflouroacetimidoyl leaving group. Glycosylations promoted with TfOH at -40°C produced oligosaccharides in high yields and complete β -selectivity. Thus, as depicted in Scheme 1.37, a 1,2-*cis*-linked dodecasaccharide **1.179** was synthesized in 11% overall yield. Donor **1.177** was first coupled to linker **1.178** and each glycosylation step was repeated twice with about 90% coupling efficiency. The Lev protecting group removal was achieved with hydrazine acetate in a mixture of pyridine and acetic acid. Upon completion of the assembly, cleavage from the solid support was performed using a metathesis reaction with ethylene in the presence of Grubbs I catalyst. Complete selectivity of the target compound was proven by NMR.

Within a plethora of applications for the Glyconeer 2.1 automated synthesizer, there has been the synthesis of a number of oligosaccharides containing furanosyl residues. The first result accomplished was the synthesis of a series of linear and branched oligoarabinofuranides,⁵³⁰ as depicted in Scheme 1.38. Thus, ethylthio glycosyl donor **1.180** is glycosidated with linker acceptor **1.150**, followed by removal of Fmoc group at C-5 in the presence of piperidine in DMF. The donor **1.181**, used for branching, is coupled to the immobilized monosaccharide in the presence on NIS and triflic acid, followed by treatment with piperidine in dimethylformamide to remove both Fmoc

protecting groups. The resulting disaccharide was treated with donor **1.180** in the presence of NIS and TfOH, followed by deprotection step, in two iterations, to obtain the immobilized pentasaccharide. Finally, treatment with sodium methoxide in methanol and catalytic hydrogenation afforded the target compound **1.182** in 63% yield. The synthesis was completed in only 42 hours. The first application of the use of furanose building blocks in solid phase was the synthesis of oligoxylanopyranosides.⁵⁵⁶ These structures are based on a linear series of β -(1,4) linked xylosides with the furanoses as branches in selected position. The oligosaccharides obtained in good yield are used to study the binding preference of anti-xylan monoclonal antibody⁵⁵⁷ on microarray systems.⁵⁵⁸

The other two series of compounds synthesized by Seeberger and co-workers are type I and II arabinogalactan (AG).^{559,560} These are present in plant cells and they can be useful to study arabinogalactan-directed antibodies binding specificity. Type I is present in pectic polysaccharide as a decoration of the main backbone and characterized by β -(1,4) linkages connecting Gal units for the linear chain, and the branching is achieved by α -(1,3) bonds between arabinofuranosides and galactosides.⁵⁶¹


Type II, on the other hand, is present as a highly branched polysaccharide attached to a hydroxyproline-rich peptide structure. The linear backbone of the glycan is based on β -(1,3) linkages while the branching occurs through β -(1,6) bonds.⁵⁶² The arabinofuranoses present on the branching are connected by α -(1,3) linkages as in the case of the Type I AG. The target compounds were obtained in good to excellent yields. The effort in the assembly of various arabinofuranosides containing oligosaccharides culminated in the formation of two complex structures containing the former and mannopyranosides.⁵⁶³



Scheme 1.38. Synthesis of the branched hexasaccharide composed of multiple arabinofuranosyl residues

These oligosaccharides are present on the cell surface of the *Mycobacterium tuberculosis*⁵⁶⁴ and constitute a synthetic challenge for their complexity. Three different building blocks are required for the assembly of the product. They are all ethylthio glycosides and protected with Fmoc on the position of elongation and branching. Another important application of this dedicated system is to the synthesis of different families of GAGs (glycosaminoglycans). These compounds are connected to a transmembrane core protein, with the function of transducing signals to the interior of the cells from extracellular environment.¹⁷

The first target was chondroitin sulfate, containing β -D-glucuronic acid and N-acetyl- β -D-galactosamine, presenting various sites of acetylation and sulfation. The advantage of the solid phase in the preparation of this polysaccharide is the establishing of a general method that with a few building blocks allows reaching a wide number of targets, hence the possibility of better understanding their biological relevance.




Scheme 1.39. Synthesis of a chondroitin sulfate

The selected chondroitin sulfate-A and chondroitin sulfate-C hexasaccharides are similar in structure and differ only in the site of sulfation along the chain. As in cases previously described here, donors contain the phosphate leaving group, the selected protecting group for the chain elongation is Fmoc, allowing mild cleavage conditions, while Lev esters mask the hydroxyl used for the introduction of sulfates. The amino group in the galactosyl building block **1.183** carries a trichloroacetate as a protecting group and the linker **1.155**, already utilized by Seeberger and co-workers, is UV labile. The synthetic sequence is based on the coupling step with alternating GalNAc **1.183** and GlcA **1.184** building blocks followed by deprotection of the Fmoc group. The acetylation at the end of the chain, the Lev group removal and the sulfation are also performed using solid phase protocols, affording the desired compound **1.185** in good yield (Scheme 1.39).

The second target was dermatan sulfate, which is a polysaccharide composed by a disaccharide repeating unit, consisting of N-acetyl- β -D-galactosamine and L-iduronic acid.⁵⁶⁵ Seeberger et al. developed a synthesis of a di- and a tetrasaccharide using the Fmoc protection at the oligosaccharide propagation position and the Lev ester at the future sulfation sites. Galactosamine is readily available in a small number of steps while iduronic acid requires a more complex synthesis.⁵⁶⁶ Both donors are equipped with phosphate leaving group and the linker utilized is the photocleavable one found in many other automated assemblies developed by the group. The yield of the two compounds obtained, a disaccharide and a tetrasaccharide, are high and consistent even when the larger acceptor is involved, averaging both 93% for each step.⁵⁶⁷

Other families of GAGs studied by Seeberger and co-workers include oligo-*N*-acetyllactosamine and keratan sulfate.⁵⁶³ The automated glycan assembly was employed to achieve a fast and facile access to a large library of compounds. For this purpose, the photocleavable linker and three orthogonal protecting groups (Fmoc, Lev and Nap) have been utilized. The orthogonal protecting groups gave a streamlined access to keratan

sulfate oligosaccharides with differential sulfation sites. The obtained products were printed on microarrays and used to study the interaction with viral receptors. One of the keratan sulfate tetrasaccharides was identified as a specific interaction partner of receptor AAVrh10.



Scheme 1.40. The synthesis of hyaluronic acid fragments


Codee and co-workers reported the synthesis of different chains of hyaluronic acid (HA), another common class of GAGs.⁵⁴² HA is a major component of connective tissue and extracellular matrix. Besides structural functions, HA has a role in inflammatory response, cell-cell adhesion and recognition. Being able to access fragments of HA would be beneficial for studying its interaction with protein CD44, related to tumors proliferation. Common challenge for all GAG syntheses is the low reactivity of building blocks that has been addressed by applying them in large excess. As depicted in Scheme 1.40, the assembly started with PTFAI glucosamine donor **1.186** that

was coupled with linker **1.178** in the presence of TfOH. The chain is then elongated with the removal of the temporary Lev protecting group and subsequent glycosylation with disaccharide donor **1.187**. After repeating the glycosylation-deprotection cycle, the products are released through olefin metathesis and purified using HPLC to afford the desired hepta-, undeca- and pentadecasaccharide in 26, 32 and 18% yield, respectively.

To show the versatility and the wide range of application the automated glycan assembly system is suitable for, Seeberger and co-workers developed a sequence where peptide and oligosaccharide solid phase syntheses are coupled.⁴⁶⁰ Homogeneous glycopeptides are extremely valuable, because regularly these compounds are isolated in heterogenous mixtures that make difficult the determination of structure-activity relationship. Normally the strategies for construction of a glycopeptide require the pre-formation of glycosylated amino acids in solution phase.^{368,568} The presented approach is advantageous because it utilizes a simple building block, readily available and with minimum synthetic requirements. Elongation of the peptide chain proceeds through Fmoc approach, using HBTU as coupling reagent and piperidine to remove the protecting group. Serine and threonine side chains are protected as *tert*-butyl or trityl ether to be removed before the glycosylation step, achieved using TMSOTF.

To illustrate the versatility of the approach, three glycopeptides were synthesized, including compounds with 1,2-*cis* linkages, requiring elongation on the glycan side and with more than one glycosylation site. All the syntheses were performed in good yields and selectivity and established the Glyconeer as a promising system to address the challenges in glycopeptides assembly (Scheme 1.41). The possibility of accessing large and complex oligosaccharides is particularly powerful in terms of understanding the

specificity of various enzymes. The knowledge acquired through the synthesis of furanose-containing oligosaccharides was useful to study the xylan-degrading enzyme since the arabinoxylans are suitable for a large number of applications, including biofuels and nutritional and pharmaceutical functions.




Scheme 1.41. Glycopeptide synthetic sequence

The synthetic approach is based on the Fmoc strategy for the elongation of the linear chain and using fully orthogonal Nap and 2-(azidomethyl)benzoyl (Azmb) for the branching. After incubation with the enzyme, the fragments were studied using LC-MS.⁵⁶⁹

A similar strategy has been used to study the hydrolysis of mixed-linked glucan chains by lichenase enzyme. This family of glycans is composed by linear 1,3- and 1,4-linked glucans, which form a gel-like material, important for the structural functions of the cells. Although the synthetic approach is similar to the general one used by Seeberger and co-workers, the formation of the 1,3- linkages was particularly challenging, requiring two glycosylation steps to avoid the formation of the deletion sequence. Again, the oligosaccharides were incubated with the enzyme and the digestion product analyzed via LC-MS, revealing new important features of the behavior of the enzyme.⁵⁷⁰

The synthesis of oligosaccharide libraries has become one of the most useful applications of Glyconeer 2.1. In addition to the aforementioned examples, Seeberger and co-workers have recently synthesized libraries of homo- and heterooligomers of mannose, glucose and glucosamine. The purpose of the library was to understand the correlation between the oligomer conformation and their macroscopic properties.⁵⁷¹

A combination of the automated glycan assembly and computational studies revealed a significant structural diversity within a series of synthetic oligomers, even within the ones comprising the same structural constituents albeit with the different position of the glycosidic linkages. The study clearly showcases the power of the automated synthesis as a tool for a better understanding of the biological significance of oligosaccharides.




Scheme 1.42. The synthesis of a representative galactosylated xyloglucan for generating of oligosaccharide libraries

Pfrengle and co-workers also contributed to the field by synthesizing numerous libraries of plant-related oligosaccharides.^{556,569,572} Two significant examples include the assembly of arabinoxylans and galactoxyloglucans, both being epitopes for monoclonal antibodies that could be used as probes to study the cell wall properties. The approach for the synthesis of both libraries is similar. The backbone is assembled using dibutyl phosphate donors, and the branching is achieved using ethyl thioarabinofuranosides or galactosyl phosphates. The xylogluco disaccharides were presynthesized prior the automation step to bypass the challenge of introducing 1,2-*cis* linkage at the later stage of the synthesis.

As depicted in Scheme 1.42, the assembly of the galactosylated xyloglucan **1.200** involved the reiteration of the glycosylation and deprotection steps with glucose building block **1.197**. The leaving group was activated with TMSOTf and the temporary Fmoc group was removed with triethylamine in dimethylformamide. The immobilized trisaccharide was then glycosylated with the preassembled disaccharide **1.198** to obtain the xylose-decorated sequence. At last, the oligosaccharide was further elongated using galactosyl donor **1.199** and the target was cleaved and deprotected to afford the desired hexasaccharide **1.200** in 7% overall yield.

1.3.5. HPLC-assisted oligosaccharide synthesis


Demchenko, Stine, and their co-workers developed a new experimental set-up based on an unmodified HPLC instrument. The system consisted of an Omnifit column containing pre-swelled beads of the TentaGel-NH₂ polymer. The column was then connected to the HPLC system consisting of a ternary reciprocating pump, a UV detector with variable range and a computer to operate the instrument through regular HPLC management software.⁵¹⁴ The glycosyl acceptor was already loaded on the resin prior to the insertion into the column and two different solutions containing glycosyl donor and promoter were mixed in the pump head and then activated donor was delivered to the column. The reaction time needed for such a protocol was short, typically 30-60 minutes and afterwards the system was purged with fresh solvent leaving the clean resin carrying the disaccharide, which could be further elongated through deprotection-glycosylation cycles. The efficacy and the versatility of the HPLC approach has to be proven, but the first application revealed its potential.



Scheme 1.43. HPLC-assisted automated oligosaccharide synthesis

As shown in Scheme 1.43, the synthesis of pentasaccharide **1.203** was successfully accomplished starting from the TentaGel-NH₂ resin preloaded with acceptor **1.202**. However, the loading could also be performed directly using the HPLC sequence. Donor **1.201**, equipped with benzoyl ester in a neighboring position to ensure stereoselectivity and Fmoc protecting group at C-6 for chain elongation, was pumped into the system together with a solution of TMSOTf as promoter. After 1h of recirculation of the solution, the system was washed with dichloromethane, followed by the deprotection of Fmoc performed with piperidine in DMF for 5 minutes, and again a sequential purging step using dichloromethane. The glycosylation-washing-deprotection-washing sequence was repeated until oligosaccharide of the desired length was obtained. After that, the product was cleaved from the solid support by using a recirculating solution of NaOMe in

methanol-dichloromethane to afford pentasaccharide **1.203** in 62% yield in 7 h total time (vs 14 days for manual synthesis).




Scheme 1.44. The use of an autosampler as the mode for reagent delivery for the

HPLC-based automation

The most recent contribution by Demchenko and Stine is the use of autosampler in a new HPLC system as solution for delivering the promoter in the glycosylation step.⁵⁰² Autosamplers in modern HPLC have the advantage of being easily programmable to enhance automation of the polymer-supported synthesis. The study covered many aspects, starting from the efficiency of different solid phases, revealing JandaJel to be the most attractive for HPLC-mediated synthesis. The effectiveness of different leaving groups ranging from reactive O-imidates and phosphate to less reactive thioimidates and thioglycosides was investigated. The chosen TCAI allowed to obtain pentasaccharide **1.206** in 67% yield over three glycosylation steps and two deprotection steps (Scheme 1.44).


To address some drawbacks of the solid phase synthesis using polymer supports, Demchenko and Stine introduced the Surface-Tethered Iterative Carbohydrate Synthesis (STICS, *vide supra*).⁴³⁸ For the purpose of the automation experiment small pieces of nanoporous gold were integrated in the Omnifit column,⁴³⁷ and the synthesis was conducted as in polymer-supported HPLC-based synthesis. The immobilization of the glycosyl acceptor **1.208** on the support is achieved using sulfur-containing linkers, such as lipoic acid, and the glycan assembly is performed. The HPLC pump was used to circulate donor **1.207** through the Omnifit column containing nanoporous gold chips (Scheme 45). To investigate the effect of the spacer, C4, C8 and C8OC8 were considered, and the series of parallel experiments showed that longer chain spacers between the glycosyl acceptor and the lipoic acid anchor increase the yield of disaccharide **1.209** from 60% to 90%.⁴³⁷



Scheme 1.45. HPLC-assisted surface-tethered synthesis of disaccharides 1.209

1.3.6. Electrochemical activation platform for automation

Chalcogenoglycosides that can be activated by electrochemical methods⁵⁷³⁻⁵⁷⁸ served as a novel automation platform introduced by Nokami and co-workers.⁵¹⁵ The glycosylation step is based on electrochemical activation of thioglycoside donors with the formation of the corresponding glycosyl triflate as the reactive intermediate. A dedicated synthesizer was developed specifically for this application, using commercially available components. Thus, the instrument was equipped with a chiller and a cooling bath, a power supply for constant current electrolysis, and a syringe pump. The assembly and all the hardware are controlled using the LabVIEW software. The reaction occurs in a H-type divided cell, with a carbon-felt anode and a platinum plate cathode. The glycosyl donor is activated in the anodic chamber, and the acceptor is added using the syringe pump.



The annotated image is used with permission from Professor Toshiki Nokami


Scheme 1.46. Automated solution phase synthesis using electrochemical activation

In the original application, the synthesis of a series of β -(1 \rightarrow 6)-linked N-acetylglucosamino glycans were assembled. As depicted in Scheme 46, the optimized aryl thioglycoside donor **1.210** was preactivated via anodic oxidation at -80 °C and 1.0

F/mol at 1.73 Volts for 40 minutes, resulting in the formation of the anomeric triflate **1.211** which reacted with the glycosyl acceptor **1.212** at -50-60 °C for 30 minutes. The obtained disaccharide **1.213** was then ready for activation, since the reaction proceeds with the growth of the glycan on the donor side, and the illustrated preactivation-glycosylation steps were repeated to synthesize the pentasaccharide **1.214** in 31% overall yield, with an average of 75% yield per cycle. The whole assembly required 10 hours.⁵¹⁵

Given the potential of such a method, which has the advantages of both the solution-phase and the automated synthesis, Nokami and co-workers recently developed a few additional applications for the electrochemical activation of chalcogenides.⁵⁷⁹⁻⁵⁸²One target reported by Nokami was TGM-chitotriomycin,^{579,580,582} a molecule of interest for the development of safer pesticides due to its selectivity in the inhibition of fungal and entomic glucosaminidases. This 1,2-*trans* linked glucosamino glycan was assembled using a similar approach affording a tetrasaccharide product in 41% overall yield.

Another molecule of interest was a GPI anchor core trisaccharide, an oligomannoside of interest to show the advantages of novel strategies for oligosaccharide synthesis.⁵⁸¹ The study started with the evaluation of the oxidation potential of different building blocks, all characterized by a participating group at the C-2 or the C-6, such as acetyl or pivaloyl. The studied compounds were compared to the 4-fluorophenyl 2,3,4,6-tetra-O-benzyl-1-thio- α -D-mannopyranoside and to better understand the changes in the potential DFT calculations were performed.



Scheme 1.47. Electrochemical approach to the core trisaccharide of GPI anchors

To verify the selectivity of the selected donors a test was performed with the assembly of different disaccharides using the electrochemical pre-activation strategy (*vide supra*). Anodic oxidation was performed at -80 °C in the presence of Bu₄NOTf with 1.00 F/mol of electricity. The proposed mechanism involves the formation of the anomeric triflate, which is then displaced by the neighboring group to form an acyloxonium ion, which undergoes substitution to afford the desired product. This was applied to the assembly of the core trisaccharide of GPI anchor oligosaccharide as shown in Scheme 1.47. The sequence was completed to provide trisaccharide **1.220** in 40% overall yield.

1.4. Conclusions and outlook

To keep pace with the expanding areas of glycosciences, it is critical to make glycans more accessible to the general chemical, biomedical and industrial audiences. The advancement of automation strategies and their broader adoption will be crucial to meeting this need. Fundamental new developments will be required both in the generalization of the automation strategies and in the optimization of methods for glycoside synthesis and oligosaccharide assembly needed for reliable implementation into automation. Manual strategies for oligosaccharide synthesis in solution require specialist knowledge of all aspects of carbohydrate chemistry and fine tuning of reactivity levels and reaction conditions. Manual polymer- or tag-supported synthesis helps to streamline the synthesis and purification, but still requires specialized knowledge of carbohydrate synthesis. The automated platform developed by Seeberger introduces an idea of operational simplicity; however, it requires a sophisticated and expensive synthesizer, and dedicated and appropriately trained personnel.

More recent developments of automation platforms make use of common laboratory equipment including parallel synthesizers syringe pumps, microreactors, and HPLC components. These approaches offer a promise to deliver simple automation using commonly available and relatively inexpensive equipment. The modular character these synthesizers allows for endless opportunities to implement existing accessories including reagent delivery modules and detecting systems that can be operated by standard computer software. Some automation platforms already are capable of reaction monitoring in real-time helping to reduce the amount of reagents needed and the reaction time. Although a viability of these new approaches and platforms has been demonstrated, many, if not all, automation platforms are still in need of major refinement. Further development of existing and new platforms for the automated synthesis is becoming a significant area of research.

One of the greatest unsolved challenges is the need for dedicated automationamenable reaction conditions. Many aspects of the automated synthesis including polymer supports and tags, large scale synthesis amenability, availability of affordable "off-the-shelf" reagent kits, catalytic, stereoselective and operationally simple glycosylations, streamlined synthesis or broader commercial availability of building blocks still need to be improved to expedite the synthesis of glycans. Broad availability of synthetic glycan sequences and libraries and/or affordable and accessible tools and technologies for automation will greatly enhance study of the roles of carbohydrates in biological and disease pathways. The produced libraries of synthetic compounds can be readily integrated with the currently available glycan microarray technologies.

The full potential of automated techniques is yet to be explored, and the versatility has to be improved to reach the diversity of manual, solution phase techniques. While most automated platforms are still in development, manual synthesis in solution will remain as an important tool to obtain complex oligosaccharides or particularly challenging sequences.

1.5. References

 Stick, R. V.; Williams, S. J.: *Carbohydrates: the essential molecules of life*; Second ed.; Elsevier: Amsterdam - Boston - Heidelberg, 2009.
 Benoff, S. Carbohydrates and fertilization: an overview. *Molecular Human Reproduction* **1997**, *3*, 599-637. (3) Varki, A.; Cummings, R. D.; Esko, J. D.; Freeze, H. H.; Bertozzi, C. R.; Stanley, P.; Hart, G. W.; Etzler, M. E.: *Essentials of glycobiology*; Second ed.; CSH Laboratory Press: New York, 2009.

(4) Cipolla, L.; Arajo, A. C.; Bini, D.; Gabrielli, L.; Russo, L.; Shaikh, N. Discovery and design of carbohydrate-based therapeutics. *Expert Opin. Drug Discovery* **2010**, *5*, 721-737.

(5) Witczak, Z. J.: Carbohydrates as new and old targets for future drug design. In *Carbohydrates in Drug Design*; Witczak, Z. J., Nieforth, K. A., Eds.; Marcel Dekker, Inc.: New York, 1997; pp 1-37.

(6) *Carbohydrate-based drug discovery*; Wong, C. H., Ed.; Wiley-VCH: Weinheim, 2003.

(7) *Carbohydrate drug design*; Klyosov, A. A.; Witczak, Z. J.; Platt, D., Eds.; ACS: Washington, 2006; Vol. 932.

(8) Duus, J. O.; Gotfredsen, C. H.; Bock, K. Carbohydrate structural determination by NMR spectroscopy: Modern methods and limitations. *Chem. Rev.* **2000**, *100*, 4589-4614.

(9) Wormald, M. R.; Petrescu, A. J.; Pao, Y. L.; Glithero, A.; Elliott, T.; Dwek, R. A. Conformational studies of oligosaccharides and glycopeptides: complementarity of NMR, X-ray crystallography, and molecular modeling. *Chem. Rev.* **2002**, *102*, 371-386.

(10) Seah, H.; Basu, A.: Carbohydrate-carbohydrate interactions. In *Encyclopedia of Chemical Biology*; Begley, T., Ed.; John Wiley & Sons, 2008.

(11) Jin, S.; Cheng, Y.; Reid, S.; Li, M.; Wang, B. Carbohydrate recognition by boronolectins, small molecules, and lectins. *Med. Res. Rev.* **2010**, *30*, 171-257.

(12) Cheng, Y.; Li, M.; Wang, S.; Peng, H.; Reid, S.; Ni, N.; Fang, H.; Xu, W.; Wang, B. Carbohydrate biomarkers for future disease detection and treatment. *Sci. China Chem.* **2010**, *53*, 3-20.

(13) Dube, D. H.; Bertozzi, C. R. Glycans in cancer and inflammation-potential for therapeutics and diagnostics. *Nature Rev.* **2005**, *4*, 477-488.

(14) Murrey, H. E.; Hsieh-Wilson, L. C. The chemical neurobiology of carbohydrates. *Chem. Rev.* **2008**, *108*, 1708-1731.

(15) Chaubard, J. L.; Krishnamurthy, C.; Yi, W.; Smith, D. F.; Hsieh-Wilson, L. C. Chemoenzymatic probes for detecting and imaging fucose-alpha(1-2)-galactose glycan biomarkers. *J. Am. Chem. Soc.* **2012**, *134*, 4489-4492.

(16) Poletti, L.; Lay, L. Chemical contributions to understanding heparin activity: synthesis of related sulfated oligosaccharides. *Eur. J. Org. Chem.* **2003**, 2999-3024.

(17) Linhardt, R. J.; Toida, T. Role of glycosaminoglycans in cellular communication. *Acc. Chem. Res.* **2004**, *37*, 431-438.

(18) Kotra, L. P.; Mobashery, S. A renaissance of interest in aminoglycoside antibiotics. *Curr. Org. Chem.* **2001**, *5*, 193-205.

(19) Ito, Y.; Manabe, S.: Other glycoconjugates: Synthesis of enediyne antibiotic oligosaccharides. In *Glycoscience: Chemistry and Chemical Biology*; Fraser-Reid, B., Tatsuta, K., Thiem, J., Eds.; Springer: Berlin - Heidelberg - New York, 2001; Vol. 3; pp 2441-2470.

(20) Lucas, A. H.; Reason, D. C. Polysaccharide vaccines as probes of antibody repertoires in man. *Immunol. Rev.* **1999**, *171*, 89-104.

(21) Kuberan, B.; Linhardt, R. J. Carbohydrate based vaccines. *Curr. Org. Chem.* **2000**, *4*, 653-677.

(22) Danishefsky, S. J.; Allen, J. R. From the laboratory to the clinic: a retrospective on fully synthetic carbohydrate-based anticancer vaccines. *Angew. Chem. Int. Ed.* **2000**, *39*, 836-863.

(23) Pozsgay, V. Oligosaccharide-protein conjugates as vaccine candidates against bacteria. *Adv. Carbohydr. Chem. Biochem.* **2001**, *56*, 153-199.

(24) Galonic, D. P.; Gin, D. Y. Chemical glycosylation in the synthesis of glycoconjugate antitumour vaccines. *Nature* **2007**, *446*, 1000-1007.

(25) Seeberger, P. H.; Werz, D. B. Synthesis and medical applications of oligosaccharides. *Nature* **2007**, *446*, 1046-1051.

(26) Alonzi, D. S.; Neville, D. C. A.; Lachmann, R. H.; Dwek, R. A.; Butters, T. D. Glucosylated free oligosaccharides are biomarkers of endoplasmic-reticulum α -glucosidase inhibition. *Biochem. J.* **2008**, *409*, 571-580.

(27) Janković, M. Glycans as biomarkers: status and perspectives. *J. Med. Biochem.* **2011**, *30*, 213-223.

(28) Drake, P. M.; Cho, W.; Li, B.; Prakobphol, A.; Johansen, E.; Anderson, N. L.; Regnier, F. E.; Gibson, B. W.; Fisher, S. J. Sweetening the pot: adding glycosylation to the biomarker discovery equation. *Clin. Chem.* **2010**, *56*, 223-236.

(29) Leymarie, N.; Zaia, J. Effective use of mass spectrometry for glycan and glycopeptide structural analysis. *Anal. Chem.* **2012**, *84*, 3040-3048.

(30) Katrlík, J.; Švitel, J.; Gemeiner, P.; Kožár, T.; Tkac, J. Glycan and lectin microarrays for glycomics and medicinal applications. *Med. Res. Rev.* **2010**, *30*, 394–418.

(31) Fujitani, N.; Furukawa, J.-i.; Araki, K.; Fujioka, T.; Takegawa, Y.; Piao, J.; Nishioka, T.; Tamura, T.; Nikaido, T.; Ito, M.; Nakamura, Y.; Shinohara, Y. Total cellular glycomics allows characterizing cells and streamlining the discovery process for cellular biomarkers. *Proc. Nat. Acad. Sci.* **2013**, *110*, 2105-2110.

(32) Celso A. Reis, H. O., Luisa Silva, Catarina Gomes, Leonor David. Alterations in glycosylation as biomarkers for cancer detection *J. Clin. Pathol.* **2010**, *63*, 322-329.

(33) Adamczyk, B.; Tharmalingam, T.; Rudd, P. M. Glycans as cancer biomarkers. *Biochim. Biophys. Acta* **2012**, *1280*, 1347-1353.

(34) Ruhaak, L. R.; Miyamoto, S.; Lebrilla, C. B. Developments in the identification of glycan biomarkers for the detection of cancer. *Molec. Cell. Proteomics* **2013**, *12*, 846-855.

(35) Lebrilla, C. B.; An, H. J. The prospects of glycan biomarkers for the diagnosis of diseases *Molec. Biosystems* **2009**, *5*, 17-20.

(36) Meany, D. L.; Zhang, Z.; Sokoll, L. J.; Zhang, H.; Chan, D. W. Glycoproteomics for prostate cancer detection: changes in serum PSA glycosylation patterns. *J. Proteome Res.* **2009**, *8*, 613-619.

(37) Futakawa, S.; Nara, K.; Miyajima, M.; Kuno, A.; Ito, H.; Kaji, H.; Shirotani, K.; Honda, T.; Tohyama, Y.; Hoshi, K.; Hanzawa, Y.; Kitazume, S.; Imamaki, R.; Furukawa, K.; Tasaki, K.; Arai, H.; Yuasa, T.; Abe, M.; Arai, H.; Narimatsu, H. A unique N-glycan on human transferrin in CSF: a possible biomarker for iNPH. *Neurobiol. Aging* **2012**, *33*, 1807-1815.

(38) Coss, K. P.; Byrne, J. C.; Coman, D. J.; Adamczyk, B.; Abrahams, J. L.; Saldova, R.; Brown, A. Y.; Walsh, O.; Hendroff, U.; Carolan, C.; Rudd, P. M.; Treacy, E. P. IgG N-glycans as potential biomarkers for determining galactose tolerance in Classical Galactosaemia. *Molec. Genet. Metab.* **2012**, *105*, 212-220.

(39) Moremen, K. W.; Tiemeyer, M.; Nairn, A. V. Vertebrate protein glycosylation: diversity, synthesis and function. *Nat. Rev. Mol Cell. Biol.* **2012**, *13*, 448-462.

(40) Helenius, A.; Aebi, M. Intracellular functions of N-linked glycans. *Science* **2001**, *291*, 2364-2369.

(41) Wang, Z.; Chinoy, Z. S.; Ambre, S. G.; Peng, W.; McBride, R.; de Vries, R. P.; Glushka, J.; Paulson, J. C.; Boons, G. J. A general strategy for the chemoenzymatic synthesis of asymmetrically branched N-glycans. *Science* **2013**, *341*, 379-383.

(42) Walczak, M. A.; Hayashida, J.; Danishefsky, S. J. Building biologics by chemical synthesis: practical preparation of di- and triantennary N-linked glycoconjugates. *J. Am. Chem. Soc.* **2013**, *135*, 4700-4703.

(43) Aussedat, B.; Vohra, Y.; Park, P. K.; Fernandez-Tejada, A.; Alam, S. M.; Dennison, S. M.; Jaeger, F. H.; Anasti, K.; Stewart, S.; Blinn, J. H.; Liao, H. X.; Sodroski, J. G.; Haynes, B. F.; Danishefsky, S. J. Chemical synthesis of highly congested gp120 V1V2 N-glycopeptide antigens for potential HIV-1-directed vaccines. *J. Am. Chem. Soc.* **2013**, *135*, 13113-13120.

(44) Wu, X.; Grathwohl, M.; Schmidt, R. R. Efficient solid-phase synthesis of a complex, branched N-glycan hexasaccharide: use of a novel linker and temporary-protecting-group pattern. *Angew. Chem. Int. Ed.* **2002**, *41*, 4489-4493.

(45) Jonke, S.; Liu, K.-g.; Schmidt, R. R. Solid-phase oligosaccharide synthesis of a small library of N-glycans. *Chem. Eur. J.* **2006**, *12*, 1274-1290.

(46) Eller, S.; Schuberth, R.; Gundel, G.; Seifert, J.; Unverzagt, C. Synthesis of pentaantennary N-glycans with bisecting GlcNAc and core fucose. *Angew. Chem. Int. Ed.* **2007**, *46*, 4173-4175.

(47) Unverzagt, C.; Eller, S.; Mezzato, S.; Schuberth, R. A double regio- and stereoselective glycosylation strategy for the synthesis of N-glycans. *Chem. Eur. J.* **2008**, *14*, 1304-1311.

(48) Huang, W.; Wang, D.; Yamada, M.; Wang, L. X. Chemoenzymatic synthesis and lectin array characterization of a class of N-glycan clusters. *J. Am. Chem. Soc.* **2009**, *131* 17963-17971.

(49) Shivatare, S. S.; Chang, S. H.; Tsai, T. I.; Ren, C. T.; Chuang, H. Y.; Hsu, L.; Lin, C. W.; Li, S. T.; Wu, C. Y.; Wong, C. H. Efficient convergent synthesis of bi-, tri-, and tetra-antennary complex type N-glycans and their HIV-1 antigenicity. *J. Am. Chem. Soc.* **2013**, *135*, 15382-15391.

(50) Song, X.; Ju, H.; Zhao, C.; Lasanajak, Y. Novel strategy to release and tag N-glycans for functional glycomics. *Bioconjug. Chem.* **2014**, *25*, 1881-1887.

(51) Li, L.; Liu, Y.; Ma, C.; Qu, J.; Calderon, A. D.; Wu, B.; Wei, N.; Wang, X.; Guo, Y.; Xiao, Z.; Song, J.; Sugiarto, G.; Li, Y.; Yu, H.; Chen, X.; Wang, P. G. Efficient chemoenzymatic synthesis of an N-glycan isomer library. *Chem. Sci.* **2015**, *6*, 5652–5661.

(52) Falguières, T.; Maak, M.; Weyhern, C. v.; Sarr, M.; Sastre, X.; Poupon, M.-F.; Robine, S.; Johannes, L.; Janssen, K.-P. Human colorectal tumors and metastases express Gb3 and can be targeted by an intestinal pathogen-based delivery tool *Molec. Cancer Therap.* **2008**, *7*, 2498-2508.

(53) Kawano, T.; Sugawara, S.; Hosono, M.; Tatsuta, T.; Ogawa, Y.; Fujimura, T.; Taka, H.; Murayama, K.; Nitta, K. Globotriaosylceramide-expressing Burkitt's

lymphoma cells are committed to early apoptotic status by rhamnose-binding lectin from catfish eggs. *Biol. Pharm. Bull.* **2009**, *32*, 345-353.

(54) Johansson, D.; Kosovac, E.; Moharer, J.; Ljuslinder, I.; Brännström, T.; Johansson, A.; Behnam-Motlagh, P. Expression of verotoxin-1 receptor Gb3 in breast cancer tissue and verotoxin-1 signal transduction to apoptosis. *BMC Cancer* **2009**, *9*.

(55) Aerts, J. M.; Groener, J. E.; Kuiper, S.; Donker-Koopman, W. E.; Strijland, A.; Ottenhoff, R.; van Roomen, C.; Mirzaian, M.; Wijburg, F. A.; Linthorst, G. E.; Vedder, A. C.; Rombach, S. M.; Cox-Brinkman, J.; Somerharju, P.; Boot, R. G.; Hollak, C. E.; Brady, R. O.; Poorthuis, B. J. Elevated globotriaosylsphingosine is a hallmark of Fabry disease *Proc. Natl. Acad. Sci.* **2008**, *105*, 2812-2817.

(56) Li, Y.; Zhou, D.; Xia, C.; Wang, P. G.; Levery, S. B. Sensitive quantitation of isoglobotriaosylceramide in the presence of isobaric components using electrospray ionization-ion trap mass spectrometry. *Glycobiology* **2008**, *18*, 166-176.

(57) Okuda, T.; Nakakita, S.-i.; Nakayama, K.-i. Structural characterization and dynamics of globotetraosylceramide in vascular endothelial cells under TNF- α stimulation. *Glycoconjugate J.* **2010**, *27*, 287-296.

(58) Nagano, K.; Yoshida, Y.; Isobe, T. Cell surface biomarkers of embryonic stem cells. *Proteomics* **2008**, *8*, 4025–4035.

(59) Gottschling, S.; Jensen, K.; Warth, A.; Herth, F. J. F.; Thomas, M.; Schnabel, P. A.; Herpel, E. Stage-specific embryonic antigen-4 is expressed in basaloid lung cancer and associated with poor prognosis *Eur. Respirat. J.* **2013**, *41*, 656-663.

(60) Malecki, M.; Anderson, M.; Beauchaine, M.; Seo, S.; Tambokane, X. TRA-1-60+, SSEA-4+, Oct4A+, Nanog+ clones of pluripotent stem cells in the embryonal carcinomas of the ovaries. *J. Stem Cell Res. Therapy* **2012**, *2*.

(61) Ragupathi, G.; Koide, F.; Livingston, P. O.; Cho, Y. S.; Endo, A.; Wan, Q.; Spassova, M. K.; Keding, S. J.; Allen, J.; Ouerfelli, O.; Wilson, R. M.; Danishefsky, S. J. Preparation and evaluation of unimolecular pentavalent and hexavalent antigenic constructs targeting prostate and breast cancer: a synthetic route to anticancer vaccine candidates. *J. Am. Chem. Soc.* **2006**, *128*, 2715-2725.

(62) Chang, W.-W.; Lee, C. H.; Lee, P.; Lin, J.; Hsu, C.-W.; Hung, J.-T.; Lin, J.-J.; Yu, J.-C.; Shao, L.-e.; Yu, J.; Wong, C.-H.; Yu, A. L. Expression of Globo H and SSEA3 in breast cancer stem cells and the involvement of fucosyl transferases 1 and 2 in Globo H synthesis. *Proc. Nat. Acad. Sci.* **2008**, *105*, 11667–11672

(63) Zhu, T.; Boons, G. J. A two-directional and highly convergent approach for the synthesis of the tumor-associated antigen Globo-H. *Angew. Chem., Int. Ed. Engl.* **1999**, *38*, 3495-3497.

(64) Allen, J. R.; Allen, J. G.; Zhang, X. F.; Williams, L. J.; Zatorski, A.; Ragupathi, G.; Livingston, P. O.; Danishefsky, S. J. A second generation synthesis of the MBr1(Globo-H) breast tumor antigen: new application of the n-pentenyl glycoside method for achieving complex carbohydrate protein linkages. *Chem. Eur. J.* **2000**, *6*, 1366-1375.

(65) Bosse, F.; Marcaurelle, L. A.; Seeberger, P. H. Linear synthesis of the tumorassociated carbohydrate antigens Globo-H, SSEA-3, and Gb3. *J. Org. Chem.* **2002**, *67*, 6659-6670. (66) Wang, Z.; Zhou, L.; Ei-Boubbou, K.; Ye, X. S.; Huang, X. Multi-component onepot synthesis of the tumor-associated carbohydrate antigen Globo-H based on preactivation of thioglycosyl donors. *J. Org. Chem.* **2007**, *72*, 6409-6420.

(67) Werz, D. B.; Castagner, B.; Seeberger, P. H. Automated synthesis of the tumorassociated carbohydrate antigens Gb-3 and Globo-H: incorporation of a-galactosidic linkages. J. Am. Chem. Soc. **2007**, *129*, 2770-2771.

(68) Jeon, I.; Iyer, K.; Danishefsky, S. J. A practical total synthesis of Globo-H for use in anticancer vaccines. *J. Org. Chem.* **2009**, *74*, 8452-8455.

(69) *Handbook of chemical glycosylation: advances in stereoselectivity and therapeutic relevance*; Demchenko, A. V., Ed.; Wiley-VCH: Weinheim, Germany, 2008.

(70) Lemieux, R. U. Some implications in carbohydrate chemistry of theories relating to the mechanisms of replacement reactions. *Adv. Carbohydr. Chem. Biochem.* **1954**, *9*, 1-57 and references therein.

(71) Capon, B. Mechanism in carbohydrate chemistry. *Chem. Rev.* **1969**, *69*, 407-496.

(72) Gervay, J.; Nguyen, T. N.; Hadd, M. J. Mechanistic studies on the stereoselective formation of glycosyl iodides: first characterization of glycosyl iodides. *Carbohydr. Res.* **1997**, *300*, 119-125.

(73) Nukada, T.; Berces, A.; Zgierski, M. Z.; Whitfield, D. M. Exploring the mechanism of neighboring group assisted glycosylation reactions. *J. Am. Chem. Soc.* **1998**, *120*, 13291-13295.

(74) Nguyen, H. M.; Chen, Y. N.; Duron, S. G.; Gin, D. Y. Sulfide-mediated dehydrative glycosylation. J. Am. Chem. Soc. 2001, 123, 8766-8772.

(75) Ayala, L.; Lucero, C. G.; Romero, J. A. C.; Tabacco, S. A.; Woerpel, K. A. Stereochemistry of nucleophilic substitution reactions depending upon substituent: evidence for electrostatic stabilization of pseudoaxial conformers of oxocarbenium ions by heteroatom substitution. *J. Am. Chem. Soc.* **2003**, *125*, 15521-15528.

(76) Crich, D.; Chandrasekera, N. S. Mechanism of 4,6-O-benzylidene-directed bmannosylation as determined by a-deuterium kinetic isotope effects. *Angew. Chem. Int. Ed.* **2004**, *43*, 5386-5389 and references therein.

(77) Boebel, T. A.; Gin, D. Y. Probing the mechanism of sulfoxide-catalyzed hemiacetal activation in dehydrative glycosylation. *J. Org. Chem.* **2005**, *70*, 5818-5826.

(78) Li, Z.; Gildersleeve, J. Mechanistic studies and methods to prevent aglycon transfer of thioglycosides. *J. Am. Chem. Soc.* **2006**, *128*, 11612-11619.

(79) Jensen, H. H.; Bols, M. Stereoelectronic substituent effects. Acc. Chem. Res. **2006**, *39*, 259-265.

(80) Whitfield, D. M. Computational studies of the role of glycopyranosyl oxacarbenium ions in glycobiology and glycochemistry. *Adv. Carbohydr. Chem. Biochem.* **2009**, *62*, 83-159.

(81) Mydock, L. K.; Demchenko, A. V. Mechanism of chemical O-glycosylation: from early studies to recent discoveries. *Org. Biomol. Chem.* **2010**, *8*, 497-510.

(82) Beaver, M. G.; Woerpel, K. A. Erosion of stereochemical control with increasing nucleophilicity: O-glycosylation at the diffusion limit. *J. Org. Chem.* **2010**, *75*, 1107-1118.

(83) Crich, D. Mechanism of a chemical glycosylation reaction. *Acc. Chem. Res.* **2010**, *43*, 1144-1153.

(84) Pedersen, C. M.; Marinescu, L. G.; Bols, M. Glycosyl donors in "unusual" conformations – influence on reactivity and selectivity. *C. R. Chimie* **2010**, *14*, 17-43.

(85) Nokami, T.; Shibuya, A.; Manabe, S.; Ito, Y.; Yoshida, J. a- and b-Glycosyl sulfonium ions: generation and reactivity. *Chem. Eur. J.* **2009**, *15*, 2252-2255.

(86) Huang, M.; Retailleau, P.; Bohe, L.; Crich, D. Cation clock permits distinction between the mechanisms of a- and b-O- and b-C-glycosylation in the mannopyranose series: evidence for the existence of a mannopyranosyl oxocarbenium ion. *J. Am. Chem. Soc.* **2012**, *134*, 14746-14749.

(87) Huang, M.; Garrett, G. E.; Birlirakis, N.; Bohe, L.; Pratt, D. A.; Crich, D. Dissecting the mechanisms of a class of chemical glycosylation using primary ¹³C kinetic isotope effects. *Nature: Chemistry* **2012**, *4*, 663-667.

(88) Crich, D. Methodology development and physical organic chemistry: a powerful combination for the advancement of glycochemistry. *J. Org. Chem.* 2011, *76*, 9193-9209.
(89) Kaeothip, S.; Yasomanee, J. P.; Demchenko, A. V. Glycosidation of thioglycosides in the presence of bromine: mechanism, reactivity, and stereoselectivity. *J. Org. Chem.* 2012, *77*, 291-299.

(90) Kononov, L. O.; Malysheva, N. N.; Orlova, A. V.; Zinin, A. I.; Laptinskaya, T. V.; Kononova, E. G.; Kolotyrkina, N. G. Concentration dependence of glycosylation outcome: a clue to reproducibility and understanding the reasons behind. *Eur. J. Org. Chem.* **2012**, 1926-1934.

(91) Whitfield, D. M. Plausible transition states for glycosylation reactions. *Carbohydr. Res.* **2012**, *356*, 180-190.

(92) Whitfield, D. M. Complications of modeling glycosylation reactions: can the anomeric conformation of a donor determine the glycopyranosyl oxacarbenium ring conformation? *Carbohydr. Res.* **2012**, *356*, 191-195.

(93) Ranade, S. C.; Demchenko, A. V. Mechanism of chemical glycosylation: focus on the mode of activation and departure of anomeric leaving groups. *J. Carbohydr. Chem.* **2013**, *32*, 1-43.

(94) Leng, W. L.; Yao, H.; He, J. X.; Liu, X. W. Venturing beyond Donor-Controlled Glycosylation: New Perspectives toward Anomeric Selectivity. *Acc. Chem. Res.* **2018**, *51*, 628-639.

(95) Smoot, J. T.; Demchenko, A. V. Oligosaccharide synthesis: from conventional methods to modern expeditious strategies. *Adv. Carbohydr. Chem. Biochem.* **2009**, *62*, 161-250.

(96) Fruchtel, J. S.; Jung, G. Organic chemistry on solid supports. *Angew. Chem. Int. Ed. Engl.* **1996**, *35*, 17-42.

(97) Winter, M.: Supports for solid-phase organic synthesis. In *Combinatorial peptide and nonpeptide libraries: a handbook*; Jung, G., Ed.; VCH: Wienheim, New York, Basel, Cambridge, Tokyo, 1996; pp 465-510.

(98) Bochkov, A. F.; Zaikov, G. E.: *Chemistry of the O-glycosidic bond: formation and cleavage*; Pergamon Press: Oxford - New York - Toronto - Sydney - Paris - Frankfurt, 1979.

(99) Adero, P. O.; Amarasekara, H.; Wen, P.; Bohé, L.; Crich, D. The experimental evidence in support of glycosylation mechanisms at the SN1–SN2 interface. *Chem. Rev.* **2018**, in press.

(100) Nukada, T.; Berces, A.; Whitfield, D. M. Can the stereochemical outcome of glycosylation reactions be controlled by the conformational preferences of the glycosyl donor? *Carbohydr. Res.* **2002**, *337*, 765-774.

(101) Kochetkov, N. K.; Klimov, E. M.; Malysheva, N. N.; Demchenko, A. V. A new stereospecific method for 1,2-cis-glycosylation. *Carbohydr. Res.* **1991**, *212*, 77-91.

(102) Kochetkov, N. K.; Klimov, E. M.; Malysheva, N. N.; Demchenko, A. V. Stereospecific 1,2-cis-glycosylation: a modified thiocyanate method. *Carbohydr. Res.* **1992**, *232*, C1-C5.

(103) Cato, D.; Buskas, T.; Boons, G.-J. Highly efficient stereospecific preparation of Tn and TF building blocks using thioglycosyl donors and the Ph₂SO/Tf₂O promotor system. *J. Carbohydr. Chem.* **2005**, *24*, 503-516.

(104) Hoang, K. L. M.; Liu, X.-W. The intriguing dual-directing effect of 2cyanobenzyl ether for a highly stereospecific glycosylation reaction. *Nat. Commun.* **2014**, *5*, 5051.

(105) Issa, J. P.; Bennett, C. S. A reagent-controlled SN2-glycosylation for the direct synthesis of beta-linked 2-deoxy-sugars. *J. Am. Chem. Soc.* **2014**, *136*, 5740-5744.

(106) Mydock, L. K.; Kamat, M. N.; Demchenko, A. V. Direct synthesis of diastereomerically pure glycosyl sulfonium salts. *Org. Lett.* **2011**, *13*, 2928-2931.

(107) Michael, A. On the synthesis of helicin and phenolglucoside. *Am. Chem. J.* **1879**, *1*, 305-312.

(108) Fischer, E. Über die glucoside der alkohole. Ber. Dtsch. Chem. Ges. 1893, 26, 2400-2412.

(109) Koenigs, W.; Knorr, E. Über einige derivate des traubenzuckers und der galactose. *Ber. Deutsch. Chem. Ges.* **1901**, *34*, 957-981.

(110) Igarashi, K. The Koenigs-Knorr reaction. Adv. Carbohydr. Chem. Biochem. 1977, 34, 243-283.

(111) Zemplen, G.; Gerecs, A. Action of mercury salts on acetohalogenosugars. IV. Direct preparation of alkyl biosides of the a-series. *Ber. Dtsch. Chem. Ges.* **1930**, *63B*, 2720-2729.

(112) Helferich, B.; Wedemeyer, K. F. Preparation of glucosides from acetobromoglucose. *Ann.* **1949**, *563*, 139-145.

(113) Helferich, B.; Zirner, J. Synthesis of tetra-O-acetyhexoses with a free 2-hydroxyl group. Synthesis of disaccharides. *Chem. Ber.* **1962**, *95*, 2604-2611.

(114) Conrow, R. B.; Bernstein, S. Steroid conjugates. VI. An improved Koenigs-Knorr synthesis of aryl glucuronides using cadmium carbonate, a new and effective catalyst. *J. Org. Chem.* **1971**, *36*, 863-870.

(115) Helferich, B.; Schmitz-Hillebrecht, E. A new method for the synthesis of glucosides of the phenols. *Ber. Dtsch. Chem. Ges.* **1933**, *66B*, 378-383.

(116) Toshima, K.; Tatsuta, K. Recent progress in O-glycosylation methods and its application to natural-products synthesis. *Chem. Rev.* **1993**, *93*, 1503-1531.

(117) Davis, B. G. Recent developments in oligosaccharide synthesis. J. Chem. Soc., Perkin Trans. 1 2000, 2137-2160.

(118) Ferrier, R. J.; Hay, R. W.; Vethaviyasar, N. A potentially versatile synthesis of glycosides. *Carbohydr. Res.* **1973**, *27*, 55-61.

(119) Nicolaou, K. C.; Seitz, S. P.; Papahatjis, D. P. A mild and general method for the synthesis of O-glycosides. *J. Am. Chem. Soc.* **1983**, *105*, 2430-2434.

(120) Garegg, P. J.; Henrichson, C.; Norberg, T. A reinvestigation of glycosidation reactions using 1-thioglycosides as glycosyl donors and thiophilic cations as promoters. *Carbohydr. Res.* **1983**, *116*, 162-165.

(121) Oscarson, S.: General synthetic methods: Reactions at the anomeric center: S-glycosylation. In *Glycoscience: Chemistry and Chemical Biology*; Fraser-Reid, B., Tatsuta, K., Thiem, J., Eds.; Springer: Berlin - Heidelberg - New York, 2001; Vol. 1; pp 643-671.

(122) Bochkov, A. F.; Kochetkov, N. K. A new approach for the synthesis of oligosaccharides. *Carbohydr. Res.* **1975**, *39*, 355-357.

(123) Kochetkov, N. K.; Backinowsky, L. V.; Tsvetkov, Y. E. Sugar thio orthoesters as glycosylating agents. *Tetrahedron Lett.* **1977**, *41*, 3681-3684.

(124) Pougny, J. R.; Jacquinet, J. C.; Nassr, M.; Duchet, D.; Milat, M. L.; Sinay, P. A novel synthesis of 1,2-cis-disaccharides. *J. Am. Chem. Soc.* **1977**, *99*, 6762-6763.

(125) Schmidt, R. R.; Michel, J. Facile synthesis of a- and b-O-glycosyl imidates; Preparation of glycosides and disaccharides. *Angew. Chem., Int. Ed. Engl.* **1980**, *19*, 731-732.

(126) Mukaiyama, T.; Nakatsuka, T.; Shoda, S. I. An efficient glucosylation of alcohol using 1-thioglucoside derivative. *Chem. Lett.* **1979**, 487-490.

(127) Hanessian, S.; Bacquet, C.; Lehong, N. Chemistry of the glycosidic linkage. Exceptionally fast and efficient formation of glycosides by remote activation. *Carbohydr. Res.* **1980**, *80*, c17-c22.

(128) Woodward, R. B.; Logusch, E.; Nambiar, K. P.; Sakan, K.; Ward, D. E.; Au-Yeung, B. W.; Balaram, P.; Browne, L. J.; Card, P. J.; Chen, C. H. Asymmetric total synthesis of erythromycin. 3. Total synthesis of erythromycin. *J. Am. Chem. Soc.* **1981**, *103*, 3215-3217.

(129) Mukaiyama, T.; Murai, Y.; Shoda, S.-i. An efficient method for glucosylation of hydroxy compounds using glucopyranosyl fluoride. *Chem. Lett.* **1981**, 431-432.

(130) Boursier, M.; Descotes, G. Activation of the anomeric carbon of sugars by the carbonate group and applications in glycosidic synthesis. *Acad. Sci.* **1989**, *308*, 919-921.

(131) Koide, K.; Ohno, M.; Kobayashi, S. A new glycosylation reaction based on a "remote activation concept": glycosyl 2-pyridinecarboxylate as a novel glycosyl donor. *Tetrahedron Lett.* **1991**, *32*, 7065-7068.

(132) Kunz, H.; Zimmer, J. Glycoside synthesis via electrophile-induced activation of N-allyl carbamates. *Tetrahedron Lett.* **1993**, *34*, 2907-2910.

(133) Kochetkov, N. K.; Klimov, E. M.; Malysheva, N. N. Novel highly stereospecific method of 1,2-cis-glycosylation. Synthesis of a-D-glucosyl-D-glucoses. *Tetrahedron Lett.* **1989**, *30*, 5459-5462.

(134) Briner, K.; Vasella, A. Glycosylidene carbenes a new approach to glycoside synthesis. Part 1. Preparation of glycosylidene-derived diaziridines and diazirines. *Helv. Chim. Acta* **1989**, *72*, 1371-1382.

(135) Marra, A.; Sinay, P. A novel stereoselective synthesis of N-acetyl-aneuraminosyl-galactose disaccharide derivatives, using anomeric S-glycosyl xanthates. *Carbohydr. Res.* **1990**, *195*, 303-308.

(136) Friesen, R. W.; Danishefsky, S. J. On the controlled oxidative coupling of glycals: A new strategy for the rapid assembly of oligosaccharides. *J. Am. Chem. Soc.* **1989**, *111*, 6656-6660.

(137) Halcomb, R. L.; Danishefsky, S. J. On the direct epoxidation of glycals: application of a reiterative strategy for the synthesis of b-linked oligosaccharides. *J. Am. Chem. Soc.* **1989**, *111*, 6661-6666.

(138) Kondo, H.; Ichikawa, Y.; Wong, C. H. b-Sialyl phosphite and phosphoramidite: synthesis and application to the chemoenzymatic synthesis of CMP-sialic acid and sialyl oligosaccharides. *J. Am. Chem. Soc.* **1992**, *114*, 8748-8750.

(139) Martin, T. J.; Schmidt, R. R. Efficient sialylation with phosphite as leaving group. *Tetrahedron Lett.* **1992**, *33*, 6123-6126.

(140) Kahne, D.; Walker, S.; Cheng, Y.; van Engen, D. Glycosylation of unreactive substrates. *J. Am. Chem. Soc.* **1989**, *111*, 6881-6882.

(141) Brown, D. S.; Ley, S. V.; Vile, S. Preparation of cyclic ether acetals from 2benzenesulphonyl derivatives: a new mild glycosidation procedure. *Tetrahedron Lett.* **1988**, *29*, 4873-4876.

(142) Mehta, S.; Pinto, B. M. Phenylselenoglycosides as novel, versatile glycosyl donors. selective activation over thioglycosides. *Tetrahedron Lett.* **1991**, *32*, 4435-4438.

(143) Fraser-Reid, B.; Konradsson, P.; Mootoo, D. R.; Udodong, U. Direct elaboration of pent-4-enyl glycosides into disaccharides. *J. Chem. Soc., Chem. Commun.* **1988**, 823-825.

(144) Marra, A.; Esnault, J.; Veyrieres, A.; Sinay, P. Isopropenyl glycosides and congeners as novel classes of glycosyl donors: theme and variations. *J. Am. Chem. Soc.* **1992**, *114*, 6354-6360.

(145) Boons, G. J.; Isles, S. Vinyl glycosides in oligosaccharide synthesis. Part 1: A new latent-active glycosylation strategy. *Tetrahedron Lett.* **1994**, *35*, 3593-3596.

(146) Huchel, U.; Schmidt, C.; Schmidt, R. R. Synthesis of hetaryl glycosides and their glycosyl donor properties. *Eur. J. Org. Chem.* **1998**, 1353-1360 and references therein.

(147) Gervay, J.; Hadd, M. J. Anionic additions to glycosyl iodides: highly stereoselective syntheses of b-C-, N-, and O-glycosides. *J. Org. Chem.* **1997**, *62*, 6961-6967.

(148) Plante, O. J.; Andrade, R. B.; Seeberger, P. H. Synthesis and use of glycosyl phosphates as glycosyl donors. *Org. Lett.* **1999**, *1*, 211-214.

(149) Stick, R. V.; Tilbrook, D. M. G.; Williams, S. J. The selective activation of telluro- over seleno- b-D-glucopyranosides as glycosyl donors: a reactivity scale for various telluro, seleno and thio sugars. *Aust. J. Chem.* **1997**, *50*, 237-240.

(150) Hinklin, R. J.; Kiessling, L. L. Glycosyl sulfonylcarbamates: new glycosyl donor with tunable reactivity. *J. Am. Chem. Soc.* **2001**, *123*, 3379-3380.

(151) Davis, B. G.; Ward, S. J.; Rendle, P. M. Glycosyldisulfides: a new class of solution and solid phase glycosyl donors. *Chem. Commun.* **2001**, 189-190.

(152) Kim, K. S.; Kim, J. H.; Lee, Y. J.; Lee, Y. J.; Park, J. 2-(Hydroxycarbonyl)benzyl glycosides: a novel type of glycosyl donors for highly efficient b-mannopyranosylation and oligosaccharide synthesis by latent-active glycosylation. *J. Am. Chem. Soc.* **2001**, *123*, 8477-8481.

(153) Demchenko, A. V.; Malysheva, N. N.; De Meo, C. S-Benzoxazolyl (SBox) glycosides as novel, versatile glycosyl donors for stereoselective 1,2-cis glycosylation. *Org. Lett.* **2003**, *5*, 455-458.

(154) Demchenko, A. V.; Pornsuriyasak, P.; De Meo, C.; Malysheva, N. N. Potent, versatile, and stable: thiazolyl thioglycosides as glycosyl donors. *Angew. Chem. Int. Ed.* **2004**, *43*, 3069-3072.

(155) Adinolfi, M.; Barone, G.; Iadonisi, A.; Schiattarella, M. Iodine/triethylsilane as a convenient promoter system for the activation of disarmed glycosyl trichloro- and N-(phenyl)trifluoroacetimidates. *Synlett* **2002**, 269-270.

(156) Adinolfi, M.; Barone, G.; Iadonisi, A.; Schiattarella, M. Efficient activation of glycosyl N-(phenyl)trifluoroacetimidate donors with ytterbium(III) triflate in the glycosylation reaction. *Tetrahedron Lett.* **2002**, *43*, 5573-5577.

(157) Li, Y.; Yang, Y.; Yu, B. An efficient glycosylation protocol with glycosyl orthoalkynylbenzoates as donors under the catalysis of Ph3PAuOTf *Tetrahedron Lett.* **2008**, *49*, 3604-3608.

(158) Mamidyala, S. K.; Finn, M. G. Glycosylation using unprotected alkynyl donors. *J. Org. Chem.* **2009**, *74*, 8417-8420.

(159) Li, Y.; Yang, X.; Liu, Y.; Zhu, C.; Yang, Y.; Yu, B. Gold(I)-catalyzed glycosylation with glycosyl ortho-alkynylbenzoates as donors: general scope and application in the synthesis of a cyclic triterpene saponin. *Chem. Eur. J.* **2010**, *16*, 1871-1882.

(160) Yang, W.; Sun, J.; Lu, W.; Li, Y.; Shan, L.; Han, W.; Zhang, W.; Yu, B. Synthesis of kaempferol 3-O-(3",6"-di-O-E-p-coumaroyl)-b-D-glucopyranoside, efficient glycosylation of flavonol 3-OH with glycosyl o-alkynylbenzoates as donors. *J. Org. Chem.* **2010**, *75*, 6879-6888.

(161) Li, Y.; Sun, J.; Yu, B. Efficient synthesis of lupane-type saponins via gold(I)-catalyzed glycosylation with glycosyl ortho-alkynylbenzoates as donors. *Org. Lett.* **2011**, *13*, 5508-5511.

(162) Ma, Y.; Li, Z.; Shi, H.; Zhang, J.; Yu, B. Assembly of Digitoxin by gold(I)-catalyzed glycosidation of glycosyl o-alkynylbenzoates. *J. Org. Chem.* **2011**, *76*, 9748-9756.

(163) Zhu, Y.; Yu, B. Characterization of the Isochromen-4-yl-gold(I) intermediate in the gold(I)-catalyzed glycosidation of glycosyl ortho-alkynylbenzoates and enhacement of the catalytic efficiency thereof. *Angew. Chem. Int. Ed.* **2011**, *50*, 8329-8332.

(164) Yang, F.; Wang, Q.; Yu, B. ortho-Alkynylphenyl thioglycosides as a new type of glycosylation donors under the catalysis of Au(I) complexes. *Tetrahedron Lett.* **2012**, *53*, 5231-5234.

(165) Tang, Y.; Li, J.; Zhu, Y.; Li, Y.; Yu, B. Mechanistic insights into the gold(I)-catalyzed activation of glycosyl ortho-alkynylbenzoates for glycosidation. *Journal of the American Chemical Society* **2013**, *135*, 18396-18405.

(166) Mishra, B.; Neralkar, M.; Hotha, S. Stable alkynyl glycosyl carbonates: catalytic anomeric activation and synthesis of a tridecasaccharide reminiscent of Mycobacterium tuberculosis cell wall lipoarabinomannan. *Angew. Chem. Int. Ed.* **2016**, *55*, 7786.

(167) McKay, M. J.; Nguyen, H. M. Recent advances in transition metal-catalyzed glycosylation. *ACS Catal.* **2012**, *2*, 1563-1595.

(168) Williams, R.; Galan, M. C. Recent advances in organocatalytic glycosylations. *Eur. J. Org. Chem.* **2017**, 6247–6264.

(169) Vibhute, A. M.; Dhaka, A.; Athiyarath, V.; Sureshan, K. M. A versatile glycosylation strategy via Au (III) catalyzed activation of thioglycoside donors. *Chem. Sci.* **2016**, *7*, 4259-4263.

(170) Balmond, E. I.; Coe, D. M.; Galan, M. C.; McGarrigle, E. M. a-Selective organocatalytic synthesis of 2-deoxygalactosides. *Angew. Chem. Int. Ed.* **2012**, *51*, 9152-9155.

(171) Palo-Nieto, C.; Sau, A.; Galan, M. C. Gold(I)-catalyzed direct stereoselective synthesis of deoxyglycosides from glycals. *J. Am. Chem. Soc.* **2017**, *139*, 14041-14044.

(172) Gin, D. Dehydrative glycosylation with 1-hydroxy donors (reprinted from Glycochemistry: Principles, Synthesis, and Applications, pg 33- 52, 2001). *J. Carbohydr. Chem.* **2002**, *21*, 645-665.

(173) Nogueira, J. M.; Issa, J. P.; Chu, A.-H. A.; Sisel, J. A.; Schum, R. S.; Bennett, C. S. Halide effects on cyclopropenium cation promoted glycosylation with deoxy sugars: highly α -selective glycosylations using a 3,3-dibromo-1,2-diphenylcyclopropene promoter. *Eur. J. Org. Chem.* **2012**, 2012, 4927-4930.

(174) Sun, L.; Wu, X.; Xiong, D. C.; Ye, X. S. Stereoselective Koenigs-Knorr glycosylation catalyzed by urea. *Angew. Chem. Int. Ed.* **2016**, *55*, 8041-8044.

(175) Park, Y.; Harper, K. C.; Kuhl, N.; Kwan, E. E.; Liu, R. Y.; Jacobsen, E. N. Macrocyclic bis-thioureas catalyze stereospecific glycosylation reactions. *Science* **2017**, *355*, 162-166.

(176) Ness, R. K.; Fletcher, H. G.; Hudson, C. S. New tribenzoyl-D-ribopyranosyl halides and their reactions with methanol. *J. Am. Chem. Soc.* **1951**, *73*, 959-963.

(177) Ness, R. K.; Fletcher, H. G. Evidence that the supposed 3,5-di-O-benzoyl-1,2-O-(1-hydroxybenzylidene)-a-D-ribose is actually 1,3,5-tri-O-benzoyl-a-D-ribose. *J. Am. Chem. Soc.* **1956**, 78, 4710-4714.

(178) Goodman, L. Neighboring-group participation in sugars. *Adv. Carbohydr. Chem. Biochem.* **1967**, *22*, 109-175.

(179) Smoot, J. T.; Demchenko, A. V. How the arming participating moieties can broaden the scope of chemoselective oligosaccharide synthesis by allowing the inverse armed-disarmed approach *J. Org. Chem.* **2008**, *73*, 8838-8850.

(180) Smoot, J. T.; Pornsuriyasak, P.; Demchenko, A. V. Development of an arming participating group for stereoselective glycosylation and chemoselective oligosaccharide synthesis. *Angew. Chem. Int. Ed.* **2005**, *44*, 7123-7126.

(181) Buda, S.; Gołębiowska, P.; Mlynarski, J. Application of the 2-nitrobenzyl group in glycosylation reactions: a valuable example of an arming participating group. *Eur. J. Org. Chem.* **2013**, 3988-3991.

(182) Tvaroska, I.; Bleha, T. Anomeric and exo-anomeric effects in carbohydrate chemistry. *Adv. Carbohydr. Chem. Biochem.* **1989**, *47*, 45-123.

(183) Kim, J. H.; Yang, H.; Boons, G. J. Stereoselective glycosylation reactions with chiral auxiliaries. *Angew. Chem. Int. Ed.* **2005**, *44*, 947-949.

(184) Kim, J. H.; Yang, H.; Park, J.; Boons, G. J. A general strategy for stereoselective glycosylations. *J. Am. Chem. Soc.* **2005**, *127*, 12090-12097.

(185) Boltje, T. J.; Kim, J.-H.; Park, J.; Boons, G.-J. Stereoelectronic effects determine oxacarbenium vs b-sulfonium ion mediated glycosylations. *Org. Lett.* **2011**, *13*, 284-287.

(186) Boltje, T. J.; Kim, J. H.; Park, J.; Boons, G. J. Chiral-auxiliary-mediated 1,2-cisglycosylations for the solid-supported synthesis of a biologically important branched α glucan. *Nature Chemistry* **2010**, *2*, 552-557.

(187) Fang, T.; Mo, K.-F.; Boons, G.-J. Stereoselective assembly of complex oligosaccharides using anomeric sulfonium ions as glycosyl donors. *J. Am. Chem. Soc.* **2012**, *134*, 7545-7552.

(188) Mensink, R. A.; Boltje, T. J. Advances in Stereoselective 1,2-cis Glycosylation using C-2 Auxiliaries. *Chem. Eur. J.* **2017**, *23*, 17637-17653.

(189) Fascione, M. A.; Adshead, S. J.; Stalford, S. A.; Kilner, C. A.; Leach, A. G.; Turnbull, W. B. Stereoselective glycosylation using oxathiane glycosyl donors. *Chem. Commun.* **2009**, 5841-5843.

(190) Fascione, M. A.; Webb, N. J.; Kilner, C. A.; Warriner, S. L.; Turnbull, W. B. Stereoselective glycosylations using oxathiane spiroketal glycosyl donors. *Carbohydr. Res.* **2012**, *348*, 6-13.

(191) Cox, D. J.; Fairbanks, A. J. Stereoselective synthesis of a-glycosides by neighboring group participation via an intermediate thiophenium ion. *Tetrahedron: Asymmetry* **2009**, *20*, 773-780.

(192) van Boeckel, C. A. A.; Beetz, T.; van Aelst, S. F. Substituent effects on carbohydrate coupling reactions promoted by insoluble silver salts. *Tetrahedron* **1984**, *40*, 4097-4107 and references therein.

(193) van Boeckel, C. A. A.; Beetz, T. Substituent effects in carbohydrate chemistry, Part II. Coupling reactions involving gluco- and galacto-pyranosyl bromides promoted by insoluble silver salts. *Recl. Trav. Chim. Pays-Bas* **1985**, *104*, 171-173.

(194) Ishikawa, T.; Fletcher, H. G. The synthesis and solvolysis of some D-glucopyranosyl bromides having a benzyl group at C-2. *J. Org. Chem.* **1969**, *34*, 563-571. (195) Eby, R.; Schuerch, C. The use of 1-O-tosyl-D-glucopyranose derivatives in a-D-glucoside synthesis. *Carbohydr. Res.* **1974**, *34*, 79-90 and references therein.

(196) Mukaiyama, T.; Suenaga, M.; Chiba, H.; Jona, H. Highly a-selective glycosylation with glycopyranosyl fluorides having diethylthiocarbamoyl group. *Chem. Lett.* **2002**, 56-57.

(197) Demchenko, A. V.; Rousson, E.; Boons, G. J. Stereoselective 1,2-cisgalactosylation assisted by remote neighboring group participation and solvent effects. *Tetrahedron Lett.* **1999**, *40*, 6523-6526.

(198) Takatani, M.; Matsuo, I.; Ito, Y. Pentafluoropropionyl and trifluoroacetyl groups for temporary hydroxyl group protection in oligomannoside synthesis. *Carbohydr. Res.* **2003**, *338*, 1073-1081.

(199) Corey, E. J.; Carpino, P. Enantiospecific total synthesis of pseudopterosins A and E. J. Am. Chem. Soc. **1989**, *111*, 5472-5473.

(200) Gerbst, A. G.; Ustuzhanina, N. E.; Grachev, A. A.; Tsvetkov, D. E.; Khatuntseva, E. A.; Nifant'ev, N. E. Effect of the nature of protecting group at O-4 on stereoselectivity of glycosylation by 4-O-substituted 2,3-di-O- benzylfucosyl bromides. *Mendeleev Commun.* **1999**, 114-116.

(201) Yamanoi, T.; Nakamura, K.; Takeyama, H.; Yanagihara, K.; Inazu, T. New synthetic methods and reagents for complex carbohydrates. 8. stereoselective a-mannopyranoside and b-mannopyranoside formation from glycosyl

dimethylphosphinothioates with the C-2 axial benzyloxyl group. *Bull. Chem. Soc. Jpn.* **1994**, *67*, 1359-1366.

(202) De Meo, C.; Kamat, M. N.; Demchenko, A. V. Remote participation-assisted synthesis of b-mannosides. *Eur. J. Org. Chem.* **2005**, 706-711.

(203) Ustyuzhanina, N.; Komarova, B.; Zlotina, N.; Krylov, V.; Gerbst, A. G.; Tsvetkov, Y.; Nifantiev, N. E. Stereoselective a-glycosylation with 3-O-acetylated D-gluco donors. *Synlett* **2006**, *6*, 921-923.

(204) Baek, J. Y.; Lee, B. Y.; Jo, M. G.; Kim, K. S. b-Directing effect of electronwithdrawing groups at O-3, O-4, and O-6 positions and a-directing effect by remote participation of 3-O-acyl and 6-O-acetyl groups of donors in mannopyranosylations. *J. Am. Chem. Soc.* **2009**, *131*, 17705-17713.

(205) Komarova, B. S.; Orekhova, M. V.; Tsvetkov, Y. E.; Nifantiev, N. E. Is an acyl group at O-3 in glucosyl donors able to control a-stereoselectivity of glycosylation? The role of conformational mobility and the protecting group at O-6. *Carbohydr. Res.* **2014**, *384*, 70–86.

(206) Crich, D.; Cai, W.; Dai, Z. Highly diastereoselective a-mannopyranosylation in the absence of participating protecting groups. *J. Org. Chem.* **2000**, *65*, 1291-1297.

(207) Crich, D.; Jayalath, P.; Hutton, T. K. Enhanced diastereoselectivity in B-mannopyranosylation through the use of sterically minimal propargyl ether protecting groups. J. Org. Chem. **2006**, *71*, 3064-3070.

(208) Zulueta, M. M.; Lin, S. Y.; Lin, Y. T.; Huang, C. J.; Wang, C. C.; Ku, C. C.; Shi, Z.; Chyan, C. L.; Irene, D.; Lim, L. H.; Tsai, T. I.; Hu, Y. P.; Arco, S. D.; Wong, C. H.; Hung, S. C. a-Glycosylation by D-glucosamine-derived donors: synthesis of heparosan and heparin analogues that interact with mycobacterial heparin-binding hemagglutinin. *J. Am. Chem. Soc.* **2012**, *134*, 8988-8995.

(209) Kalikanda, J.; Li, Z. Study of the stereoselectivity of 2-azido-2-deoxygalactosyl donors: remote protecting group effects and temperature dependency. *J. Org. Chem.* **2011**, *76*, 5207-5218.

(210) Ngoje, G.; Li, Z. Study of the stereoselectivity of 2-azido-2-deoxyglucosyl donors: protecting group effects. *Org. Biomol. Chem.* **2013**, *11*, 1879-1886.

(211) Yasomanee, J. P.; Demchenko, A. V. The effect of remote picolinyl and picoloyl substituents on the stereoselectivity of chemical glycosylation. *J. Am. Chem. Soc.* **2012**, *134*, 20097-20102.

(212) Yasomanee, J. P.; Demchenko, A. V. Hydrogen bond-mediated aglycone delivery (HAD): a highly stereoselective synthesis of 1,2-cis α -D-glucosides from common glycosyl donors in the presence of bromine. *Chem. Eur. J.* **2015**, *21*, 6572-6581.

(213) Pistorio, S. G.; Yasomanee, J. P.; Demchenko, A. V. Hydrogen bond-mediated aglycone delivery: focus on β -mannosylation. *Org. Lett.* **2014**, *16*, 716-719.

(214) Yasomanee, J. P.; Demchenko, A. V. Hydrogen bond-mediated aglycone delivery: the synthesis of linear and branched α -glucans. *Angew. Chem. Int. Ed.* **2014**, *53*, 10453–10456.

(215) Ruei, J.-H.; Venukumar, P.; Ingle, A. B.; Mong, K.-K. T. C6 Picoloyl protection: a remote stereodirecting group for 2-deoxy-b-glycoside formation. *Chem. Commun.* **2015**, *51*, 5394-5397.

(216) Escopy, S.; Geringer, S. A.; De Meo, C. Combined effect of the picoloyl protecting group and triflic acid in sialylation. *Org. Lett.* **2017**, *19*, 2638-2641.

(217) Wu, Y. F.; Tsai, Y. F. Assistance of the C-7,8-picoloyl moiety for directing the glycosyl acceptors into the alpha-orientation for the glycosylation of sialyl donors. *Org. Lett.* **2017**, *19*, 4171-4174.

(218) Liu, Q.-W.; Bin, H.-C.; Yang, J.-S. β -Arabinofuranosylation using 5-O-(2-quinolinecarbonyl) substituted ethyl thioglycoside donors. *Org. Lett.* **2013**, *15*, 3974-3977.

(219) Crich, D.; Cai, W. Chemistry of 4,6-O-benzylidene-D-glucopyranosyl triflates: Contrasting behavior between the gluco and manno series. *J. Org. Chem.* **1999**, *64*, 4926-4930.

(220) Crich, D.; Sun, S. Direct synthesis of b-mannopyranosides by the sulfoxide method. J. Org. Chem. **1997**, 62, 1198-1199.

(221) Crich, D.; Sun, S. Are glycosyl triflates intermediates in the sulfoxide glycosylation method? a chemical and ¹H, ¹³C, and ¹⁹F NMR spectroscopic investigation. *J. Am. Chem. Soc.* **1997**, *119*, 11217-11223.

(222) Fraser-Reid, B.; Wu, Z.; Andrews, C. W.; Skowronski, E. Torsional effects in glycoside reactivity: saccharide couplings mediated by acetal protecting groups. *J. Am. Chem. Soc.* **1991**, *113*, 1434-1435.

(223) Jensen, H. H.; Nordstrom, L. U.; Bols, M. The disarming effect of the 4,6-acetal group on glycoside reactivity: torsional or electronic? *J. Am. Chem. Soc.* **2004**, *126*, 9205-9213.

(224) Benakli, K.; Zha, C.; Kerns, R. J. Oxazolidinone protected 2-amino-2-deoxy-D-glucose derivatives as versatile intermediates in stereoselective oligosaccharide synthesis and the formation of a-linked glycosides. *J. Am. Chem. Soc.* **2001**, *123*, 9461-9462.

(225) Kerns, R. J.; Zha, C.; Benakli, K.; Liang, Y.-Z. Extended applications and potential limitations of ring-fused 2,3-oxazolidinone thioglycosides in glycoconjugate synthesis. *Tetrahedron Lett.* **2003**, *44*, 8069-8072.

(226) Wei, P.; Kerns, R. J. Factors affecting stereocontrol during glycosidation of 2,3-oxazolidinone-protected 1-tolylthio-N-acetyl-D-glucosamine. *J. Org. Chem.* **2005**, *70*, 4195-4198.

(227) Wei, P.; Kerns, R. J. Chemoselective deprotection and functional group interconversion of ring-fused 2N,3O-oxazolidinones of N-acetyl-D-glucosamine. *Tetrahedron Lett.* **2005**, *46*, 6901-6905.

(228) Boysen, M.; Gemma, E.; Lahmann, M.; Oscarson, S. Ethyl 2-acetamido-4,6-di-Obenzyl-2,3-N,O-carbonyl-2-deoxy-1-thio-b-D-glycopyranoside as a versatile GlcNAc donor. *Chem. Commun.* **2005**, *24*, 3044-3046.

(229) Geng, Y.; Zhang, L.-H.; Ye, X.-S. Stereoselectivity investigation on glycosylation of oxazolidinone protected 2-amino-2-deoxy-D-glucose donors based on pre-activation protocol. *Tetrahedron* **2008**, *64*, 4949-4958.

(230) Geng, Y.; Zhang, L.-H.; Ye, X.-S. Pre-activation protocol leading to highly stereoselectivity-controllable glycosylations of oxazolidinone protected glucosamines. *Chem. Commun.* **2008**, 597–599.

(231) Yang, L.; Ye, X. S. A highly a-selective glycosylation for the convenient synthesis of repeating a-(1-->4)-linked N-acetyl-galactosamine units. *Carbohydr. Res.* **2010**, *345*, 1713-1721.

(232) Geng, Y.; Qin, Q.; Ye, X.-S. Lewis acids as α -directing additives in glycosylations by using 2,3-O-carbonate-protected glucose and galactose thioglycoside donors based on preactivation protocol. *J. Org. Chem.* **2012**, *77*, 5255-5270.

(233) Manabe, S.; Ishii, K.; Ito, Y. N-Benzyl-2,3-oxazolidinone as a glycosyl donor for selective a-glycosylation and one-pot oligosaccharide synthesis involving 1,2-cis-glycosylation. *J. Am. Chem. Soc.* **2006**, *128*, 10666-10667.

(234) Manabe, S.; Ishii, K.; Ito, Y. N-Benzyl-2,3-trans-carbamate-bearing glycosyl donors for 1,2-cis-selective glycosylation reactions. *Eur. J. Org. Chem.* **2011**, 497-516.

(235) Crich, D.; Picione, J. Direct synthesis of the b-L-rhamnopyranosides. *Org. Lett.* **2003**, *5*, 781-784.

(236) Crich, D.; Jayalath, P. Stereocontrolled formation of b-glucosides and related linkages in the absence of neighboring group participation: influence of a *trans*-fused 2,3-O-carbonate group. *J. Org. Chem.* **2005**, *70*, 7252-7259.

(237) Lu, Y.-S.; Li, Q.; Zhang, L.-H.; Ye, X.-S. Highly direct a-selective glycosylations of 3,4-O-carbonate-protected 2-deoxy and 2,6-dideoxythioglycosides by preactivation protocol. *Org. Lett.* **2008**, *10*, 3445-3448.

(238) Tanaka, H.; Nishiura, Y.; Takahashi, T. Stereoselective synthesis of oligo-a-(2-8)-sialic acids. J. Am. Chem. Soc. **2006**, 128, 7124-7125.

(239) Farris, M. D.; De Meo, C. Application of 4,5-O,N-oxazolidinone protected thiophenyl sialosyl donor to the synthesis of a-sialosides. *Tetrahedron Lett.* **2007**, *48*, 1225-1227.

(240) Crich, D.; Li, W. O-Sialylation with N-acetyl-5-N,4-O-carbonyl-protected thiosialoside donors in dichloromethane: facile and selective cleavage of the oxazolidinone ring. *J. Org. Chem.* **2007**, *72*, 2387-2391.

(241) Paulsen, H.: Selectivity and reactivity in oligosaccharide synthesis. In *Selectivity - a Goal for Synthetic Efficiency*; Bartmann, W., Trost, B. M., Eds.; Verlag Chemie: Weinheim, 1984; pp 169-190.

(242) Uriel, C.; Gomez, A. M.; Lopez, J. C.; Fraser-Reid, B. Reciprocal donor-acceptor selectivity: the influence of the donor O-2 substituent in the regioselective mannosylation of myo-inositol orthopentanoate. *Eur. J. Org. Chem.* **2009**, 403-411.

(243) Jayaprakash, K. N.; Lu, J.; Fraser-Reid, B. Synthesis of a lipomannan component of the cell-wall complex of Mycobacterium tuberculosis is based on Paulsen's concept of donor/acceptor "match". *Angew. Chem. Int. Ed.* **2005**, *44*, 5894-5898.

(244) Uriel, C.; Gomez, A. M.; Lopez, J. C.; Fraser-Reid, B. Further insight into 'matching' of donors and acceptors via reciprocal donor acceptor selectivity (RDAS) studies. *Synlett* **2003**, 2203-2207.

(245) Mach, M.; Schlueter, U.; Mathew, F.; Fraser-Reid, B.; Hazen, K. C. Comparing n-pentenyl orthoesters and n-pentenyl glycosides as alternative glycosyl donors. *Tetrahedron* **2002**, *58*, 7345-7354.

(246) Fraser-Reid, B.; Lopez, J. C.; Radhakrishnan, K. V.; Nandakumar, M. V.; Gomez, A. M.; Uriel, C. One pot/two donors /one diol give one differentiated trisaccharide: powerful evidence for reciprocal donor-acceptor selectivity (RDAS). *Chem. Commun.* **2002**, 2104-2105.

(247) Spijker, N. M.; van Boeckel, C. A. A. Double stereodifferentiation in carbohydrate coupling reactions: the mismatched interaction of donor and acceptor as an

unprecedented factor governing the a/b-ratio of glycoside formation. *Angew. Chem. Int. Edit. Engl.* **1991**, *30*, 180-183.

(248) Kimura, T.; Sekine, M.; Takahashi, D.; Toshima, K. Chiral Brønsted acid mediated glycosylation with recognition of alcohol chirality. *Angew. Chem. Int. Ed.* **2013**, *52*, 12131-12134.

(249) Andersson, F.; Fugedi, P.; Garegg, P. J.; Nashed, M. Synthesis of 1,2-cis-linked glycosides using dimethyl(methylthio)sulfonium triflate as promoter and thioglycosides as glycosyl donors. *Tetrahedron Lett.* **1986**, *27*, 3919-3922.

(250) Manabe, S.; Ito, Y.; Ogawa, T. Solvent effect in glycosylation reaction on polymer support. *Synlett* **1998**, 628-630.

(251) Schmidt, R. R.; Rucker, E. Stereoselective glycosidations of uronic acids. *Tetrahedron Lett.* **1980**, *21*, 1421-1424.

(252) Dohi, H.; Nishida, Y.; Tanaka, H.; Kobayashi, K. O-Methoxycarbonylphenyl 1thio-b-D-galactopyranoside, a non-malodorous thio glycosylation donor for the synthesis of globosyl a-(1-4)-linkages. *Synlett* **2001**, 1446-1448.

(253) Wulff, G.; Rohle, G. Results and problems of O-glycoside synthesis. *Angew. Chem., Int. Edit. Engl.* **1974**, *13*, 157-170.

(254) Demchenko, A.; Stauch, T.; Boons, G. J. Solvent and other effects on the stereoselectivity of thioglycoside glycosidations. *Synlett* **1997**, 818-820.

(255) Ishiwata, A.; Munemura, Y.; Ito, Y. Synergistic solvent effect in 1,2-cisglycosides formation. *Tetrahedron* **2008**, *64*, 92-102.

(256) Chao, C. S.; Lin, C. Y.; Mulani, S.; Hung, W. C.; Mong, K. K. Neighboringgroup participation by C-2 ether functions in glycosylations directed by nitrile solvents. *Chem. Eur. J.* **2011**, *17*, 12193-12202.

(257) Knoben, H.; Schuluter, U.; Redlich, H. Synthesis of *N*-unsubstituted, mono- and di-substituted carbohydrate-1-*O*-carbamates and their behaviour in glycoside syntheses. *Carbohydr. Res.* **2004**, *339*, 2821-2833.

(258) Jayakanthan, K.; Vankar, Y. D. Glycosyl trichloroacetylcarbamate: a new glycosyl donor for O-glycosylation. *Carbohydr. Res.* **2005**, *340*, 2688-2692.

(259) Shirahata, T.; Matsuo, J.-i.; Teruya, S.; Hirata, N.; Kurimoto, T.; Akimoto, N.; Sunazuka, T.; Kaji, E.; Omura, S. Improved catalytic and stereoselective glycosylation with glycosyl N-trichloroacetylcarbamate: application to various 1-hydroxy sugars. *Carbohydr. Res.* **2010**, *345*, 740-749.

(260) Wasonga, G.; Zeng, Y.; Huang, X. Pre-activation based stereoselective glycosylations: stereochemical control by additives and solvent. *Sci. China Chem.* **2011**, *54*, 66-73.

(261) Satoh, H.; Hansen, H. S.; Manabe, S.; van Gunsteren, W. F.; Hunenberger, P. H. Theoretical investigation of solvent effects on glycosylation reactions: stereoselectivity controlled by preferential conformations of the intermediate oxacarbenium-counterion complex. *J. Chem. Theory Comput.* **2010**, *6*, 1783-1797.

(262) Liu, C.-Y. I.; Mulani, S.; Mong, K.-K. T. Iterative one-pot α-glycosylation strategy: application to oligosaccharide synthesis. *Adv. Synth. Catal.* **2012**, *354*, 3299-3310.

(263) Zhu, X.; Schmidt, R. R.: Glycoside synthesis from 1-oxygen-substituted glycosyl imidates. In *Handbook of Chemical Glycosylation*; Demchenko, A. V., Ed.; Wiley-VCH: Weinheim, Germany, 2008; pp 143-185.

(264) Schmidt, R. R.; Jung, K. H.: Trichloroacetimidates. In *Carbohydrates in Chemistry and Biology*; Ernst, B., Hart, G. W., Sinay, P., Eds.; Wiley-VCH: Weinheim, New York, 2000; Vol. 1; pp 5-59.

(265) Yu, B.; Sun, J. Glycosylation with glycosyl N-phenyltrifluoroacetimidates (PTFAI) and a perspective of the future development of new glycosylation methods. *Chem. Commun.* **2010**, *46*, 4668-4678.

(266) Nakamura, S.; Nambu, H.; Hashimoto, S.: Phosphates, phosphites and other O-P derivatives. In *Handbook of Chemical Glycosylation*; Demchenko, A. V., Ed.; Wiley-VCH: Weinheim, Germany, 2008; pp 223-259.

(267) Yang, J.; Cooper-Vanosdell, C.; Mensah, E. A.; Nguyen, H. M. Cationic palladium(II)-catalyzed stereoselective glycosylation with glycosyl trichloroacetimidates. *J. Org. Chem.* **2008**, *73*, 794-800.

(268) Mensah, E. A.; Azzarelli, J. M.; Nguyen, H. M. Palladium-controlled β -selective glycosylation in the absence of the C(2)-ester participatory group. *J. Org. Chem.* **2009**, 74, 1650-1657.

(269) Goswami, M.; Ellern, A.; Pohl, N. L. Bismuth(V)-mediated thioglycoside activation. *Angew. Chem. Int. Ed. Engl.* 2013, *52*, 8441-8445.

(270) Kabotso, D. E. K.; Pohl, N. L. B. Pentavalent bismuth as a universal promoter for S-containing glycosyl donors with a thiol additive. *Org. Lett.* **2017**, *19*, 4516-4519.

(271) Hotha, S.; Kashyap, S. Propargyl glycosides as stable glycosyl donors: anomeric activation and glycosyl syntheses. *J. Am. Chem. Soc.* **2006**, *128*, 9620-9621.

(272) Sureshkumar, G.; Hotha, S. Propargyl 1,2-orthoesters as glycosyl donors: stereoselective synthesis of 1,2-trans glycosides and disaccharides. *Tetrahedron Lett.* **2007**, *48*, 6564-6568.

(273) Hashmi, A. S. K. Gold-catalyzed organic reactions. *Chem. Rev.* **2007**, *107*, 3180-3211.

(274) Yu, B. Gold(I)-Catalyzed Glycosylation with Glycosyl o-Alkynylbenzoates as Donors. *Acc. Chem. Res.* **2018**, *51*, 507-516.

(275) Reisman, S. E.; Doyle, A. G.; Jacobsen, E. N. Enantioselective thiourea-catalyzed additions to oxocarbenium ions. *J. Am. Chem. Soc.* **2008**, *130*, 7198–7199.

(276) Geng, Y.; Kumar, A.; Faidallah, H. M.; Albar, H. A.; Mhkalid, I. A.; Schmidt, R. R. Cooperative catalysis in glycosidation reactions with O-glycosyl trichloroacetimidates as glycosyl donors. *Angew. Chem. Int. Ed.* **2013**, *52*, 10089–10092.

(277) Romero, J. A. C.; Tabacco, S. A.; Woerpel, K. A. Stereochemical reversal of nuclephilic substitution reactions depending upon substituent: reactions of heteroatom-substituted six-membered-ring oxocarbenium ions through pseudoaxial conformers. *J. Am. Chem. Soc.* **2000**, *122*, 168-169.

(278) Baghdasarian, G.; Woerpel, K. A. Electrostatic effects on the reactions of cyclohexanone oxocarbenium ions. J. Org. Chem. 2006, 71, 6851-6858.

(279) Billings, S. B.; Woerpel, K. A. Nucleophilic substitution reactions of sulfursubstituted cyclohexanone acetals: an analysis of the factors controlling stereoselectivity. *J. Org. Chem.* **2006**, *71*, 5171-5178.

(280) Yang, M. T.; Woerpel, K. A. The effect of electrostatic interactions on conformational equilibria of multiply substituted tetrahydropyran oxocarbenium ions. *J. Org. Chem.* **2009**, *74*, 545-553.

(281) Bérces, A.; Enright, G.; Nukada, T.; Whitfield, D. M. The conformational origin of the barrier to the formation of neighboring group assistance in glycosylation reactions: a dynamical density functional theory study. *J. Am. Chem. Soc.* **2001**, *123*, 5460-5464.

(282) Nukada, T.; Berces, A.; Wang, L.; Zgierski, M. Z.; Whitfield, D. M. The twoconformer hypothesis: 2,3,4,6-tetra-O-methyl-mannopyranosyl and -glucopyranosyl oxacarbenium ions. *Carbohydr. Res.* **2005**, *340*, 841-852.

(283) Jensen, H. H.; Lyngbye, L.; Bols, M. A free-energy relationship between the rate of acidic hydrolysis of glycosides and the pK_a of isofagomines. *Angew. Chem. Int. Ed.* **2001**, *113*, 3555-3557.

(284) Jensen, H. H.; Bols, M. Steric effects are not the cause of the rate difference in hydrolysis of stereoisomeric glycosides. *Org. Lett.* **2003**, *5*, 3419-3421.

(285) Jensen, H. H.; Pedersen, C. M.; Bols, M. Going to extremes: "super" armed glycosyl donors in glycosylation chemistry. *Chem. Eur. J.* **2007**, *13*, 7576-7582.

(286) Pedersen, C. M.; Nordstrom, L. U.; Bols, M. "Super armed" glycosyl donors: conformational arming of thioglycosides by silylation. *J. Am. Chem. Soc.* **2007**, *129*, 9222-9235.

(287) Pedersen, C. M.; Marinescu, L. G.; Bols, M. Conformationally armed glycosyl donors: reactivity quantification, new donors and one pot reactions. *Chem. Commun.* **2008**, 2465-2467.

(288) Heuckendorff, M.; Pedersen, C. M.; Bols, M. Quantifying electronic effects of common carbohydrate protecting groups in a piperidine model system. *Chem. Eur. J.* **2010**, *16*, 13982-13994.

(289) Beaver, M. G.; Billings, S. B.; Woerpel, K. A. C-Glycosylation reactions of sulfur-substituted glycosyl donors: Evidence against the role of neighboring-group participation. *J. Am. Chem. Soc.* **2008**, *130*, 2082-2086.

(290) Garcia, A.; Sanzone, J. R.; Woerpel, K. A. Participation of alkoxy groups in reactions of acetals: violation of the reactivity/selectivity principle in a Curtin-Hammett kinetic scenario. *Angew. Chem. Int. Ed. Engl.* **2015**, *54*, 12087-12090.

(291) Shenoy, S. R.; Woerpel, K. A. Investigations into the role of ion pairing in reactions of heteroatom-substituted cyclic oxocarbenium ions. *Org. Lett.* **2005**, *7*, 1157-1160.

(292) Doores, K. J.; Davis, B. G. Reagent switchable stereoselective beta(1,2) mannoside mannosylation: OH-2 of mannose is a privileged acceptor. *Org. Biomol. Chem.* **2008**, *6*, 2692-2696.

(293) Pornsuriyasak, P.; Vetter, C.; Kaeothip, S.; Kovermann, M.; Balbach, J.; Steinborn, D.; Demchenko, A. V. Coordination chemistry approach to the long-standing challenge of anomeric stereoselectivity. *Chem. Commun.* **2009**, 6379-6381.

(294) Lu, S. R.; Lai, Y. H.; Chen, J. H.; Liu, C. Y.; Mong, K. K. Dimethylformamide: an unusual glycosylation modulator. *Angew. Chem. Int. Ed.* **2011**, *50*, 7315-7320.

(295) Mulani, S. K.; Hung, W. C.; Ingle, A. B.; Shiau, K. S.; Mong, K. K. Modulating glycosylation with exogenous nucleophiles: an overview. *Org. Biomol. Chem.* **2014**, *12*, 1184-1197.

(296) Kayastha, A. K.; Jia, X. G.; Yasomanee, J. P.; Demchenko, A. V. 6-O-Picolinyl and 6-O-picoloyl building blocks as glycosyl donors with switchable stereoselectivity. *Org. Lett.* **2015**, *17*, 4448-4451.

(297) Xiang, S.; Hoang Kle, M.; He, J.; Tan, Y. J.; Liu, X. W. Reversing the stereoselectivity of a palladium-catalyzed O-glycosylation through an inner-sphere or outer-sphere pathway. *Angew. Chem. Int. Ed.* **2015**, *54*, 604-607.

(298) Yasomanee, J. P.; Parameswar, A. R.; Pornsuriyasak, P.; Rath, N. P.; Demchenko, A. V. 2,3-Di-O-picolinyl building blocks as glycosyl donors with switchable stereoselectivity. *Org. Biomol. Chem.* **2016**, *14*, 3159-3169.

(299) Wang, L.; Overkleeft, H. S.; van der Marel, G. A.; Codee, J. D. C. Reagent controlled stereoselective synthesis of alpha-glucans. *J. Am. Chem. Soc.* **2018**, *140*, 4632-4638.

(300) Veyrieres, A.: Special problems in glycosylation reactions: 2-deoxy sugars. In *Carbohydrates in Chemistry and Biology*; Ernst, B., Hart, G. W., Sinay, P., Eds.; Wiley-VCH: Weinheim, New York, 2000; Vol. 1; pp 367-406.

(301) Marzabadi, C. H.; Franck, R. W. The synthesis of 2-deoxyglycosides: 1988-1999. *Tetrahedron* **2000**, *56*, 8385-8417.

(302) Bennett, C. S.; Galan, M. C. Methods for 2-deoxyglycoside synthesis. *Chem. Rev.* **2018**, *this issue*, in press.

(303) Varki, A. Biological roles of oligosaccharides: all of the theories are correct. *Glycobiology* **1993**, *3*, 97-130.

(304) Sasaki, K.; Tohda, K. Recent topics in β -stereoselective mannosylation. *Tetrahedron Lett.* **2018**, *59*, 496-503.

(305) Crich, D. Chemistry of glycosyl triflates: synthesis of b-mannopyranosides (Reprinted from Glycochemistry: Principles, Synthesis, and Applications, pg 53-75, 2001). *J. Carbohydr. Chem.* **2002**, *21*, 667-690.

(306) El Ashry, E. S. H.; Rashed, N.; Ibrahim, E. S. I. Strategies of synthetic methodologies for constructing b-mannosidic linkage. *Curr. Org. Synth.* **2005**, *2*, 175-213.

(307) van den Bos, L. J.; Dinkelaar, J.; Overkleeft, H. S.; van der Marel, G. A. Stereocontrolled synthesis of b-D-mannuronic acid esters: synthesis of an alginate trisaccharide. *J. Am. Chem. Soc.* **2006**, *128*, 13066-13067.

(308) Codee, J. D. C.; van den Bos, L. J.; de Jong, A.-R.; Dinkelaar, J.; Lodder, G.; Overkleeft, H. S.; van der Marel, G. A. The stereodirecting effect of the glycosyl C5-carboxylate ester: stereoselective synthesis of b-mannuronic acid alginates. *J. Org. Chem.* **2009**, *74*, 38-47.

(309) Walvoort, M. T. C.; Lodder, G.; Mazurek, J.; Overkleeft, H. S.; Codee, J. D. C.; van der Marel, G. A. Equatorial anomeric triflates from mannuronic acid esters. *J. Am. Chem. Soc.* **2009**, *131*, 12080-12081.

(310) Walvoort, M. T. C.; Lodder, G.; Overkleeft, H. S.; Codee, J. D. C.; van der Marel, G. A. Mannosazide methyl uronate donors. Glycosylating properties and use in the construction of β -ManNAcA-containing oligosaccharides. *J. Org. Chem.* **2010**, *75*, 7990–8002.

(311) Jung, K. H.; Muller, M.; Schmidt, R. R. Intramolecular O-glycoside bond formation. *Chem. Rev.* **2000**, *100*, 4423-4442.

(312) Madsen, J.; Bols, M.: Intramolecular glycosylation reaction. In *Carbohydrates in Chemistry and Biology*; Ernst, B., Hart, G. W., Sinay, P., Eds.; Wiley-VCH: Weinheim, New York, 2000; Vol. 1; pp 449-466.

(313) Ziegler, T.: The twenty first century view of chemical O-glycosylation. In *Handbook of Chemical Glycosylation*; Demchenko, A. V., Ed.; Wiley-VCH Verlag GmbH & Co: Weinheim, Germany, 2008; pp 469-496.

(314) Fairbanks, A. J. Intramolecular aglycon delivery (IAD): The solution to 1,2-cis stereocontrol for oligosaccharide synthesis? *Synlett* **2003**, 1945-1958.

(315) Ishiwata, A.; Lee, Y. J.; Ito, Y. Recent advances in stereoselective glycosylation through intramolecular aglycon delivery. *Org. Biomol. Chem.* **2010**, *8*, 3596-3608.

(316) Cumpstey, I. Intramolecular aglycon delivery. *Carbohydr. Res.* **2008**, *343*, 1553-1573.

(317) Bols, M.; Skrydstrup, T. Silicon-tethered reactions. *Chem. Rev.* **1995**, *95*, 1253–1277.

(318) Jia, X. G.; Demchenko, A. V. Intramolecular glycosylation. *Beilstein J. Org. Chem.* 2017, 13, 2028-2048.

(319) Barresi, F.; Hindsgaul, O. Synthesis of b-mannosides by intramolecular aglycon delivery. *J. Am. Chem. Soc.* **1991**, *113*, 9376-9377.

(320) Stork, G.; Kim, G. Stereocontrolled synthesis of disaccharides via the temporary silicon connection. *J. Am. Chem. Soc.* **1992**, *114*, 1087-1088.

(321) Bols, M. Stereocontrolled synthesis of a-glucosides by intramolecular glycosidation. *J. Chem. Soc., Chem. Commun.* **1992**, 913-914.

(322) Seward, C. M. P.; Cumpstey, I.; Aloui, M.; Ennis, S. C.; Redgrave, A. J.; Fairbanks, A. J. Stereoselective cis glycosylation of 2-O-allyl protected glycosyl donors by intramolecular aglycon delivery (IAD). *Chem. Commun.* **2000**, 1409-1410.

(323) Ishiwata, A.; Munemura, Y.; Ito, Y. NAP ether mediated intramolecular aglycone delivery: a unified strategy for 1,2-cis-glycosylation. *Eur. J. Org. Chem.* **2008**, 4250-4263.

(324) Yong, J. L.; Ishiwata, A.; Ito, Y. Stereoselective synthesis of β -L-rhamnopyranosides. *J. Am. Chem. Soc.* **2008**, *130*, 6330-6331.

(325) Ishiwata, A.; Ito, Y. Development of highly efficient and stereocontrolled O-glycosylation methodologies and its application to the construction of bacterial glycans. *Trends Glycosci. Glycotechnol.* **2009**, *21*, 266-289.

(326) Ishiwata, A.; Kaeothip, S.; Takeda, Y.; Ito, Y. Synthesis of the highly glycosylated hydrophilic motif of extensins. *Angew. Chem. Int. Ed.* **2014**, *53*, 9812-9816.

(327) Ishiwata, A.; Ito, Y. Synthesis of docosasaccharide arabinan motif of mycobacterial cell wall. J. Am. Chem. Soc. 2011, 133, 2275-2291.

(328) Ishiwata, A.; Sakurai, A.; Nishimiya, Y.; Tsuda, S.; Ito, Y. Synthetic study and structural analysis of the antifreeze agent xylomannan from Upis ceramboides. *J. Am. Chem. Soc.* **2011**, *133*, 19524-19535.

(329) Ishiwata, A.; Ito, Y. Intramolecular aglycon delivery and its application to stereoselective synthesis of glycans. *Yuki Gosei Kagaku Kyokaishi/J. Synth. Org. Chem.* **2012**, *70*, 382-394.

(330) Kaeothip, S.; Ishiwata, A.; Ito, Y. Stereoselective synthesis of Arabidopsis CLAVATA3 (CLV3) glycopeptide, unique protein post-translational modifications of secreted peptide hormone in plant. *Org. Biomol. Chem.* **2013**, *11*, 5892-5907.

(331) Ishiwata, A.; Ito, Y.: Synthesis of bacterial cell envelope components. In *Glycochemical Synthesis: Strategies and Applications*, 2015; pp 361-406.

(332) Gelin, M.; Ferrieres, V.; Plusquellec, D. A general and diastereoselective synthesis of 1,2-cis-hexofuranosides from 1,2-trans-thiofuranosyl donors. *Eur. J. Org. Chem.* **2000**, 1423-1431.

(333) Lowary, T. L. D-Arabinofuranosides from mycobacteria: Synthesis and conformation (Reprinted from Glycochemistry: Principles, Synthesis, and Applications, pg 133-162, 2001). *J. Carbohydr. Chem.* **2002**, *21*, 691-722.

(334) Gadikota, R. R.; Callam, C. S.; Lowary, T. L. Stereocontrolled synthesis of 2,3-anhydro-b-D-lyxofuranosyl glycosides. *Org. Lett.* **2001**, *3*, 607-610.

(335) Bai, Y.; Lowary, T. L. 2,3-Anhydrosugars in glycoside bond synthesis. Application to a-D-galactofuranosides. *J. Org. Chem.* **2006**, *71*, 9658-9671.

(336) Zhu, X.; Kawatkar, S.; Rao, Y.; Boons, G. J. Practical approach for the stereoselective introduction of b-arabinofuranosides. *J. Am. Chem. Soc.* **2006**, *128*, 11948-11957.

(337) Crich, D.; Pedersen, C. M.; Bowers, A. A.; Wink, D. J. On the use of 3,5-Obenzylidene and 3,5-O-(di-tert-butylsilylene)-2-O-benzylarabinothiofuranosides and their sulfoxides as glycosyl donors for the synthesis of β -arabinofuranosides: importance of the activation method. *J. Org. Chem.* **2007**, 72, 1553-1565.

(338) Ishiwata, A.; Akao, H.; Ito, Y. Stereoselective synthesis of a fragment of mycobacterial arabinan. *Org. Lett.* **2006**, *8*, 5525-5528.

(339) Boons, G. J.; Demchenko, A. V. Recent advances in O-sialylation. *Chem. Rev.* **2000**, *100*, 4539-4565.

(340) Ress, D. K.; Linhardt, R. J. Sialic acid donors: chemical synthesis and glycosylation. *Curr. Org. Synth.* **2004**, *1*, 31-46.

(341) Ikeda, K.; Sato, M.; Torisawa, Y. Some aspects of sialic acid modification. *Curr. Med. Chem.* **2004**, *3*, 339-350.

(342) De Meo, C. Synthesis of N-5-derivatives of neuraminic acid and their application as sialosyl donors. *ACS Symp. Ser.* **2007**, *960*, 118-131.

(343) De Meo, C.; Boons, G. J.; Demchenko, A. V.: Synthesis of glycosides of sialic acid: chemical aspects (scope and limitations). In *Comprehensive Glycoscience - From Chemistry to Systems Biology*; Kamerling, J. P., Ed.; Elsevier, 2007.

(344) Muthana, S.; Cao, H.; Chen, X. Recent progress in chemical and chemoenzymatic synthesis of carbohydrates. *Curr. Opin. Chem. Biol.* **2009**, *13*, 573-581.

(345) Mandhapati, A. R.; Rajender, S.; Shaw, J.; Crich, D. The isothiocyanato moiety: an ideal protecting group for the stereoselective synthesis of sialic acid glycosides and subsequent diversification. *Angew. Chem. Int. Ed.* **2015**, *54*, 1275-1278.

(346) Paquet, F.; Sinay, P. Intramolecular oximercuration-demercuration reaction: A new stereocontrolled approach to sialic acid containing disaccharides. *Tetrahedron Lett.* **1984**, *25*, 3071-3074.

(347) Ohtake, H.; Ichiba, N.; Ikegami, S. A highly stereoselective construction of bglycosyl linkages by reductive cleavage of cyclic sugar ortho esters. *J. Org. Chem.* **2000**, *65*, 8171-8179.

(348) Babu, R. S.; Zhou, M.; O'Doherty, G. A. De novo synthesis of oligosaccharides using a palladium-catalyzed glycosylation reaction. *J. Am. Chem. Soc.* **2004**, *126*, 3428-3429.

(349) Zhou, M.; O'Doherty, G. A. De novo approach to 2-deoxy-a-glycosides: asymmetric syntheses of digoxose and digitoxin. *J. Org. Chem.* **2007**, *72*, 2485-2493.

(350) Guo, H.; O'Doherty, G. A. De novo asymmetric synthesis of anthrax tetrasaccharide and related tetrasaccharide. *J. Org. Chem.* **2008**, *73*, 5211-5220.

(351) Zhou, M.; O'Doherty, G. A. The de novo synthesis of oligosaccharides: application to the medicinal chemical study of Digitoxin. *Curr. Topics Med. Chem.* **2008**, *8*, 114-125.

(352) Demchenko, A. V. Strategic approach to the chemical synthesis of oligosaccharides. *Lett. Org. Chem.* **2005**, *2*, 580-589.

(353) Love, K. R.; Andrade, R. B.; Seeberger, P. H. Linear synthesis of a protected htype II pentasaccharide using glycosyl phosphate building blocks. *J. Org. Chem.* **2001**, *66*, 8165-8176.

(354) Seeberger, P. H.; Haase, W. C. Solid-phase oligosaccharide synthesis and combinatorial carbohydrate libraries. *Chem. Rev.* **2000**, *100*, 4349-4393.

(355) Miura, T.; Goto, K.; Waragai, H.; Matsumoto, H.; Hirose, Y.; Ohmae, M.; Ishida, H.; Satoh, A.; Inazu, T. Rapid oligosaccharide synthesis using a fluorous protective group. *J. Org. Chem.* **2004**, *69*, 5348-5353.

(356) Koto, S.; Uchida, T.; Zen, S. Syntheses of isomaltose, isomaltotetraose, and isomaltooctaose. *Bull. Chem. Soc. Jpn.* **1973**, *46*, 2520-2523.

(357) Paulsen, H. Advances in selective chemical syntheses of complex oligosaccharides. *Angew. Chem. Int. Edit. Engl.* **1982**, *21*, 155-173.

(358) Ogawa, T.; Yamamoto, H.; Nukada, T.; Kitajima, T.; Sugimoto, M. Synthetic approach to glycan chains of a glycoprotein and proteoglycan. *Pure Appl. Chem.* **1984**, *56*, 779-795.

(359) Sardar, M. Y. R.; Mandhapati, A. R.; Park, S.; Wever, W. J.; Cummings, R. D.; Chaikof, E. L. Convergent Synthesis of Sialyl LewisX- O-Core-1 Threonine. *J. Org. Chem.* **2018**, *83*, 4963-4972.

(360) Goto, K.; Sawa, M.; Tamai, H.; Imamura, A.; Ando, H.; Ishida, H.; Kiso, M. The total synthesis of starfish ganglioside GP3 bearing a unique sialyl glycan architecture. *Chem. Eur. J.* **2016**, *22*, 8323–8331.

(361) Demchenko, A. V.; Boons, G. J. A highly convergent synthesis of a complex oligosaccharide derived from group B type III *Streptococcus. J. Org. Chem.* **2001**, *66*, 2547-2554.

(362) Backinowsky, L. V.; Abronina, P. I.; Shashkov, A. S.; Grachev, A. A.; Kochetkov, N. K.; Nepogodiev, S. A.; Stoddart, J. F. An efficient approach towards the convergent synthesis of "fully-carbohydrate" mannodendrimers. *Chem. Eur. J.* **2002**, *8*, 4412-4423.

(363) Xue, J.; Guo, Z. Convergent synthesis of a GPI containing an acylated inositol. *J. Am. Chem. Soc.* **2003**, *125*, 16334-16339.

(364) Liu, X.; Kwon, Y. U.; Seeberger, P. H. Convergent synthesis of a fully lipidated glycosylphosphatidylinositol anchor of Plasmodium falciparum. *J. Am. Chem. Soc.* **2005**, *127*, 5004-5005.

(365) Wang, Z. G.; Warren, J. D.; Dudkin, V. Y.; Zhang, X.; Iserloh, U.; Visser, M.; Eckhardt, M.; Seeberger, P. H.; Danishefsky, S. J. A highly convergent synthesis of an N-linked glycopeptide presenting the H-type 2 human blood group determinant. *Tetrahedron* **2006**, *62*, 4954-4978.

(366) Crich, D.; Wu, B.; Jayalath, P. Convergent synthesis of a b-(1--3)-mannohexaose. *J. Org. Chem.* **2007**, *72*, 6806-6815.

(367) Rao, Y.; Boons, G.-J. A highly convergent chemical synthesis of conformational epitopes of rhamnogalactan II. *Angew. Chem. Int. Ed.* **2007**, *46*, 6148-6151.

(368) Vohra, Y.; Buskas, T.; Boons, G.-J. Rapid assembly of oligosaccharides: a highly convergent strategy for the assembly of a glycosylated amino acid derived from PSGL-1. *J. Org. Chem.* **2009**, *74*, 6064-6071.

(369) Wu, Y.; Xiong, D. C.; Chen, S. C.; Wang, Y. S.; Ye, X. S. Total synthesis of mycobacterial arabinogalactan containing 92 monosaccharide units. *Nat. Commun.* **2017**, *8*, 14851.

(370) Mootoo, D. R.; Konradsson, P.; Udodong, U.; Fraser-Reid, B. "Armed" and "disarmed" n-pentenyl glycosides in saccharide couplings leading to oligosaccharides. *J. Am. Chem. Soc.* **1988**, *110*, 5583-5584.

(371) Fraser-Reid, B.; Udodong, U. E.; Wu, Z. F.; Ottosson, H.; Merritt, J. R.; Rao, C. S.; Roberts, C.; Madsen, R. n-Pentenyl glycosides in organic chemistry: a contemporary example of serendipity. *Synlett* **1992**, 927-942 and references therein.

(372) Fraser-Reid, B.; Jayaprakash, K. N.; López, J. C.; Gómez, A. M.; Uriel, C.: Protecting groups in carbohydrate chemistry profoundly influence all selectivities in glycosyl couplings. In ACS Symp. Ser. (Frontiers in Modern Carbohydrate Chemistry) Demchenko, A. V., Ed.; ACS Symp. Ser; Oxford Univ. Press, 2007; Vol. 960; pp 91-117. (373) Bandara, M. D.; Yasomanee, J. P.; Demchenko, A. V.: Application of armed, disarmed, superarmed and superdisarmed building blocks in stereocontrolled glycosylation and expeditious oligosaccharide synthesis. In Selective Glycosylations: Synthetic Methods and Catalysts; Bennett, C. S., Ed.; Wiley, 2017; pp 29-58.

(374) Wilson, B. G.; Fraser-Reid, B. n-Pentenyl glycoside based methodology for determining the relative reactivities of variously protected pairs of glycosides. *J. Org. Chem.* **1995**, *60*, 317-320.

(375) Douglas, N. L.; Ley, S. V.; Lucking, U.; Warriner, S. L. Tuning glycoside reactivity: new tool for efficient oligosaccharides synthesis. *J. Chem. Soc., Perkin Trans. 1* **1998**, 51-65.

(376) Zhang, Z.; Ollmann, I. R.; Ye, X. S.; Wischnat, R.; Baasov, T.; Wong, C. H. Programmable one-pot oligosaccharide synthesis. *J. Am. Chem. Soc.* **1999**, *121*, 734-753.

(377) Fridman, M.; Solomon, D.; Yogev, S.; Baasov, T. One-pot synthesis of glucosamine oligosaccharides. *Org. Lett.* **2002**, *4*, 281-283.

(378) Zhu, T.; Boons, G. J. Thioglycosides protected as trans-2,3-cyclic carbonates in chemoselective glycosylations. *Org. Lett.* **2001**, *3*, 4201-4203.

(379) Kamat, M. N.; Demchenko, A. V. Revisiting the armed-disarmed concept rationale: chemoselective activation of the S-benzoxazolyl glycosides in oligosaccharide synthesis. *Org. Lett.* **2005**, *7*, 3215-3218.

(380) Mydock, L. K.; Demchenko, A. V. Superarming the S-benzoxazolyl glycosyl donors by simple 2-O-benzoyl-3,4,6-tri-O-benzyl protection. *Org. Lett.* **2008**, *10*, 2103-2106.

(381) Mydock, L. K.; Demchenko, A. V. Application of the superarmed glycosyl donor to chemoselective oligosaccharide synthesis. *Org. Lett.* **2008**, *10*, 2107-2110.

(382) Premathilake, H. D.; Mydock, L. K.; Demchenko, A. V. Superarming common glycosyl donors by simple 2-O-benzoyl-3,4,6-tri-O-benzyl protection. *J. Org. Chem.* **2010**, *75*, 1095-1100.

(383) Heuckendorff, M.; Premathilake, H. D.; Pornsuriyasak, P.; Madsen, A. Ø.; Pedersen, C. M.; Bols, M.; Demchenko, A. V. Superarming of glycosyl donors by combined neighboring and conformational effects. *Org. Lett.* **2013**, *15*, 4904–4907.

(384) Bandara, M. D.; Yasomanee, J. P.; Rath, N. P.; Pedersen, C. M.; Bols, M.; Demchenko, A. V. Conformationally superarmed S-ethyl glycosyl donors as effective building blocks for chemoselective oligosaccharide synthesis in one pot. *Org. Biomol. Chem.* **2017**, *15*, 559-563.

(385) Kaeothip, S.; Demchenko, A. V. On orthogonal and selective activation of glycosyl thioimidates and thioglycosides: application to oligosaccharide assembly. *J. Org. Chem.* **2011**, *76*, 7388-7398.

(386) Paulsen, H. Progress in oligosaccharide synthesis through a new orthogonal glycosylation strategy. *Angew. Chem. Int. Ed. Engl.* **1995**, *34*, 1432-1434.

(387) Kanie, O.: Orthogonal strategy in oligosaccharide synthesis. In *Carbohydrates in Chemistry and Biology*; Ernst, B., Hart, G. W., Sinay, P., Eds.; Wiley-VCH: Weinheim, New York, 2000; Vol. 1; pp 407-426.

(388) Kanie, O.; Ito, Y.; Ogawa, T. Orthogonal glycosylation strategy in oligosaccharide synthesis. J. Am. Chem. Soc. **1994**, 116, 12073-12074.

(389) Demchenko, A. V.; De Meo, C. semi-Orthogonality of O-pentenyl and S-ethyl glycosides: application for the oligosaccharide synthesis. *Tetrahedron Lett.* **2002**, *43*, 8819-8822.

(390) Lopez, J. C.; Agocs, A.; Uriel, C.; Gomez, A. M.; Fraser-Reid, B. Iterative, orthogonal strategy for oligosaccharide synthesis based on the regioselective glycosylation of polyol acceptors with partially unprotected *n*-pentenyl-orthoesters: further evidence for reciprocal donor acceptor selectivity (RDAS). *Chem. Commun.* **2005**, 5088-5090.

(391) Ako, T.; Daikoku, S.; Ohtsuka, I.; Kato, R.; Kanie, O. A method of orthogonal oligosaccharide synthesis leading to a combinatorial library based on stationary solid-phase reaction. *Chem. Asian J.* **2006**, *1*, 798-813.

(392) Kanie, O.; Ohtsuka, I.; Ako, T.; Daikoku, S.; Kanie, Y.; Kato, R. Orthogonal glycosylation reactions on solid phase and synthesis of a library consisting of a complete set of fucosyl galactose isomers. *Angew. Chem. Int. Ed.* **2006**, *45*, 3851-3854.

(393) Pornsuriyasak, P.; Demchenko, A. V. S-Thiazolinyl (STaz) glycosides as versatile building blocks for convergent selective, chemoselective, and orthogonal oligosaccharide synthesis. *Chem. Eur. J.* **2006**, *12*, 6630-6646.

(394) Lopez, J. C.; Uriel, C.; Guillamon-Martin, A.; Valverde, S.; Gomez, A. M. IPy₂BF₄-Mediated transformation of *n*-pentenyl glycosides to glycosyl fluorides: a new pair of semiorthogonal glycosyl donors. *Org. Lett.* **2007**, *9*, 2759-2762.

(395) Kaeothip, S.; Pornsuriyasak, P.; Rath, N. P.; Demchenko, A. V. Unexpected orthogonality of S-benzoxazolyl and S-thiazolinyl derivatives: application to expeditious oligosaccharide assembly. *Org. Lett.* **2009**, *11*, 799-802.

(396) Vidadala, S. R.; Thadke, S. A.; Hotha, S. Orthogonal activation of propagyl and n-pentenyl glycosides and 1,2-orthoesters. *J. Org. Chem.* **2009**, *74*, 9233-9236.

(397) Fujikawa, K.; Vijaya Ganesh, N.; Tan, Y. H.; Stine, K. J.; Demchenko, A. V. Reverse orthogonal approach to oligosaccharide synthesis. *Chem. Commun.* **2011**, 10602-10604.

(398) Kaeothip, S.; Demchenko, A. V. Expeditious oligosaccharide synthesis via selective and orthogonal activation. *Carbohydr. Res.* **2011**, *346*, 1371-1388.

(399) Hasty, S. J.; Bandara, M. D.; Rath, N. P.; Demchenko, A. V. S-Benzimidazolyl (SBiz) imidates as a platform for oligosaccharide synthesis via active-latent, armeddisarmed, selective and orthogonal activations. *J. Org. Chem.* **2017**, *82*, 1904-1911.

(400) Roy, R.; Andersson, F. O.; Letellier, M. "Active" and "latent" thioglycosyl donors in oligosaccharide synthesis. Application to the synthesis of a-sialosides. *Tetrahedron Lett.* **1992**, *33*, 6053-6056.

(401) Nicolaou, K. C.; Dolle, R. E.; Papahatjis, D. P.; Randall, J. L. Practical synthesis of oligosaccharides. Partial synthesis of avermectin B1a. *J. Am. Chem. Soc.* **1984**, *106*, 4189-4192.

(402) Nicolaou, K. C.; Caulfield, T.; Kataoka, H.; Kumazawa, T. A practical and enantioselective synthesis of glycosphingolipids and related compounds. Total synthesis of globotriaosylceramide (Gb₃). *J. Am. Chem. Soc.* **1988**, *110*, 7910-7912.

(403) Yamago, S.; Yamada, T.; Hara, O.; Ito, H.; Mino, Y.; Yoshida, J. A new, iterative strategy of oligosaccharide synthesis based on highly reactive b-bromoglycosides derived from selenoglycosides. *Org. Lett.* **2001**, *3*, 3867-3870.

(404) Murray, R. W.; Jeyaraman, R. Dioxiranes: synthesis and reactions of methyldioxiranes. J. Org. Chem. **1985**, 50, 2847-2853.

(405) Danishefsky, S. J.; Bilodeau, M. T. Glycals in organic synthesis: the evolution of comprehensive strategies for the assembly of oligosaccharides and glycoconjugates of biological consequence. *Angew. Chem. Int. Ed. Engl.* **1996**, *35*, 1380-1419.

(406) Deshpande, P. P.; Kim, H. M.; Zatorski, A.; Park, T. K.; Ragupathi, G.; Livingston, P. O.; Live, D.; Danishefsky, S. J. Strategy in oligosaccharide synthesis: an application to a concise total synthesis of the KH-1(adenocarcinoma) antigen. *J. Am. Chem. Soc.* **1998**, *120*, 1600-1614.

(407) Gammon, D. W.; Sels, B. F.: Other methods for glycoside synthesis: dehydro and anhydro derivatives. In *Handbook of Chemical Glycosylation*; Demchenko, A. V., Ed.; Wiley-VCH: Weinheim, Germany, 2008; pp 416-448.

(408) Huang, X.; Huang, L.; Wang, H.; Ye, X. S. Iterative one-pot synthesis of oligosaccharides. *Angew. Chem. Int. Ed.* 2004, 43, 5221-5224.

(409) Wang, Y.; Yan, Q.; Wu, J.; Zhang, L. H.; Ye, X. S. A new one-pot synthesis of α -Gal epitope derivatives involved in the hyperacute rejection response in xenotransplantation. *Tetrahedron* **2005**, *61*, 4313-4321.

(410) Yang, B.; Yang, W.; Ramadan, S.; Huang, X. Pre-activation-vased stereoselective glycosylations. *Eur. J. Org. Chem.* **2018**, *2018*, 1075-1096.

(411) Wang, C.; Wang, H.; Huang, X.; Zhang, L. H.; Ye, X. S. Benzenesulfinyl morpholine: a new promoter for one-pot oligosaccharide synthesis using thioglycosides by pre-activation strategy. *Synlett* **2006**, 2846-2850.

(412) Zeng, Y.; Wang, Z.; Whitfield, D.; Huang, X. Installation of electron-donating protective groups, a strategy for glycosylating unreactive thioglycosyl acceptors using the preactivation-based glycosylation method. *J. Org. Chem.* **2008**, *73*, 7952-7962.

(413) Peng, P.; Ye, X.-S. O,O-Dimethylthiophosphonosulfenyl bromide-silver triflate: A new powerful promoter system for the preactivation of thioglycosides. *Org. Biomol. Chem.* **2011**, *9*, 616-622.

(414) Yang, L.; Qin, Q.; Ye, X.-S. Preactivation: an alternative strategy in stereoselective glycosylation and oligosaccharide synthesis. *Asian J. Org. Chem.* **2013**, *2*, 30-49.

(415) Bouhall, S. K.; Sucheck, S. J. In situ preactivation strategies for the expeditious synthesis of oligosaccharides: A review. *J. Carbohydr. Chem.* **2014**, *33*, 347-367.

(416) Peng, P.; Xiong, D. C.; Ye, X. S. ortho-Methylphenylthioglycosides as glycosyl building blocks for preactivation-based oligosaccharide synthesis. *Carbohydr. Res.* **2014**, *384*, 1-8.

(417) Zhu, T.; Boons, G. J. Two-directional, convergent synthesis of a pentasaccharide that is involved in the hyperacute rejection response in xenotransplantation from pig to man. *J. Chem. Soc.*, *Perkin Trans. 1* **1998**, 857-862.

(418) Boons, G. J.; Bowers, S.; Coe, D. M. Trityl ethers in oligosaccharide synthesis: a novel strategy for the convergent assembly of oligosaccharides. *Tetrahedron Lett.* **1997**, *38*, 3773-3776.

(419) Zhu, T.; Boons, G. J. A two directional glycosylation strategy for the convergent assembly of oligosaccharides. *Tetrahedron Lett.* **1998**, *39*, 2187-2190.

(420) Zhu, T.; Boons, G. J. A two-directional approach for the solid-phase synthesis of trisaccharide libraries. *Angew. Chem. Int. Ed.* **1998**, *37*, 1898-1900.

(421) Wang, Y.; Ye, X. S.; Zhang, L. H. Oligosaccharide assembly by one-pot multistep strategy. *Org. Biomol. Chem.* **2007**, *5*, 2189-2200.

(422) Parameswar, A. R.; Demchenko, A. V.: One-pot oligosaccharide synthesis. In *Progress in the synthesis of complex carbohydrate chains of plant and microbial polysaccharides*; Nifantiev, N. E., Ed.; Transworld Res. Network: Kerala, 2009; pp 463-488.

(423) Kulkarni, S. S.; Wang, C.-C.; Sabbavarapu, N. M.; Podilapu, A. R.; Liao, P.-H.; Hung, S.-C. "One-pot" protection, glycosylation, and protection–glycosylation strategies of carbohydrates. *Chem. Rev.* **2018**, in press.

(424) Raghavan, S.; Kahne, D. A one-step synthesis of ciclamycin trisaccharide. J. Am. Chem. Soc. **1993**, 115, 1580-1581.

(425) Pornsuriyasak, P.; Demchenko, A. V. Glycosyl thioimidates in a highly convergent one-pot strategy for oligosaccharide synthesis. *Tetrahedron: Asymmetry* **2005**, *16*, 433-439.

(426) Valverde, S.; Garcia, M.; Gomez, A. M.; Lopez, J. C. A combined intramolecular–intermolecular one-pot glycosylation approach for the synthesis of a branched trisaccharide. *Chem. Commun.* **2000**, 813-814.

(427) Hermkens, P. H. H.; Ottenheijm, H. C. J.; Rees, D. Solid-phase organic reactions: a review of the recent literature. *Tetrahedron* **1996**, *52*, 4527-4554.

(428) Brown, R. C. D. Recent developments in solid-phase organic synthesis. J. Chem. Soc., Perkin Trans. 1 1998, 3293-3320.

(429) Merrifield, B. The role of the support in solid phase peptide synthesis *Br. Polym. J.* **1984**, *16*, 173-178.

(430) *Solid-phase organic synthesis*; Toy, P. H.; Lam, Y., Eds.; John Wiley & Sons, Inc. : Hoboken, 2012.

(431) Merrifield, R. B. Solid phase peptide synthesis. I. The synthesis of a tetrapeptide. *J. Am. Chem. Soc.* **1963**, *85*, 2149-2154.

(432) Frechet, J. M.; Schuerch, C. Solid-phase synthesis of oligosaccharides. I. Preparation of the solid support. Poly[p-(1-propen-3-ol-1-yl)styrene]. *J. Am. Chem. Soc.* **1971**, *93*, 492-496.

(433) Kunz, H.; Schultz, M.: Glycopeptide synthesis in solution and on the solid phase. In *Carbohydrates in Chemistry and Biology*; Ernst, B., Hart, G. W., Sinay, P., Eds.; Wiley-VCH: Weinheim, New York, 2000; Vol. 1; pp 267-304.

(434) Schmidt, R. R.; Jonke, S.; Liu, K.: New aspects of glycoside bond formation: solid-phase oligosaccharide synthesis In *ACS Symp. Ser. (Frontiers in Modern Carbohydrate Chemistry)* Demchenko, A. V., Ed.; ACS Symp. Ser; Oxford Univ. Press, 2007; Vol. 960; pp 209-237.

(435) Toy, P. H.; Janda, K. D. New supports for solid-phase organic synthesis: development of polystyrene resins containing tetrahydrofuran derived cross-linkers. *Tetrahedron Lett.* **1999**, *40*, 6329-6332.

(436) Heckel, A.; Mross, E.; Jung, K. H.; Rademann, J.; Schmidt, R. R. Oligosaccharide synthesis on controlled-pore glass as solid phase material. *Synlett* **1998**, 171-173.

(437) Vijaya Ganesh, N.; Fujikawa, K.; Tan, Y. H.; Nigudkar, S. S.; Stine, K. J.; Demchenko, A. V. Surface-tethered iterative carbohydrate synthesis: a spacer study. *J. Org. Chem.* **2013**, *78*, 6849-6857.

(438) Pornsuriyasak, P.; Ranade, S. C.; Li, A.; Parlato, M. C.; Sims, C. R.; Shulga, O. V.; Stine, K. J.; Demchenko, A. V. STICS: surface-tethered iterative carbohydrate synthesis. *Chem. Commun.* **2009**, 1834-1836.

(439) Bennett, C. S. Principles of modern solid-phase oligosaccharide synthesis. *Org. Biomol. Chem.* **2014**, *12*, 1686-1698.

(440) Douglas, S. P.; Withfield, D. M.; Krepinsky, J. J. Polymer-supported solution synthesis of oligosaccharides using a novel versatile linker for the synthesis of D-mannopentaose, a structural unit of Dmannans of pathogenic yeasts. *J. Am. Chem. Soc.* **1995**, *117*, 2116-2117.

(441) Rodebaugh, R.; Fraser-Reid, B.; Geysen, H. M. A new o-nitrobenzyl photocleavable linker for solid phase synthesis. *Tetrahedron Lett.* **1997**, *38*, 7653-7656.

(442) Weigelt, D.; Magnusson, G. A linker for solid phase carbohydrate synthesis, permitting the introduction of variable anomeric functionality in the release step. *Tetrahedron Lett.* **1998**, *39*, 2839-2842.

(443) Andrade, R. B.; Plante, O. J.; Melean, L. G.; Seeberger, P. H. Solid-phase oligosaccharide synthesis: preparation of complex structures using a novel linker and different glycosylating agents. *Org. Lett.* **1999**, *1*, 1811-1814.

(444) Fukase, K.; Nakai, Y.; Egusa, K.; Porco, J. A.; Kusumoto, S. A novel oxidatively removable linker and its application to a-selective solid-phase oligosaccharide synthesis on a macroporous polystyrene support. *Synlett* **1999**, 1074-1078.

(445) James, I. W. Linkers for solid phase organic synthesis. *Tetrahedron* **1999**, *55*, 4855-4946.

(446) Guillier, F.; Orain, D.; Bradley, M. Linkers and cleavage strategies in solid-phase organic synthesis and combinatorial chemistry. *Chem. Rev.* **2000**, *100*, 2091-2157.

(447) Brase, S.; Dahmen, S.: Linkers for solid-phase synthesis. In *Handbook of Combinatorial Chemistry*, 2002; Vol. 1; pp 59-169.

(448) Hunt, D. K.; Seeberger, P. H. Linker influence on the stereochemical outcome of glycosylations utilizing solid support-bound glycosyl phosphates. *Org. Lett.* **2002**, *4*, 2751-2754.

(449) Mogemark, M.; Gustafson, L.; Bengtsson, C.; Elofsson, M.; Kihlberg, J. A fluorinated selenide linker for solid-phase synthesis of n-pentenyl glycosides. *Org. Lett.* **2004**, *6*, 4885-4888.

(450) Boas, U.; Brask, J.; Jensen, K. J. Backbone amide linker in solid-phase synthesis. *Chem. Rev.* **2009**, *109*, 2092-2118.

(451) Mar Kayser, M.; de Paz, J. L.; Nieto, P. M. Polymer-supported synthesis of oligosaccharides using a diisopropylsiloxane linker and trichloroacetimidate donors. *Eur. J. Org. Chem.* **2010**, 2010, 2138-2147.

(452) Czechura, P.; Guedes, N.; Kopitzki, S.; Vazquez, N.; Martin-Lomas, M.; Reichardt, N. C. A new linker for solid-phase synthesis of heparan sulfate precursors by sequential assembly of monosaccharide building blocks. *Chem. Commun.* **2011**, *47*, 2390-2392.

(453) Scott, P. J. H.: Linker strategies in modern solid-phase organic synthesis. In *Solid-Phase Organic Synthesis*; Toy, P. H., Lam, Y., Eds.; John Wiley & Sons, Inc. : Hoboken, 2012; pp 3-82.

(454) de Jong, A. R.; Volbeda, A. G.; Hagen, B.; van den Elst, H.; Overkleeft, H. S.; van der Marel, G. A.; Codée, J. D. C. A second-generation tandem ring-closing metathesis cleavable linker for solid-phase oligosaccharide synthesis. *Eur. J. Org. Chem.* **2013**, *2013*, 6644-6655.

(455) Pornsuriyasak, P.; Jia, X. G.; Kaeothip, S.; Demchenko, A. V. Templated oligosaccharide synthesis: the linker effect on the stereoselectivity of glycosylation. *Org. Lett.* **2016**, *18*, 2316-2319.

(456) Krock, L.; Esposito, D.; Castagner, B.; Wang, C.-C.; Bindschadler, P.; Seeberger, P. H. Streamlined access to conjugation-ready glycans by automated synthesis. *Chem. Sci.* **2012**, *3*, 1617-1622.

(457) Yin, J.; Eller, S.; Collot, M.; Seeberger, P. H. Acylsulfonamide safety-catch linker: promise and limitations for solid-phase oligosaccharide synthesis. *Beilstein. J. Org. Chem.* **2012**, *8*, 2067-2071.

(458) Eller, S.; Collot, M.; Yin, J.; Hahm, H. S.; Seeberger, P. H. Automated solid-phase synthesis of chondroitin sulfate glycosaminoglycans. *Angew. Chem. Int. Ed.* **2013**, *52*, 5858-5861.

(459) Wilsdorf, M.; Schmidt, D.; Bartetzko, M. P.; Dallabernardina, P.; Schuhmacher, F.; Seeberger, P. H.; Pfrengle, F. A traceless photocleavable linker for the automated glycan assembly of carbohydrates with free reducing ends. *Chem. Commun.* **2016**, *52*, 10187-10189.

(460) Hurevich, M.; Seeberger, P. H. Automated glycopeptide assembly by combined solid-phase peptide and oligosaccharide synthesis. *Chem. Commun.* **2014**, *50*, 1851-1853. (461) Roussel, F.; Takhi, M.; Schmidt, R. R. Solid-phase synthesis of a branched hexasaccharide using a highly efficient synthetic strategy. *J. Org. Chem.* **2001**, *66*, 8540-8548.

(462) Randolph, J. T.; McClure, K. F.; Danishefsky, S. J. Major simplifications in oligosaccharide syntheses arising from a solid-phase based method: an application to the synthesis of the Lewis b antigen. *J. Am. Chem. Soc.* **1995**, *117*, 5712-5719.

(463) Zheng, C.; Seeberger, P. H.; Danishefsky, S. J. Amidoglycosylation of polymerbound glycals: a complete solid-phase synthesis of the oligosaccharide domain of the Lewis b blood group determinant. *Angew. Chem. Int. Ed.* **1998**, *37*, 786-789.

(464) Parlato, M. C.; Kamat, M. N.; Wang, H.; Stine, K. J.; Demchenko, A. V. Application of glycosyl thioimidates in solid-phase oligosaccharide synthesis. *J. Org. Chem.* **2008**, *73*, 1716-1725.

(465) Ito, Y.; Kanie, O.; Ogawa, T. Orthogonal glycosylation strategy for rapid assembly of oligosaccharides on a polymer support. *Angew. Chem. Int. Ed.* **1996**, *35*, 2510-2512.

(466) Tennant-Eyles, R. J.; Davis, B. G.; Fairbanks, A. J. Peptide templated glycosidic bond formation: a new strategy for oligosaccharide synthesis. *Chem. Commun.* **1999**, 1037-1038.

(467) Tennant-Eyles, R. J.; Davis, B. G.; Fairbanks, A. J. Peptide templated glycosylation reactions. *Tetrahedron: Asymmetry* **2000**, *11*, 231-243.

(468) Tennant-Eyles, R. J.; Davis, B. G.; Fairbanks, A. J. Solid phase peptide templated glycosidic bond formation. *Tetrahedron: Asymmetry* **2003**, *14*, 1201-1210.

(469) Greenwell, D. R.; Ibnouzaki, A. F.; Warriner, S. L. Peptide-templated saccharide synthesis on a solid support. *Angew. Chem. Int. Ed.* **2002**, *41*, 1215-1218.

(470) Shulga, O. V.; Jefferson, K.; Khan, A. R.; D'Souza, V. T.; Liu, J.; Demchenko, A. V.; Stine, K. J. Preparation and characterization of porous gold and its application as a platform for immobilization of acetylcholine esterase. *Chem. Mater.* **2007**, *19*, 3902-3911.

(471) Tan, Y. H.; Davis, J. A.; Fujikawa, K.; Ganesh, N. V.; Demchenko, A. V.; Stine, K. J. Surface area and pore size characteristics of nanoporous gold subjected to thermal, mechanical, or surface modification studied using gas adsorption isotherms, cyclic voltammetry, thermogravimetric analysis, and scanning electron microscopy. *J. Mater. Chem.* **2012**, *22*, 6733-6745.

(472) Bhattarai, J. K.; Sharma, A.; Fujikawa, K.; Demchenko, A. V.; Stine, K. J. Electrochemical synthesis of nanostructured gold film for the study of carbohydratelectin interactions using localized surface plasmon resonance spectroscopy. *Carbohydr. Res.* **2015**, *405*, 55-65.

(473) Kim, S. H. Nanoporous gold: Preparation and applications to catalysis and sensors. *Curr. Appl. Phys.* **2018**, *18*, 810-818.

(474) Gravert, D. J.; Janda, K. D. Organic synthesis on soluble polymer supports: liquid-phase methodologies. *Chem. Rev.* **1997**, *97*, 489-509.

(475) Tanaka, K.; Fukase, K.: Oligosaccharide synthesis on solid, soluble polymer, and tag supports. In *Solid-Phase Organic Synthesis*; Toy, P. H., Lam, Y., Eds.; John Wiley & Sons, Inc. : Hoboken, 2012; pp 489-530.

(476) Ando, H.; Manabe, S.; Nakahara, Y.; Ito, Y. Solid-phase capture - release strategy applied to oligosaccharide synthesis on a soluble polymer support. *Angew. Chem. Int. Ed.* **2001**, *40*, 4725-4728.

(477) Yan, F.; Gilbert, M.; Wakarchuk, W. W.; Brisson, J. R.; Whitfield, D. M. Chemoenzymatic iterative synthesis of difficult linkages of oligosaccharides on soluble polymeric supports. *Org. Lett.* **2001**, *3*, 3265-3268.

(478) Ojeda, R.; de Paz, J. L.; Martin-Lomas, M. Synthesis of heparin-like oligosaccharides on a soluble polymer support. *Chem. Commun.* **2003**, 2486-2487.

(479) Majumdar, D.; Zhu, T.; Boons, G.-J. Synthesis of oligosaccharides on soluble high molecular-weight-branched polymers in combination with purification by nanofiltration. *Org. Lett.* **2003**, *5*, 3591-3594.

(480) Zhu, T.; Boons, G.-J. A novel and efficient synthesis of a dimeric Le^x oligosaccharide on polymeric support. *J. Am. Chem. Soc.* **2000**, *122*, 10222-10223.

(481) Huo, C.; Chan, T. H. A novel liquid-phase strategy for organic synthesis using organic ions as soluble supports. *Chem. Soc. Rev.* **2010**, *39*, 2977-3006.

(482) Galan, M. C.; Corfield, A. P. Ionic liquids in oligosaccharide synthesis: Towards mucin-type glycan probes. *Biochem. Soc. Trans.* **2010**, *38*, 1368-1373.

(483) Pathak, A. K.; Yerneni, C. K.; Young, Z.; Pathak, V. Oligomannan synthesis using ionic liquid supported glycosylation. *Org. Lett.* **2008**, *10*, 145-148.

(484) Yerneni, C. K.; Pathak, V.; Pathak, A. K. Imidazolium cation supported solutionphase assembly of homolinear $\alpha(1\rightarrow 6)$ -linked octamannoside: an efficient alternate approach for oligosaccharide synthesis. *J. Org. Chem.* **2009**, *74*, 6307-6310.

(485) Pépin, M.; Hubert-Roux, M.; Martin, C.; Guillen, F.; Lange, C.; Gouhier, G. First examples of α -(1 \rightarrow 4)-glycosylation reactions on ionic liquid supports. *Eur. J. Org. Chem.* **2010**, 6366-6371.

(486) Krishnamurthy, V. R.; Dougherty, A.; Kamat, M.; Song, X.; Cummings, R. D.; Chaikof, E. L. Synthesis of an Fmoc-threonine bearing core-2 glycan: a building block for PSGL-1 via Fmoc-assisted solid-phase peptide synthesis. *Carbohydr. Res.* **2010**, *345*, 1541-1547.

(487) Zhong, W.; Boons, G.-J.: Glycoside synthesis from 1-sulfur/selenium-substituted derivatives: thioglycosides in oligosaccharide synthesis. In *Handbook of Chemical Glycosylation*; Demchenko, A. V., Ed.; Wiley-VCH: Weinheim, Germany, 2008; pp 261-303.

(488) Codee, J. D. C.; Litjens, R. E. J. N.; van den Bos, L. J.; Overkleeft, H. S.; van der Marel, G. A. Thioglycosides in sequential glycosylation strategies. *Chem. Soc. Rev.* **2005**, *34*, 769-782.

(489) Oscarson, S.: Thioglycosides. In *Carbohydrates in Chemistry and Biology*; Ernst, B., Hart, G. W., Sinay, P., Eds.; Wiley-VCH: Weinheim, New York, 2000; Vol. 1; pp 93-116.

(490) Garegg, P. J. Thioglycosides as glycosyl donors in oligosaccharide synthesis. *Adv. Carbohydr. Chem. Biochem.* **1997**, *52*, 179-205.

(491) Schmidt, R. R.; Jung, K. H.: Oligosaccharide synthesis with trichloroacetimidates. In *Preparative Carbohydrate Chemistry*; Hanessian, S., Ed.; Marcel Dekker, Inc.: New York, 1997; pp 283-312.

(492) Schmidt, R. R.; Kinzy, W. Anomeric-oxygen activation for glycoside synthesis: the trichloroacetimidate method. *Adv. Carbohydr. Chem. Biochem.* **1994**, *50*, 21-123.

(493) Crotti, S.; Adamo, R. New strategies for the synthesis of bio-medically relevant oligosaccharides: recent updates on 1,2-cis-O-glycosylation and α -O-sialylation. *Curr. Org. Synth.* **2013**, *10*, 501-524.

(494) Yu, B.; Sun, J.; Yang, X. Assembly of naturally occurring glycosides, evolved tactics, and glycosylation methods. *Acc. Chem. Res.* **2012**, *45*, 1227-1236.

(495) Garcia, B. A.; Gin, D. Y. Dehydrative glycosylation with activated diphenyl sulfonium reagents. Scope, mode of C(1)-hemiacetal activation, and detection of reactive glycosyl intermediates. *J. Am. Chem. Soc.* **2000**, *122*, 4269-4279.

(496) Ravidà, A.; Liu, X.; Kovacs, L.; Seeberger, P. H. Synthesis of glycosyl phosphates from 1,2-orthoesters and application to in situ glycosylation reactions. *Org. Lett.* **2006**, *8*, 1815-1818.

(497) Carrel, F. R.; Geyer, K.; Codée, J. D. C.; Seeberger, P. H. Oligosaccharide synthesis in microreactors. *Org. Lett.* **2007**, *9*, 2285-2288.

(498) Seeberger, P. H. Automated oligosaccharide synthesis. *Chem. Soc. Rev.* 2008, *37*, 19-28.

(499) Lai, C. H.; Hahm, H. S.; Liang, C. F.; Seeberger, P. H. Automated solid-phase synthesis of oligosaccharides containing sialic acids. *Beilstein. J. Org. Chem.* **2015**, *11*, 617-621.

(500) Nigudkar, S. S.; Parameswar, A. R.; Pornsuriyasak, P.; Stine, K. J.; Demchenko, A. V. O-Benzoxazolyl imidates as versatile glycosyl donors for chemical glycosylation. *Org. Biomol. Chem.* **2013**, *11*, 4068-4076.

(501) Nigudkar, S. S.; Wang, T.; Pistorio, S. G.; Yasomanee, J. P.; Stine, K. J.; Demchenko, A. V. OFox imidates as versatile glycosyl donors for chemical glycosylation. *Org. Biomol. Chem.* **2017**, *15*, 348-359.

(502) Pistorio, S. G.; Nigudkar, S. S.; Stine, K. J.; Demchenko, A. V. HPLC-assisted automated oligosaccharide synthesis: the implementation of the autosampler as a mode of the reagent delivery. *J. Org. Chem.* **2016**, *81*, 8796-8805.

(503) Seeberger, P. H. The logic of automated glycan assembly. *Acc. Chem. Res.* **2015**, *48*, 1450-1463.

(504) Ley, S. V. The Engineering of Chemical Synthesis: Humans and Machines Working in Harmony. *Angew. Chem. Int. Ed.* **2018**, *57*, 5182-5183.

(505) Trobe, M.; Burke, M. D. The molecular industrial revolution: automated synthesis of small molecules. *Angew. Chem. Int. Ed.* **2018**, *57*, 4192-4214.

(506) Koeller, K. M.; Wong, C. H. Synthesis of complex carbohydrates and glycoconjugates: Enzyme-based and programmable one-pot strategies. *Chem. Rev.* **2000**, *100*, 4465-4493.

(507) Sears, P.; Wong, C. H. Toward automated synthesis of oligosaccharides and glycoproteins. *Science* **2001**, *291*, 2344-2350.

(508) Takahashi, T.; Adachi, M.; Matsuda, A.; Doi, T. Combinatorial synthesis of trisaccharides via solution-phase one-pot glycosylation. *Tetrahedron Lett.* **2000**, *41*, 2599-2603.

(509) Plante, O. J.; Palmacci, E. R.; Seeberger, P. H. Automated solid-phase synthesis of oligosaccharides. *Science* **2001**, *291*, 1523-1527.

(510) Plante, O. J.; Palmacci, E. R.; Seeberger, P. H. Development of an automated oligosaccharide synthesizer. *Adv. Carbohydr. Chem. Biochem.* **2003**, *58*, 35-54.

(511) Tanaka, H.; Matoba, N.; Tsukamoto, H.; Takimoto, H.; Yamada, H.; Takahashi, T. Automated parallel synthesis of a protected oligosaccharide library based upon the structure of dimeric Lewis X by one-pot sequential glycosylation. *Synlett* **2005**, 824-828.

(512) Machida, K.; Hirose, Y.; Fuse, S.; Sugawara, T.; Takahashi, T. Development and application of a solution-phase automated synthesizer, 'ChemKonzert'. *Chem. Pharm. Bull.* **2010**, *58*, 87-93.

(513) Jaipuri, F. A.; Pohl, N. L. Toward solution-phase automated iterative synthesis: fluorous-tag assisted solution-phase synthesis of linear and branched mannose oligomers. *Org. Biomol. Chem.* **2008**, *6*, 2686-2691.

(514) Vijaya Ganesh, N.; Fujikawa, K.; Tan, Y. H.; Stine, K. J.; Demchenko, A. V. HPLC-assisted automated oligosaccharide synthesis. *Org. Lett.* **2012**, *14*, 3036-3039.

(515) Nokami, T.; Hayashi, R.; Saigusa, Y.; Shimizu, A.; Liu, C.-Y.; Mong, K.-K. T.; Yoshida, J.-i. Automated solution-phase synthesis of oligosaccharides via iterative electrochemical assembly of thioglycosides. *Org. Lett.* **2013**, *15*, 4520-4523.

(516) Hsu, C. H.; Hung, S. C.; Wu, C. Y.; Wong, C. H. Toward automated oligosaccharide synthesis. *Angew. Chem. Int. Ed.* **2011**, *50*, 11872-11923.

(517) Huang, T. Y.; Zulueta, M. M. L.; Hung, S. C. One-pot strategies for the synthesis of the tetrasaccharide linkage region of proteoglycans. *Org. Lett.* **2011**, *13*, 1506-1509.

(518) Huang, Y. L.; Hung, J. T.; Cheung, S. K.; Lee, H. Y.; Chu, K. C.; Li, S. T.; Lin, Y. C.; Ren, C. T.; Cheng, T. J.; Hsu, T. L.; Yu, A. L.; Wu, C. Y.; Wong, C. H. Carbohydrate-based vaccines with a glycolipid adjuvant for breast cancer. *Proc. Nat. Acad. Sci.* **2013**, *110*, 2517-2522.

(519) Grice, P.; Ley, S. V.; Pietruszka, J.; Priepke, H. W. M.; Walther, E. P. E. Tuning the reactivity of glycosides: efficient one-pot oligosaccharide synthesis. *Synlett* **1995**, 781-784.

(520) Baeschlin, D. K.; Chaperon, A. R.; Charbonneau, V.; Green, L. G.; Ley, S. V.; Lucking, U.; Walther, E. Rapid assembly of oligosaccharides: Total synthesis of a glycosylphosphatidylinositol anchor of trypanosoma brucei. *Angew. Chem. Int. Edit.* **1998**, *37*, 3423-3428.

(521) *Reactivity tuning in oligosaccharide assembly*; Fraser-Reid, B.; Lopez, J. C., Eds.; Springer-Verlag: Berlin-Heidelberg, 2011; Vol. 301.

(522) Tanaka, H.; Yamada, H.; Takahashi, T. Rapid synthesis of oligosaccharides based on one-pot glycosylation. *Trends Glycosci. Glycotechnol.* **2007**, *19*, 183-193.

(523) Seeberger, P. H. Automated carbohydrate synthesis to drive chemical glycomics. *Chem. Commun.* **2003**, 115-1121.

(524) Seeberger, P. H.; Werz, D. B. Automated synthesis of oligosacchraides as a basis for drug discovery. *Nature Rev.* **2005**, *4*, 751-763.

(525) Lepenies, B.; Yin, J.; Seeberger, P. H. Applications of synthetic carbohydrates to chemical biology. *Curr. Opin. Chem. Biol.* **2010**, *14*, 404-411.

(526) Palmacci, E. R.; Plante, O. J.; Hewitt, M. C.; Seeberger, P. H. Automated synthesis of oligosaccharides. *Helv. Chim. Acta* **2003**, *86*, 3975-3990.

(527) Melean, L. G.; Love, K. R.; Seeberger, P. H. Toward the automated solid-phase synthesis of oligoglucosamines: Systematic evaluation of glycosyl phosphate and glycosyl trichloroacetimidate building blocks. *Carbohydr. Res.* **2002**, *337*, 1893-1916.

(528) Kanemitsu, T.; Seeberger, P. H. Use of olefin cross-metathesis to release azidecontaining sugars from solid support. *Org. Lett.* **2003**, *5*, 4541-4544.

(529) Esposito, D.; Hurevich, M.; Castagner, B.; Wang, C. C.; Seeberger, P. H. Automated synthesis of sialylated oligosaccharides. *Beilstein J. Org. Chem.* **2012**, *8*, 1601-1609.

(530) Kandasamy, J.; Hurevich, M.; Seeberger, P. H. Automated solid phase synthesis of oligoarabinofuranosides. *Chem. Commun.* **2013**, *49*, 4453-4455.

(531) Love, K. R.; Seeberger, P. H. Automated solid-phase synthesis of protected tumor-associated antigen and blood group determinant oligosaccharides. *Angew. Chem. Int. Ed.* **2004**, *43*, 602-605.

(532) Grubbs, R. H.; Miller, S. J.; Fu, G. C. Ring-closing metathesis and related processes in organic synthesis. *Acc. Chem. Res.* **1995**, *28*, 446-452.

(533) Hakomori, S. Glycosphingolipids in cellular interaction, differentiation, and oncogenesis. *Ann. Rev. Biochem.* **1981**, *50*, 733-764.

(534) Hakomori, S. Tumor-associated carbohydrate antigens. Annu. Rev. Immunol. **1984**, 2, 103-126.

(535) Hakomori, S. Cancer-associated glycosphingolipid antigens: their structure, organization and function. *Acta Anat.* **1998**, *161*, 79-90.

(536) Hakomori, S. Structure and function of glycosphingolipids and sphingolipids: recollections and future trends. *Biochim. Biophys. Acta* **2008**, *1780*, 325-346.

(537) Guo, Z.; Wang, Q. Recent development in carbohydrate-based cancer vaccines. *Curr. Opinion in Chem. Biology* **2009**, *13*, 608-617.

(538) Codée, J. D. C.; Kröck, L.; Castagner, B.; Seeberger, P. H. Automated solid-phase synthesis of protected oligosaccharides containing β -mannosidic linkages. *Chem. Eur. J.* **2008**, *14*, 3987-3994.

(539) Crich, D.; Sun, S. Direct formation of b-mannopyranosides and other hindered glycosides from thioglycosides. J. Am. Chem. Soc. **1998**, 120, 435-436.

(540) Pitsch, S.; Weiss, P. A.; Wu, X.; Ackermann, D.; Honegger, T. Fast and reliable automated synthesis of RNA and partially 2'-O- protected precursors ('Caged RNA') based on two novel, orthogonal 2'-O-protecting groups, preliminary communication. *Helv. Chim. Acta* **1999**, *82*, 1753-1761.

(541) Crich, D.; Jayalath, P. 2-O-Propargyl ethers: readily cleavable, minimally intrusive protecting groups for β -mannosyl donors. *Org. Lett.* **2005**, *7*, 2277-2280.

(542) Walvoort, M. T. C.; van den Elst, H.; Plante, O. J.; Krock, L.; Seeberger, P. H.; Overkleeft, H. S.; van der Marel, G. A.; Codee, J. D. C. Automated solid-phase synthesis of b-mannuronic acid alginates. *Angew. Chem. Int. Ed.* **2012**, *51*, 4393-4396.

(543) Ratner, D. M.; Murphy, E. R.; Jhunjhunwala, M.; Snyder, D. A.; Jensen, K. F.; Seeberger, P. H. Microreactor-based reaction optimization in organic chemistry - glycosylation as a challenge. *Chem. Commun.* **2005**, 578-580.

(544) Alley, W. R.; Mann, B. F.; Hruska, V.; Novotny, M. V. Isolation and purification of glycoconjugates from complex biological sources by recycling high-performance liquid chromatography. *Anal. Chem.* **2013**, *85*, 10408-10416.

(545) Nagy, G.; Peng, T.; Kabotso, D. E. K.; Novotny, M. V.; Pohl, N. L. B. Protocol for the purification of protected carbohydrates: toward coupling automated synthesis to alternate-pump recycling high-performance liquid chromatography. *Chem. Commun.* **2016**, *52*, 13253-13256.

(546) Tang, S.-L.; Linz, L. B.; Bonning, B. C.; Pohl, N. L. B. Automated solution-phase synthesis of insect glycans to probe the binding affinity of pea enation mosaic virus. *J. Org. Chem.* **2015**, *80*, 10482-10489.

(547) Tang, S.-L.; Pohl, N. L. B. Automated solution-phase synthesis of β -1,4-mannuronate and β -1,4-mannan. *Org. Lett.* **2015**, *17*, 2642-2645.

(548) Bhaduri, S.; Pohl, N. L. B. Fluorous-tag assisted syntheses of sulfated keratan sulfate oligosaccharide fragments. *Org. Lett.* **2016**, *18*, 1414-1417.

(549) Tang, S.-L.; Pohl, N. L. B. Automated fluorous-assisted solution-phase synthesis of β -1,2-, 1,3-, and 1,6-mannan oligomers. *Carbohydr. Res.* **2016**, *430*, 8-15.

(550) Calin, O.; Eller, S.; Seeberger, P. H. Automated polysaccharide synthesis: assembly of a 30mer mannoside. *Angew. Chem. Int. Ed.* **2013**, *52*, 5862-5865.

(551) Naresh, K.; Schumacher, F.; Hahm, H. S.; Seeberger, P. H. Pushing the limits of automated glycan assembly: synthesis of a 50mer polymannoside. *Chem. Commun.* **2017**, *53*, 9085-9088.

(552) Chu, K.-C.; Ren, C.-T.; Lu, C.-P.; Hsu, C.-H.; Sun, T.-H.; Han, J.-L.; Pal, B.; Chao, T.-A.; Lin, Y.-F.; Wu, S.-H.; Wong, C.-H.; Wu, C.-Y. Efficient and stereoselective synthesis of $\alpha(2\rightarrow 9)$ oligosialic acids: from monomers to dodecamers. *Angew. Chem. Int. Ed.* **2011**, *50*, 9391-9395.

(553) Fair, R. J.; Hahm, H. S.; Seeberger, P. H. Combination of automated solid-phase and enzymatic oligosaccharide synthesis provides access to alpha(2,3)-sialylated glycans. *Chem. Commun.* **2015**, *51*, 6183-6185.

(554) Yu, H.; Chokhawala, H.; Karpel, R.; Yu, H.; Wu, B.; Zhang, J.; Zhang, Y.; Jia, Q.; Chen, X. A multifunctional Pasteurella multocida sialyltransferase: a powerful tool for the synthesis of sialoside libraries. *J. Am. Chem. Soc.* **2005**, *127*, 17618-17619.

(555) Hahm, H. S.; Hurevich, M.; Seeberger, P. H. Automated assembly of oligosaccharides containing multiple cis-glycosidic linkages. *Nat. Commun.* **2016**, *7*, 12482.

(556) Schmidt, D.; Schuhmacher, F.; Geissner, A.; Seeberger, P. H.; Pfrengle, F. Automated synthesis of arabinoxylan-oligosaccharides enables characterization of antibodies that recognize plant cell wall glycans. *Chem. Eur. J.* **2015**, *21*, 5709-5713.

(557) Pattathil, S.; Avci, U.; Baldwin, D.; Swennes, A. G.; McGill, J. A.; Popper, Z.; Bootten, T.; Albert, A.; Davis, R. H.; Chennareddy, C.; Dong, R.; Shea, B.; Rossi, R.; Leoff, C.; Freshour, G.; Narra, R.; Neil, M.; York, W. S.; Hahn, M. G. A comprehensive toolkit of plant cell wall glycan-directed monoclonal antibodies. *Plant Physiol.* **2010**, *153*, 514.

(558) Rillahan, C. D.; Paulson, J. C. Glycan microarrays for decoding the glycome. *Ann. Rev. Biochem.* **2011**, *80*, 797-823.

(559) Mohnen, D. Pectin structure and biosynthesis. *Curr. Opin. Plant Biol.* 2008, 11, 266-277.

(560) Tan, L.; Showalter, A.; Egelund, J.; Hernandez-Sanchez, A.; Doblin, M.; Bacic, A. Arabinogalactan-proteins and the research challenges for these enigmatic plant cell surface proteoglycans. *Frontiers in Plant Science* **2012**, *3*, 140.

(561) Bartetzko, M. P.; Schuhmacher, F.; Seeberger, P. H.; Pfrengle, F. Determining substrate specificities of β 1,4-endogalactanases using plant arabinogalactan oligosaccharides synthesized by automated glycan assembly. *J. Org. Chem.* **2017**, *82*, 1842-1850.

(562) Bartetzko, M. P.; Schuhmacher, F.; Hahm, H. S.; Seeberger, P. H.; Pfrengle, F. Automated glycan assembly of oligosaccharides related to arabinogalactan proteins. *Org. Lett.* **2015**, *17*, 4344-4347.

(563) Hahm, H. S.; Schlegel, M. K.; Hurevich, M.; Eller, S.; Schuhmacher, F.; Hofmann, J.; Pagel, K.; Seeberger, P. H. Automated glycan assembly using the Glyconeer 2.1 synthesizer. *Proc. Natl. Acad. Sci.* **2017**, *114*, E3385-E3389.

(564) Brennan, P. J.; Nikaido, H. The envelope of Mycobacteria. Ann. Rev. Biochem. **1995**, 64, 29-63.

(565) Osborne, S. A.; Daniel, R. A.; Desilva, K.; Seymour, R. B. Antithrombin activity and disaccharide composition of dermatan sulfate from different bovine tissues. *Glycobiology* **2008**, *18*, 225-234.

(566) Bindschädler, P.; Adibekian, A.; Grünstein, D.; Seeberger, P. H. De novo synthesis of differentially protected l-iduronic acid glycosylating agents. *Carbohydr. Res.* **2010**, *345*, 948-955.

(567) Kandasamy, J.; Schuhmacher, F.; Hahm, H. S.; Klein, J. C.; Seeberger, P. H. Modular automated solid phase synthesis of dermatan sulfate oligosaccharides. *Chem. Commun.* **2014**, *50*, 1875-1877.

(568) Koeller, K. M.; Smith, M. E. B.; Huang, R.-F.; Wong, C.-H. Chemoenzymatic synthesis of a PSGL-1 N-terminal glycopeptide containing tyrosine sulfate and α -O-linked sialyl Lewis X. J. Am. Chem. Soc. **2000**, 122, 4241-4242.

(569) Senf, D.; Ruprecht, C.; de Kruijff, G. H. M.; Simonetti, S. O.; Schuhmacher, F.; Seeberger, P. H.; Pfrengle, F. Active site mapping of xylan-deconstructing enzymes with arabinoxylan oligosaccharides produced by automated glycan assembly. *Chem. Eur. J.* **2017**, *23*, 3197-3205.

(570) Dallabernardina, P.; Schuhmacher, F.; Seeberger, P. H.; Pfrengle, F. Mixedlinkage glucan oligosaccharides produced by automated glycan assembly serve as tools to determine the substrate specificity of lichenase. *Chem. Eur. J.* **2017**, *23*, 3191-3196.

(571) Delbianco, M.; Kononov, A.; Poveda, A.; Yu, Y.; Diercks, T.; Jimenez-Barbero, J.; Seeberger, P. H. Well-defined oligo- and polysaccharides as ideal probes for structural studies. *J. Am. Chem. Soc.* **2018**, *140*, 5421-5426.

(572) Dallabernardina, P.; Ruprecht, C.; Smith, P. J.; Hahn, M. G.; Urbanowicz, B. R.; Pfrengle, F. Automated glycan assembly of galactosylated xyloglucan oligosaccharides and their recognition by plant cell wall glycan-directed antibodies. *Org. Biomol. Chem.* **2017**, *15*, 9996-10000.

(573) Amatore, C.; Jutand, A.; Mallet, J. M.; Meyer, G.; Sinay, P. Electrochemical glycosylation using phenyl S-glycosides. *J. Chem. Soc., Chem. Commun.* **1990**, 718-719.

(574) Balavoine, G.; Berteina, S.; Gref, A.; Fischer, J. C.; Lubineau, A. Thio glycosides as potential glycosyl donors in electrochemical glycosidation reactions. Part 1. Their preparation and reactivity toward simple alcohols. *J. Carbohydr. Chem.* **1995**, *14*, 1217-1236.

(575) Yamago, S.; Kokubo, K.; Yoshida, J.-i. O-Glycosidation of telluroglycoside by electrochemical oxidation. *Chem. Lett.* **1997**, *26*, 111-112.

(576) Yamago, S.; Kokubo, K.; Hara, O.; Masuda, S.; Yoshida, J. Electrochemistry of chalcogenoglycosides. Rational design of iterative glycosylation based on reactivity control of glycosyl donors and acceptors by oxidation potentials. *J. Org. Chem.* **2002**, *67*, 8584-8592.

(577) France, R. R.; Compton, R. G.; Davis, B. G.; Fairbanks, A. J.; Rees, N. V.; Wadhawan, J. D. Selective electrochemical glycosylation by reactivity tuning. *Org. Biomol. Chem.* **2004**, *2*, 2195-2202.

(578) Nokami, T.; Shibuya, A.; Tsuyama, H.; Suga, S.; Bowers, A. A.; Crich, D.; Yoshida, J. Electrochemical generation of glycosyl triflate pools. *J. Am. Chem. Soc.* **2007**, *129*, 10922-10928.

(579) Nokami, T.; Isoda, Y.; Sasaki, N.; Takaiso, A.; Hayase, S.; Itoh, T.; Hayashi, R.; Shimizu, A.; Yoshida, J.-i. Automated electrochemical assembly of the protected

potential TMG-chitotriomycin precursor based on rational optimization of the carbohydrate building block *Org. Lett.* **2015**, *17*, 1525–1528.

(580) Isoda, Y.; Sasaki, N.; Kitamura, K.; Takahashi, S.; Manmode, S.; Takeda-Okuda, N.; Tamura, J. I.; Nokami, T.; Itoh, T. Total synthesis of TMG-chitotriomycin based on an automated electrochemical assembly of a disaccharide building block. *Beilstein J. Org. Chem.* **2017**, *13*, 919-924.

(581) Manmode, S.; Sato, T.; Sasaki, N.; Notsu, I.; Hayase, S.; Nokami, T.; Itoh, T. Rational optimization of the mannoside building block for automated electrochemical assembly of the core trisaccharide of GPI anchor oligosaccharides. *Carbohydr. Res.* **2017**, *450*, 44-48.

(582) Sasaki, N.; Nokami, T.; Itoh, T. Synthesis of a TMG-chitotriomycin precursor based on electrolyte-free electrochemical glycosylation using an ionic liquid tag. *Chem. Lett.* **2017**, *46*, 683-685.

CHAPTER 2

Bromine-promoted glycosidation of

conformationally superarmed

thioglycosides


Panza, M.; Civera, M.; Yasomanee, J. P.; Belvisi, L.; Demchenko, A. V. Brominepromoted glycosidation of conformationally superarmed thioglycosides. *Chem. Eur. J.*, **2019**, 25, 11831-11836


2.1. Introduction

While understanding the structure and functions of carbohydrates is difficult,¹⁻³ it is glycosylation that is flawlessly executed by enzymes⁴⁻⁵ has proven a particularly challenging reaction to chemists. With the aid of modern methods, strategies, and technologies, the formation of many glycosidic bonds can now be achieved.⁶⁻¹⁰ The development of glycosylation reactions that will offer new capabilities for obtaining complex glycans with exclusive stereoselectivity and enhanced purity remains an important area of research in the field of synthetic chemistry. The goal of controlling glycosylation has been pursued in many ways, with main focus recently shifting to studying stereoelectronics and conformation of the starting material and key reaction intermediates. Although some model studies have helped to establish general trends,¹¹⁻¹⁸ practical application of the stereoelectronic and conformational factors to stereocontrol of glycosylations is still limited.

Fraser-Reid's seminal work on the armed-disarmed approach showed that the building block reactivity can be modulated through the choice of protecting groups.¹⁹⁻²⁰ In recent years, the scope of the original armed-disarmed concept has been expanded, and a number of reactivity levels that extend beyond the traditional armed-disarmed boundary have been established.²¹ Following other early work in the area,²²⁻²⁴ our group reported that 2-O-benzyl-3,4,6-tri-O-benzoyl protected donors are less reactive (superdisarmed) than their disarmed per-Bz counterparts.²⁵ This unexpected protecting group effect was explained by the existence of the O2/O5 cooperative effect that takes into consideration the stabilization of reaction intermediates, rather than only the electronics of the starting material. While studying the activation of superdisarmed thioglycosides with Br₂, we

developed conditions at which the β -bromide was the only intermediate leading to products (Scheme 2.1A).²⁶ The oxacarbenium ion either did not form or had no contribution to the formation of glycosides. As a result, the nucleophilic displacement of the β -bromide intermediate took place in the concerted fashion leading to exclusive α-stereoselectivity of all glycosylations. Since the α -bromide remained totally unreactive in this reaction, α thiogly coside precursor was fond to be a more suitable precursor to generate the desired β bromide intermediate stereoselectively (Scheme 2.1B). This strategic adjustment led to improved yields, however, unreactive glycosyl acceptors still produced only moderate yields.





<u>B. Superdisarmed α -SEt donor</u>: complete selectivity, improved yields (67% yield, >25/1 α/β)

$$\begin{array}{c} BzO \\ BzO \\ BzO \\ BnO \\ SEt \end{array} \xrightarrow{Br_2} BzO \\ BnO \\ BnO \\ BrO \\ BnO \\ BnO$$

<u>C. Armed glycosyl donor</u>: poor selectivity, high yields, fast reactions (71% yield, 2.2/1 α/β) $\begin{array}{c} OBn \\ BnO \\$

Scheme 2.1. Previous glycosidations of thioglycosides with Br2

To enhance the reaction rates and achieve more practical yields, we also investigated per-benzylated armed thioglycosides (Scheme 2.1C). Although those reactive donors could indeed be glycosidated quite rapidly in the presence of Br₂ providing good vields, a decreased stereoselectivity was encountered.²⁶ These reactions proceeded via the intermediacy of the α -bromide that was sufficiently reactive in the armed series to couple with an acceptor. Low temperature NMR experiments²⁷ showed that the β -bromide was also present at the early stage of the reaction. However, it was thought to be an insignificant intermediate *en route* to the product formation due to its rapid anomerization into the α counterpart

Described herein is our dedicated effort to extend the bromine-promoted glycosylation reaction to the investigation of glycosyl donors of the superarmed series. There are two known concepts for superarming glycosyl donors. The first concept, wherein the enhancement of reactivity was achieved by changing the equatorial-rich ${}^{4}C_{1}$ conformation to an axial-rich skew-boat conformation by creating steric congestion with tbutyldimethylsilyl (TBS) protecting groups at the C-2, 3 and 4, was introduced by Bols and co-workers.²⁸⁻³² The second concept introduced by our group involves the electronic superarming using conventions of the O2/O5 cooperative effect. According to this effect, intermediates obtained from the 2-O-benzoyl-3,4,6-tri-O-benzyl-protected glycosyl donors are stabilized both anchimerically by the ester substituent at O-2 and electronically by the O-5 that is surrounded by electron-rich ethers.³³⁻³⁵ Bols' and our groups have also jointly developed glycosyl donors with combined conformational and anchimeric superarming.³⁶⁻ ³⁷ However, none of the superarmed donors developed to date can be applied to the stereoselective synthesis of 1,2-cis glycosides. The development of highly reactive (superarmed) α -stereoselective glycosyl donors would be very useful for all investigators working on synthesizing 1,2-cis-linked glycans in solution and solid supports.³⁸

2.2. Results and discussion


With a goal of investigating superarmed glycosyl donors in application to 1,2-*cis* glycosylation, we began studying conformational properties of a series of β -ethylthio glycosides β -2.1-2.3, prepared from a common diol precursor β -2.1.³⁹ ¹H spectrum was

recorded at rt and the coupling constants were consistent with those expected for the standard ${}^{4}C_{1}$ chair conformation, typical for D-glucose derivatives.^{40,42} We have also recorded a ${}^{13}C$ { ${}^{1}H$ } NMR spectrum, and the list of signals is included in Table 2.1. Diol precursor β -**2.1** was then protected with TBS groups at C-3 and C-4 positions to obtain compound β -**2.2**. ${}^{1}H$ and ${}^{13}C$ NMR spectra were recorded at rt. The coupling constants obtained from the ${}^{1}H$ spectrum clearly showed an increasing distortion in the conformation of β -**2.2** from the standard ${}^{4}C_{1}$ conformation observed for β -**2.1**. The ${}^{HH}J$ values were consistent with the previously reported values for similar compounds.^{21, 28-30} The difference was particularly noticeable in the values for $J_{2,3}$ and $J_{3,4}$. Thus, $J_{2,3}$ decreases noticeably from 9.2 in β -**2.1** to 3.9 Hz in β -**2.2** and $J_{3,4}$ decreases from 9.2 Hz in β -**2.1** to 5.0 Hz in β -**2.2**. This change was also associated with a shift of the anomeric proton downfield from 4.51 in β -**2.1** to 4.79 ppm in β -**2.2**. This shift could be a sign of a particular distribution of functional groups around the ring. The remaining ring protons H-2-5 are all shifted downfield when TBS groups are added.

A further conformational change was observed for 3,4-di-O-triisopropylsilyl (TIPS) glucoside β -2.3 as judged by the coupling constants of $J_{2,3} = J_{3,4} = J_{4,5} = 0$ Hz. The value could be related to compound β -2.3 adopting an axial-rich conformation to release the steric strain caused by bulky silyl groups at C-3,4. All ring proton signals H-2-5 in β -2.3 experience even greater downfield $\Delta\delta$ shift than those recorded for β -2.2, while the shifts for the H-6 protons are not affected by the 3,4-*O*-silylation.

Interesting trends have also been observed by comparing the ¹³C {¹H} NMR spectra of compounds β -2.1-2.3. The chemical shifts of C-1, C-2 and C-5 were found to be particularly diagnostic of the conformational changes undergone by the ring. The trend

identified is in shifting of the C-1 and C-3 signals upfield, whereas C-2, C-4 and C-5 shift downfield. For example, the C-1 signal moves from 85.06 for β -2.1 to 82.81 of β -2.2 and to 81.23 ppm for β -2.3. In contrast, C-5 shifts from 77.82 to 79.41 to 80.79 ppm in the same sequence of compounds.



Cmpd	Signal	¹ H NMR, ppm	J, Hz	¹³ C NMR, ppm	
β-2.1	H/C-1	4.51 (d)	$J_{1,2} = 9.7$	85.06	
	H/C-2	3.28 (dd)	$J_{2,3} = 9.2$	80.87	
	H/C-3	3.63 (dd)	$J_{3,4} = 8.7$	77.95	
	H/C-4	3.47 (dd)	$J_{4,5} = 9.2$	70.13	
	H/C-5	3.55-3.59 (m)	ND	77.82	
	H/C-6	4.57 (br d) 4.69-6.62 (m)	$J_{6a,6b} = 12.1$	64.16	
β-2.2	H/C-1	4.79 (d)	$J_{1,2} = 8.3$	82.81	
	H/C-2	3.42 (dd)	$J_{2,3} = 3.9$	82.50	
	H/C-3	3.91-3.86 (m)	$J_{3,4} = 5.0$	76.45	
	H/C-4	3.80 (t)	J _{4,5} =5.0	71.68	
	H/C-5	3.97-3.91 (m)	$J_{5,6a} = 7.4$ $J_{5,6b} = 4.9$	79.41	
	H/C-6	4.41 (dd) 4.61 (dd)	$J_{6a,6b} = 11.3$	65.52	
β-2.3	H/C-1	5.05 (d)	$J_{1,2} = 8.5$	81.23	
	H/C-2	3.60 (d)	$J_{2,3} = 0$	83.09	
	H/C-3	4.16 (bs)	$J_{3,4} = 0$	70.89	
	H/C-4	4.27 (bs)	<i>J</i> _{4,5} =0	75.71	
	H/C-5	4.24 (t)	$J_{5,6a} = 6.9$ $J_{5,6b} = 6.9$	80.79	
	H/C-6	4.50 (dd) 4.62 (dd)	$J_{6a,6b} = 11.0$	66.13	

Table 2.1. N	NMR	data	for	thioglyc	osides	β-2.	1-2	.3
--------------	-----	------	-----	----------	--------	------	-----	----

Due to the significant changes in the coupling constants, ring distortion was anticipated. Computational experiments were set up to investigate whether the *in silico* data would support the experimental data, in collaboration with the laboratory of Prof. Laura Belvisi. The calculations were conducted by Dr. Monica Civera. A series of computational studies was performed on the compounds β -**2.1-2.3**. Computational models of thioglycosides β -**2.2** and β -**2.3** were built by implementing the following workflow. 1) Monte Carlo/Energy Minimization (MC/EM) conformational search was carried out at the molecular mechanics level (OPLS2005 force field) leaving all dihedral angles free to move. 2) Representative minimum-energy geometries of MC/EM search was optimized at the DFT B3LYP/6-31G* level of theory. 3) The obtained stationary points were confirmed as minima by calculating vibrational frequencies at the same level of theory and their thermochemical properties, including the final denoted total Gibbs free energy, were computed. DFT minimum energy structures and relative energy differences, resulting from these computational studies, are summarized in Table 2.2.

Cmpd	Conformation	Relative energy
β-2.2	⁴ C ₁ chair	0.00 kcal mol ⁻¹
	¹ C ₄ chair	0.75 kcal mol ⁻¹
	^{3,0} B boat	1.32 kcal mol ⁻¹
	${}^{2}S_{O}$ skew-boat	2.53 kcal mol ⁻¹
β-2.3	³ S ₁ skew-boat	0.00 kcal mol ⁻¹
	¹ C ₄ chair	2.24 kcal mol ⁻¹
	² S ₀ skew-boat	4.72 kcal mol ⁻¹

Table 2.2. DFT B3LYP/6-31G* minimum energy structures of thioglycosides β-2.2 and β-2.3 with relative Gibbs free energies

In the case of compound β -2.2, the standard ${}^{4}C_{1}$ chair conformation is the most stable, whereas the axial-rich ${}^{1}C_{4}$ chair and ${}^{3,O}B$ boat conformations lie 0.75 and 1.32 kcal mol⁻¹, respectively, above the minimum energy structure, likely contributing to the conformational equilibrium. Interestingly, the axial-rich skew-boat conformation ${}^{3}S_{1}$ was located by DFT calculations as the lowest energy minimum of the 3,4-OTIPS glucoside β -2.3 (Figure 2.1), followed by the ${}^{1}C_{4}$ chair at 2.24 kcal mol⁻¹. The computational data achieved for thioglycosides β -2.2 and β -2.3 match well the experimental trend, with the calculated coupling constant values of the most stable skew-boat conformation of β -2.3 being very close to the experimental ones (See appendix, Table A-1 and A-2)




Figure 2.1. DFT-optimized ³S₁ skew-boat conformation of the 3,4-OTIPS thioglucoside β-2.3 (hydrogens and phenyl groups have been omitted for clarity in the ball and stick 3D-representation)

To study the reactivity of thioglycoside β -2.2, the respective bromide 2.4 was generated by the reaction with Br₂ following previously established reaction conditions.²⁶ We theorized that the activation of superarmed donors with Br₂ will allow us to investigate

whether the conformational superarming may offer additional stabilization modes to the anticipated β -bromide intermediate. When donors in the traditional ${}^{4}C_{1}$ conformation are used for the synthesis of β -bromides, the latter are able to undergo conformational changes to adopt the axial or pseudoaxial orientation (Figure 2.2).⁴³ Since this adopted conformation is unstable, the β -bromide equilibrates into the thermodynamically stable α counterpart and hence returns to its original ⁴C₁ conformation. Conversely, if the starting donor is already present as a skew-boat, as determined for the conformationally superarmed donors, the formation of β -bromide will additionally reinforce the all-axial conformation. If the axial β -bromide is stabilized by the anomeric effect, as in compounds with the preferred ${}^{1}C_{4}$ conformation (Figure 2.2), it will be both kinetically and thermodynamically stable and will not equilibrate (or will equilibrate much slower) into the α -counterpart. The analogy is found in Matsuda and Shuto's study of xylose derivatives and their observation of altered anomeric effect and reversed stereoselectivity in glycosylations.⁴⁴⁻⁴⁵ However, the hexose chair is much more difficult to flip due to the CH₂OR substituent at C-5 that has a strong propensity to reside equatorially.⁴⁶





Figure 2.2. Conformation and stereoselectivity of β-bromides

Thus, bromide **2.4** obtained from 3,4-O-TBS donor β -**2.2** was studied using a 300 MHz NMR as depicted in Scheme 2.2. Molecular bromine was injected into a frozen

solution of the donor in CDCl₃. The mixture was allowed to melt at -50 °C and then ¹H NMR spectra were recorded at different time points. The starting material has been completely consumed within the first 5 min of the reaction monitoring, as judged by disappearance of the diagnostic signal for H-2 at 3.42 ppm. The presence of both α - and β -bromides **2.4** was also detected at this timepoint. The signal for H-1 at 6.50 ppm is diagnostic, but it cannot be used for quantifying the ratios of bromides because it coincides for both anomers. In this respect, reaction monitoring using more diagnostic signals at 3.94 ppm for H-2, H-3 of β -**2.4** and at 3.25 ppm for H-2 of α -**2.4** was proven most convenient.

As shown in Scheme 2.2, the anomeric mixture of bromides 2.4 has almost completely converted into the α -anomer at 30 min timepoint. Also evident at this timepoint is the presence of a decomposed by-product due to the anticipated partial loss of TBS protecting groups. This was an indication that the chosen starting β -thioglycoside is probably not the most suitable precursor for generating the β -bromide, even with the assistance of the TBS groups. It should be noted that we also attempted to convert thioglycoside β -2.3 into the corresponding bromide. Unfortunately, this attempt was largely unsuccessful due to a very rapid cleavage of TIPS groups the presence of Br₂, perhaps due to a significant weakening of the O-Si bonds due to the steric congestion that these compounds experience.

In the attempt of achieving a more stereocontrolled formation of the reactive β bromide intermediate, we turned our attention to investigating α -configured SEt donor. The analogy can be found in our previous study wherein superdisarmed α -SEt precursor produced the corresponding β -bromide predominantly.²⁶ Starting from diol α -**2.1**, we obtained TBS and TIPS protected thioglycosides, α -**2.2** and α -**2.3**, respectively. The coupling constants calculated from their proton NMR spectra clearly demonstrated the conformational changes taking place. Thus, in the series of compounds α -2.1, α -2.2 and α -2.3, the $J_{2,3}$ value decreases from 9.5 to 7.4 to 3.7 Hz. Coupling constants $J_{3,4}$ and $J_{4,5}$ behave similarly showing a steady decrease (Table 2.3). Differently from the β -series, no dramatic signal shifts were observed in the ¹H and ¹³C NMR spectra of the α -series. As a matter of fact, the chemical shift difference between α -2.1 and α -2.2 is minimal, with somewhat more significant changes observed for α -2.3. This observation may be an indication of notable changes taking place upon transition from TBS to sterically more demanding TIPS groups.



Scheme 2.2. Conversion of 3,4-di-O-TBS β-SEt glucoside β-2.2 into α,β-bromides 2.4

The computational data for α -thioglycosides was also consistent with the experimental observations. Computational models of thioglycosides α -2.2 and α -2.3 were built by implementing the same protocol as that applied to the β -series. Only ⁴C₁ and ¹C₄ chair conformations were located as minimum energy structures, showing the importance


of the axial-rich ${}^{1}C_{4}$ chair geometry for compound α -**2.3** always higher than that for α -**2.2**, according to both relative SCF DFT/B3LYP and Gibbs free energies (see appendix, Tables A-3 and A-4).

To study the reactivity of this series of compounds, the NMR monitoring of the formation of anomeric bromide **2.4** from thioglycoside α -**2.2** was conducted. The procedure used herein was the same as that applied to the β -counterpart of **2.2** (*vide supra*). After 5 minutes, only β -bromide **2.4** was detected. At the 10-minute timepoint, the intermediate is still largely β -**2.4**, and only a small peak at $\delta \approx 3.3$ ppm is indicating the beginning of the anomerization process to α -**2.4**. Only after 2 hours, the reactive bromide β -**2.4** has completely anomerized to α -**2.4**.

Computational models of α - and β -bromides **2.4** were built by implementing the same protocol applied for thioglycosides yet using the LACVP basis set due to the presence of bromine atoms. Only standard ⁴C₁ chair conformations were achieved for compound α -**2.4**, whereas a distorted ^{1,4}B boat (or an unusual ⁴S₂ skew-boat) conformation was located by DFT calculations as the lowest energy minimum of compound β -**2.4** (Appendix, Tables A-5-2.-6).

Having acquired the evidence of adequate stability of the reactive intermediate β -2.4, glycosidations of donor α -2.2 with model glycosyl acceptors were conducted. At first, when Br₂ was added to the reaction mixture containing donor α -2.2 and a glycosyl acceptor at -50°C we observed that the formation of the desired disaccharide was accompanied by the formation of multiple by-products. These products were formed as a result of competing side reactions including hydrolysis and partial deprotection of the TBS groups. Therefore, to suppress the side reactions, we chose to add a sub-stoichiometric amount of

a base to each glycosylation reaction mixture. Three basic additives were investigated: triethylamine (TEA), N,N-diisopropylethylamine (DIPEA) and 1,8-diazabicycloundec-7-ene (DBU), and all three provided comparable results.




Cmpd	Signal	¹ H NMR, ppm	J, Hz	¹³ C NMR, ppm
α-2.1	H/C-1	5.44 (d)	$J_{1,2} = 5.4$	82.69
	H/C-2	3.64 (dd)	$J_{2,3} = 9.5$	78.56
	H/C-3	3.85 (t)	$J_{3,4} = 9.4$	73.60
	H/C-4	3.50 (t)	$J_{4,5} = 9.4$	70.21
	H/C-5	4.32 (ddd)	$J_{5,6a} = 5.1$ $J_{5,6b} = 1.9$	69.86
	H/C-6	4.58-4.47 (m) 4.69 (dd)	$J_{6a,6b} = 12.1$	63.98
α-2.2	H/C-1	5.41 (d)	$J_{1,2} = 4.9$	82.54
	H/C-2	3.61 (dd)	$J_{2,3} = 7.4$	79.25
	H/C-3	3.96-3.93 (m)	$J_{3,4} = 6.0$	73.92
	H/C-4	3.65 (dd)	$J_{4,5} = 8.7$	72.95
	Н/С-5	4.35-4.31 (m)	$J_{5,6a} = 7.0$ $J_{5,6b} = 2.1$	71.65
	H/C-6	4.38 (dd) 4.59 (dd)	$J_{6a,6b} = 11.5$	64.52
α-2.3	H/C-1	5.41 (d)	$J_{1,2} = 3.4$	79.73
	H/C-2	3.68 (t)	$J_{2,3} = 3.7$	78.31
	H/C-3	4.26-4.22 (m)	$J_{3,4} = 2.7$	71.94
	H/C-4	3.96 (dd)	$J_{4,5} = 4.9$	71.39
	Н/С-5	4.42-4.37 (m)	$J_{5,6a} = 7.9$ $J_{5,6b} = 3.4$	75.12
	H/C-6	4.45 (dd) 4.74 (dd)	$J_{6a,6b} = 11.8$	63.48

Table 2.3. NMR data for thioglycosides α-2.1-2.3

Under these reaction conditions, glycosidation of donor α -2.2 with primary 6-OH glycosyl acceptor 2.5 afforded the desired disaccharide 2.6 in high yields of 82-95% and with complete α -stereoselectivity (entry 1, Table 2.4). Glycosidation of donor α -2.2 with secondary 2-OH glycosyl acceptor 2.7 afforded the desired disaccharide 2.8 in good yields of 74-79% and with good α -stereoselectivity ($\alpha/\beta = 8-13/1$, entry 2). Highly reactive aliphatic alcohols such as 'PrOH, cyclohexanol, and benzyl alcohol were investigated, affording the target glucosides 2.9-2.11 in high yields 78-99%, albeit unremarkable stereoselectivity ($\alpha/\beta = 2-5/1$, entries 3-5). This poor stereoselectivity may be a result of a direct displacement of the anomeric α -bromide with powerful nucleophiles that does not take place with sugar acceptors. 3,4-OTIPS protected donor α -2.3 provided a similar reactivity trend, summarized in Table 2.5, but its glycosidations were compromised by the competing silyl group cleavage, even in the presence of a base (see the experimental for additional experimental data).


2.3. Conclusions

We expanded the application of Br_2 -mediated glycosidation of thioglycosides to glycosyl donors of the superarmed series. Over the course of this study, we investigated the formation of the reactive intermediates that were monitored and characterized by NMR spectroscopic techniques. An extensive conformational analysis of the donor through coupling constants values and carbon-hydrogen correlation was performed. Furthermore, the stability of β -bromide in solution over time was studied using NMR. The experimental data are supported by the molecular mechanic calculations and the DFT studies. Glycosylation reactions were performed with a group of standard acceptors, achieving high yields and high to complete stereoselectivity sugar acceptors. These results complement our other recent studies dedicated to the activation of glycosyl halides.⁴⁷⁻⁵⁰



Entry	Acceptor	Base	Product	Yield and α/β ratio
1	BnO BnO BnO BnO _{OMe} 2.5	none TEA DBU DIPEA	TBSO TBSO BnO BnO BnO BnO BnO BnO CMe 2.6	Multiple products 82%, α-only 95%, α-only 95%, α-only
2	BnO BnO HO OMe 2.7	None TEA DBU DIPEA	TBSO TBSO BnO BnO BnO BnO C SnO C SnO C SnO C SnO C SnO C S C S C S C S C S C S C S C S C S C	Multiple products 79%, 13.0/1 74%, 8.5/1 74%, 8.0/1
3	ⁱ PrOH	TEA DBU DIPEA	TBSO TBSO Bno S	99%, 5.0/1 94%, 5.0/1 94%, 4.0/1
4	СуОН	TEA DBU DIPEA	TBSO TBSO BnO O 2.10	99%, 2.0/1 78%, 4.0/1 78%, 4.0/1
5	BnOH	TEA DBU DIPEA	TBSO TBSO BnO _{OBn} 2.11	99%, 3.0/1 81%, 4.0/1 84%, 3.0/1

Table 2.5. Reactions of 3,4-O-TIPS donor



Entry	Acceptor	Base	Product	Yield and α/β ratio
1	Bno OH Bno Bno OMe Bno OMe	TEA DBU DIPEA	TIPSO TIPSO BnO BnO BnO BnO BnO OMe 2.12	81%, α-only 70%, 7.5/1 68%, 7.5/1
2	Bno Bno Ho OMe 2.6	TEA DBU DIPEA	TIPSO TIPSO Bno Bno Bno Bno C Bno C Bno C Bno C C C C C C C C C C C C C C C C C C C	24%, 3.0/1 50%, 8.5/1 35%, 8.0/1
3	ⁱ PrOH	TEA DBU DIPEA		99%, 1/1 70%, 1/1.4 72%, 1/1.4
4	СуОН	TEA DBU DIPEA	TIPSO TIPSO BNO O 2.15	99%, 1/1 74%, 1/1.3 86%, 1.6/1
5	BnOH	TEA DBU DIPEA	TIPSO TIPSO Bno OBn 2.16	99%, 1/1 61%, 1.2/1 44%, 1/1.4

2.4. Experimental

2.4.1. General experimental

Column chromatography was performed on silica gel 60 (70-230 mesh), reactions were monitored by TLC on Kieselgel 60 F254. The compounds were detected by examination under UV light and by charring with 10% sulfuric acid in methanol. Solvents were removed under reduced pressure at <40 °C. CH₂Cl₂ was distilled from CaH₂ directly prior to application. Molecular sieves (3 Å or 4 Å), used for reactions, were crushed and activated *in vacuo* at 390 °C for 16 h in the first instance and then for 2-3 h at 390 °C directly prior to application. Optical rotations were measured at 'Jasco P-2000' polarimeter. Unless noted otherwise, ¹H NMR spectra were recorded in CDCl₃ at 300 or 600 MHz, ¹³C NMR spectra were recorded in CDCl₃ at 75 or 151 MHz. HRMS determinations were made with the use of a mass spectrometer with FAB ionization and ion-trap detection.

2.4.2. Synthesis of glycosyl donors and acceptors

Ethyl 6-*O*-benzoyl-2-*O*-benzyl-1-thio- α -D-glucopyranoside (α -2.1). Et₃N (12 mL) was added to a stirring solution of ethyl 2-*O*-benzyl-1-thio- α -D-glucopyranoside³⁷ (2.17, 560 mg, 1.8 mmol) in MeCN (25 mL). The resulting solution was cooled at -30 °C, a solution of BzCN (237 mg, 1.9 mmol) in MeCN (20 mL) was added, and the resulting mixture was stirred for 2 h at -30 °C. After that, the reaction was quenched with MeOH (~ 2 mL), and the volatiles were removed *in vacuo*. The residue was purified by column chromatography on silica gel (hexanes-ethyl acetate gradient elution) to give the title compound as a white amorphous solid in 70% yield (527 mg). Analytical data for α -2.1: R_f = 0.6 (methanol/DCM, 1/9, v/v); $[\alpha]_{D}^{22}$ +151.3 (*c* 1, CHCl₃); ¹H NMR (600 MHz, CDCl₃): δ , 8.01-8.06 (m, 2H, aromatic), 7.56 (dd, 1H, *J* = 10.6, 4.3 Hz, aromatic), 7.43 (t, 2H, *J* = 7.8 Hz, aromatic), 7.39 (d, 2H, *J* = 7.0 Hz, aromatic), 7.35 (dd, 2H, *J* = 10.1, 4.7 Hz, aromatic), 7.31 (dd, *J* = 8.3, 6.0 Hz, 1H, aromatic), 5.44 (d, 1H, *J*_{1,2} = 5.4 Hz, H-1), 4.73 (d, 1H, ²*J* = 11.4 Hz, C*H*₂Ph), 4.69 (dd, 1H, *J*_{6a,6b} = 12.1 Hz, H-6a), 4.49-4.55 (m, 2H, H-6b, C*H*₂Ph), 4.32 (ddd, 1H, *J*_{5,6a} = 1.9 Hz, *J*_{5,6b} = 5.1 Hz, H-5), 3.85 (dd, 1H, H-3), 3.64 (dd, 1H, *J*_{2,3} = 9.5 Hz, H-2), 3.50 (dd, 1H, *J*_{3,4} = *J*_{4,5} = 9.4 Hz, H-4), 3.17 (s, 1H, OH), 2.97 (s, 1H, OH), 2.55 (m, 2H, CH₂CH₃), 1.26 (t, 3H, *J* = 7.4 Hz, CH₂CH₃) ppm; ¹³C NMR (151 MHz, CDCl₃): δ , 167.06 (C=O), 137.41 (aromatic), 128.51 (x2, aromatic), 128.39 (x2, aromatic), 128.30 (aromatic), 82.69 (C-1), 78.56 (C-2), 73.60 (C-3), 72.10 (CH₂Ph), 70.21 (C-4), 69.86 (C-5), 63.98 (C-6), 23.95 (CH₂CH₃), 14.89 (CH₂CH₃) ppm; HR-FAB MS [M+Na]⁺ calcd for C₂₂H₂₆NaO₆S⁺ 441.1348, found 441.1338.

Ethyl 6-*O*-benzoyl-2-*O*-benzyl-3,4-di-*O*-tert-butyldimethylsilyl-1-thio- α -D-glucopyranoside (α -2.2). TBSOTf (1.8 mL, 8.1 mmol) was added to a solution of α -2.1 (1.35 g, 3.2 mmol) in 2,6-lutidine (12 mL) and the resulting mixture was stirred for 16 h at 100 °C. After that, the reaction mixture was diluted with DCM (~100 mL) and washed successively with 1 M HCl (3 x 10 mL), sat. aq. NaHCO₃ (3 x 10 mL), and water (3 x10 mL). The organic layer was separated, dried with MgSO₄, and concentrated *in vacuo*. The residue was purified by column chromatography on silica gel (hexanes-ethyl acetate gradient elution) to afford the title compound as a colorless syrup in 99% yield (2.05 g). Analytical data for α -2.2: $R_f = 0.8$ (ethyl acetate/hexane, 1/4, v/v); $[\alpha]_D^{22}$ +97.8 (*c* 1,

CHCl₃); ¹H NMR (600 MHz, CDCl₃): δ , 8.08-8.03 (m, 2H, aromatic), 7.56 (t, J = 7.4 Hz, 1H, aromatic), 7.43 (dd, J = 14.1, 7.3 Hz, 4H, aromatic), 7.33 (t, J = 7.4 Hz, 2H, aromatic), 7.28 (t, J = 7.3 Hz, 1H, aromatic), 5.41 (d, $J_{1,2} = 4.9$ Hz, 1H, H-1), 4.63 (d, ${}^{2}J = 11.3$ Hz, 1H, CH₂Ph), 4.59 (dd, $J_{5.6a} = 2.1$, $J_{6a,6b} = 11.5$ Hz, 1H, H-6a), 4.55 (d, 1H, CH₂Ph), 4.38 $(dd, J_{5,6b} = 7.0 \text{ Hz}, 1\text{H}, \text{H-6b}), 4.35-4.31 \text{ (m, 1H, H-5)}, 3.95 \text{ (m, } J_{3,4} = 8.7 \text{ Hz}, 1\text{H}, \text{H-3}),$ 3.65 (dd, $J_{4,5} = 6.0$ Hz, 1H, H-4), 3.61 (dd, $J_{2,3} = 7.4$ Hz, 1H, H-2), 2.61-2.49 (m, 2H, CH₂CH₃), 1.21 (t, J = 7.4 Hz, 3H, CH₂CH₃), 0.92 (s, 9H, Si'Bu), 0.86 (s, 9H, Si'Bu), 0.15 (s, 3H, SiMe), 0.10 (s, 3H, SiMe), 0.04 (s, 3H, SiMe), 0.00 (s, 3H, SiMe) ppm; ¹³C NMR (151 MHz, CDCl₃): δ, 166.51 (C=O), 137.79 (aromatic), 133.08 (aromatic), 130.22 (aromatic), 129.76 (x2, aromatic), 128.46 (x2, aromatic), 128.43 (x2, aromatic), 128.30 (x2, aromatic), 127.87 (aromatic), 82.49 (C-1), 79.19 (C-2), 73.86 (C-3), 72.90 (C-4), 72.50 (CH₂Ph), 71.60 (C-5), 64.47 (C-6), 26.42 (x3, SiC(CH₃)₃), 26.20 (x3, SiC(CH₃)₃), 23.75 (CH₂CH₃), 18.33 (SiC(CH₃)₃), 18.23 (SiC(CH₃)₃), 14.86 (CH₂CH₃), -2.60 (SiMe), -2.80 (SiMe), -3.38 (SiMe), -4.15 (SiMe) ppm; HR-FAB MS [M+Na]⁺ calcd for C₃₄H₅₄NaO₆SSi₂⁺ 669.3072, found 669.3082.

Ethyl 6-*O*-benzoyl-2-*O*-benzyl-1-thio-3,4-di-*O*-triisopropylsilyl- α -D-glucopyranoside (α -2.3). TIPSOTf (1.46 mL, 5.4 mmol) was added dropwise to a solution α -2.1 (450 mg, 1.08 mmol) in 2,6-lutidine (8.0 mL) and the resulting mixture was stirred for 16 h at 100 °C. After that, the reaction mixture was diluted with DCM (~50 mL) and washed successively with 1 M aq. HCl (3 x 10 mL), NaHCO₃ (3 x 10 mL) and water (3 x 10 mL). The organic layer was separated, dried with MgSO₄, and concentrated *in vacuo*. The residue purified by column chromatography on silica gel (hexanes-ethyl acetate gradient

elution) to obtain the title compound as a colorless syrup in 99% yield (782 mg). Analytical data for α -2.3: $R_f = 0.8$ (ethyl acetate/hexane, 1/4, v/v); $[\alpha]_D^{23} + 58.1$ (c 0.7, CHCl₃); ¹H NMR (600 MHz, CDCl₃): δ , 8.06 (d, J = 8.1 Hz, 2H, aromatic), 7.57-7.53 (m, 1H, aromatic), 7.42 (dd, J = 15.1, 7.4 Hz, 4H, aromatic), 7.31 (t, J = 7.6 Hz, 2H, aromatic), 7.25 (dd, J = 10.2, 4.0 Hz, 1H, aromatic), 5.41 (d, $J_{1,2} = 3.4$ Hz, 1H, H-1), 4.74 (dd, $J_{5,6a} =$ 7.9, $J_{6a,6b} = 11.8$ Hz, 1H, H-6a), 4.70-4.63 (m, 2H, CH₂Ph), 4.45 (dd, $J_{5,6b} = 3.4$ Hz, 1H, H-6b), 4.42-4.37 (m, 1H, H-5), 4.26-4.22 (m, $J_{3,4}$ = 2.7 Hz, 1H, H-3), 3.96 (dd, $J_{4,5}$ = 4.9 Hz, 1H, H-4), 3.68 (dd, $J_{2,3} = 3.7$ Hz, 1H, H-2), 2.71-2.59 (m, 2H), 1.23 (t, J = 7.4 Hz, 3H), 1.10-1.01 (m, 42H) ppm; ¹³C NMR (151 MHz, CDCl₃): δ, 166.53 (C=O), 138.08 (aromatic), 133.06 (aromatic), 130.20 (aromatic), 129.81 (x2, aromatic), 128.37 (x2, aromatic), 128.17 (x2, aromatic), 127.82 (x2, aromatic), 127.56 (aromatic), 79.73 (C-1), 78.31 (C-2), 75.12 (C-5), 72.49 (CH₂Ph), 71.94 (C-3), 71.39 (C-4), 63.48 (C-6), 24.81 (CH₂CH₃), 18.40 (x3, iPr), 18.32 (x3, iPr), 18.30 (x3, iPr), 18.29 (x3, iPr), 17.83 (iPr), 15.13 (CH₂CH₃), 12.97(x2, iPr), 12.77(x2, iPr), 12.40 (iPr) ppm; HR-FAB MS [M+Na]⁺ calcd for C₃₄H₅₄NaO₆SSi₂⁺ 753.4016, found 753.4031.

Ethyl 6-*O***-benzoyl-2-***O***-benzyl-1-thio-β-D-glucopyranoside (β-2.1) was synthesized in accordance with the reported procedure³⁷ and its analytical data were in accordance with that previously described.³⁷ Selected analytical data for β-2.1: ¹H NMR (600 MHz, CDCl₃): \delta, 8.06 (d,** *J* **= 8.0 Hz, 2H, aromatic), 7.58 (t,** *J* **= 7.4 Hz, 1H, aromatic), 7.45 (t,** *J* **= 7.1 Hz, 2H, aromatic), 7.42-7.27 (m,** *J* **= 30.7, 16.7, 7.4 Hz, 5H, aromatic), 4.97 (d, ²***J* **= 11.0 Hz, 1H, CH₂Ph), 4.69-4.62 (m, 2H, H-6a, CH₂Ph), 4.57 (br d,** *J***_{6a,6b} = 12.1 Hz, 1H, H-6b), 4.51 (d,** *J***_{1,2} = 9.7 Hz, 1H, H-1), 3.63 (dd,** *J***_{3,4} = 8.7 Hz, 1H, H-3), 3.59-3.55 (m, 1H, H-5), 3.47**

(dd, $J_{4,5} = 9.2$ Hz, 1H, H-4), 3.28 (dd, $J_{2,3} = 9.2$ Hz, 1H, H-2), 3.09 (br s, 1H, OH), 2.82-2.69 (m, 2H, CH_2CH_3), 2.66 (br s, 1H, OH), 1.32 (t, J = 7.4 Hz, 3H, CH_2CH_3) ppm; ¹³C NMR (151 MHz, CDCl₃): δ , 167.26 (C=O), 138.03 (aromatic), 133.44 (aromatic), 129.99 (x2, aromatic), 129.76 (aromatic), 128.78 (x2, aromatic), 128.54 (x2, aromatic), 128.49 (x2, aromatic), 128.32 (aromatic), 85.06 (C-1), 80.87 (C-2), 77.95 (C-3), 77.82 (C-5), 75.30 (CH₂Ph), 70.13 (C-4), 64.16 (C-6), 25.32 (CH₂CH₃), 15.26 (CH₂CH₃).

6-O-benzoyl-2-O-benzyl-3,4-di-O-tert-butyldimethylsilyl-1-thio-β-D-Ethyl glucopyranoside (β -2.2) was synthesized in accordance with the reported procedure and its analytical data were in accordance with that previously described.³⁶ Analytical data for **β-2.2**: $R_f = 0.8$ (ethyl acetate/hexane 1/4 v/v); ¹H NMR (600 MHz, CDCl₃): δ, 8.09-8.01 (m, 2H, aromatic), 7.56 (t, J = 7.4 Hz, 1H, aromatic), 7.48-7.27 (m, 7H, aromatic), 4.87-4.77 (m, 2H, $J_{1,2} = 8.4$ Hz, H-1, $\frac{1}{2}$ CH₂Ph), 4.68 (d, $^{2}J = 11.2$ Hz, 1H, CH₂Ph), 4.61 (dd, $J_{5,6a} = 4.9$, $J_{6a,6b} = 11.3$ Hz, 1H, H-6a), 4.41 (dd, $J_{5,6b} = 7.4$ Hz, 1H, H-6b), 3.97-3.91 (m, 1H, H-5), 3.91-3.86 (m, $J_{3,4} = 5.0$ Hz, 1H, H-3), 3.80 (dd, $J_{4,5} = 5.0$ Hz, 1H, H-4), 3.42 (dd, $J_{2,3} = 3.9$ Hz, 1H, H-2), 2.83-2.61 (m, 2H, CH₂CH₃), 1.28 (t, J = 7.4 Hz, 3H, CH₂CH₃), 0.92 (s, 9H, Si^tBu), 0.89 (s, 9H, Si^tBu), 0.11 (s, 3H, SiMe), 0.09 (s, 6H, SiMe₂), 0.05 (s, 3H, SiMe) ppm; ¹³C NMR (151 MHz, CDCl₃): δ, 166.34 (C=O), 138.42 (aromatic), 133.09 (aromatic), 130.19 (aromatic), 129.74 (x2, aromatic), 128.43 (x2, aromatic), 128.26 (x2, aromatic), 127.71 (x2, aromatic), 127.56 (aromatic), 82.81 (C-1), 82.50 (C-2), 79.41 (C-5), 76.44 (C-3), 73.51 (CH₂Ph), 71.68 (C-4), 65.52 (C-6), 26.31 (x3, SiC(CH₃)₃), 26.06 $(x_3, SiC(CH_3)_3), 25.37 (CH_2CH_3), 18.20 (SiC(CH_3)_3), 18.14 (SiC(CH_3)_3), 15.21$ (CH₂CH₃), -3.30 (SiMe), -3.41 (SiMe), -3.89 (SiMe), -4.26 (SiMe) ppm.

Ethyl 6-O-benzoyl-2-O-benzyl-1-thio-3,4-di-O-triisopropylsilyl-B-D-glucopyranoside (β -2.3) was obtained in 99% yield (amount) as described for the synthesis of α -2.3. Analytical data for **β-2.3**: $R_f = 0.7$ (ethyl acetate/hexane 1/4 v/v); $[\alpha]_D^{23}$ -7.0 (*c* 1, CHCl₃); ¹H NMR (600 MHz, CDCl3): δ , 8.04 (d, J = 8.0 Hz, 2H, aromatic), 7.56 (t, J = 7.4 Hz, 1H, aromatic), 7.43 (t, J = 7.1 Hz, 2H, aromatic), 7.36-7.23 (m, 5H, aromatic), 5.05 (d, $J_{1,2} =$ 8.5 Hz, 1H, H-1), 4.91 (d, ${}^{2}J$ = 11.3 Hz, 1H, ${}^{1}/_{2}$ CH₂Ph), 4.66-4.59 (m, 2H, $J_{5,6a}$ = 6.6 Hz, H-6a, $\frac{1}{2}$ CH₂Ph), 4.50 (dd, $J_{5.6b} = 6.6$ Hz, $J_{6a.6b} = 11.0$, 1H, H-6b), 4.27 (br s, 1H, H-4), 4.24 (dd, 1H, H-5), 4.16 (d, *J*_{3,4} = 3.0 Hz, 1H, H-3), 3.60 (d, 1H, H-2), 2.83-2.68 (m, 2H), 1.32 $(m, J = 7.4, 1.5 \text{ Hz}, 3\text{H}, \text{CH}_2\text{CH}_3), 1.08 (s, 21\text{H}), 1.01 (m, 21\text{H}) \text{ ppm}; {}^{13}\text{C} \text{ NMR} (151 \text{ MHz}, 1.5 \text{ Hz}, 1.5 \text{ Hz}, 3.5 \text{ Hz})$ CDCl₃): δ, 166.39 (C=O), 138.74 (aromatic), 133.05 (aromatic), 130.28 (aromatic), 129.80 (x2, aromatic), 128.37 (x2, aromatic), 128.10 (x2, aromatic), 127.75 (x2, aromatic), 127.38 (aromatic), 83.09 (C-2), 81.23 (C-1), 80.79 (C-5), 75.71 (C-4), 73.62 (CH₂Ph), 70.89 (C-3), 66.13 (C-6), 25.27 (CH₂CH₃), 18.31 (x3, iPr), 18.24 (x3, iPr), 18.15 (x6, iPr), 15.32 (CH_2CH_3) , 12.48 (x3, iPr), 12.33 (x3, iPr) ppm; HR-FAB MS $[M+Na]^+$ calcd for C₃₄H₅₄NaO₆SSi₂⁺ 753.4016, found 753.4025.

Methyl 2,3,4-tri-O-benzyl- α -D-glucopyranoside (2.5) was synthesized in accordance with the reported procedure and its analytical data was in accordance with that previously described.⁵⁸⁻⁵⁹

Methyl 3,4,6-tri-O-benzyl- α -D-glucopyranoside (2.7) was synthesized in accordance with the reported procedure and its analytical data was in accordance with that previously described.⁵⁸⁻⁵⁹

2.4.3. Synthesis of glycosides

General glycosylation procedure. A mixture of a glycosyl donor (0.046 mmol), glycosyl acceptor (0.046 mmol), and freshly activated molecular sieves (3 Å, 120 mg) in CH₂Cl₂ (2.0 mL) was stirred under argon for 3 h at rt. The mixture was cooled to -50 °C, Br₂ (0.092 mmol, 15.0 μ L) and a base (0.014 mmol) were added and the resulting mixture was stirred for 5 min. After that, the reaction mixture was allowed to warm to rt and stirred for additional 16 h. Triethylamine (~0.1 mL) was added, the solid was filtered off and rinsed successively with CH₂Cl₂. The combined filtrate (~60 mL) was concentrated *in vacuo*. The residue was purified by column chromatography on silica gel (toluene-ethyl acetate gradient elution) to afford the corresponding glycoside.

Methyl 6-*O*-(6-*O*-benzoyl-2-*O*-benzyl-3,4-di-*O*-tert-butyldimethylsilyl- α -D-glucopyranosyl)-2,3,4-tri-*O*-benzyl- α -D-glucopyranoside (2.6) was prepared as a colorless syrup from donor α -2.2 and acceptor 2.5 in accordance with the general procedure in the presence of TEA, DBU or DIPEA in 82, 95 or 95% yield, respectively. Analytical data for 2.6: $R_f = 0.65$ (ethyl acetate/toluene, 1/9, v/v); $[\alpha]_D^{24}$ +83.9 (*c* 1, CHCl₃); ¹H NMR (300 MHz, CDCl₃): δ , 8.00 (d, J = 7.6 Hz, 2H, aromatic), 7.53 (t, J = 7.3 Hz, 1H, aromatic), 7.43-7.14 (m, 24H, aromatic), 4.96 (d, ²J = 11.0 Hz, 1H, CH₂Ph), 4.90-4.74 (m, 3H, CH₂Ph, H-1'), 4.68 (d, ²J = 12.0 Hz, 1H, ¹ $_{2}$ CH₂Ph), 4.64-4.43 (m, 6H, H-1, 6b', 2 x CH₂Ph,), 4.24

(dd, $J_{5',6a'} = 6.7$ Hz, $J_{6a',6b'} = 11.5$, 1H, H-6a'), 4.06-3.89 (m, $J_{3',4'} = 9.2$ Hz 3H, H-3, 3', 5), 3.79-3.68 (m, 2H, H-5, 6b), 3.59-3.49 (m, 2H, H-4, 6a), 3.44 (dd, $J_{4',5'} = 9.2$ Hz, 1H, H-4'), 3.40-3.22 (m, 5H, H-2, 2', OCH₃), 0.89 (s, 9H, Si'Bu), 0.85 (s, 9H, Si'Bu), 0.13 (s, 3H, SiMe), 0.10 – -0.06 (m, 9H, 3x SiMe); ¹³C NMR (151 MHz, CDCl₃): δ , 166.4, 139.1, 138.5, 138.4, 133.0, 130.4, 129.8, 128.5 (x3), 128.4 (x2), 128.2, 128.1, 128.0, 127.8 (x2), 127.7, 127.6, 98.0, 96.4, 82.3, 80.4 (x2), 78.4, 77.4, 77.2, 77.0, 75.7, 75.2, 74.1, 73.5, 73.1, 72.5, 71.0, 70.4, 65.8, 64.4, 55.1, 26.8, 26.4, 18.6, 18.3, 0.1, -2.0, -2.1, -2.8, -3.9 ppm; HR-FAB MS [M+Na]⁺ calcd for C₆₀H₈₀NaO₁₂Si₂⁺ 1071.5086, found 1071.5088.

Methyl 2-*O*-(6-*O*-benzoyl-2-*O*-benzyl-3,4-di-*O*-*tert*-butyldimethylsilyl-*α*/β-Dglucopyranosyl)-3,4,6-tri-*O*-benzyl-*α*-D-glucopyranoside (2.8) was prepared as a colorless syrup from donor *α*-2.2 and acceptor 2.7 in accordance with the general procedure in the presence of TEA, DBU or DIPEA in 79, 74 or 74% yield, respectively. Selected analytical data for *α*-2.8: $R_f = 0.6$ (ethyl acetate/toluene, 1/9, v/v); ¹H NMR (300 MHz, CDCl₃) δ, 8.10-8.04 (m, 2H, aromatic), 7.47-7.10 (m, 29H, aromatic), 5.25 (d, $J_{1',2'} = 3.4$ Hz, 1H, H-1'), 5.11 (d, ²*J* = 11.0 Hz, 1H, ¹/₂ CH₂Ph), 4.99 (d, $J_{1,2} = 3.2$ Hz, 1H, H-1), 4.84-4.38 (m, 10H, H-6a', 4 ¹/₂ CH₂Ph), 4.22 (dd, $J_{6a',6b'} = 11.4$, $J_{5',6b'} = 7.0$ Hz, 1H, H-6b'), 4.14-3.93 (m, 5H, H-2', 3, 3', 4, 5'), 3.83-3.76 (m, 1H, H-6a), 3.69 (br s, 1H, H-6b), 3.61-3.47 (m, 2H, H-4', 5), 3.42 (dd, $J_{2,3} = 9.0$ Hz, 1H, H-2), 3.27 (s, 3H, OCH₃), 0.89 (s, 10H, Si'Bu), 0.82 (s, 9H, Si'Bu), 0.15 (s, 3H, SiMe), 0.09 (d, *J* = 2.9 Hz, 5H, SiMe), -0.04 (m, 6H, 2 x SiMe); ¹³C NMR (151 MHz, CDCl₃) δ 166.5, 138.8, 138.5, 138.3, 138.1, 133.0, 130.3, 129.9, 128.6, 128.5, 128.4, 128.2, 128.0, 127.9, 127.8 (x3), 127.7 (x2), 127.6, 96.4, 91.8, 81.2, 79.4, 77.8, 75.8, 75.2, 74.6, 74.5, 73.6, 72.9, 71.4, 71.3, 70.4, 69.1, 64.6, 54.8, 26.7, 26.4, 18.5, 18.3, 0.1, -2.0, -2.2, -2.9, -3.9 ppm; Selected analytical data for β -2.8: R_f = 0.6 (ethyl acetate/ toluene, 1/9, v/v); ¹H NMR (300 MHz, CDCl₃): δ , 3.36 (s, 3H, OCH₃) ppm; ¹³C NMR (151 MHz, CDCl₃): δ , 103.2, 100.2, 83.4, 81.4, 80.9, 78.3, 77.8, 76.0, 75.4, 75.1, 73.7, 73.0, 71.5, 70.1, 69.0, 65.6 ppm; HR-FAB MS [M+Na]⁺ calcd for C₆₀H₈₀NaO₁₂Si₂⁺ 1071.5086, found 1071.5081.

Isopropyl 6-*O*-benzoyl-2-*O*-benzyl-3,4-di-*O*-*tert*-butyldimethylsilyl-*α*/β-Dglucopyranoside (2.9) was prepared as a colorless syrup from donor *α*-2.2 and isopropanol in accordance with the general procedure in the presence of TEA, DBU or DIPEA in 99, 94 or 94% yield, respectively. Selected analytical data for *α*-2.9: $R_f = 0.7$ (ethyl acetate/ toluene, 1/9, v/v); ¹H NMR (300 MHz, CDCl₃): δ , 4.91 (d, 1H, $J_{1,2} = 3.5$ Hz, H-1), 3.55 (dd, 1H, $J_{4,5} = 8.1$ Hz, H-4), 3.30 (dd, 1H, $J_{2,3} = 9.2$ Hz, H-2) ppm; ¹³C NMR (151 MHz, CDCl₃): δ , 95.0 (C-1) ppm. Selected analytical data for *β*-2.9: $R_f = 0.7$ (ethyl acetate/toluene, 1/9, v/v); ¹H NMR (300 MHz, CDCl₃): δ , 4.75 (d, 1H, $J_{1,2} = 7.2$ Hz, H-1); ¹³C NMR (151 MHz, CDCl₃): δ , 101.0 (C-1) ppm; HR-FAB MS [M+Na]⁺ calcd for C₃₅H₅₆NaO₇Si₂⁺ 667.3457, found 667.3469.

Cyclohexyl 6-*O*-benzoyl-2-*O*-benzyl-3,4-di-*O*-*tert*-butyldimethylsilyl-α/β-Dglucopyranoside (2.10) was prepared as a colorless syrup from donor α-2.2 and cyclohexanol in accordance with the general procedure in the presence of TEA, DBU or DIPEA in 99, 78 or 78% yield, respectively. Selected analytical data for α-2.10: $R_f = 0.8$ (ethyl acetate/ toluene, 1/9, v/v); ¹H NMR (300 MHz, CDCl₃): δ, 4.96 (d, $J_{1,2} = 3.4$ Hz, 1H, H-1), 4.65 (dd, $J_{5,6a} = 2.1$ Hz, $J_{6a,6b} = 11.5$, 1H, H-6a), 4.27 (dd, $J_{5,6b} = 7.6$ Hz, 1H, H-6b), 4.02 (dd, $J_{3,4} = 9.5$ Hz, 2H, H-3, 5), 3.52 (dd, $J_{4,5} = 8.3$ Hz, 1H, H-4), 3.30 (dd, $J_{2,3} = 9.2$ Hz, 1H, H-2) ppm; ¹³C NMR (151 MHz, CDCl₃): δ , 96.4 (C-1) ppm. Selected analytical data for β -2.10: $R_f = 0.8$ (ethyl acetate/ toluene, 1/9, v/v); ¹H NMR (300 MHz, CDCl₃): δ , 4.74 (d, $J_{1,2} = 7.2$ Hz, 1H, H-1) ppm; ¹³C NMR (151 MHz, CDCl₃): δ , 100.8 (C-1) ppm; HR-FAB MS [M+Na]⁺ calcd for C₃₈H₆₀NaO₇Si₂⁺ 707.3775, found 707.3779.

Benzyl 6-*O*-benzyl-2-*O*-benzyl-3,4-di-*O*-tert-butyldimethylsilyl-*a*/β-Dglucopyranoside (2.11) was prepared as a colorless syrup from donor *α*-2.2 and benzyl alcohol in the presence of TEA, DBU or DIPEA in 99, 81 or 84% yield, respectively. Selected analytical data for *α*-2.11: R_f = 0.8 (ethyl acetate/ toluene, 1/9, v/v); ¹H NMR (300 MHz, CDCl₃): δ, 4.83 (d, $J_{1,2}$ = 3.4 Hz, 1H, H-1), 4.09 (m, $J_{4,5}$ = 9.2 Hz, 1H, H-4), 4.00 (m, $J_{5,6a}$ = 6.9, $J_{5,6b}$ = 2.1 Hz, 3H, H-5), 3.59 (dd, $J_{3,4}$ = 8.0 Hz, 1H, H-3), 3.36 (dd, $J_{2,3}$ = 9.1 Hz, 1H, H-2) ppm; ¹³C NMR (151 MHz, CDCl₃): δ, 95.4 (C-1), 64.6 (C-6) ppm. Selected analytical data for *β*-2.11: R_f = 0.8 (ethyl acetate/ toluene, 1/9, v/v); ¹H NMR (300 MHz, CDCl₃): δ, 4.80 (d, $J_{1,2}$ = 6.8 Hz, 1H, H-1), 3.93-3.86 (m, 1H, H-4), 3.84-3.73 (m, 2H, H-3, 5), 3.44 (dd, $J_{2,3}$ = 4.8 Hz, 1H, H-2) ppm; ¹³C NMR (151 MHz, CDCl₃): δ, 100.7 (C-1), 65.4 (C-6) ppm; HR-FAB MS [M+Na]⁺ calcd for C₃₉H₅₆NaO₇Si₂⁺ 715.3462, found 715.3474.

Methyl 6-*O*-(6-*O*-benzoyl-2-*O*-benzyl-3,4-di-*O*-triisopropylsilyl- α -D-glucopyranosyl)-2,3,4-tri-*O*-benzyl- α -D-glucopyranoside (2.12) was prepared as a colorless syrup from donor α -2.3 and acceptor 2.5 in the presence of TEA, DBU or DIPEA in 81, 70 or 68% yield, respectively. Analytical data for α -2.12: $R_f = 0.7$ (ethyl acetate/ toluene, 1/9, v/v); [α]_{D²⁴ +58.7 (*c* 1, CHCl₃); ¹H NMR (300 MHz, CDCl₃): δ, 8.01 (d, J = 7.4 Hz, 2H, aromatic), 7.53 (t, J = 7.3 Hz, 1H, aromatic), 7.43-7.13 (m, 23H, aromatic), 5.09 (d, $J_{1',2'} = 2.2$ Hz, 1H, H-1'), 4.95 (d, ²J = 11.1 Hz, 1H, ½ CH₂Ph), 4.86-4.64 (m, 5H, 2 ½ CH₂Ph), 4.61-4.42 (m, 5H, $J_{1,2} = 3.5$ Hz, H-1, 6a', 6b', CH₂Ph), 4.24-4.17 (m, 1H, H-5'), 4.17-4.10 (m, 1H, H-3'), 4.05-3.90 (m, 2H, H-3, 5), 3.86-3.79 (m, 1H, H-4'), 3.71 (dd, $J_{5,6a} = 2.7$, $J_{6a,6b} = 9.4$ Hz, 1H, H-6a), 3.66-3.53 (m, 2H, H-4, 6b), 3.53-3.46 (m, 1H, H-2'), 3.36 (dd, $J_{2,3} = 9.5$ Hz, 1H, H-2), 3.29 (s, 3H, OCH₃), 1.02 (m, 42H, 2 x Si*i*Pr₃) ppm; ¹³C NMR (151 MHz, CDCl₃): δ, 166.5, 139.2, 138.7, 138.6, 138.4, 133.1, 130.3, 129.8, 128.5, 128.5, 128.2, 128.1, 128.0 (x 2), 127.9 (x 2), 127.7, 127.6, 127.5, 98.2, 95.5, 82.2, 80.3, 78.2, 78.1, 77.4, 77.2, 77.0, 75.7, 75.3, 74.3, 74.1, 73.6, 72.5, 72.0, 70.5, 65.9, 63.9, 55.1, 29.8, 18.5, 18.4, 18.4, 18.3, 13.5, 13.3, 0.1 ppm; HR-FAB MS [M+Na]⁺ calcd for C₆₆H₉₂NaO₁₂Si₂⁺ 1155.6025, found 1155.6021.}

Methyl 2-*O*-(6-*O*-benzoyl-2-*O*-benzyl-3,4-di-*O*-triisopropylsilyl-α/β-Dglucopyranosyl)-3,4,6-tri-*O*-benzyl-α-D-glucopyranoside (2.13) was prepared as a colorless syrup from donor α-2.3 and acceptor 2.7 in the presence of TEA, DBU or DIPEA in 24, 50 or 35% yield, respectively. Selected analytical data for α-2.13: $R_f = 0.6$ (ethyl acetate/ toluene, 1/9, v/v); ¹H NMR (300 MHz, CDCl₃): δ , 5.33 (d, $J_{1',2'} = 3.3$ Hz, 1H, H-1'), 4.99 (d, $J_{1,2} = 2.7$ Hz, 1H, H-1), 3.28 (s, 3H, OCH₃) ppm. Selected analytical data for β-2.13: $R_f = 0.6$ (ethyl acetate/ toluene, 1/9, v/v); ¹H NMR (300 MHz, CDCl₃): δ , 5.23 (d, $J_{1',2'} = 6.4$ Hz, 1H, H-1'), 5.07 (d, $J_{1,2} = 3.5$ Hz, 1H, H-1), 3.36 (s, 3H, OCH₃) ppm; HR-FAB MS [M+Na]⁺ calcd for C₆₆H₉₂NaO₁₂Si₂⁺ 1155.6025, found 1155.6029. **Isopropyl 6-***O***-benzoyl-2-***O***-benzyl-3,4-di**-*O***-triisopropylsilyl-***α*/**β-D-glucopyranoside** (**2.14**) was prepared as a colorless syrup from donor *α***-2.3** and isopropyl alcohol in the presence of TEA, DBU or DIPEA in 99, 70 or 72% yield, respectively. Selected analytical data for *α***-2.14**: $R_f = 0.8$ (ethyl acetate/ toluene, 1/9, v/v); ¹H NMR (300 MHz, CDCl₃): δ, 5.12 (d, $J_{1,2} = 2.9$ Hz, 1H, H-1), 3.45 (dd, $J_{2,3} = 6.4$ Hz, 1H, H-2) ppm: ¹³C NMR (151 MHz, CDCl₃): δ, 93.8 (C-1) ppm. Selected analytical data for *β***-2.14**: $R_f = 0.8$ (ethyl acetate/ toluene, 1/9, v/v); ¹H NMR (300 MHz, CDCl₃): δ, 5.17 (d, $J_{1,2} = 6.7$ Hz, 1H, H-1), 3.54 (d, 1H, H-2) ppm; ¹³C NMR (151 MHz, CDCl₃): δ, 99.2 (C-1) ppm; HR-FAB MS [M+Na]⁺ calcd for C₄₁H₆₈NaO₇Si₂⁺ 751.4396, found 751.4402.

Cyclohexyl 6-*O***-benzoyl-2-***O***-benzyl-3,4-di**-*O***-triisopropylsilyl-***α*/**β-D-glucopyranoside** (**2.15**) was prepared as a colorless syrup from donor *α***-2.3** and cyclohexyl alcohol in the presence of TEA, DBU or DIPEA in 99, 74 or 86% yield, respectively. Selected analytical data for *α***-2.15**: $\mathbf{R}_f = 0.8$ (ethyl acetate/ toluene, 1/9, v/v); ¹H NMR (300 MHz, CDCl₃): δ, 5.17 (d, $J_{1,2} = 3.0$ Hz, 1H, H-1), 3.79 (dd, $J_{3,4} = 7.0$, $J_{4,5} = 5.2$ Hz, 1H, H-4), 3.45 (dd, $J_{2,3} = 6.6$ Hz, 1H, H-2) ppm; ¹³C NMR (151 MHz, CDCl₃): δ, 93.4 (C-1) ppm. Selected analytical data for **β-2.15**: $\mathbf{R}_f = 0.8$ (ethyl acetate/ toluene, 1/9, v/v); ¹H NMR (300 MHz, CDCl₃): δ, 5.20 (d, $J_{1,2} = 6.5$ Hz, 1H, H-1), 3.53 (m, 1H, H-2) ppm; ¹³C NMR (151 MHz, CDCl₃): δ, 98.7 (C-1) ppm; HR-FAB MS [M+Na]⁺ calcd for C₄₄H₇₂NaO₇Si₂⁺ 791.4709, found 791.4720.

Benzyl 6-*O*-benzyl-2-*O*-benzyl-3,4-di-*O*-triisopropylsilyl- α/β -D-glucopyranoside (2.16) was prepared as a colorless syrup from donor α-2.3 and benzyl alcohol in the

presence of TEA, DBU and DIPEA in 99, 61 or 44% yield, respectively. Selected analytical data for **a**-2.16: $R_f = 0.8$ (ethyl acetate/ toluene, 1/9, v/v); ¹H NMR (300 MHz, CDCl₃): δ , 5.03 (d, $J_{1,2} = 2.9$ Hz, 1H, H-1), 4.85 (d, ²J = 12.4 Hz, 1H, ¹/₂ CH₂Ph), 4.67 (d, ²J = 11.8 Hz, 1H, ¹/₂ CH₂Ph), 4.61-4.45 (m, 4H, H-6a, 6b, CH₂Ph), 4.25 (m, 1H, H-5), 4.14 (dd, $J_{3,4} = 4.5$ Hz, 1H, H-3), 3.85 (dd, $J_{4,5} = 6.4$ Hz, 1H, H-4), 3.51 (dd, $J_{2,3} = 6.0$ Hz, 1H, H-2) ppm; ¹³C NMR (151 MHz, CDCl₃): δ , 94.2 (C-1), 64.2 (C-6) ppm. Selected analytical data for **β**-2.16: $R_f = 0.8$ (ethyl acetate/ toluene, 1/9, v/v); ¹H NMR (300 MHz, CDCl₃): δ , 5.14 (d, $J_{1,2} = 6.4$ Hz, 1H, H-1), 4.94 (d, ²J = 12.0 Hz, 1H, ¹/₂ CH₂Ph), 4.79 (d, ²J = 11.7 Hz, 1H, ¹/₂ CH₂Ph), 4.71-4.61 (m, 2H, H-6b, ¹/₂ CH₂Ph), 4.61-4.52 (m, 2H, H-6a, ¹/₂ CH₂Ph), 4.27 (m, $J_{5,6a} = J_{5,6b} = 6.8$ Hz, 1H, H-5), 4.16 (d, $J_{3,4} = 3.3$ Hz, 1H, H-3), 4.10 (d, 1H, H-4), 3.62 (d, 1H, H-2) ppm; ¹³C NMR (151 MHz, CDCl₃): δ , 99.8 (C-1), 66.0 (C-6) ppm; HR-FAB MS [M+Na]⁺ calcd for C₄₅H₆₈NaO₇Si₂⁺ 799.4396, found 799.4413.

2.4.4. NMR studies of reaction intermediates

NMR studies were performed at 300 MHz. Molecular bromine (2.0 eq) was injected into a frozen solution of the donor (15 mg) in CDCl₃. The mixture was allowed to melt at -50 °C and then ¹H NMR spectra were recorded at different time points.

2.4.5. Computational studies

All calculations were run using the Schrödinger suite of programs through the Maestro graphical interface.⁵¹ A protocol that relies on the following steps was implemented to identify representative minimum-energy geometries.

Molecular Mechanics calculations. Monte Carlo/energy minimization (MC/EM) conformational searches⁵² of thioglycosides β -2.2, β -2.3, α -2.2 and α -2.3 and of Br derivatives β -2.4 and α -2.4 were performed as the first step within the framework of MacroModel version 11.1,⁵³ using the OPLS2005 force field⁵⁴ and the implicit water or chloroform GB/SA solvation model,⁵⁵ to generate starting geometries for subsequent DFT calculations. The torsional space of each glycoside was randomly varied with the usage-directed Monte Carlo conformational search. A ring-closure bond was defined in the six-membered pyranose ring. For each search, at least 1000 starting structures for each variable torsion angle were generated and minimized until the gradient was <0.05 kJÅ⁻¹mol⁻¹ using the truncated Newton–Raphson algorithm.⁵⁶ Duplicate conformations and those with energy >6 kcalmol⁻¹ above the global minimum were discarded.

DFT optimization and thermochemical analysis. Representative structures obtained from the above-described conformational search (sampling both the pyranose ring conformations and the substituent orientations) were fully optimized with DFT calculations at the B3LYP/6-31G* level (β -2.2, β -2.3, α -2.2 and α -2.3) or at the B3LYP/LACVP level (β -2.4 and α -2.4) of theory using the Jaguar version 9.1.⁵⁷ Default convergence criteria were employed. The obtained stationary points were confirmed as minima by frequency calculation at the same level of theory and their thermochemical properties, including the final total Gibbs free energy, were computed. The relative energies (both SCF Energy DFT/B3LYP and Total Gibbs free energy) of the most stable conformations located by the DFT calculations for the pyranose ring in each compound are reported in Tables A-1 to A-6. The structures are characterized by the values of the four pyranose HCCH dihedral angles and the corresponding vicinal ³*J* HCCH calculated by Schrodinger Maestro V16.

2.5. References

- Woods, R. J. Predicting the Structures of Glycans, Glycoproteins, and Their Complexes. *Chem. Rev.* 2018, *118*, 8005–8024.
- Ruhaak, L. R.; Xu, G.; Li, Q.; Goonatilleke, E.; Lebrilla, C. B. Mass
 Spectrometry Approaches to Glycomic and Glycoproteomic Analyses. *Chem. Rev.* 2018, *118*, 7886–7930.
- Lu, G.; Crihfield, C. L.; Gattu, S.; Veltri, L. M.; Holland, L. A. Capillary
 Electrophoresis Separations of Glycans. *Chem. Rev.* 2018, *118*, 7867–7885.
- Wen, L.; Edmunds, G.; Gibbons, C.; Zhang, J.; Gadi, M. R.; Zhu, H.; Fang, J.;
 Liu, X.; Kong, Y.; Wang, P. G. Toward Automated Enzymatic Synthesis of
 Oligosaccharides. *Chem. Rev.* 2018, *118*, 8151–8187.
- Li, C.; Wang, L. X. Chemoenzymatic Methods for the Synthesis of Glycoproteins. *Chem. Rev.* 2018, *118*, 8359-8413.
- Panza, M.; Pistorio, S. G.; Stine, K. J.; Demchenko, A. V. Automated Chemical Oligosaccharide Synthesis: Novel Approach to Traditional Challenges. *Chem. Rev.* 2018, *118*, 8105–8150.
- (7) Nielsen, M. M.; Pedersen, C. M. Catalytic Glycosylations in Oligosaccharide Synthesis. *Chem. Rev.* 2018, *118*, 8285-8358.
- Kulkarni, S. S.; Wang, C. C.; Sabbavarapu, N. M.; Podilapu, A. R.; Liao, P. H.;
 Hung, S. C. "One-Pot" Protection, Glycosylation, and Protection-Glycosylation
 Strategies of Carbohydrates. *Chem. Rev.* 2018, *118*, 8025-8104.

- Bennett, C. S.; Galan, M. C. Methods for 2-Deoxyglycoside Synthesis. *Chem. Rev.* 2018, *118*, 7931–7985.
- Adero, P. O.; Amarasekara, H.; Wen, P.; Bohe, L.; Crich, D. The Experimental Evidence in Support of Glycosylation Mechanisms at the SN1-SN2 Interface. *Chem. Rev.* 2018, *118*, 8242-8284.
- (11) Romero, J. A. C.; Tabacco, S. A.; Woerpel, K. A. Stereochemical reversal of nuclephilic substitution reactions depending upon substituent: reactions of heteroatom-substituted six-membered-ring oxocarbenium ions through pseudoaxial conformers. J. Am. Chem. Soc. 2000, 122, 168-169.
- (12) Ayala, L.; Lucero, C. G.; Romero, J. A. C.; Tabacco, S. A.; Woerpel, K. A.
 Stereochemistry of nucleophilic substitution reactions depending upon substituent: evidence for electrostatic stabilization of pseudoaxial conformers of oxocarbenium ions by heteroatom substitution. *J. Am. Chem. Soc.* 2003, *125*, 15521-15528.
- (13) Shenoy, S. R.; Woerpel, K. A. Investigations into the role of ion pairing in reactions of heteroatom-substituted cyclic oxocarbenium ions. *Org. Lett.* 2005, *7*, 1157-1160.
- (14) Baghdasarian, G.; Woerpel, K. A. Electrostatic effects on the reactions of cyclohexanone oxocarbenium ions. J. Org. Chem. 2006, 71, 6851-6858.
- (15) Billings, S. B.; Woerpel, K. A. Nucleophilic substitution reactions of sulfursubstituted cyclohexanone acetals: an analysis of the factors controlling stereoselectivity. *J. Org. Chem.* 2006, *71*, 5171-5178.

- (16) Yang, M. T.; Woerpel, K. A. The effect of electrostatic interactions on conformational equilibria of multiply substituted tetrahydropyran oxocarbenium ions. J. Org. Chem. 2009, 74, 545-553.
- (17) Beaver, M. G.; Woerpel, K. A. Erosion of stereochemical control with increasing nucleophilicity: O-glycosylation at the diffusion limit. *J. Org. Chem.* 2010, 75, 1107-1118.
- (18) Garcia, A.; Sanzone, J. R.; Woerpel, K. A. Participation of alkoxy groups in reactions of acetals: violation of the reactivity/selectivity principle in a Curtin-Hammett kinetic scenario. *Angew. Chem. Int. Ed. Engl.* 2015, *54*, 12087-12090.
- Mootoo, D. R.; Konradsson, P.; Udodong, U.; Fraser-Reid, B. "Armed" and "disarmed" n-pentenyl glycosides in saccharide couplings leading to oligosaccharides. *J. Am. Chem. Soc.* **1988**, *110*, 5583-5584.
- (20) Fraser-Reid, B.; Udodong, U. E.; Wu, Z. F.; Ottosson, H.; Merritt, J. R.; Rao, C.
 S.; Roberts, C.; Madsen, R. n-Pentenyl glycosides in organic chemistry: a contemporary example of serendipity. *Synlett* 1992, 927-942 and references therein.
- (21) Bandara, M. D.; Yasomanee, J. P.; Demchenko, A. V.: Application of armed, disarmed, superarmed and superdisarmed building blocks in stereocontrolled glycosylation and expeditious oligosaccharide synthesis. In *Selective Glycosylations: Synthetic Methods and Catalysts*; Bennett, C. S., Ed.; Wiley, 2017; pp 29-58.
- (22) Zhu, T.; Boons, G. J. Thioglycosides protected as trans-2,3-cyclic carbonates in chemoselective glycosylations. *Org. Lett.* 2001, *3*, 4201-4203.

- (23) Zhang, Z.; Ollmann, I. R.; Ye, X. S.; Wischnat, R.; Baasov, T.; Wong, C. H.
 Programmable one-pot oligosaccharide synthesis. *J. Am. Chem. Soc.* 1999, *121*, 734-753.
- (24) Douglas, N. L.; Ley, S. V.; Lucking, U.; Warriner, S. L. Tuning glycoside reactivity: new tool for efficient oligosaccharides synthesis. *J. Chem. Soc., Perkin Trans. 1* 1998, 51-65.
- (25) Kamat, M. N.; Demchenko, A. V. Revisiting the armed-disarmed concept rationale: chemoselective activation of the S-benzoxazolyl glycosides in oligosaccharide synthesis. *Org. Lett.* 2005, 7, 3215-3218.
- (26) Kaeothip, S.; Yasomanee, J. P.; Demchenko, A. V. Glycosidation of thioglycosides in the presence of bromine: mechanism, reactivity, and stereoselectivity. *J. Org. Chem.* 2012, 77, 291-299.
- (27) Frihed, T. G.; Bols, M.; Pedersen, C. M. Mechanisms of glycosylation reactions studied by low-temperature nuclear magnetic resonance. *Chem. Rev.* 2015, *115*, 4963-5013.
- (28) Jensen, H. H.; Pedersen, C. M.; Bols, M. Going to extremes: "super" armed glycosyl donors in glycosylation chemistry. *Chem. Eur. J.* 2007, *13*, 7576-7582.
- (29) Pedersen, C. M.; Nordstrom, L. U.; Bols, M. "Super armed" glycosyl donors: conformational arming of thioglycosides by silylation. *J. Am. Chem. Soc.* 2007, *129*, 9222-9235.
- Pedersen, C. M.; Marinescu, L. G.; Bols, M. Conformationally armed glycosyl donors: reactivity quantification, new donors and one pot reactions. *Chem. Commun.* 2008, 2465-2467.

- (31) Heuckendorff, M.; Pedersen, C. M.; Bols, M. Quantifying electronic effects of common carbohydrate protecting groups in a piperidine model system. *Chem. Eur. J.* 2010, *16*, 13982-13994.
- (32) Pedersen, C. M.; Marinescu, L. G.; Bols, M. Glycosyl donors in "unusual"
 conformations influence on reactivity and selectivity. *C. R. Chimie* 2011, *14*, 17-43.
- (33) Mydock, L. K.; Demchenko, A. V. Superarming the S-benzoxazolyl glycosyl donors by simple 2-O-benzoyl-3,4,6-tri-O-benzyl protection. *Org. Lett.* 2008, *10*, 2103-2106.
- (34) Mydock, L. K.; Demchenko, A. V. Application of the superarmed glycosyl donor to chemoselective oligosaccharide synthesis. *Org. Lett.* **2008**, *10*, 2107-2110.
- (35) Premathilake, H. D.; Mydock, L. K.; Demchenko, A. V. Superarming common glycosyl donors by simple 2-O-benzoyl-3,4,6-tri-O-benzyl protection. *J. Org. Chem.* 2010, 75, 1095-1100.
- (36) Heuckendorff, M.; Premathilake, H. D.; Pornsuriyasak, P.; Madsen, A. Ø.;
 Pedersen, C. M.; Bols, M.; Demchenko, A. V. Superarming of glycosyl donors by combined neighboring and conformational effects. *Org. Lett.* 2013, *15*, 4904–4907.
- (37) Bandara, M. D.; Yasomanee, J. P.; Rath, N. P.; Pedersen, C. M.; Bols, M.;
 Demchenko, A. V. Conformationally superarmed S-ethyl glycosyl donors as effective building blocks for chemoselective oligosaccharide synthesis in one pot. *Org. Biomol. Chem.* 2017, *15*, 559-563.

- (38) Nigudkar, S. S.; Demchenko, A. V. Stereocontrolled 1,2-cis glycosylation as the driving force of progress in synthetic carbohydrate chemistry. *Chem. Sci.* 2015, *6*, 2687–2704.
- (39) Bandara, M. D.; Yasomanee, J. P.; Rath, N. P.; Pedersen, C. M.; Bols, M.;
 Demchenko, A. V. Conformationally superarmed S-ethyl glycosyl donors as effective building blocks for chemoselective oligosaccharide synthesis in one pot. *Organic & Biomolecular Chemistry* 2017, *15*, 559-563.
- (40) Homans, S. W.: Conformational analysis in solution by NMR. In *Carbohydrates in Chemistry and Biology*; Ernst, B., Hart, G. W., Sinay, P., Eds.; Wiley-VCH: Weinheim, New York, 2000; Vol. 1; pp 947-966.
- (41) Wormald, M. R.; Petrescu, A. J.; Pao, Y. L.; Glithero, A.; Elliott, T.; Dwek, R. A. Conformational studies of oligosaccharides and glycopeptides: complementarity of NMR, X-ray crystallography, and molecular modeling. *Chem. Rev.* 2002, *102*, 371-386.
- (42) Widmalm, G.: General NMR Spectroscopy of Carbohydrates and Conformational Analysis in Solution. In *Comprehensive Glycoscience: From Chemistry to Systems Biology*; Kamerling, J., Boons, G.-J., Lee, Y. C., Suzuki, A., Taniguchi, N., Voragen, A. G. J., Eds.; Elsevier:

Amsterdam–Boston–Heidelberg–London–N.Y., 2007; Vol. 2; pp 101-132.

(43) Lemieux, R. U.; Hendriks, K. B.; Stick, R. V.; James, K. Halide ion catalyzed glycosylation reactions. Syntheses of a-linked disaccharides. *J. Am. Chem. Soc.* 1975, *97*, 4056-4062 and references therein.

- (44) Abe, H.; Shuto, S.; Matsuda, A. Highly a- and b- selective radical C-glycosylation reactions using a controlling anomeric effect based on the conformational restriction strategy. A study on the conformation anomeric effect stereoselectivity relationship in anomeric radical reactions. *J. Am. Chem. Soc.* 2001, *123*, 11870-11882.
- (45) Shuto, S.; Yahiro, Y.; Ichikawa, S.; Matsuda, A. Synthesis of 3,7-Anhydro-Dglycero-D-ido-octitol 1,5,6-Trisphosphate as an IP₃ Receptor Ligand Using a Radical Cyclization Reaction with a Vinylsilyl Tether as the Key Step.
 Conformational Restriction Strategy Using Steric Repulsion Between Adjacent Bulky Protecting Groups on a Pyranose Ring. *J. Org. Chem.* 2000, *65*, 5547-5557.
- (46) Yin, J.; Eller, S.; Collot, M.; Seeberger, P. H. Acylsulfonamide safety-catch linker: promise and limitations for solid-phase oligosaccharide synthesis. *Beilstein J. Org. Chem.* 2012, *8*, 2067-2071.
- (47) Singh, Y.; Demchenko, A. V. Koenigs-Knorr Glycosylation Reaction Catalyzed by Trimethylsilyl Trifluoromethanesulfonate. *Chem. Eur. J.* 2019, 25, 1461-1465.
- (48) Singh, Y.; Wang, T.; Geringer, S. A.; Stine, K. J.; Demchenko, A. V.Regenerative Glycosylation. *J. Org. Chem.* 2018, *83*, 374-381.
- (49) Geringer, S. A.; Demchenko, A. V. Iron(III) Chloride-Catalyzed Activation of Glycosyl Chlorides. Org. Biomol. Chem. 2018, 16, 9133-9137.
- (50) Nigudkar, S. S.; Stine, K. J.; Demchenko, A. V. Regenerative glycosylation under nucleophilic catalysis. J. Am. Chem. Soc. 2014, 136, 921-923.

- (51) Maestro, release 2016-1, Schrödinger, LLC, New York, NY. Maestro, release 2016-1, Schrödinger, LLC, New York, NY, 2016.
- (52) Chang, G.; Guida, W. C.; Still, W. C. J. Am. Chem. Soc. 1989, 111, 4379.
- (53) MacroModel, version 11.1, Schrödinger, LLC, New York, NY. MacroModel, version 11.1, Schrödinger, LLC, New York, NY, 2016.
- (54) Banks, J. L. B., H. S.; Cao, Y.; Cho, A. E.; Damm, W.; Farid, R.; Felts, A. K.;
 Halgren, T. A.; Mainz, D. T.; Maple, J. R.; Murphy, R.; Philipp, D. M.; Repasky,
 M. P.; Zhang, L. Y.; Berne, B. J.; Friesner, R. A.; Gallicchio, E.; Levy, R. M. . *Comp. Chem.* 2005, 26, 1752.
- (55) Still, W. C. T., A.; Hawley, R. C.; Hendrickson, T. . J. Am. Chem. Soc. 1990, 112, 6127.
- (56) Ponder, J. W. R., F. M. J. Comp. Chem. 1987, 8, 1016.
- (57) Jaguar, version 9.1, release 14, Schrödinger, LLC, New York, NY. Jaguar, version 9.1, release 14, Schrödinger, LLC, New York, NY, 2016.

CHAPTER 3

HPLC-assisted automated

oligosaccharide synthesis: the

implementation of the two-way split

valve as a mode of complete

automation

3.1. Introduction

With improved understanding of functions of glycans, the demand for robust methods to produce both natural glycans and their mimetics has increased.¹⁻² Traditional glycan synthesis in solution involves reiteration of glycosylation-deprotection steps, with aqueous work-up to remove excess reagents after most steps, and purification of most intermediates. Many advanced strategies that streamline oligosaccharide synthesis are based on either chemoselective or selective activation of building blocks.³ Fraser-Reid's armed-disarmed,⁴⁻⁵ Danishefsky's,⁶ Roy's⁷ and Boons'⁸ active-latent, Ogawa-Ito's orthogonal,⁹⁻¹⁰ Ley's tunable,¹¹⁻¹² Wong's programmable,¹³⁻¹⁴ and Huang-Ye's preactivation¹⁵ are among the most effective strategies known for glycan synthesis in solution. Nevertheless, there is still no universal synthetic route to glycans, and this type of synthesis requires relevant training and qualifications, so it is practically impossible to implement these reactions outside specialized labs. This significantly hampers the development in glycosciences, whereas other biopolymers, peptides¹⁶⁻¹⁷ and oligonucleotides,¹⁸ can now be produced by machines. Efforts to automate solution synthesis of glycans using parallel synthesizers have been reported by Takahashi,¹⁹⁻²⁰ Pohl,²¹⁻²⁴ and Nokami.²⁵⁻²⁶ Being still relatively unexplored, these approaches offer viable alternatives to automated enzymatic syntheses being developed by Wong,²⁷⁻²⁸ Nishimura,²⁹ Chen,³⁰⁻³² Wang,³³⁻³⁴ and Boons.³⁵

3.2. Results and discussion

Solid-phase synthesis also involves reiteration of glycosylation-deprotection steps, but it eliminates the need for conventional reaction work-up and purification of intermediates.³⁶⁻³⁸ Another strength of the solid phase synthesis is its automation amenability, which was demonstrated in 2001 by Seeberger who adapted a peptide synthesizer to glycan synthesis.³⁹⁻⁴² In 2012, Seeberger reported "*the first fully automated solid-phase oligosaccharide synthesizer*"⁴³ that was then commercialized as Glyconeer 2.1.⁴⁴ Also in 2012, Demchenko and Stine reported HPLC-based automation (HPLC-A) of solid phase synthesis.⁴⁵ The underpinning idea for this technology is to use the standard lab equipment that will allow recording a successful synthetic sequence as a computer program. To advance our original HPLC-A set-up based on Tentagel,⁴⁵ we identified JandaJel resin as a more efficient support for HPLC-A.⁴⁶ We also implemented the standard analytical HPLC autosampler for delivering TMSOTf, the promoter for glycosylation.⁴⁶ This approach was recently applied to the synthesis of the N-glycan core pentasaccharide.⁴⁷

Even with the addition of the autosampler to deliver the promoter of glycosylation, the manual component of HPLC-A remained. The building block intake/delivery remained semi-manual because the reagent bottle swap required the operator. Also switching between the reaction and discharge/collection modes required the operator intervention. To enhance our automation capabilities, reported herein is our enhanced HPLC-A platform that incorporates a preparative autosampler to deliver all building blocks and all reagents for all steps of the synthesis and a standard two-way split valve. In this application, the split valve was programmed to switch between the discharge and the product collection modes, 1 and 2, respectively (Figure 3.1).




Figure 3.1. Modified HPLC-A set-up to achieve complete automation

This new automated set-up completely eliminates all variabilities that could be caused by the operator. No operator intervention is necessary after the software start button, initiating the programmed synthetic sequence, has been pressed and until the final product has been delivered to the collection flask. This approach was showcased by the synthesis of regular and alternating $1 \rightarrow 6$ and $1 \rightarrow 4$ -linked glucans **3.1-3.3** shown in Figure 3.1. The HPLC was programmed to perform the entire sequence of reactions consisting of a series of glycosylations with Fmoc deprotections in between, followed by the off-resin cleavage, and collection of the final product, all in 12 h in the completely automated "press of a button" mode. To perform the assembly of all oligosaccharide sequences described herein we chose building blocks **3.4-3.7** shown in Figure 3.1. Glycosyl donor **3.4** and acceptors **3.6** and **3.7** were synthesized as previously reported,⁴⁵⁻⁴⁶ while trichloroacetimidate donor **3.5** was derived from known thioglycoside precursor.^{43, 48}




Figure 3.2. Glycan sequences 3.1-3.3 obtained in the fully automated mode and building blocks 3.4-3.7 needed for all syntheses

In accordance with our approach, the first building block, glycosyl acceptor, is conjugated to the resin on a large scale (5-10 g of the resin) prior the automation steps. The extent of loading is determined by cleavage/validation sequence on a small portion (50 mg) of the entire load. This approach helps to avoid overestimation of loading and to ensure


reproducibility of multiple experiments. Resin functionalized with glycosyl acceptor **3.6** or **3.7** (typical scale 50 mg, typical loading 0.02 mmol) is then packed in an Omnifit column and the latter is integrated into the HPLC system. Glycosyl donors **3.4** and/or **3.5**, promoter (TMSOTf), and other reagents such as piperidine for Fmoc removal are dissolved in separate vials that are placed into the autosampler tray. All subsequent steps are automated by programming the standard operation software without manual intervention.

All glycosylation sequences follow the same basic blueprint. The resin is washed/swelled with the HPLC grade methylene chloride. Then, the flow rate is lowered, and the donor and promoter are delivered as follows. The robotic arm of the autosampler brings the vial containing the donor from the sample tray to the needle that draws the programmed amount of the donor solution. The robotic arm of the autosampler returns the donor vial to the sample tray and then brings the vial containing the promoter solution to the needle. The needle draws the required amount of the promoter, and the donor and acceptor are premixed in the "needle seat," a capillary that connects the needle to the valve of the autosampler. The resulting solution of the pre-activated donor is then injected into the system. After that, the autosampler needle is washed using a dedicated vial in the autosampler tray to avoid cross contamination with vials used in subsequent steps. In our current configuration, recirculation previously performed for each glycosylation, has been substituted by multiple injections. This ensures that the system is supplemented with small portions of fresh preactivated donor until the glycosylation completed, as accessed by the detector monitored at 254 nm. The number of injections, and the amount of the donor utilized for every injection can be tuned to ensure that only the desired amount of the donor has been delivered. For instance, 7.5 equiv of donor **3.4** were utilized for each glycosylation

step for the synthesis of $1\rightarrow 6$ linked pentasaccharide **3.1**, and 10 equiv of the respective donors were used to obtain $1\rightarrow 4$ linkages in glycans **3.2** and **3.3**.

The glycosylations were followed by the Fmoc group removal, and this operation is performed by delivering a solution of piperidine in DMF/CH₂Cl₂. This step is monitored at 254 and 301 nm, with the second wavelength being specific for monitoring dibenzofulvene-piperidine adduct. Once the desired oligosaccharide sequence is achieved via the reiteration of the glycosylation and deprotection steps, the reagent for cleavage, sodium methoxide in methanol-DCM, is delivered to affect the off-resin cleavage. At this stage, the split valve is programmed to direct the flow towards the collection flask (Figure 3.1, mode 2).

A representative protocol, general for the synthesis of all target glycans, is exemplified by the synthesis of glycan **3.1** as depicted in Scheme 3.2. Compound **3.8** is obtained with the iterations of glycosylations and Fmoc removal steps. The complete sequence of synthetic steps is built as lists of multiple operations including draw, mix, and inject commands. These operations are then modulated as needed for the synthesis of a particular target. This approach allows for flexible adaptation to specific targets to maximize the efficiency and yield. Compound **3.9**, resulting from the off-resin cleavage, is manipulated through a series of post-automation steps, which include acetylation and purification via column chromatography, to afford the final product **3.1** in 33% yield. The final yields for glycans **3.2** and **3.3** were 20% and 30%, respectively. Differently from glycan **3.1**, $(1\rightarrow 4)$ linked compound **3.2** and compound **3.3** with alternating $(1\rightarrow 6)$ and $(1\rightarrow 4)$ linkages were obtained through benzoylation after the off-resin cleavage step.



Scheme 3.1. Automated synthesis of glycan 3.1

3.3. Conclusions

A new experimental set-up for the HPLC-based automated synthesizer has been developed. The sequences were written to achieve complete automation of all steps, starting from delivering sugar building blocks to obtaining glycan targets in the collection flask. This was made possible by implementing the new two-way switch valve used to direct the flow and by programming the preparative autosampler to deliver all reagents for all steps of the synthesis. Machine-assisted synthesis also helps to eliminate variabilities, and to accurately reproduce experiments multiple times. This in turn will simplify the implementation of our protocols in other interested labs, all pre-recorded computer program sequences for all steps of the synthesis are readily available.

3.4. Experimental

3.4.1. General methods

The reactions were performed using commercial reagents and the ACS grade solvents were purified and dried according to standard procedures. HPLC grade solvents used for automation were utilized without purification. Column chromatography was performed on silica gel 60 (70-230 mesh) or using flash purification system Biotage Isolera One, reactions were monitored by TLC on Kieselgel 60 F254. The compounds were detected by examination under UV light and by charring with 10% sulfuric acid in methanol. Solvents were removed under reduced pressure at <40 °C. CH₂Cl₂ was distilled from CaH_2 directly prior to application. Amberlite IR20 (H⁺) was washed three times with MeOH and stored under MeOH. Optical rotations were measured using a Jasco 'P-2000' polarimeter. ¹H NMR spectra were recorded at 300 or 600 MHz, ¹³C NMR spectra were recorded at 75 or 150 MHz. The ¹H chemical shifts are referenced to the signal of the residual CHCl₃ ($\delta H = 7.24$ ppm). The ¹³C chemical shifts are referenced to the central signal of CDCl₃ ($\delta C = 77.23$ ppm). HRMS determinations were made with the use of a mass spectrometer with FAB ionization and ion-trap detection. Agilent 1260 infinity II HPLC System and Agilent 1260 Variable Wavelength UV-vis Detector were used to assemble the automated synthesizer.

3.4.2. Set up of the HPLC-A synthesizer

The HPLC based synthesizer has been assembled using

- 1260 Agilent Infinity II series Quaternary Pump
- Variable Wavelength Detector with dual-wavelength mode
- The Autosampler is the preparative module from 1260 Infinity series. The

autosampler is equipped a 900 μ L preparative loop and two trays holding 15 x 6 mL vials each. The wells of the left tray are numbered from 1 to 15 while the ones of the right tray are numbered from 101 to 115.

- The valve is a 2-way 6-port Quick Change Valve.
- The column utilized is an Omnifit Solvent Plus 50 mm.

The synthesis sequences are programmed using Chemstation software and the autosampler programming option.




Figure 3.3. The synthesizer set up with the two channels of the valve

3.4.3. Synthesis of glycosyl donors and glycosyl acceptors

2,3,4-Tri-O-benzoyl-6-O-(9-fluorenylmethoxycarbonyl)-α/β-D-glucopyranosyl

trichloroacetimidate (3.4) was obtained in accordance with the reported procedure and its analytical data were in accordance with that previously described.^[1]

2-O-Benzoyl-3,6-di-O-benzyl-4-O-(9-fluorenylmethoxycarbonyl)-α/β-D-

glucopyranosyl trichloroacetimidate (3.5). Water (8.0 mL) and N-bromosuccinimide (NBS, 1.25 g, 7.03 mmol) were added to a solution of ethyl 2-O-benzoyl-3,6-di-O-benzyl-4-O-(9-fluorenylmethoxycarbonyl)-1-thio- β -D-glucopyrano-side^[2] (3.10, 4.50 g, 6.39 mmol) in methylene chloride (80 mL) and the resulting mixture was stirred vigorously for 2 h at rt. The reaction was quenched with 10% aq. $Na_2S_2O_3$ and diluted with methylene chloride (~120 mL). The organic phase was separated and washed with brine (2 x 30 mL), dried with MgSO₄ and concentrated in *vacuo*. The residue was filtered through a pad of silica gel (hexanes - ethyl acetate isocratic elution, 7/3, v/v) to afford 2-O-benzoyl-3,6-di-O-benzyl-4-O-(9-fluorenylmethoxycarbonyl)-D-glucopyranose (3.11). Crude residue containing hemiacetal **3.11** (3.53 g, 5.14 mmol) was dissolved in anhydrous methylene chloride (80 mL). Trichloroacetonitrile (7.73 mL, 77.10 mmol) and NaH (60% suspension in mineral oil, 0.025 g, 0.62 mmol) were added and the resulting mixture was stirred under argon for 3 h at rt. The volatiles were removed under the reduced pressure, and the residue was purified using a Biotage Isolera One (50 g SNAP ULTRA cartidge, hexane - ethyl acetate elution) to afford the title compound as an amorphous solid (3.90 g, 73% over two steps, $\alpha/\beta = 12.5/1$). Selected analytical data for **3.5a**: $R_f = 0.54$ (hexane/ethyl acetate, 7/3, v/v); ¹H NMR (300 MHz, CDCl3): δ, 8.54 (s, 1H), 8.02-7.93 (m, 2H, aromatic), 7.77 (dd,

2H, J = 7.4, 2.7 Hz, aromatic), 7.68-7.51 (m, 4H, aromatic), 7.48-7.05 (m, 20H, aromatic), 6.67 (d, 1H, $J_{1,2} = 3.5$ Hz, H-1), 5.41 (dd, 1H, $J_{2,3} = 10.0$ Hz, H-2), 5.24 (dd, 1H, $J_{3,4} = J_{4,5} = 9.9$ Hz, H-4), 4.69 (s, 2H, CH_2 Ph), 4.61-4.52 (m, 2H, CH_2 Ph), 4.42-4.21 (m, 4H, H-3, 5, 6a, CH/Fmoc), 4.15 (dd, 1H, $J_{5,6a} = J_{6a,6b} = 6.9$ Hz, H-6b), 3.77-3.60 (m, 2H, CH₂/Fmoc) ppm; ¹³C NMR (75 MHz, CDCl₃): δ , 165.36, 160.50, 154.25, 143.34, 143.21, 141.41, 137.75, 137.51, 133.58, 129.93, 129.16, 128.56, 128.44, 128.34, 128.04, 128.02, 127.88, 127.79, 127.32, 125.18, 125.10, 120.22, 93.62, 90.96, 76.60, 74.99, 74.54, 73.71, 72.28, 71.54, 70.21, 68.52, 46.80; HR-TOF MS [M+Na+] calcd 852.15044 found 852.15296.

Selected analytical data for **3.5** β : R_f = 0.50 (hexane/ethyl acetate, 7/3, v/v); ¹H NMR (300 MHz, CDCl₃): δ , 5.97 (d, 1H, H-1), 5.61 (m, 1H, H-2) ppm.

Conjugate 3.6 was obtained from methyl 2,3-di-*O*-benzyl-6-*O*-(3-hydroxycarbonylpropanoyl)- α -D-glucopyranoside and JandaJel in accordance with the reported procedure.⁴ The acceptor loading of 0.40 mmol/g for conjugate **3.6** was determined by direct cleavage from the solid support (50 mg of resin) and quantifying on HPLC to mimic conditions for the subsequent reactions.

Conjugate 3.7 was obtained by reaction of 8-(3-carboxypropanoyloxy)oct-1-yl 2,3,4-tri-*O*-benzyl-6-*O*-triphenylmethyl- α -D-glucopyranoside with JandaJel performed in accordance with the reported procedure.⁴ The acceptor loading of 0.33 mmol/g for conjugate **3.7** was determined by direct cleavage from the solid support (50 mg of resin) and quantifying on HPLC to mimic conditions for the subsequent reactions.

3.4.4. Preparation of the reagent vials

All the solutions were freshly prepared using the HPLC grade solvents and kept at room temperature for the duration of the synthesis.

<u>Donor:</u> a solution of glycosyl donor (0.08-0.2 mmol) in CH₂Cl₂ (3.5 mL).
 <u>Promoter:</u> a solution of TMSOTf (0.04-0.16 mmol) in CH₂Cl₂ (2.0 mL
 <u>Reagents for Fmoc removal:</u> a solution of piperidine in DMF (5.0 mL, 2/3, v/v).
 <u>Reagents for cleaving off the resin</u>: a solution prepared from 1M NaOMe in MeOH (1.5 mL), CH₂Cl₂ (1.0 mL) and MeOH (1.0 mL).

Washing solutions and blanks: methylene chloride (6.0 mL).

3.4.5. The automated assembly of oligosaccharides

All reactions were carried out using 50 mg of preloaded resin. The acceptor is loaded on the resin prior automation, therefore the loading depended on the batch of the resin. Syntheses with acceptors **3.6** and **3.7** were performed with 0.02 and 0.0165 mmol, respectively.

Glycosylations. The sequences are comprehensive of washings of the resin pre and after glycosylation steps. The glycosylations are split in two interations of 5 injections each. The donor and the promoter are drawn from the vial, mixed in the needle seat and the injected. Once the activated donor has passed through the column, the same operation is repeated. The resin is washed with CH₂Cl₂ and DMF and 5 more injections are performed. The volume of solvent in the vials is constant, hence the concentration of donor and promoter varies depending on the equivalents required to successfully glycosylate the acceptor. Figure 3.3 depicts the programming of the components of the synthesizer. 3.3A shows the pump timetable, 3.3B shows the autosampler programming and 3.3C the variable wave-length detector (VWD). The valve was on position 1 during the whole sequence.

						Advanced						
		0.500 🗧 m	L/min			Timetable (39/10	00 events)					
lvents	_					Time [min]	A [%]	B [%]	C [%]	D [%]	Flow	Max. Pressure
A: 100.0	. %					0.00				0.0	[mL/min] 0.500	Limit [bar] 60.00
B: 0.0 (. %					1.00				0.0		
В: Ц 0.0 ,	~ /•					10.00	100.0	0.0	0.0	0.0		
C: 🔽 0.0	%					11.00				0.0		
	_					55.00				0.0 0.0		
D: 0.0	%				=	65.00				0.0		
						66.00					0.500	60.00
essure Limits						105.00						
Min: 0.00 🛟 bar Max: 60.00 🛟 bar				106.00				0.0 0.0				
						111.00						
optime		Posttime				113.00						
• • • • • •		<u> </u>				114.00	100.0	0.0	0.0	0.0	0.500	60.0
As Injector/N		۲	Off	-								
120.00	0 📜 n	nin O	1.00 ‡	min								
Inject												
Wait Repeat Draw Draw Wash Mix Inject Wait Valve	* * * * *	-	om sample with om vial+ 1 with location "112' n seat with ma	n maximur "1 times	m sp	peed using defau peed using defau I for 1 times						
Repeat Draw Draw Wash Mix Inject Wait	* * * * * *	Wait 8 min Repeat 5 time(s Draw 500 µL fro Draw 100 µL fro Wash needle in Mix 600 µL fron Inject Wait 3 min Switch valve to	"m sample with om vial+ 1 with location "112" n seat with ma "Bypass"	n maximur " 1 times ximum sp	m sp beed	peed using defau	It offset					
Repeat Draw Draw Wash Mix Inject Wait Valve	* * * * * *	Wait 8 min Repeat 5 time(s Draw 500 µL fro Draw 100 µL fro Wash needle in Mix 600 µL fron Inject Wait 3 min Switch valve to	"m sample with om vial+ 1 with location "112" n seat with ma "Bypass"	n maximur " 1 times ximum sp	m sp beed	peed using defaul	It offset					
Repeat Draw Draw Wash Mix Inject Wait Valve Eject	* * * * * * *	Wait 8 min Repeat 5 time(s Draw 500 µL fro Draw 100 µL fro Wash needle in Mix 600 µL fron Inject Wait 3 min Switch valve to Eject maximum	"m sample with om vial+ 1 with location "112" n seat with ma "Bypass"	n maximur " 1 times ximum sp	m sp beed	peed using defaul	It offset					
Repeat Draw Draw Wash Mix Inject Wait Valve Eject End Repeat Wait		Wait 8 min Repeat 5 time(s Draw 500 µL fro Draw 100 µL fro Wash needle in Mix 600 µL fron Inject Wait 3 min Switch valve to Eject maximum End Repeat Wait 35 min	" om sample with om vial+ 1 with location "112" n seat with ma "Bypass" volume to se	n maximur " 1 times ximum sp	m sp beed	peed using defaul	It offset					
Repeat Draw Draw Wash Mix Inject Wait Valve Eject End Repeat		Wait 8 min Repeat 5 time(s Draw 500 µL fro Draw 100 µL fro Wash needle in Mix 600 µL fron Inject Wait 3 min Switch valve to Eject maximum End Repeat Wait 35 min Repeat 5 time(s	"Bypass" volume to se	n maximur * 1 times ximum sp vat with ma	m sp beed	peed using defau I for 1 times	It offset	offset				
Repeat Draw Draw Wash Mix Inject Wait Valve Eject End Repeat Wait Repeat Draw		Wait 8 min Repeat 5 time(s Draw 500 µL fro Draw 100 µL fro Wash needle in Mix 600 µL fron Inject Wait 3 min Switch valve to Eject maximum End Repeat Wait 35 min Repeat 5 time(s Draw 500 µL fro	"Bypass" volume to se	n maximur " 1 times ximum sp at with maximu h maximu	m sp beed axin	peed using defau f for 1 times num speed using peed using defau	It offset	offset				
Repeat Draw Draw Wash Mix Inject Wait Valve Eject End Repeat Wait Repeat Draw		Wait 8 min Repeat 5 time(s Draw 500 µL fro Draw 100 µL fro Wash needle in Mix 600 µL fron Inject Wait 3 min Switch valve to Eject maximum End Repeat Wait 35 min Repeat 5 time(s Draw 500 µL fro Draw 100 µL fro	m sample with om vial+ 1 with location "112" n seat with ma "Bypass" volume to se s) om sample with om vial+ 1 with	n maximur * 1 times ximum sp at with ma h maximu n maximur	m sp peed axin um s m sp	peed using defau I for 1 times	It offset	offset				
Repeat Draw Draw Wash Mix Inject Wait Valve Eject Eind Repeat Wait Repeat Draw Wash		Wait 8 min Repeat 5 time(s Draw 500 µL fro Draw 100 µL fro Wash needle in Mix 600 µL fron Inject Wait 3 min Switch valve to Eject maximum End Repeat Wait 35 min Repeat 5 time(s Draw 500 µL fro Draw 100 µL fro Wash needle in	m sample with om vial+ 1 with location "112" n seat with ma "Bypass" volume to se s) om sample with om vial+ 1 with location "112"	n maximur * 1 times ximum sp vat with maximu h maximu n maximur * 1 times	m sp peed axin m s m sp	peed using defau for 1 times num speed using peed using defau peed using defau	It offset	offset				
Repeat Draw Draw Wash Mix Inject Wait Valve Eject End Repeat Wait Repeat Draw		Wait 8 min Repeat 5 time(s Draw 500 µL fro Draw 100 µL fro Wash needle in Mix 600 µL fron Inject Wait 3 min Switch valve to Eject maximum End Repeat Wait 35 min Repeat 5 time(s Draw 500 µL fro Draw 100 µL fro	m sample with om vial+ 1 with location "112" n seat with ma "Bypass" volume to se s) om sample with om vial+ 1 with location "112"	n maximur * 1 times ximum sp vat with maximu h maximu n maximur * 1 times	m sp peed axin m s m sp	peed using defau for 1 times num speed using peed using defau peed using defau	It offset	offset				

Dual-Wavelength S	ettings	
Enable D	Jual-Wavelength	
	Wavelength	
Signal A:	250 📫 nm	
Signal B:	301 ≑ nm	
Peakwidth:	< 0.4 min (4 s resp. time) (2.5 Hz)	•
Peakwidth:	< 0.4 min (4 s resp. time) (2.5 Hz)	T

Figure 3.4. Settings of the components of the HPLC synthesizer during glycosylation

Fmoc removal. The reaction is monitored at $\lambda = 250$ and $\lambda = 301$ nm. The dibenzofulvene absorbance at 301 nm is a clear indication of the reaction completion. The removal is completed within 1 hour, including the washings and the resin is reacidified with TMSOTf as a last step. Even in this case, the valve was left in position 1 (waste) for the duration of the sequence. Figure 3.4 A, B and C depicts the settings of the pump, autosampler and VWD, respectively.

Final cleavage. The cleavage is performed in Zemplen conditions, with the solution prepared as reported above. The valve after the 30 seconds of the sequence switches from position 1 to position 2 and divert the flow to the collection flask. The reaction is monitored at both 250 and 301 nm and the sequence consist of 4 consecutive injections of the cleaving solution. Figure 3.5 A, B and C depicts the settings of the modules.

Detection. Representative UV traces for each sequence are depicted in Figure 3.6 A, B and C. The absorbance of the donor at $\lambda = 301$ nm is significantly lower compared to 250 nm, therefore the signals are not saturated and in some cases is easier to understand the proceeding of the reaction. The glycosylation trace **A** shows a progressive increase in the concentration of the donor with the number of injections, indication of the lower availability of free acceptor that can still be glycosylated. The Fmoc removal trace **B** clearly indicates the majority of the temporary protecting group being removed in the first injection of the piperidine solution, with only minor amounts cleaved in the following injections. The final cleavage trace **C** shows high absorbance during the injections, corresponding the the prograssive cleavage of the oligosaccharides from the resin and the Bz and Fmoc groups from the glycans. The absorbance decreases progressively during the washings.

B: 0.0 : % 30.00 50.0 0.0 1.000 60.00 C: ✓ 50.0 : % 31.00 100.0 0.0 0.0 1.000 60.00 40.00 100.0 0.0 0.0 1.000 60.00 41.00 0.0 0.0 100.0 0.0 1.000 60.00 0.0 :	Flow			Advanced						
A 500 1 %			1.000 🗘 mL/min	▲ Timetable (18/1	00 events)					
A 000 500 00 1000 600 B 001 % 000 500 000 500 000 500 600 1000 600 C Ø Ø00 % 000 1000 600 000 1000 600 C Ø Ø00 % 000 1000 000 000 1000 600 D: 001 % 000 1000 000 000 1000 600				Time [min]	A[%]	B [%]	C [%]	D [%]	Flow [m] /min]	
B 00 1 % 300 500 60 00 1000 600 00 1000 600 00 1000 600 00 00 600 C: Ø 500 1 % 00 1 000 00 00 00 00 00 1000 600 00 1000 600 00 1000 600 00 1000 600 00 1000 600 D: 00 1 % 00 0 1000 00 00 00 00 1000 00 1000 600 00 1000 600 00 1000 600 00 1000 600 Pressue Limits Min: 000 1 bar Max: 60.00 1 bar 60.00 1 000 600 00 1000 600 Pressue Limits Min: 0.00 1 000 1 000 100 1000 1000 1000 100	A: 50.0), %		0.00	50.0	0.0	50.0	0.0		
3100 1000 00 00 1000 600 C: 2 500; % 1000 600 00 1000 600 D: 00; % 1000 600 00 1000 600 D: 00; % 1000 600 1000 00 1000 600 Pressure Limits 100; bar Max 6000; bar 6000; bar 6000 600 Pressure Limits 100; bar Max 6000; bar 6000; <td< th=""><th>B: 0.0</th><th>2</th><th></th><th></th><th></th><th></th><th></th><th></th><th></th><th></th></td<>	B: 0.0	2								
C: W (00, 1) 1										
D: 00: % 000<	C: 🗸 50.0) 🕂 🕺								
Dr: 00 , 1 x Pressure Limits Min: 00 ; bar Postime Postime A Injector/No Limit 0 Off @ 60.00 ; min 100 ; min Injection 0 ff Injection volume: 500.00 ; µl Draw speed: 500 ; µL/min Eject speed: 500 ; µL/min Draw position: 0.0 ; mm Function Parameter • Repeat • Repeat 5 time(s) Draw Draw default volume from location "3" with maximum speed using default offset Inject I hject Wait • Wait 3 min Valve • Switch valve to "Bypass" Eject • Eject default volume to seat with default speed using default offset Draw • Draw maximum volume from location "111" with maximum speed using default offset Eject • Eject maximum volume from location "2" with maximum speed using default offset Draw • Draw maximum volume from location "2" with maximum speed using default offset Inject • Inject Wait • Wait 30 min Draw • Draw maximum volume from location "111" with default speed using default offset				50.00						
Mir: 0.00 ; bar Max: 60.00 ; bar Stoptime Posttime O As Injector/No Limit Off @ 60.00 ; min 100 ; min Injection Injection volume: 500.00 ; µl Draw speed: 500 ; µL/min Eject speed: 500 ; µL/min Draw position: 0.0 ; mm Function Parameter Repeat Repeat 5 time(s) Draw Draw default volume from location "3" with maximum speed using default offset Inject Inject Valve Switch valve to "Bypass" Eject Eject default volume from location "111" with maximum speed using default offset End Repeat End Repeat Draw Draw maximum volume from location "111" with maximum speed using default offset Eject Eject default volume from location "2" with maximum speed using default offset Inject Using default offset Uraw Draw maximum volume from location "2" with maximum speed using default offset Inject Using default volume to seat with default speed using default offset Uraw Draw maximum volume from location "111" with default speed using default offset	D: [] [0.0) (%			100.0	0.0	0.0	0.0	1.000	60.00
Stoptime Posttime	Pressure Limits									
 As Injector/No Limit Off 60.00 î min 1.00 î min Injection Injection volume: 500.00 î µL/min Linjection volume: 500.00 î µL Draw speed: 500 î µL/min Linjection volume: 500.00 î µL Prameter Repeat • Repeat • Repeat 5 time(s) Draw • Draw default volume from location "3" with maximum speed using default offset Inject Inject Valve • Switch valve to "Bypass" Eject Eject default volume from location "111" with maximum speed using default offset Erand Repeat End Repeat Draw • Draw maximum volume from location "111" with maximum speed using default offset Eject • Eject maximum volume from location "2" with maximum speed using default offset Eject • Eject maximum volume from location "111" with maximum speed using default offset Inject • Inject Valvah • Vash needle in location "112" 3 times Vait • Vash needle in location "111" with default speed using default offset Eject • Eject default volume to seat with default speed using default offset Inject • Urist 30 min <th>Min:</th> <th>0.00</th> <th>bar Max: 60.00 tor</th> <th></th> <th></th> <th></th> <th></th> <th></th> <th></th> <th></th>	Min:	0.00	bar Max: 60.00 tor							
 € 0.00 î min 100 î min Injection Injection volume: 500.00 î µl Draw speed: 500 î µl/min Eject speed: 500 î µl/min Draw position: 0.0 î mm Function Parameter Repeat Repeat 5 time(s) Draw Draw default volume from location "3" with maximum speed using default offset Inject Inject Valve Switch valve to "Bypass" Eject Eject default volume to seat with default speed using default offset End Repeat Eraw maximum volume from location "111" with maximum speed using default offset Eject Eject = Lipic default volume from location "2" with maximum speed using default offset Inject Inject Inject Valve Switch valve to seat with maximum speed using default offset Eject Eject maximum volume from location "2" with maximum speed using default offset Inject Vait Vait 30 min Draw Draw maximum volume from location "111" with default speed using default offset Eject Eject default volume to seat with default speed using default offset Eject Vait Vait 30 min Draw Draw maximum volume from location "111" with default speed using default offset Eject Eject default volume to seat with default speed using default offset Eject Eject default volume to seat with default speed using default offset Eject Eject default volume to seat with default speed using default offset Eject default volume to seat with default speed using default offset Eject Ejec	Stoptime		Posttime							
Injection Injection volume: 500.00 ; µl Draw speed: 500 ; µL/min Eject speed: 500 ; µL/min Draw position: 0.0 ; mm Function Parameter Repeat Repeat Repeat Clime(s) Draw Draw default volume from location "3" with maximum speed using default offset Inject Vait Vait Vait Vait Eict default volume to seat with default speed using default offset Eject Eject Eject maximum volume from location "111" with maximum speed using default offset Inject Inject Vash Vash needle in location "112" 3 times Vait Eject Eject default volume to seat with default speed using default offset Eject Eject Vash Vash needle in location "111" with default speed using default offset Eject Eject Eject Eject default volume from location "111" with default speed using default offset Eject Eject Eject Eject default volume from location "111" with default speed using default offset Eject Eject Eject default volume from location "111" with default speed using default offset Eject Eject Eject Eject default volume from location "111" with default speed using default offset Eject Eject Eject default volume from location "111" with default speed using default offset Eject Eject Eject Eject default volume from location "111" with default speed using default offset Eject Eject Eject Eject Eject default volume from location "111" with default speed using default offset Eject Eject Eject Eject default volume from location "111" with default speed using default offset Eject Eject Eject Eject default volume from location "111" with default speed using default offset Eject Eject Eject Eject default volume from location "111" with default speed using default offset Eject Eject Eject Eject default volume from location "111" with default speed using default offset Eject Eject Eject Eject default volume to seat with default speed using default offset Eject Eject Eject Eject Eject default volume to seat with default speed using default offset Eject Eject Eject default volume to seat with default speed using default offset Eject Eject default volume to seat with de	O As Injector	r/No Lim	it 💿 Off							
Injection Draw speed: 500 : µL/min Injection volume: 500.00 : µL Eject speed: 500 : µL/min Draw position: 0.0 : mm Function Parameter Repeat Repeat 5 time(s) Draw Draw default volume from location "3" with maximum speed using default offset Inject Inject Wait Valve Switch valve to "Bypass" Eject Eject default volume from location "111" with maximum speed using default offset End Repeat End Repeat Draw Draw maximum volume from location "111" with maximum speed using default offset Eject Eject maximum volume from location "111" with maximum speed using default offset Draw Draw maximum volume from location "111" with maximum speed using default offset Inject Inject Valve Valve Wash Vash needle in location "112" 3 times Wait Valva from location "111" with default speed using default offset Inject Draw maximum volume from location "111" with default speed using default offset Eject Vash needle in location "112" 3 times Wait Vast go min Draw </th <th>60</th> <th>0.00 🛟</th> <th>min O 1.00 🗘 min</th> <th></th> <th></th> <th></th> <th></th> <th></th> <th></th> <th></th>	60	0.00 🛟	min O 1.00 🗘 min							
Injection Injection volume: 500.00 ÷ µL Function Parameter Repeat Repeat 5 time(s) Draw Draw default volume from location "3" with maximum speed using default offset Inject Inject Wait Wait 3 min Valve Switch valve to "Bypass" Eject Eject default volume from location "111" with maximum speed using default offset Draw Draw maximum volume from location "111" with maximum speed using default offset Eject Eject maximum volume from location "111" with maximum speed using default offset Draw Draw maximum volume from location "2" with maximum speed using default offset Inject Inject Wash Wash needle in location "112" 3 times Wait Wait 30 min Draw Draw maximum volume from location "111" with default speed using default offset Inject Wait Wash Wash needle in location "112" 3 times Wait Wait 30 min Draw Draw maximum volume from location "111" with default speed using default offset Eject Eject default volume to seat with default speed using default offset Eject Eject default volume to	ł									
Injection volume: 500.00 ; µl Draw position: 0.0 ; mm Function Parameter ▶ Repeat • Repeat 5 time(s) Draw • Draw default volume from location "3" with maximum speed using default offset Inject Inject Wait • Wait 3 min Valve • Switch valve to "Bypass" Eject • Eject default volume to seat with default speed using default offset End Repeat • End Repeat Draw • Draw maximum volume from location "111" with maximum speed using default offset Eject • Eject maximum volume from location "2" with maximum speed using default offset Inject Inject Wash Wash needle in location "112" 3 times Wait Wait 30 min Draw Draw maximum volume from location "111" with default speed using default offset Inject Inject Wash • Wash needle in location "112" 3 times Wait • Wait 30 min Draw • Draw maximum volume from location "111" with default speed using default offset Eject • Eject default volume to seat with default speed using default offset Eject • Eject default volume to seat with default speed using	Injection			Draw speed:		500	μL/m	in		
Injection volume: 500.00 ; µl Draw position: 0.0 ; mm Function Parameter ▶ Repeat Repeat 5 time(s) Draw Draw default volume from location "3" with maximum speed using default offset Inject Inject Wait Wait 3 min Valve Switch valve to "Bypass" Eject Eject default volume to seat with default speed using default offset End Repeat End Repeat Draw Draw maximum volume from location "111" with maximum speed using default offset Eject Eject maximum volume from location "2" with maximum speed using default offset Inject Inject Vash Wash needle in location "112" 3 times Wait Wait 30 min Draw Draw maximum volume from location "111" with default speed using default offset Inject Inject Wash Wash needle in location "112" 3 times Wait Wait 30 min Draw Draw maximum volume from location "111" with default speed using default offset Eject Eject default volume to seat with default speed using default offset Eject Eject default volume to seat with default speed using default off				Eiect speed:		500	uL/m	in		
Function Parameter Repeat Repeat 5 time(s) Draw Draw default volume from location "3" with maximum speed using default offset Inject Inject Wait Valva Valve Switch valve to "Bypass" Eject Eject default volume to seat with default speed using default offset End Repeat End Repeat Draw Draw maximum volume from location "111" with maximum speed using default offset Eject Eject maximum volume from location "2" with maximum speed using default offset Inject Inject Valve Valve Valve Eject default volume to seat with maximum speed using default offset Eject Eject maximum volume from location "2" with maximum speed using default offset Inject Inject Wash Wash needle in location "112" 3 times Wait Vait 30 min Draw Draw maximum volume from location "111" with default speed using default offset Eject Eject default volume to seat with default speed using default offset Eject Eject default volume to seat with default speed using default offset		Ir	ijection volume: 500.00 📫 μl							
Repeat Repeat 5 time(s) Draw Draw default volume from location "3" with maximum speed using default offset Inject Inject Wait Wait 3 min Valve Switch valve to "Bypass" Eject Eject default volume to seat with default speed using default offset End Repeat End Repeat Draw Draw maximum volume from location "111" with maximum speed using default offset Eject Eject maximum volume from location "111" with maximum speed using default offset Draw Draw maximum volume from location "2" with maximum speed using default offset Inject Inject Wash Wash needle in location "112" 3 times Wait Wait 30 min Draw Draw maximum volume from location "111" with default speed using default offset Eject Fject default volume to seat with default speed using default offset Inject Inject Wash Wash needle in location "112" 3 times Wait Wait 30 min Draw Draw maximum volume from location "111" with default speed using default offset Eject Eject default volume to seat with default speed using default offset				Draw position:		0.0	. mm			
DrawDraw default volume from location "3" with maximum speed using default offsetInjectInjectWaitWait 3 minValveSwitch valve to "Bypass"EjectEject default volume to seat with default speed using default offsetEnd RepeatEnd RepeatDrawDraw maximum volume from location "111" with maximum speed using default offsetEjectEject maximum volume from location "111" with maximum speed using default offsetEjectInjectDrawDraw maximum volume from location "2" with maximum speed using default offsetInjectInjectWashWash needle in location "112" 3 timesWaitWait 30 minDrawDraw maximum volume from location "111" with default speed using default offsetEjectEject default volume to seat with default speed using default offsetEjectVashWaitWash needle in location "112" 3 timesWaitEject default volume to seat with default speed using default offsetEjectEject default volume to seat with default speed using default offsetEjectEject default volume to seat with default speed using default offsetEjectEject default volume to seat with default speed using default offsetEjectEject default volume to seat with default speed using default offset	Function		Parameter]		
DrawDraw default volume from location "3" with maximum speed using default offsetInjectInjectWaitWait 3 minValveSwitch valve to "Bypass"EjectEject default volume to seat with default speed using default offsetEnd RepeatEnd RepeatDrawDraw maximum volume from location "111" with maximum speed using default offsetEjectEject maximum volume from location "111" with maximum speed using default offsetEjectInjectDrawDraw maximum volume from location "2" with maximum speed using default offsetInjectInjectWashWash needle in location "112" 3 timesWaitWait 30 minDrawDraw maximum volume from location "111" with default speed using default offsetEjectEject default volume to seat with default speed using default offsetEjectVashWaitWash needle in location "112" 3 timesWaitEject default volume to seat with default speed using default offsetEjectEject default volume to seat with default speed using default offsetEjectEject default volume to seat with default speed using default offsetEjectEject default volume to seat with default speed using default offsetEjectEject default volume to seat with default speed using default offset	Repeat									
Wait Wait 3 min Valve Switch valve to "Bypass" Eject Eject default volume to seat with default speed using default offset End Repeat End Repeat Draw Draw maximum volume from location "111" with maximum speed using default offset Eject Eject maximum volume to seat with maximum speed using default offset Draw Draw maximum volume from location "2" with maximum speed using default offset Inject Inject Wash Wash needle in location "112" 3 times Wait Wait 30 min Draw Draw maximum volume from location "111" with default speed using default offset Eject Eject default volume to seat with default speed using default offset		-	Draw default volume from location "3" with	maximum speed us	ing defau	ult offset				
Wait Wait 3 min Valve Switch valve to "Bypass" Eject Eject default volume to seat with default speed using default offset End Repeat End Repeat Draw Draw maximum volume from location "111" with maximum speed using default offset Eject Eject maximum volume to seat with maximum speed using default offset Draw Draw maximum volume from location "2" with maximum speed using default offset Inject Inject Wash Wash needle in location "112" 3 times Wait Wait 30 min Draw Draw maximum volume from location "111" with default speed using default offset Eject Eject default volume to seat with default speed using default offset	Iniect		· -							
Eject Eject default volume to seat with default speed using default offset End Repeat End Repeat Draw Draw maximum volume from location "111" with maximum speed using default offset Eject Eject maximum volume to seat with maximum speed using default offset Draw Draw maximum volume from location "2" with maximum speed using default offset Draw Draw maximum volume from location "2" with maximum speed using default offset Inject Inject Wash Wash needle in location "112" 3 times Wait Wait 30 min Draw Draw maximum volume from location "111" with default speed using default offset Eject Eject default volume to seat with default speed using default offset	Wait		-							
Eject Eject default volume to seat with default speed using default offset End Repeat End Repeat Draw Draw maximum volume from location "111" with maximum speed using default offset Eject Eject maximum volume to seat with maximum speed using default offset Draw Draw maximum volume from location "2" with maximum speed using default offset Draw Draw maximum volume from location "2" with maximum speed using default offset Inject Inject Wash Wash needle in location "112" 3 times Wait Wait 30 min Draw Draw maximum volume from location "111" with default speed using default offset Eject Eject default volume to seat with default speed using default offset	Valve	-								
End Repeat End Repeat Draw Draw maximum volume from location "111" with maximum speed using default offset Eject Eject maximum volume to seat with maximum speed using default offset Draw Draw maximum volume from location "2" with maximum speed using default offset Inject Inject Wash Wash needle in location "112" 3 times Wait Wait 30 min Draw Draw maximum volume from location "111" with default speed using default offset Eject Eject default volume to seat with default speed using default offset										
Draw Draw maximum volume from location "111" with maximum speed using default offset Eject Eject maximum volume to seat with maximum speed using default offset Draw Draw maximum volume from location "2" with maximum speed using default offset Inject Inject Wash Wash needle in location "112" 3 times Wait Wait 30 min Draw Draw maximum volume from location "111" with default speed using default offset Eject Eject default volume to seat with default speed using default offset										
Eject Eject maximum volume to seat with maximum speed using default offset Draw Draw maximum volume from location "2" with maximum speed using default offset Inject Inject Wash Wash needle in location "112" 3 times Wait Wait 30 min Draw Draw maximum volume from location "111" with default speed using default offset Eject Eject default volume to seat with default speed using default offset			•							
Draw Draw maximum volume from location "2" with maximum speed using default offset Inject Inject Wash Wash needle in location "112" 3 times Wait Wait 30 min Draw Draw maximum volume from location "111" with default speed using default offset Eject Eject default volume to seat with default speed using default offset				-						
Inject Inject Wash Wash needle in location "112" 3 times Wait Wait 30 min Draw Draw maximum volume from location "111" with default speed using default offset Eject Eject default volume to seat with default speed using default offset										
Wash Wash needle in location "112" 3 times Wait Wait 30 min Draw Draw maximum volume from location "111" with default speed using default offset Eject Eject default volume to seat with default speed using default offset				nan maximum speed	aoniy de	aduit Ulk	50L			
Wait • Wait 30 min Draw • Draw maximum volume from location "111" with default speed using default offset Eject • Eject default volume to seat with default speed using default offset		•	*							
Draw Draw maximum volume from location "111" with default speed using default offset Eject Eject default volume to seat with default speed using default offset 		•								
Eject Eject default volume to seat with default speed using default offset		•								
				-		tault offs	et			
	Eject	•	Eject default volume to seat with default sp	eed using default of	fset					
	2							L		

al-Wavelength S	ettings	
🗹 Enable D	ual-Wavelength	
	Wavelength	
Signal A:	250 📫 nm	
Signal B:	301 🔶 nm	
Peakwidth:	< 0.4 min (4 s resp. time) (2.5 Hz)	•

Figure 3.5. Settings of the components of the HPLC synthesizer during Fmoc removal

Flow	> Advanced						
0.500 ÷ mL/min	▲ Timetable (18/10	00 events)					
							function cent
Solvents	Time (min)	A [%]	D [%]	C [%]	D [%]	Flow	Max. Pressure
A: 50.0 0 %	Time [min]	A[%]	B [%] 50.0	0.0		Flow [mL/min] 0.500	Limit [bar] 60.00
B: ☑ 50.0 ÷ %	30.00	50.0	50.0	0.0	0.0	0.500	60.00
	31.00 35.00	100.0 100.0	0.0 0.0	0.0		2.000 2.000	60.00 60.00
C: 0.0 ¢ %	36.00	0.0	100.0	0.0	0.0	2.000	60.00
D: 0.0 0 %	40.00		0.0 0.0	0.0 0.0		2.000 0.500	60.00 60.00
Pressure Limits							
Min: 0.00 to bar Max: 60.00 to bar							
Stoptime Posttime							
O As Injector/No Limit Off							
● 50.00 → min O 1.00 ↓ min							
Α							
Injection							
Injection volume: 500.00 📮 µl							
Function Parameter							
▶ Repeat							
Draw - Draw default volume from location	n "113" with de	fault sp	beed u	sing de	fault of	fset	
Wash Wash needle in location "112" 2 ti	mes						
Inject 👻 Inject							
Wait 👻 Wait 3 min	✓ Wait 3 min						
Eject Eject default volume to seat with r	ct Eject default volume to seat with maximum speed using default offset						
End Repeat 👻 End Repeat							
Draw - Draw maximum volume from local	Draw maximum volume from location "111" with default speed using default offset						
Eject Eject default volume to seat with default speed using default offset							
B							-
Dual-Wavelength Settings							

Enable Dual-Wavelength

	Wavelength
Signal A:	250 📫 nm
Signal B:	301 📫 nm
Peakwidth:	< 0.4 min (4 s resp. time) (2.5 Hz) 💌

С

Figure 3.6. Settings of the components of the HPLC synthesizer during the final cleavage




Figure 3.7. UV traces for the synthetic steps


3.4.6. Synthesis of oligosaccharides

8-Acetyloxyoct-1-yl O-(2,3,4,6-tetra-O-acetyl- β -D-glucopyranosyl)-(1 \rightarrow 6)-O-(2,3,4-tri-O-acetyl- β -D-glucopyranosyl)-(1 \rightarrow 6)-O-(2,3,4-tri-O-acetyl- β -D-glucopyranosyl)-

 $(1 \rightarrow 6) \textbf{-} \textbf{O} \textbf{-} (2, \textbf{3}, \textbf{4} \textbf{-} tri \textbf{-} \textbf{O} \textbf{-} acetyl \textbf{-} \beta \textbf{-} \textbf{D} \textbf{-} glucopyranosyl) \textbf{-} (1 \rightarrow 6) \textbf{-} 2, \textbf{3}, \textbf{4} \textbf{-} tri \textbf{-} \textbf{O} \textbf{-} benzyl \textbf{-} \alpha \textbf{-} \textbf{D} \textbf{-} acetyl \textbf{-} \beta \textbf{-} \textbf{D} \textbf{-} glucopyranosyl) \textbf{-} (1 \rightarrow 6) \textbf{-} 2, \textbf{3}, \textbf{4} \textbf{-} tri \textbf{-} \textbf{O} \textbf{-} benzyl \textbf{-} \alpha \textbf{-} \textbf{D} \textbf{-} acetyl \textbf{-} \beta \textbf{-} \beta$

glucopyranoside (3.1). Automation modules: The Omnifit column is filled with resin (50 mg) preloaded with acceptor 3.7 (0.016 mmol). The vials were prepared according to the general methods and organized as depicted below. Vial 1 contains donor 3.4 (71 mg, 0.08 mmol, 5.0 equiv), vial 2 contains of TMSOTf (14 μ L, 0.08 mmol, 5.0 equiv), and vial 3 contains a piperidine-DMF solution prepared as indicated in the general methods. Vials B, W and C are blank, washing, and final off-resin cleavage, respectively, were prepared as described in the general methods.

Vial trays organization:



Automation Sequence:

Glycosylation 120 min

Fmoc removal 60 min

Glycosylation 120 min

Fmoc removal 60 min

Glycosylation 120 min

Fmoc removal 60 min

Glycosylation 120 min

Final Cleavage 50 min

Post Automation: The reaction mixture collected from cleavage step was evaporated under reduced pressure, then diluted with MeOH (2.0 mL) and quenched with Amberlite IR20 H⁺ form. The resin was filtrated and washed with MeOH, the solvent was evaporated and dried in vacuo for 1 h. The crude was dissolved in pyridine (2.0 mL) and acetic anhydride (0.5 mL) was added. The resulting mixture was stirred under argon at room temperature for 16 h. The reaction was guenched with MeOH, then the solvent was evaporated and co-evaporated with toluene. The residue was purified by column chromatography on silica gel (hexanes-acetone gradient elution) to afford compound 3.1 in 33% (10.0 mg, 0.0055 mmol) yield. Analytical data for **3.1:** $R_f = 0.50$ (hexane/acetone, 1/1, v/v); $[\alpha]_D^{21}$ -2.7 (c 1, CHCl₃); ¹H NMR (600 MHz, CDCl₃): δ , 7.39 – 7.21 (m, 15H), 5.23 - 5.05 (m, 6H), 5.02 - 4.83 (m, 9H), 4.80 - 4.74 (m, 2H), 4.71 (d, J = 3.2 Hz, 1H), 4.62 (d, J = 12.0 Hz, 1H), 4.58 - 4.47 (m, 5H), 4.27 (dd, J = 12.3, 4.9 Hz, 1H), 4.15 - 4.02(m, 5H), 4.01 - 3.84 (m, 5H), 3.76 - 3.47 (m, 13H), 3.33 (dd, J = 16.0, 6.5 Hz, 1H), 2.14 -1.87 (m, 42H), 1.67 – 1.53 (m, 8H), 1.31 (s, 8H) ppm; ¹³C NMR (151 MHz, CDCl₃): δ, 171.41, 170.78, 170.43, 170.32, 170.27, 170.24, 169.81, 169.74, 169.66, 169.61, 169.59, 169.53, 169.32, 169.19, 138.97, 138.40, 138.27, 128.75, 128.56, 128.50, 128.15, 128.09, 127.99, 127.97, 127.69, 101.00, 100.77, 100.63, 96.80, 81.98, 80.17, 77.54, 75.76, 75.13, 73.29, 73.27, 73.17, 73.10, 72.92, 72.85, 72.78, 72.10, 71.51, 71.49, 71.24, 71.12, 71.10, 69.75, 69.24, 69.16, 69.10, 68.49, 68.43, 68.16, 68.15, 68.12, 68.07, 64.77, 62.05, 62.02, 61.95, 29.85, 29.60, 29.51, 29.49, 29.36, 28.74, 26.32, 26.08, 21.20, 20.92, 20.89, 20.87, 20.85, 20.82, 20.80, 20.78, 20.76 ppm; HR-TOF MS [M+Na⁺] calcd 1837.6728 found 1837.6672


 $\label{eq:constraint} Methyl \qquad O-(2,4-di-O-benzoyl-3,6-di-O-benzyl-\beta-D-glucopyranosyl)-(1\rightarrow 4)-O-(2-O-benzoyl-3,6-di-O-benzyl-\beta-D-glucopyranosyl)-(1\rightarrow 4)-O-(2-O-benzoyl-3,6-di-O-benzyl-\beta-D-glucopyranosyl)-(1\rightarrow 4)-O-(2-O-benzoyl-3,6-di-O-benzyl-\beta-D-glucopyranosyl)-(1\rightarrow 4)-O-(2-O-benzoyl-3,6-di-O-benzyl-\beta-D-glucopyranosyl)-(1\rightarrow 4)-O-(2-O-benzoyl-3,6-di-O-benzyl-\beta-D-glucopyranosyl)-(1\rightarrow 4)-O-(2-O-benzoyl-3,6-di-O-benzyl-\beta-D-glucopyranosyl)-(1\rightarrow 4)-O-(2-O-benzoyl-3,6-di-O-benzyl-\beta-D-glucopyranosyl)-(1\rightarrow 4)-O-(2-O-benzoyl-3,6-di-O-benzyl-\beta-D-glucopyranosyl)-(1\rightarrow 4)-O-(2-O-benzoyl-3,6-di-O-benzyl-3,0-di-O-benzyl-3,0-di-O-benzyl-3,0-di-O-benzyl-3,0-di-O-benzyl$

benzyl-β-D-glucopyranosyl)-(1→4)-O-(2-O-benzoyl-3,6-di-O-benzyl-β-D-

glucopyranosyl)- $(1 \rightarrow 4)$ -6-*O*-benzoyl-2,3-di-*O*-benzyl- α -D-glucopyranoside (3.2).

Automation modules: The Omnifit column is filled with resin (50 mg) preloaded with acceptor **3.6** (0.02 mmol). The vials were prepared according to the general methods and organized as depicted below. Vial 1 contains donor **3.5** (160 mg, 0.20 mmol, 10.0 equiv), vial 2 contains of TMSOTf (5 μ L, 0.03 mmol, 1.5 equiv), and vial 3 contains a piperidine-DMF solution prepared as indicated in the general methods. Vials B, W and C are blank, washing, and final off-resin cleavage, respectively, were prepared as described in the general methods.

Vial trays organization:



Automation Sequence:

Glycosylation 120 min Glycosylation 120 min Fmoc removal 60 min Glycosylation 120 min Glycosylation 120 min

Fmoc removal 60 min

Glycosylation 120 min

Glycosylation 120 min

Fmoc removal 60 min

Glycosylation 120 min

Glycosylation 120 min

Final Cleavage 50 min


Post Automation: The reaction mixture collected from cleavage step was evaporated under reduced pressure, then diluted with MeOH (2.0 mL) and quenched with Amberlite IR20 H⁺ form. The resin was filtrated and washed with MeOH, the solvent was evaporated and dried *in vacuo* for 1 h. The crude was dissolved in pyridine (2.0 mL) and benzoyl chloride (0.5 mL) was added. The resulting mixture was stirred under argon at room temperature for 16 h. The reaction was quenched with MeOH, then the solvent was evaporated and co-evaporated with toluene. The residue was purified by column chromatography on silica gel (hexanes-ethyl acetate gradient elution) to afford compound **3.2** in 20% (10.3 mg, 0.0044 mmol) yield. Analytical data for **3.2**: $R_f = 0.20$ (hexane/EtOAc, 7/3, v/v); $[\alpha]_D^{21} + 25.7$ (*c* 1, CHCl₃); ¹H NMR (600 MHz, CDCl₃): δ , 8.07

- 7.68 (m, 38H), 7.68 - 6.59 (m, 196H), 5.40 - 5.31 (m, 6H), 5.20 - 5.08 (m, 7H), 5.05 - 4.94 (m, 7H), 4.94 - 4.78 (m, 12H), 4.73 (dd, J = 9.8 Hz, 8H), 4.63 - 4.28 (m, 42H), 4.28 - 4.02 (m, 22H), 4.02 - 3.72 (m, 26H), 3.68 (s, 5H), 3.65 - 3.42 (m, 22H), 3.42 - 3.15 (m, 31H), 2.87 (d, J = 8.8 Hz, 1H), 2.75 (d, J = 10.1 Hz, 3H) ppm; ¹³C NMR (151 MHz, CDCl₃): δ , 165.87, 165.34, 165.13, 165.08, 165.02, 164.90, 164.86, 164.79, 138.90, 138.76, 138.38, 138.16, 137.81, 137.54, 133.59, 133.38, 133.09, 132.96, 129.84, 129.60, 129.00, 128.65, 128.57, 128.45, 128.27, 128.12, 127.93, 127.68, 127.39, 127.30, 127.12, 127.02, 101.31, 100.16, 100.03, 99.97, 97.91, 80.41, 80.28, 80.06, 79.88, 79.45, 78.29, 77.37, 77.16, 76.95, 76.44, 76.13, 75.18, 74.90, 74.72, 74.48, 74.00, 73.88, 73.78, 73.56, 73.44, 72.09, 69.95, 68.43, 67.45, 67.16, 62.84, 55.31, 32.08, 29.85, 29.51, 29.28, 22.85, 14.28 ppm; HR-TOF MS [M+Na⁺] calcd 2390.9097 found 2390.9045.

Methyl $O-(2,3,4,6-tetra-O-benzoyl-\beta-D-glucopyranosyl)-(1\rightarrow 4)-O-(2-O-benzoyl-3,6-di-O-benzyl-\beta-D-glucopyranosyl)-(1\rightarrow 6)-O-(2,3,4-tetra-O-benzoyl-\beta-D-$

glucopyranosyl)- $(1 \rightarrow 4)$ -6-*O*-benzoyl-2,3-di-*O*-benzyl- α -D-glucopyranoside (3.3). Automation modules: The Omnifit column is filled with resin (50 mg) preloaded with acceptor **3.6** (0.02 mmol). The vials were prepared according to the general methods and organized as depicted below. Vial 1 contains donor **3.4** (130 mg, 0.15 mmol, 7.5 equiv), vial 2 contains of TMSOTf (10 μ L, 0.05 mmol, 2.5 equiv), and vial 3 contains a piperidine-DMF solution prepared as indicated in the general methods. Vial 4 contains donor **3.5** (83 mg, 0.10 mmol, 5.0 equiv) and vial 2 contains of TMSOTf (7.5 μ L, 0.04 mmol, 2.0 equiv). Vials B, W and C are blank, washing, and final off-resin cleavage, respectively, were prepared as described in the general methods.

Vial trays organization:



Automation Sequence:

Glycosylation 120 min Fmoc removal 60 min Glycosylation 120 min Glycosylation 120 min Fmoc removal 60 min Glycosylation 120 min Final Cleavage 50 min

Post Automation: The reaction mixture collected from cleavage step was evaporated under reduced pressure, then diluted with MeOH (2.0 mL) and quenched with Amberlite IR20 H⁺ form. The resin was filtrated and washed with MeOH, the solvent was evaporated and dried *in vacuo* for 1 h. The crude was dissolved in pyridine (2.0 mL) and benzoyl chloride (0.5 mL) was added. The resulting mixture was stirred under argon at room temperature for 16 h. The reaction was quenched with MeOH, then the solvent was evaporated and co-evaporated with toluene. The residue was purified by column

chromatography on silica gel (hexanes-ethyl acetate gradient elution) to afford compound **3.3** in 30% (13 mg, 0.0066 mmol) yield. Analytical data for **3.3**: $R_f = 0.15$ (hexane/EtOAc, 7/3, v/v); $[\alpha]_{D}^{21}$ +1.8 (c 1, CHCl₃); ¹H NMR (600 MHz, CDCl₃): δ , 7.98 – 7.71 (m, 26H), 7.61 – 7.12 (m, 66H), 7.05 – 6.87 (m, 9H), 5.66 (m, 2H), 5.53 – 5.46 (m, 2H), 5.43 – 5.39 (m, 1H), 5.33 - 5.26 (m, 2H), 5.17 - 5.12 (m, 1H), 4.91 (dd, J = 11.5, 6.2 Hz, 4H), 4.77(dd, J = 14.6, 9.6 Hz, 2H), 4.69 (d, J = 12.0 Hz, 1H), 4.63 - 4.58 (m, 2H), 4.55 (d, J = 12.5)Hz, 1H), 4.41 (dd, J = 20.2, 7.6 Hz, 3H), 4.33 (d, J = 12.1 Hz, 1H), 4.07 (ddd, J = 18.1, 10.4, 6.3 Hz, 4H), 3.89 - 3.85 (m, 1H), 3.81 - 3.68 (m, 7H), 3.61 (dd, J = 12.4, 7.2 Hz, 1H), 3.50 – 3.44 (m, 3H), 3.39 – 3.34 (m, 1H), 3.33 – 3.22 (m, 4H), 3.14 – 3.07 (m, 1H), 2.76 (d, J = 9.6 Hz, 1H), 1.26 (s, 17H), 0.94 – 0.77 (m, 5H) ppm; ¹³C NMR (151 MHz, CDCl₃): δ, 166.16, 166.08, 165.84, 165.79, 165.63, 165.50, 165.32, 165.26, 165.20, 164.82, 139.23, 138.49, 138.41, 138.24, 138.16, 133.76, 133.54, 133.49, 133.44, 133.31, 133.25, 133.15, 133.06, 129.97, 129.91, 129.84, 129.69, 129.61, 129.16, 129.09, 128.95, 128.89, 128.80, 128.66, 128.52, 128.48, 128.42, 128.37, 128.35, 128.22, 128.20, 128.11, 128.05, 127.98, 127.85, 127.50, 127.44, 127.22, 100.66, 100.59, 100.51, 98.16, 80.71, 80.63, 80.60, 77.83, 77.76, 76.21, 74.86, 74.26, 74.21, 73.67, 73.26, 73.05, 72.47, 72.20, 72.11, 69.94, 69.78, 68.55, 67.22, 66.82, 63.12, 63.08, 55.37, 32.08, 31.10, 29.85, 29.52, 22.85 ppm; HR-TOF MS [M+NH₄⁺] calcd 1995.6984 found 1995.7010.

3.5. References

- Kiessling, L. L.; Splain, R. A. Chemical approaches to glycobiology. *Annu. Rev. Biochem.* 2010, 79, 619-653.
- Kiessling, L. L. Chemistry-driven glycoscience. *Bioorg. Med. Chem.* 2018, 26, 5229-5238.

- (3) Smoot, J. T.; Demchenko, A. V. Oligosaccharide synthesis: from conventional methods to modern expeditious strategies. *Adv. Carbohydr. Chem. Biochem.* 2009, 62, 161-250.
- Mootoo, D. R.; Konradsson, P.; Udodong, U.; Fraser-Reid, B. "Armed" and "disarmed" n-pentenyl glycosides in saccharide couplings leading to oligosaccharides. *J. Am. Chem. Soc.* 1988, *110*, 5583-5584.
- (5) Fraser-Reid, B.; Udodong, U. E.; Wu, Z. F.; Ottosson, H.; Merritt, J. R.; Rao, C.
 S.; Roberts, C.; Madsen, R. n-Pentenyl glycosides in organic chemistry: a contemporary example of serendipity. *Synlett* 1992, 927-942 and references therein.
- (6) Williams, L. J.; Garbaccio, R. M.; Danishefsky, S. J.: Iterative assembly of glycals and glycal derivatives: the synthesis of glycosylated natural products and complex oligosaccharides. In *Carbohydrates in Chemistry and Biology*; Ernst, B., Hart, G. W., Sinay, P., Eds.; Wiley-VCH: Weinheim, New York, 2000; Vol. 1; pp 61-92.
- Roy, R.; Andersson, F. O.; Letellier, M. "Active" and "latent" thioglycosyl donors in oligosaccharide synthesis. Application to the synthesis of a-sialosides.
 Tetrahedron Lett. 1992, *33*, 6053-6056.
- (8) Boons, G. J.; Isles, S. Vinyl glycosides in oligosaccharide synthesis. Part 1: A new latent-active glycosylation strategy. *Tetrahedron Lett.* **1994**, *35*, 3593-3596.
- (9) Paulsen, H. Progress in oligosaccharide synthesis through a new orthogonal glycosylation strategy. *Angew. Chem. Int. Ed. Engl.* **1995**, *34*, 1432-1434.

- Kanie, O.: Orthogonal strategy in oligosaccharide synthesis. In *Carbohydrates in Chemistry and Biology*; Ernst, B., Hart, G. W., Sinay, P., Eds.; Wiley-VCH:
 Weinheim, New York, 2000; Vol. 1; pp 407-426.
- (11) Douglas, N. L.; Ley, S. V.; Lucking, U.; Warriner, S. L. Tuning glycoside reactivity: new tool for efficient oligosaccharides synthesis. *J. Chem. Soc., Perkin Trans. 1* 1998, 51-65.
- (12) Green, L. G.; Ley, S. V.: Protecting groups: effects on reactivity, glycosylation specificity and coupling efficiency. In *Carbohydrates in Chemistry and Biology*; Ernst, B., Hart, G. W., Sinay, P., Eds.; Wiley-VCH: Weinheim, New York, 2000; Vol. 1; pp 427-448.
- (13) Zhang, Z.; Ollmann, I. R.; Ye, X. S.; Wischnat, R.; Baasov, T.; Wong, C. H.
 Programmable one-pot oligosaccharide synthesis. *J. Am. Chem. Soc.* 1999, *121*, 734-753.
- (14) Ye, X. S.; Wong, C. H. Anomeric reactivity-based one-pot oligosaccharide synthesis: a rapid route to oligosaccharide libraries. *J. Org. Chem.* 2000, 65, 2410-2431.
- (15) Huang, L.; Wang, Z.; Huang, X. One-pot oligosaccharide synthesis: reactivity tuning by post-synthetic modification of aglycone. *Chem. Commun.* 2004, 1960-1961.
- (16) Merrifield, B. The role of the support in solid phase peptide synthesis *Br. Polym.J.* 1984, *16*, 173-178.
- (17) Krishnamurthy, V. R.; Dougherty, A.; Kamat, M.; Song, X.; Cummings, R. D.;Chaikof, E. L. Synthesis of an Fmoc-threonine bearing core-2 glycan: a building

block for PSGL-1 via Fmoc-assisted solid-phase peptide synthesis. *Carbohydr. Res.* **2010**, *345*, 1541-1547.

- (18) Solid-phase organic synthesis; Toy, P. H.; Lam, Y., Eds.; John Wiley & Sons, Inc. : Hoboken, 2012.
- (19) Tanaka, H.; Matoba, N.; Tsukamoto, H.; Takimoto, H.; Yamada, H.; Takahashi,
 T. Automated parallel synthesis of a protected oligosaccharide library based upon the structure of dimeric Lewis X by one-pot sequential glycosylation. *Synlett* 2005, 824-828.
- Machida, K.; Hirose, Y.; Fuse, S.; Sugawara, T.; Takahashi, T. Development and application of a solution-phase automated synthesizer, 'ChemKonzert'. *Chem. Pharm. Bull.* 2010, *58*, 87-93.
- (21) Jaipuri, F. A.; Pohl, N. L. Toward solution-phase automated iterative synthesis: fluorous-tag assisted solution-phase synthesis of linear and branched mannose oligomers. *Org. Biomol. Chem.* **2008**, *6*, 2686-2691.
- (22) Song, E.-H.; Osanya, A. O.; Petersen, C. A.; Pohl, N. L. B. Synthesis of Multivalent Tuberculosis and Leishmania-Associated Capping Carbohydrates Reveals Structure-Dependent Responses Allowing Immune Evasion. *J. Am. Chem. Soc.* 2010, *132*, 11428–11430.
- (23) Liu, L.; Pohl, N. L. B. A Fluorous Phosphate Protecting Group with Applications to Carbohydrate Synthesis. *Org. Lett.* **2011**, *13*, 1824–1827.
- (24) Ratner, D. M.; Swanson, E. R.; Seeberger, P. H. Automated Synthesis of a Protected N-Linked Glycoprotein Core Pentasaccharide. *Org. Lett.* 2003, *5*, 4717-4720.

- (25) Nokami, T.; Hayashi, R.; Saigusa, Y.; Shimizu, A.; Liu, C.-Y.; Mong, K.-K. T.;
 Yoshida, J.-i. Automated solution-phase synthesis of oligosaccharides via iterative electrochemical assembly of thioglycosides. *Org. Lett.* 2013, *15*, 4520-4523.
- (26) Grob, V. D.; Squires, T. G.; Vercellotti, J. R. Glycosyl chlorides through reaction with zinc chloride-thionyl chloride *Carbohydr. Res.* **1969**, *10*, 595-597.
- (27) Sears, P.; Wong, C. H. Toward automated synthesis of oligosaccharides and glycoproteins. *Science* 2001, 291, 2344-2350.
- (28) Hsu, C. H.; Hung, S. C.; Wu, C. Y.; Wong, C. H. Toward automated oligosaccharide synthesis. *Angew. Chem. Int. Ed.* 2011, *50*, 11872-11923.
- Matsushita, T.; Nagashima, I.; Fumoto, M.; Ohta, T.; Yamada, K.; Shimizu, H.;
 Hinou, H.; Naruchi, K.; Ito, T.; Kondo, H.; Nishimura, S.-I. Artificial Golgi
 Apparatus: Globular Protein-like Dendrimer Facilitates Fully Automated
 Enzymatic Glycan Synthesis. J. Am. Chem. Soc. 2010, 132, 16651-16656.
- (30) Sugiarto, G.; Lau, K.; Qu, J.; Li, Y.; Lim, S.; Mu, S.; Ames, J. B.; Fisher, A. J.;
 Chen, X. A sialyltransferase mutant with decreased donor hydrolysis and reduced sialidase activities for directly sialylating Lewis(x). *ACS Chem. Biol.* 2012, *7*, 1232-1240.
- (31) Chen, Y.; Thon, V.; Li, Y.; Yu, H.; Ding, L.; Lau, K.; Qu, J.; Hie, L.; Chen, X.
 One-pot three-enzyme synthesis of UDP-GlcNAc derivatives. *Chem. Commun.* **2011**, *47*, 10815-10817.
- (32) Muthana, M. M.; Qu, J.; Li, Y.; Zhang, L.; Yu, H.; Ding, L.; Malekan, H.; Chen,X. Efficient one-pot multienzyme synthesis of UDP-sugars using a promiscuous

UDP-sugar pyrophosphorylase from Bifidobacterium longum (BLUSP). *Chem. Commun.* **2012**, *48*, 2728-2730.

- (33) Li, L.; Liu, Y.; Ma, C.; Qu, J.; Calderon, A. D.; Wu, B.; Wei, N.; Wang, X.; Guo, Y.; Xiao, Z.; Song, J.; Sugiarto, G.; Li, Y.; Yu, H.; Chen, X.; Wang, P. G.
 Efficient chemoenzymatic synthesis of an N-glycan isomer library. *Chem. Sci.* 2015, *6*, 5652–5661.
- (34) Zhang, J.; Chen, C.; Gadi, M. R.; Gibbons, C.; Guo, Y.; Cao, X.; Edmunds, G.;
 Wang, S.; Liu, D.; Yu, J.; Wen, L.; Wang, P. G. Machine-Driven Enzymatic
 Oligosaccharide Synthesis by Using a Peptide Synthesizer. *Angew. Chem. Int. Ed. Engl.* 2018, *57*, 16638-16642.
- Li, T.; Liu, L.; Wei, N.; Yang, J.-Y.; Chapla, D. G.; Moremen, K. W.; Boons, G.-J. An automated platform for the enzyme-mediated assembly of complex oligosaccharides. *Nature Chem.* 2019, *11*, 229-236.
- (36) Frechet, J. M.; Schuerch, C. Solid-phase synthesis of oligosaccharides. I.
 Preparation of the solid support. Poly[p-(1-propen-3-ol-1-yl)styrene]. J. Am. *Chem. Soc.* 1971, 93, 492-496.
- (37) Seeberger, P. H.; Haase, W. C. Solid-phase oligosaccharide synthesis and combinatorial carbohydrate libraries. *Chem. Rev.* **2000**, *100*, 4349-4393.
- (38) Tanaka, K.; Fukase, K.: Oligosaccharide synthesis on solid, soluble polymer, and tag supports. In *Solid-Phase Organic Synthesis*; Toy, P. H., Lam, Y., Eds.; John Wiley & Sons, Inc. : Hoboken, 2012; pp 489-530.
- (39) Plante, O. J.; Palmacci, E. R.; Seeberger, P. H. Automated solid-phase synthesis of oligosaccharides. *Science* **2001**, *291*, 1523-1527.

- (40) Seeberger, P. H. Automated oligosaccharide synthesis. *Chem. Soc. Rev.* 2008, *37*, 19-28.
- (41) Plante, O. J.; Palmacci, E. R.; Seeberger, P. H. Development of an automated oligosaccharide synthesizer. *Adv. Carbohydr. Chem. Biochem.* **2003**, *58*, 35-54.
- (42) Seeberger, P. H. The logic of automated glycan assembly. *Acc. Chem. Res.* 2015, 48, 1450-1463.
- (43) Krock, L.; Esposito, D.; Castagner, B.; Wang, C.-C.; Bindschadler, P.; Seeberger,
 P. H. Streamlined access to conjugation-ready glycans by automated synthesis. *Chem. Sci.* 2012, *3*, 1617-1622.
- (44) Hahm, H. S.; Schlegel, M. K.; Hurevich, M.; Eller, S.; Schuhmacher, F.;
 Hofmann, J.; Pagel, K.; Seeberger, P. H. Automated glycan assembly using the
 Glyconeer 2.1 synthesizer. *Proc. Natl. Acad. Sci.* 2017, *114*, E3385-E3389.
- (45) Vijaya Ganesh, N.; Fujikawa, K.; Tan, Y. H.; Stine, K. J.; Demchenko, A. V.
 HPLC-assisted automated oligosaccharide synthesis. *Org. Lett.* 2012, *14*, 3036-3039.
- (46) Pistorio, S. G.; Nigudkar, S. S.; Stine, K. J.; Demchenko, A. V. HPLC-assisted automated oligosaccharide synthesis: the implementation of the autosampler as a mode of the reagent delivery. *J. Org. Chem.* **2016**, *81*, 8796-8805.
- (47) Pistorio, S. G.; Geringer, S. A.; Stine, K. J.; Demchenko, A. V. Manual and automated syntheses of the N-linked glycoprotein core glycans. *J. Org. Chem.* 2019, *84*, 6576-6588.

- (48) Delbianco, M.; Kononov, A.; Poveda, A.; Yu, Y.; Diercks, T.; Jimenez-Barbero, J.; Seeberger, P. H. Well-defined oligo- and polysaccharides as ideal probes for structural studies. *J. Am. Chem. Soc.* 2018, *140*, 5421-5426.
- (49) Pornsuriyasak, P.; Jia, X. G.; Kaeothip, S.; Demchenko, A. V. Templated oligosaccharide synthesis: the linker effect on the stereoselectivity of glycosylation. *Org. Lett.* **2016**, *18*, 2316-2319.

CHAPTER 4

The development of a dedicated polymer support for the solid-phase oligosaccharide synthesis

4.1. Introduction

With the advances of the field of glycosciences and the increasing number of structures elucidated and applied in all areas of the field, the need for reliable approaches to the synthesis of glycans has grown exponentially.^{1,2} Traditional glycan synthesis in solution involves iteration of glycosylation and deprotection steps, but some advanced strategies based on either chemoselective or selective activation of building blocks help to streamline the oligosaccharide assembly significantly.³ However, no universal route to glycans can be established, which dramatically hinders progress in glycosciences, whereas other biopolymers, peptides^{4,5} and oligonucleotides,⁶ can be produced by automated machines. Solid-phase synthesis (SPS) eliminates the need for conventional reaction work-up and purification of intermediates,^{7,9} and offers promising automation amenability. Since early efforts in 2001,¹⁰⁻¹³ Seeberger *et al.* developed a dedicated automated oligosaccharide synthesizer in 2012¹⁴ that was later commercialized as Glyconeer 2.1.

Also in 2012, we reported High Performance Liquid Chromatography equipmentbased automation (HPLC-A) of SPS.¹⁵ The general idea for developing the HPLC-A is that a computer interface coupled with standard HPLC components will allow recording a successful automated sequence as a computer program that can then be reproduced with the "press of a button." However, SPS of glycans suffers from certain inherent weaknesses. "*The chemistry and biology of carbohydrates has been a Cinderella field*,"¹⁶ and the area of SPS wherein everything is "borrowed" from other fields illustrates this problem very clearly. For example, instead of developing dedicated supports, commercial resins designed specifically for peptide or nucleotide SPS¹⁷⁻¹⁹ are meticulously evaluated to determine their possible suitability for glycan synthesis, which often demands different characteristics.²⁰

Presented herein is the first step of our strategic goal to tackle the key weaknesses in our previous automation efforts, and those of the SPS in general, both automated and manual. While HPLC-A and other automated approaches have a potential to revolutionize the way glycan synthesis is conducted, all current platforms suffer from inherent weaknesses of SPS as applied to glycans, among which is poor compatibility of existing commercial resins. Seeberger automation relies on the traditional polystyrenebased Merrifield resin. Our original HPLC-A set-up was based on Tentagel, a polystyrene grafted with PEG chains.¹⁵ Later on, we identified JandaJel polystyrene resin crosslinked with tetrahydrofuran-derived chains as a better support for HPLC-A.²¹ Although JandaJel has better swelling properties compared to the traditional Merrifield resin, it has low stability in the presence of large amounts of trimethylsilyl trifluoromethanesulfonate (TMSOTf).²²

4.2. Results and Discussion

JandaJel and more traditional Merrifield or Tentagel resins²¹ are all based on polystyrene, but differ in functionalization / crosslinking, albeit none were designed specifically with the SPS of glycans in mind.²³ Cross-linked polystyrenes are mechanically stable and can be obtained on a large scale from broadly available and inexpensive precursors. However, phenol-based cross-linking used in JandaJel (**4.1**, Figure 4.1) may potentially have marginal stability under strongly (Lewis) acidic conditions that are commonly employed in SPS of glycans. Although this degradation was not thought to significantly hinder general progress, we came to the realization that beads designed for peptides do not have the necessary properties suitable for glycan SPS. To address this potential weakness, described herein is the investigation of benzyl alcohol-derived ethylene glycol chain cross-linking (**4.2**, Figure 4.1) due to the anticipated greater stability of such structures under (strongly) acidic reaction conditions.^{24,25} This type of resin was first synthesized by Itsuno *et al*,²⁵ but its application in SPS is unknown. Interestingly, benzylic attachments have been considered by Janda and co-workers,^{26,27} but were deemed inferior due to their marginal stability toward strongly basic reagents, such as BuLi.





Figure 4.1. Selection of the attachment strategies and cross-linkers

To increase the swelling properties in polar protic solvents, we chose to replace the tetrahydrofuran chain used by Janda with the diethylene glycol (DEG) derived structure **4.2** depicted in Figure 4.1. Ethylene-glycol,²⁸ its homologs, and other similar molecules²⁷ have been previously investigated as crosslinkers, but the application of such resins in SPS is unknown.²⁵ Crosslinker monomer **4.2** was synthesized using paravinylbenzyl chloride **4.3** and diethylene glycol **4.4** in the presence of NaH in DMF, affording the desired compound in a good yield 85% (Scheme 4.1). The cross-linker monomer **4.2** was then used in the synthesis of a 2% cross-linked polymer **4.6**. Monomers **4.2**, **4.3**, and **4.5** in a respective ratio of 2/10/88 (w/w/w) were polymerized in the presence of benzoyl peroxide, sodium chloride and Arabic gum in water at 85 °C for 16 h following a procedure previously described by Janda.²² The desired polymer **4.6** was then purified using a Soxhlet extractor and *i*-PrOH. The chlorobenzyl group was further functionalized following Gabriel's synthesis protocol, wherein the chloride was displaced with phthalimide in DMF at 55 °C. The resulting phthlaloyl group was then removed with hydrazine hydrate in a mixture of MeOH and chloroform. This two-step procedure produced PanzaGel **4.7** equipped with the primary amine functional groups (Scheme 4.1) with a nominal loading capacity of 1.0 mmol/g.



Scheme 4.1. Synthesis of PanzaGel 4.7

Then, the swelling properties of the polymer were investigated. Swelling was measured following described procedures,²⁹ using a syringe equipped with a sintered frit. The volume of dry resin was measured, then solvent was introduced in the syringe and the mixture was allowed to equilibrate for 1 h. After being vortexed, extra solvent was removed using another syringe. As listed in Table 1, both polar and non-polar solvents

were tested, all of them showing good swelling, similar to the volumes reported for JandaJel.²² The exception is MeOH, which still exhibits better swelling if compared to data available for JandaJel.

Solvent	Vol	ume of resin (mL/g)
	PanzaGel	JandaJel ²²	Merrifield ²²
None	1.75	1.5	1.5
CH ₂ Cl ₂	9.0	11.8	5.8
MeOH	2.5	1.5	1.8
DMF	8.5	14	4.2
THF	10.0	12	5.4
Toluene	8.0	ND	ND

 Table 4.1. Comparison of swelled JandaJel and Panzagel

A set of experiments were then conducted to determine physical properties of the resin and recorded in collaboration with Prof. Stine laboratory by Dharmendra Neupane . Thermal degradation properties of PanzaGel was assessed by thermogravimetric analysis (TGA). As shown in Figure 4.2, the thermal decomposition of PanzaGel **4.7** was investigated at various temperatures. PanzaGel was found thermally stable up to 360 °C, but about 97% weight loss occurs by 460 °C. To assess the chemical stability of PanzaGel, the polymer was treated with trimethylsilyl trifluoromethanesulfonate, as this Lewis acid was found to degrade JandaJel.³⁰ Upon treatment of 100 mg of resin with 100 μ L of TMSOTf in 1.0 mL of methylene chloride for 1 h, which exceeds the typical conditions employed in chemical glycosylations using polymer supports, no

decomposition was observed. The thermal decomposition temperature and the SEM images of the polymer showed no significant difference before and after the treatment with TMSOTf. PanzaGel treated with TMSOTf decomposed by about 85% upon heating to 600 °C leaving behind a residue, indicating a chemical structure unaltered by the prolonged contact with the acid.




Figure 4.2. Thermogravimetric analysis (TGA) plots (black line) and Weight derivatives curves (red line) of PanzaGel

The prepared polymer was also investigated by scanning electron microscopy, with images recorded by Dharmendra Neupane. As shown in Figure 4.3, polymer **4.7** was prepared in the form of monospheres with an average size of 157.64 μ m (average of 30 polymer beads). Nitrogen adsorption/desorption isotherm plots have been used to evaluate the pore volume (Vp) and the surface area (S) of the synthesized material. The total pore volume was calculated as 0.0033 mL/g. The BET surface area was found to be 0.84 m²/g.

To explore the synthetic application of the novel resin, we then moved on to synthesize disaccharide **4.8** and pentasaccharide **4.9** (Figure 4.4). Our lab has recently

achieved a full automation of the synthesis of oligosaccharides using a two-way spilt valve.³¹ Differently from our previous experimental set up involving reagent delivery with a preparative autosampler, herein we investigated an HPLC system equipped with an analytical autosampler instead. This module is common on HPLC systems, which would allow to broaden the scope of HPLC-A. To accommodate this adjustment, a higher concentration of donor **4.11** was used. 7.5 equiv of donor were dissolved in 2.7 mL of methylene chloride and the donor solution was split in two vials.




Figure 4.3. SEM images of PanzaGel polymer at 100x (a) and 150x magnification (b)

The autosampler was programmed to draw 500 μ L of donor **4.11** solution (0.12 mmol) and 100 μ L of TMSOTf solution in methylene chloride, mix them in the needle seat and inject them onto the column. After 1.0 minute, the appropriate amount of time needed to allow all of the activated donor to flow into the column containing the acceptor-bound resin **4.10**, the flowrate was lowered to 0.02 ml/min to maximize the time of exposure of the acceptor to the reactive donor. The flow rate was kept at the minimum level for 10 min, then increased to 1.0 mL/min of CH₂Cl₂ to wash the column and prepare for a new injection of the activated donor. The same operation was repeated for five iterations and the glycosylation sequence was completed by alternating washings of methylene chloride and DMF. Following the glycosylation step, the temporary Fmoc

group was removed using a 20% solution of piperidine in DMF. Three injections of the piperidine solution were performed, and the reaction was followed using the variable wavelength detector set at 301 nm. The sequence was completed by washings using CH_2Cl_2 and DMF. Last, the polystyrene resin was reacidified through an injection of TMSOTf. The two reactions were repeated to afford the target glycans. As previously described, the two-way split valve diverts the flow to a collection flask. The compounds are then cleaved using a solution of sodium methoxide in MeOH/CH₂Cl₂ (1/1, v/v). The partially deprotected oligosaccharides, through a series a post automation steps afforded the target glycans **4.8** and **4.9** in 80% and 30% yield, respectively. Noticeably, both syntheses were conducted at room temperature and without utilizing an inert atmosphere.




Figure 4.4. Target compounds and building blocks to investigate how well the new resin

works in application to SPS

4.3. Conclusions

A new polystyrene-based resin for polymer supported glycan synthesis has been developed. The resin showed similar swelling properties to other existing solid supports but superior TMSOTf stability compared to JandaJel that was routinely used in our lab. The synthesis of these resins is fairly straightforward, and the length of the linker and its composition can easily be varied to achieve best results in terms of swelling, mechanical and chemical stability, flow-through applicability, and loading capacity. The glycan synthesis performed at the end of this study showcased how the improved polymeric support works in application to the HPLC-A. The target oligosaccharides were obtained using the same spilt valve introduced recently in the HPLC-A, albeit with the use of an analytical autosampler. New sequences were specifically developed for this modified setup. A new solid support available specifically for oligosaccharide synthesis will increase the attractiveness of automated technologies, setting the ground for further improvements.

4.4. Experimental

4.4.1. General Methods

The reactions were performed using commercial reagents and the ACS grade solvents were purified and dried according to standard procedures. HPLC grade solvents used for automation were utilized without any further purification. Column chromatography was performed on silica gel 60 (70–230 mesh) or on Biotage Isolera One, reactions were monitored by TLC on Kieselgel 60 F254. The compounds were detected by examination under UV light and by charring with 10% sulfuric acid in methanol. Solvents were removed under reduced pressure at <40 °C. CH₂Cl₂ was

distilled from CaH₂ directly prior to application. Pyridine was dried by refluxing with CaH₂ and then distilled and stored over molecular sieves (3 Å). Amberlite IR20 (H⁺) was washed three times with MeOH and stored under MeOH. Optical rotations were measured using a Jasco 'P-2000' polarimeter. IR spectra were recorded using an Agilent Cary 630 FTIR or a Thermo Nicolet Avatar 360 FTIR. ¹H NMR spectra were recorded at 300 or 600 MHz, ¹³C NMR spectra were recorded at 75 or 150 MHz. The ¹H chemical shifts are referenced to the signal of the residual CHCl₃ ($\delta H = 7.26$ ppm). The ¹³C chemical shifts are referenced to the central signal of CDCl3 ($\delta C = 77.23$ ppm). HRMS determinations were made with the use of a mass spectrometer with FAB ionization and ion-trap detection. Agilent 1260 infinity II HPLC System and Agilent 1260 Variable Wavelength UV–vis Detector were used to assemble the automated synthesizer.

4.4.2. Set up of the HPLC-A synthesizer

The HPLC based synthesizer has been assembled using

- 1260 Agilent Infinity I series Quaternary Pump
- Variable Wavelength Detector with single-wavelenght mode
- The Autosampler is the analytical module from 1260 Infinity series. The autosampler is equipped a 900 μ L loop and one tray holding 100 x 2 mL vials.
- The valve is a 2-way 6-port Quick Change Valve.
- The column utilized is an Omnifit Solvent Plus 50 mm.

The synthesis sequences are programmed using Chemstation software and the autosampler programming option.




Figure 4.5. The synthesizer set up

4.4.3. Synthesis of Panzagel crosslinker and Panzagel resin

Di (ethylene glycol) bis (4-vinylbenzyl) ether (4.2) was obtained in accordance with the reported procedure and its analytical data were in accordance with that previously described.³⁰ Selected analytical data for 2: $R_f = 0.49$ (hexane/acetone, 7/3, v/v); ¹H NMR (300 MHz, CDCl₃) δ 7.38 (d, J = 8.2 Hz, 4H, aromatic), 7.30 (d, J = 8.2 Hz, 4H, aromatic), 6.71 (dd, J = 17.6, 10.9 Hz, 2H, CHCH₂), 5.74 (dd, J = 17.6, 0.8 Hz, 2H, CHCH₂-*trans*), 5.23 (dd, J = 10.9, 0.7 Hz, 2H, CHCH₂-*cis*), 4.56 (s, 4H, PhCH₂), 3.66 (m 16H, OCH₂CH₂); ¹³C NMR (75 MHz, CDCl₃) δ 137.94 (CCH₂), 136.98 (CCH), 136.59 (CCHCH₂), 128.02 (CH aromatic), 126.28 (CH aromatic), 113.83 (CH₂CH), 73.02 (PhCH₂), 70.77 (CH₂O), 69.46 (CH₂O).

Panzagel-Cl Resin (4.6) was obtained in accordance with the reported procedure.²⁷ In a round bottom flask equipped with a paddle mechanical stirrer, acacia gum (9 g) and NaCl (5.62 g) were added to water (225 mL) under vigorous stirring. Flush Ar through the

resulting solution to deoxygenate. Styrene (11.7 mL, 102 mmol), vinylbenzyl chloride (2.1 mL, 15 mmol), cross-linker **4.2** (0.79g, 2.34 mmol) and benzoyl peroxide (0.22g) were dissolved in chlorobenzene (15 mL). The resulting solution was added dropwise to the aqueous mixture under vigorous stirring and the emulsion was heated at 85 °C for 16h. The obtained beads were washed in a sintered funnel with water (2x50 mL), acetone (2x50 mL), methylene chloride (2x70 mL) and methanol (2x50 mL). The polymer was then further purified in a Soxhlet extractor with *i*PrOH for 16 h and dried in vacuo. The beads were analyzed using solid state FT-IR.

Panzagel-NH₂ Resin (4.7)

Panzagel-Cl beads (**6**, 1.0 g) and dimethylformamide (15 mL) were added to a round-bottom flask equipped with a mechanical stirrer, and the resin was allowed to swell for 1 h at rt. Potassium phthalimide (1.0 g) was added, and the resulting mixture was stirred for 16 h at 55 °C. The resin was filtered off and washed successively with CH_2Cl_2 (3 x 30 mL), MeOH (3 x 30 mL), acetone (3 x 30 mL) and water (3 x 30 mL) and dried at 60 °C in *vacuo*. The resulting resin and MeOH/CHCl₃ (20 mL, 3/7, v/v) were added to a found-bottom flask equipped with a mechanical stirrer, and the resin was allowed to swell for 1 h at rt. H₂NNH₂-H₂O (3.0 mL) was added and the resulting mixture was stirred at rt for 48 h. The resin was filtered off and washed successively with CH_2Cl_2 (3 x 30 mL), acetone (3 x 30 mL) and water (3 x 30 mL) and dried at 60 °C in *vacuo*. The polymer was characterized using FT-IR, SEM, BET and the presence of NH₂ groups was confirmed using the Kaiser test. **Analytical data for 4.7:** FT-IR: 3025, 2920, 1493, 1452, 1082, 1028, 820, 756 cm⁻¹.

4.4.4. Synthesis of glycosyl donors and glycosyl acceptors

2,3,4-Tri-*O***-benzoyl-6-***O***-(9-fluorenylmethoxycarbonyl)**- α/β -D-glucopyranosyl trichloroacetimidate (4.11) was obtained in accordance with the reported procedure and its analytical data were in accordance with that previously described.¹⁵

Conjugate 4.10 was obtained by reaction of 8-(3-carboxypropanoyloxy)oct-1-yl 2,3,4tri-*O*-benzyl-6-*O*-triphenylmethyl- α -D-glucopyranoside with JandaJel in accordance with the reported procedure.²¹ The loading of 0.33 mmol/g for **4.10** was determined by direct cleavage from the solid support (50 mg) on HPLC to mimic conditions for the subsequent reactions.

4.4.5. Preparation of the reagent vials

All the solutions were freshly prepared using the ACS-grade solvents and kept at room temperature for the duration of the synthesis.

<u>Donor:</u> a solution of glycosyl donor (0.120 mmol) in CH_2Cl_2 (2.7 mL), split in two vials containing 1.6 mL and 1.1 mL of solution.

<u>Promoter:</u> a solution of TMSOTf (0.124 mmol) in CH_2Cl_2 (500 µL). Both the amounts were doubled to prepare an excess of acidic solution to acidify the resin after Fmoc removal.

<u>Reagents for Fmoc removal:</u> a solution of piperidine in DMF (2.5 mL, 2/3, v/v).

Reagents for cleaving the products from the resin: a solution prepared from 1M NaOMe in MeOH (1.5 mL), CH₂Cl₂ (1.0 mL) and MeOH (1.0 mL), split equally in 2 vials.

<u>Washing solutions and blanks</u>: methylene chloride in W_1 , MeOH in W_2 and methylene chloride in B (2.0 mL).

4.4.6. The automated assembly of oligosaccharides

All reactions were carried using 50 mg of the preloaded resin. The acceptor was loaded on the resin prior automation, therefore the loading depended on the batch of the resin. Syntheses with acceptor **4.10** were performed with 0.0165 mmol.

Glycosylation. The sequences included washing of the resin before and after glycosylation steps. The glycosylations were performed in five iterations of donor injections. The donor and the promoter are drawn from the vial, mixed in the autosampler needle seat and the injected. The flowrate was then lowered to maximize the presence of the donor in the column. Once the activated donor has passed through the column, the same operation was repeated. At the end of the glycosylation the resin was washed with CH_2Cl_2 and DMF.

Figure 4.6 depicts programming of the components of the synthesizer. Figure 4.6A shows the pump timetable, Figure 4.6B shows the autosampler programming. The valve was in position 1 during the whole sequence.

Fmoc removal. The reaction was monitored using the UV detector set at $\lambda_{max} =$ 301 nm. The dibenzofulvene absorbance at 301 nm is a clear indication of the reaction completion. The removal is completed within 1 h, including the washings and the resin is reacidified with TMSOTf as a last step. Even in this case, the valve was left in postion 1

(waste) for the duration of the sequence. In figure 4.7 A, B and C the settings of the pump, autosampler and VWD respectively, are reported. Default volume is $500 \,\mu$ L.


Final cleavage from the resin. The cleavage is performed in Zemplen conditions, with the solution prepared as reported above. The valve after the 30 seconds of the sequence switches from position 1 to position 2 and divert the flow to the collection flask. The reaction is monitored at both 250 nm and the sequence consists of 4 consecutive injections of the cleaving solution. In figure 4.8 A, B and C are depicted the settings of the modules.

	4 events) A [%] 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0	B [%] 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0	C [%] 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0	D [%] 0.0 0.0 0.0 0.0 0.0 0.0	Flow [mL/min] 0.500 2.000 2.000 1.000	60.00 60.00
0.00 1.00 15.00 16.00 16.75 16.80 28.00 28.10 30.75 30.80 42.00 42.10	100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0	0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0	0.0 0.0 0.0 0.0 0.0 0.0 0.0	0.0 0.0 0.0 0.0 0.0	Flow [mL/min] 0.500 2.000 2.000 1.000	Max. Pressure Limit [bar] 60.00 60.00 60.00
0.00 1.00 15.00 16.00 16.75 16.80 28.00 28.10 30.75 30.80 42.00 42.10	100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0	0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0	0.0 0.0 0.0 0.0 0.0 0.0 0.0	0.0 0.0 0.0 0.0 0.0	[mL/min] 0.500 2.000 2.000 1.000	Limit [bar] 60.00 60.00 60.00
1.00 15.00 16.00 16.75 16.80 28.00 28.10 30.75 30.80 42.00 42.10	100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0	0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0	0.0 0.0 0.0 0.0 0.0 0.0	0.0 0.0 0.0 0.0	0.500 2.000 2.000 1.000	60.00 60.00 60.00
1.00 15.00 16.00 16.75 16.80 28.00 28.10 30.75 30.80 42.00 42.10	100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0	0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0	0.0 0.0 0.0 0.0 0.0 0.0	0.0 0.0 0.0 0.0	2.000 2.000 1.000	60.00 60.00
15.00 16.00 16.75 16.80 28.00 28.10 30.75 30.80 42.00 42.10	100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0	0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0	0.0 0.0 0.0 0.0 0.0	0.0 0.0 0.0	2.000 1.000	60.00
16.00 16.75 16.80 28.00 28.10 30.75 30.80 42.00 42.10	100.0 100.0 100.0 100.0 100.0 100.0 100.0	0.0 0.0 0.0 0.0 0.0 0.0	0.0 0.0 0.0 0.0	0.0	1.000	
16.75 16.80 28.00 28.10 30.75 30.80 42.00 42.10	100.0 100.0 100.0 100.0 100.0 100.0	0.0 0.0 0.0 0.0 0.0	0.0 0.0 0.0	0.0		
16.80 28.00 28.10 30.75 30.80 42.00 42.10	100.0 100.0 100.0 100.0 100.0	0.0 0.0 0.0 0.0	0.0 0.0			60.00
28.00 28.10 30.75 30.80 42.00 42.10	100.0 100.0 100.0 100.0	0.0 0.0 0.0	0.0			
28.10 30.75 30.80 42.00 42.10	100.0 100.0 100.0	0.0 0.0		0.0		
30.75 30.80 42.00 42.10	100.0 100.0	0.0		0.0		
30.80 42.00 42.10	100.0		0.0	0.0		
42.00 42.10			0.0	0.0		
42.10		0.0	0.0	0.0		
	100.0	0.0	0.0	0.0		
	100.0	0.0	0.0	0.0		
44.80	100.0	0.0	0.0	0.0		
56.00	100.0	0.0	0.0	0.0		
56.10	100.0	0.0	0.0	0.0		
58.75	100.0	0.0	0.0	0.0		
58.80	100.0	0.0	0.0	0.0		
70.00						
70.10						
72.75						
72.80						
90.00						
90.10	100.0					
96.00						
97.00						
07.00	0.0	0.0	100.0			
08.00						
15.00	100.0	0.0				
70 72 90 90 97 07 07	0.10 2.75 2.80 0.00 0.10 5.00 7.00 7.00 3.00	10 100.0 2.75 100.0 2.80 100.0 0.00 100.0 1.10 100.0 0.00 100.0 0.00 100.0 0.00 100.0 0.00 0.00 0.00 0.0 0.00 0.0 8.00 100.0	110 100.0 0.0 275 100.0 0.0 280 100.0 0.0 0.00 100.0 0.0 101 100.0 0.0 100 0.0 0.0 101 100.0 0.0 100 0.0 0.0 100 0.0 0.0 00 100.0 0.0 700 0.0 0.0 3.00 100.0 0.0	1.10 100.0 0.0 0.0 1.75 100.0 0.0 0.0 1.80 100.0 0.0 0.0 1.00 100.0 0.0 0.0 1.00 100.0 0.0 0.0 1.10 100.0 0.0 0.0 1.00 0.0 0.0 0.0 1.00 0.0 0.0 0.0 1.00 0.0 0.0 0.0 1.00 0.0 0.0 100.0 1.00 0.0 0.0 100.0 1.00 0.0 0.0 100.0 1.00 0.0 0.0 100.0 1.00 0.0 0.0 0.0	1.10 100.0 0.0 0.0 0.0 1.75 100.0 0.0 0.0 0.0 1.80 100.0 0.0 0.0 0.0 1.00 0.0 0.0 0.0 0.0 1.00 0.0 0.0 0.0 0.0 1.00 0.0 0.0 0.0 0.0 1.00 0.0 0.0 0.0 0.0 1.00 0.0 0.0 0.0 0.0 1.00 0.0 0.0 0.0 0.0 1.00 0.0 0.0 0.0 0.0 1.00 0.0 0.0 0.0 0.0 1.00 0.0 0.0 0.0 0.0 1.00 0.0 0.0 0.0 0.0 3.00 100.0 0.0 0.0 0.0	1.10 100.0 0.0 0.0 0.0 1.000 2.75 100.0 0.0 0.0 0.0 1.000 2.80 100.0 0.0 0.0 0.0 0.0 0.050 0.00 100.0 0.0 0.0 0.0 0.050 0.055 0.01 100.0 0.0 0.0 0.0 0.055 0.0 1.000 0.01 100.0 0.0 0.0 0.0 0.0 1.000 0.00 100.0 0.0 0.0 0.0 1.000 1.000 0.00 0.00 100.0 0.0 1.000 1.000 1.000 7.00 0.00 0.0 10.00 0.0 1.000 1.000 3.00 100.0 0.0 0.0 0.0 1.000 1.000

A

inction	Parameter
Draw	 Draw 100 µL from vial+ 1 with default speed using default offset
Inject	✓ Inject
Wait	✓ Wait 13 min
Repeat	 Repeat 3 time(s)
Draw	 Draw 500 μL from sample with 700 μL/min using default offset
Draw	 Draw 100 μL from vial+ 1 with 200 μL/min using default offset
Wash	 Wash needle in location "97" 1 times
Mix	 Mix 600 µL from seat with maximum speed for 2 times
Inject	✓ Inject
Wait	✓ Wait 0.8 min
Valve	 Switch valve to "Bypass"
Wait	
Eject	✓ Eject maximum volume to seat with maximum speed using default offset
End Repeat	✓ End Repeat
Repeat	 Repeat 2 time(s)
Draw	 Draw 500 μL from vial+ 2 with 700 μL/min using default offset
Draw	 Draw 100 μL from vial+ 1 with 200 μL/min using default offset
Wash	✓ Wash needle in location "97" 1 times
Mix	 Mix 600 μL from seat with maximum speed for 2 times
Inject	✓ Inject
Wait	✓ Wait 0.8 min
Valve	 Switch valve to "Bypass"
Wait	✓ Wait 10 min
Eject	- Eject maximum volume to seat with maximum speed using default offset
End Repeat	✓ End Repeat

Figure 4.6. Settings of the components of the HPLC synthesizer during glycosylation.



A

unction	Parameter
Repeat	✓ Repeat 3 time(s)
Draw	 Draw default volume from sample with default speed using default offset
Inject	▼ Inject
Wait	▼ Wait 3 min
Valve	 Switch valve to "Bypass"
Eject	 Eject default volume to seat with default speed using default offset
End Repeat	✓ End Repeat
Draw	▼ Draw maximum volume from location "96" with maximum speed using default offset
Eject	 Eject maximum volume to seat with maximum speed using default offset
Draw	 Draw 100 μL from vial+ -2 with 300 μL/min using default offset
Inject	✓ Inject
Wash	 Wash needle in location "97" 3 times
Wait	✓ Wait 30 min
Draw	 Draw 100 µL from location "96" with default speed using default offset
Eject	 Eject default volume to seat with default speed using default offset

B

Signal

	Acquire	Wavelength	
Signal A:	\checkmark	301 📫	nm
Peakwidth:	> 0.1 min	(2 s resp. time) (3.43	Hz) 🔻

С

Figure 4.7. Settings of the components of the HPLC synthesizer during Fmoc removal.

	Time [min]		A [%]	B [%]	C [%]	D [%]	Flow [mL/min]	Max. Pressure Limit [bar]	
		0.00	0.0	100.0	0.0	0.0	1.000	60.00	
		30.00	50.0	50.0	0.0	0.0	0.500	60.00	
		31.00	100.0	0.0	0.0	0.0	1.500	60.00	
		35.00	100.0	0.0	0.0	0.0	1.500	60.00	
		36.00		100.0				60.00	
		40.00		100.0				60.00	
		41.00		0.0		0.0		60.00	
		0.50	50.0	50.0	0.0	0.0	0.500		
Max: 60.00 🗧 bar									
Max: 00.00 - Dar									
sttime									
Off Off									
<u> </u>			-		~				
O 1.00 0 min	Add		Remo	ve	Clear /	411	Clear Empty		
	Cut		Сор	у	Paste	•	Shift Times	0.00	min
	-								
								_	
1				/	V	$\overline{\mathbf{N}}$		Flow	
4			/		1	<u> </u>	_	- Solvent Ra	atio A
-				/	Δ	- 1	_	Solvent R	ntio P
A				1	Λ	Λ			
5 10 15	20	25	30		35	40	45 mir	Solvent R	atio C
5 10 15	20	20	30		30	40	45 mir		

tion	
	Injection volume: 500.00 📜 µl
ait	✓ Wait 2 min
epeat	 Repeat 2 time(s)
ъ	 Draw default volume from location "99" with 250 μL/min using default off
ect	✓ Inject
ait	
lve	 Switch valve to "Bypass"
ect	 Eject maximum volume to seat with maximum speed using default offset
ash	
ash	✓ Wash needle in location "98" 1 times
eedle	✓ Move needle into seat
nd Repeat	✓ End Repeat
epeat	Repeat 2 time(s)
aw	
ect	✓ Inject
ait	✓ Wait 2.5 min
lve	 Switch valve to "Bypass"
ect	 Eject maximum volume to seat with maximum speed using default offset
ash	✓ Wash needle in location "97" 1 times
ash	✓ Wash needle in location "98" 1 times
edle	✓ Move needle into seat
nd Repeat	✓ End Repeat
ect	 Eject default volume to seat with default speed using default offset
	Acquire Wavelength
C:	
Signal A:	✓ 250 ÷ nm
Peakwidth:	>0.1 min (2 s resp. time) (3.43 Hz)
r oakwiadi.	v et min (z e reep, une) (ette nz)
ne	Posttime
	0.01
As Pump/In	ijector


Figure 4.8. Settings of the components of the HPLC synthesizer during the final

cleavage.


Detection. Representative UV traces for each sequence are depicted in Figure 4.9A and B. The absorbance of the donor at $\lambda = 301$ nm is significantly lower compared to 250 nm, therefore the signals are not saturated and in some cases is easier to understand the proceeding of the reaction.

The Fmoc removal trace A clearly indicates the majority of the temporary protecting group being removed in the first injection of the piperidine solution, with only minor amounts cleaved in the following injections.

The final cleavage trace **B** shows high absorbance during the injections, corresponding the the prograssive cleavage of the oligosaccharides from the resin and the Bz and Fmoc groups from the glycans. The absorbance decreases progressively during the washings.



A. Representative trace for Fmoc removal



B. Representative trace for the final cleavage


Figure 4.9. UV traces for the synthetic steps

4.4.7. Synthesis of oligosaccharides

8-Acetyloxyoct-1-yl O-(2,3,4,6-tetra-O-acetyl- β -D-glucopyranosyl)-(1 \rightarrow 6)-2,3,4-tri-O-benzyl- α -D-glucopyranoside (4.8).

Automation modules: The Omnifit column is filled with resin (50 mg) preloaded with acceptor 4.10 (0.016 mmol). The vials were prepared according to the general methods and organized as depicted below. Vials 1 and 3 contain donor 4.11 solution (106 mg, 0.12 mmol, 7.5 equiv) split as described in the general methods, vial 2 contains of TMSOTf (22 μ L, 0.12 mmol, 7.5 equiv), and vial 3 contains a piperine-DMF solution prepared as indicated in the general methods. Vials B, W and C are blank, washing, and final off-resin cleavage, respectively, were prepared as described in the general methods.

Vial tray organization:



Automation Sequence:

Glycosylation 120 min


Fmoc removal 60 min

Post Automation: The reaction mixture collected from cleavage step was evaporated under reduced pressure, then diluted with MeOH (2.0 mL) and quenched with Amberlite IR20 H⁺ form. The resin was filtrated and washed with MeOH, the solvent was evaporated and dried *in vacuo* for 1h. The crude was dissolved in pyridine (2.0 mL) and acetic anhydride (0.5 mL) was added. The resulting mixture was stirred under argon at room temperature for 16h. The reaction was quenched with MeOH, then the solvent was evaporated and co-evaporated with toluene. The residue was purified by column chromatography on silica gel (hexanes-acetone gradient elution) to afford compound **4.8** in 80% yield. Analytical data matched what has been previously reported.³²

8-Acetyloxyoct-1-yl O-(2,3,4,6-tetra-O-acetyl- β -D-glucopyranosyl)-(1 \rightarrow 6)-O-(2,3,4-tri-O-acetyl- β -D-glucopyranosyl)-(1 \rightarrow 6)-O-(2,3,4-tri-O-acetyl- β -D-glucopyranosyl)-(1 \rightarrow 6)-O-(2,3,4-tri-O-benzyl- α -D-glucopyranoside (4.9).

Automation modules: The Omnifit column is filled with resin (50 mg) preloaded with acceptor **4.10** (0.016 mmol). The vials were prepared according to the general methods and organized as depicted below. Vials 1 and 3 contain a solution of donor **4.11** (106 mg, 0.12 mmol, 7.5 equiv) split as described in the general methods, vial 2 contains of TMSOTf (22 μ L, 0.12 mmol, 7.5 equiv), and vial 3 contains a piperine-DMF solution prepared as indicated in the general methods. Vials B, W and C are blank, washing, and final off-resin cleavage, respectively, were prepared as described in the general methods.

Vial tray organization



Automation Sequence:

Glycosylation 120 min Fmoc removal 60 min Glycosylation 120 min Fmoc removal 60 min Glycosylation 120 min Fmoc removal 60 min Glycosylation 120 min Final Cleavage 50 min

Post Automation: The reaction mixture collected from cleavage step was evaporated under reduced pressure, then diluted with MeOH (2.0 mL) and quenched with Amberlite IR20 H⁺ form. The resin was filtrated and washed with MeOH, the solvent was evaporated and dried *in vacuo* for 1h. The crude was dissolved in pyridine (2.0 mL) and acetic anhydride (0.5 mL) was added. The resulting mixture was stirred under argon at room temperature for 16h. The reaction was quenched with MeOH, then the solvent was evaporated and co-evaporated with toluene. The residue was purified by column chromatography on silica gel (hexanes-acetone gradient elution) to afford compound **4.9** in 30% yield. Analytical data matched what has been previously reported.

4.5. References

- Kiessling, L. L. Chemistry-driven glycoscience. *Bioorg. Med. Chem.* 2018, 26, 5229-5238.
- Kiessling, L. L.; Splain, R. A. Chemical approaches to glycobiology. *Annu. Rev. Biochem.* 2010, 79, 619-653.

- (3) Smoot, J. T.; Demchenko, A. V. Oligosaccharide synthesis: from conventional methods to modern expeditious strategies. *Adv. Carbohydr. Chem. Biochem.* 2009, 62, 161-250.
- (4) Merrifield, B. The role of the support in solid phase peptide synthesis *Br. Polym. J.* 1984, *16*, 173-178.
- (5) Krishnamurthy, V. R.; Dougherty, A.; Kamat, M.; Song, X.; Cummings, R. D.; Chaikof, E. L. Synthesis of an Fmoc-threonine bearing core-2 glycan: a building block for PSGL-1 via Fmoc-assisted solid-phase peptide synthesis. *Carbohydr. Res.* 2010, *345*, 1541-1547.
- (6) Solid-phase organic synthesis; Toy, P. H.; Lam, Y., Eds.; John Wiley & Sons, Inc.: Hoboken, 2012.
- (7) Frechet, J. M.; Schuerch, C. Solid-phase synthesis of oligosaccharides. I.
 Preparation of the solid support. Poly[p-(1-propen-3-ol-1-yl)styrene]. *J. Am. Chem. Soc.* 1971, 93, 492-496.
- (8) Seeberger, P. H.; Haase, W. C. Solid-phase oligosaccharide synthesis and combinatorial carbohydrate libraries. *Chem. Rev.* 2000, *100*, 4349-4393.
- (9) Tanaka, K.; Fukase, K.: Oligosaccharide synthesis on solid, soluble polymer, and tag supports. In *Solid-Phase Organic Synthesis*; Toy, P. H., Lam, Y., Eds.; John Wiley & Sons, Inc. : Hoboken, 2012; pp 489-530.
- (10) Plante, O. J.; Palmacci, E. R.; Seeberger, P. H. Automated solid-phase synthesis of oligosaccharides. *Science* 2001, 291, 1523-1527.
- (11) Seeberger, P. H. Automated oligosaccharide synthesis. *Chem. Soc. Rev.* 2008, *37*, 19-28.

- (12) Plante, O. J.; Palmacci, E. R.; Seeberger, P. H. Development of an automated oligosaccharide synthesizer. *Adv. Carbohydr. Chem. Biochem.* **2003**, *58*, 35-54.
- (13) Seeberger, P. H. The logic of automated glycan assembly. *Acc. Chem. Res.* 2015, 48, 1450-1463.
- (14) Krock, L.; Esposito, D.; Castagner, B.; Wang, C.-C.; Bindschadler, P.; Seeberger,
 P. H. Streamlined access to conjugation-ready glycans by automated synthesis. *Chem. Sci.* 2012, *3*, 1617-1622.
- (15) Vijaya Ganesh, N.; Fujikawa, K.; Tan, Y. H.; Stine, K. J.; Demchenko, A. V.
 HPLC-assisted automated oligosaccharide synthesis. *Org. Lett.* 2012, *14*, 3036-3039.
- (16) Hurtley, S.; Service, R.; Szuromi, P. Cinderella's Coach Is Ready. *Science* 2001, 291, 2337.
- (17) Sherrington, D. C. Preparation, structure and morphology of polymer supports. *Chem. Comm.* **1998**, 2275-2286.
- (18) Labadie, J. W. Polymeric supports for solid phase synthesis. *Curr. Opin. Chem. Biol.* 1998, *2*, 346-352.
- (19) Lu, J.; Toy, P. H. Organic Polymer Supports for Synthesis and for Reagent and Catalyst Immobilization. *Chem. Rev.* 2009, 109, 815-838.
- (20) Collot, M.; Eller, S.; Weishaupt, M.; Seeberger, P. H. Glycosylation efficiencies on different solid supports using a hydrogenolysis-labile linker. *Beilstein J. Org. Chem.* 2013, 9, 97-105.

- (21) Pistorio, S. G.; Nigudkar, S. S.; Stine, K. J.; Demchenko, A. V. HPLC-assisted automated oligosaccharide synthesis: the implementation of the autosampler as a mode of the reagent delivery. *J. Org. Chem.* **2016**, *81*, 8796-8805.
- (22) Toy, P. H.; Janda, K. D. New supports for solid-phase organic synthesis: development of polystyrene resins containing tetrahydrofuran derived crosslinkers. *Tetrahedron Lett.* **1999**, *40*, 6329-6332.
- (23) Panza, M.; Pistorio, S. G.; Stine, K. J.; Demchenko, A. V. Automated Chemical Oligosaccharide Synthesis: Novel Approach to Traditional Challenges. *Chem. Rev.* 2018, *118*, 8105–8150.
- (24) Itsuno, S.; Sakurai, Y.; Ito, K.; Maruyama, T.; Nakahama, S.; Fréchet, J. M. J.
 New Solid-Phase Catalysts for Asymmetric Synthesis: Cross-Linked Polymers
 Containing a Chiral Shiff Base-Zinc Complex. J. Org. Chem. 1990, 55, 304-310.
- (25) Kamahori, K.; Ito, K.; Itsuno, S. Asymmetric Diels-Alder Reaction of Methacrolein with Cyclopentadiene Using Polymer-Supported Catalysts: Design of Highly Enantioselective Polymeric Catalysts. *J. Org. Chem.* **1996**, *61*, 8321-8324.
- (26) Garibay, P.; Toy, P. H.; Hoeg-Jensen, T.; Janda, K. D. Application of a New Solid-Phase Resin: Benzamide ortho-Lithiation and the Synthesis of a Phthalide Library. *Synlett* 1999, 1438-1440.
- (27) Toy, P. H.; Reger, T. S.; Garibay, P.; Garno, J. C.; Malikayil, J. A.; Liu, G.-y.;
 Janda, K. D. Polytetrahydrofuran Cross-Linked Polystyrene Resins for Solid-Phase
 Organic Synthesis. *J. Comb. Chem.* 2001, *3*, 117-124.

- (28) Wilson, M. E.; Paech, K.; Zhou, W.-J.; Kurth, M. J. Solvent and Reagent Accessibility within Oligo(ethylene glycol) Ether [PEG] Cross-Linked Polystyrene Beads. *The Journal of Organic Chemistry* 1998, 63, 5094-5099.
- (29) Santini, R.; Griffith, M. C.; Qi, M. A Measure of Solvent Effects on Swelling of Resins for Solid Phase Organic Synthesis. *Tetrahedron Lett.* 1998, *39*, 8951-8954.
- (30) Toy, P. H.; Janda, K. D. New supports for solid-phase organic synthesis: development of polystyrene resins containing tetrahydrofuran derived crosslinkers. *Tetrahedron Letters* **1999**, *40*, 6329-6332.
- (31) Panza, M.; Stine, K. J.; Demchenko, A. V. HPLC-assisted automated oligosaccharide synthesis: the implementation of the two-way split valve as a mode of complete automation. *submitted* 2019.
- (32) Pistorio, S. G.; Nigudkar, S. S.; Stine, K. J.; Demchenko, A. V. HPLC-Assisted Automated Oligosaccharide Synthesis: Implementation of the Autosampler as a Mode of the Reagent Delivery. *The Journal of Organic Chemistry* 2016, *81*, 8796-8805.

APPENDIX





Table A-1. DFT-optimized structures (hydrogens and protecting groups have beenomitted for clarity in 3D ball and stick representations) and calculated coupling

constants of compound β-2.2



Conformation	ΔE (kcal/mol)	ΔG (kcal/mol)	Dihedral angle (degrees)	Calculated J (Hz)
⁴ C ₁ chair	0.00	0.00	H-C1-C2-H (172.6°)	$J_{1,2} = 8.7$
			H-C2-C3-Н (-167.0°)	$J_{2,3} = 7.7$
			H-C3-C4-H (172.5°)	$J_{3,4} = 8.3$

			H-C4-C5-H (-176.5°)	$J_{4,5} = 9.0$
¹ C ₄ chair	2.83	0.75	H-C1-C2-H (85.5°)	$J_{1,2} = 0.8$
			H-C2-C3-H (-79.1°)	$J_{2,3} = 1.7$
			H-C3-C4-H (75.2°)	$J_{3,4} = 2.2$
			H-C4-C5-H (-80.2°)	$J_{4,5} = 0.8$
300.1	0.74	1.22		
^{3,0} B boat	2.74	1.32	H-C1-C2-H (120.9°) H-C2-C3-H (-78.7°)	$J_{1,2} = 3.1$ $J_{2,3} = 1.7$
			H-C3-C4-H (91.4°)	$J_{2,3} = 1.7$ $J_{3,4} = 0.4$
			H-C4-C5-H (-147.0°)	$J_{4,5} = 6.5$
² S ₀ skew-boat	3.39	2.53	H-C1-C2-H (151.4°)	$J_{1,2} = 7.0$
			H-C2-C3-H (175.2°)	$J_{2,3} = 9.6$
			H-C3-C4-H (163.2°)	$J_{3,4} = 6.9$
			H-C4-C5-H (-112.6°)	$J_{4,5} = 2.0$





 Table A-2. DFT-optimized structures (hydrogens and protecting groups have been omitted for clarity in 3D ball and stick representations) and calculated coupling

constants of compound β-2.3



Conformation	ΔE (kcal/mol)	∆G (kcal/mol)	Dihedral angle (degrees)	Calculated J (Hz)
³ S ₁ skew-boat	0.00	0.00	H-C1-C2-H (156.4°)	$J_{1,2} = 7.5$
			H-C2-C3-H (-96.1°)	$J_{2,3} = 0.3$
			H-C3-C4-H (66.9°)	$J_{3,4} = 3.3$
			H-C4-C5-H (-100.0°)	$J_{4,5} = 1.0$
¹ C ₄ chair	1.66	2.24	H-C1-C2-H (90.9°)	$J_{1,2} = 0.8$
			H-C2-C3-Н (-82.4°)	<i>J</i> _{2,3} = 1.3
			H-C3-C4-H (73.8°)	$J_{3,4} = 2.3$
			H-C4-C5-H (-77.2°)	$J_{4,5} = 0.9$
² S ₀ skew-boat	4.33	4.72	H-C1-C2-H (153.8°)	$J_{1,2} = 7.3$
			H-C2-C3-H (178.0°)	$J_{2,3} = 9.4$
			H-C3-C4-H (156.8°)	$J_{3,4} = 5.9$
			H-C4-C5-H (-106.2°)	$J_{4,5} = 1.4$






Table A-3. DFT-optimized structures (hydrogens and protecting groups have beenomitted for clarity in 3D ball and stick representations) and calculated coupling


constants of compound α -2.2




Conformation	∆E (kcal/mol)	∆G (kcal/mol)	Dihedral angle (degrees)	Calculated J (Hz)
¹ C ₄ chair	2.10	0.00	H-C1-C2-H (-49.1°)	$J_{1,2} = 1.1$
			H-C2-C3-H (-75.0°)	$J_{2,3} = 2.2$
			H-C3-C4-H (74.7°)	$J_{3,4} = 2.2$

			H-C4-C5-H (-80.6°)	$J_{4,5} = 0.8$
⁴ C ₁ chair	0.00	0.39	H-C1-C2-H (47.5°)	$J_{1,2} = 5.7$
			H-C2-C3-H (-173.3°)	$J_{2,3} = 8.5$
			H-C3-C4-H (174.9°)	$J_{3,4} = 8.6$
			H-C4-C5-H (-176.7°)	$J_{4,5} = 9.0$





constants of compound α-2.3



Conformation	∆E (kcal/mol	∆G (kcal/mol)	Dihedral angle (degrees)	Calculated J (Hz)
¹ C ₄ chair	0.58	0.00	H-C1-C2-H (-47.3°)	$J_{1,2} = 1.3$
			H-C2-C3-H (-75.2°)	$J_{2,3} = 2.1$
			H-C3-C4-H (74.8°)	$J_{3,4} = 2.2$

			H-C4-C5-H (-79.5°)	$J_{4,5} = 0.8$
⁴ C ₁ chair	0.00	1.07	H-C1-C2-H (46.4°)	$J_{1,2} = 5.8$
			H-C2-C3-Н (-172.7°)	$J_{2,3} = 8.5$
			H-C3-C4-H (174.6°)	$J_{3,4} = 8.5$
			H-C4-C5-H (179.3°)	$J_{4,5} = 9.1$






Table A-5. DFT-optimized structures (hydrogens and protecting groups have beenomitted for clarity in 3D ball and stick representations) and calculated coupling


constants of compound β -2.4



Conformation	ΔE (kcal/mol)	ΔG (kcal/mol)	Dihedral angle (degrees)	Calculated J (Hz)			
^{1,4} B boat or unusual ⁴ S ₂ skew-boat	0.00	0.00	H-C1-C2-Н (54.7°)	$J_{1,2} = 2.9$			

			H-C2-C3-H (-95.0°)	$J_{2,3} = 0.3$
			H-C3-C4-H (149.3°)	$J_{3,4} = 4.6$
			H-C4-C5-H (-178.4°)	$J_{4,5} = 9.0$
⁴ C ₁ chair	3.09	2.89	H-C1-C2-H (169.0°)	$J_{1,2} = 7.8$
			H-C2-C3-H (-168.3°)	$J_{2,3} = 8.0$
			H-C3-C4-H (173.5°)	$J_{3,4} = 8.4$
			H-C4-C5-H (-177.3°)	$J_{4,5} = 9.0$
2 S ₀ skew-boat	1.84	4.88	H-C1-C2-H (141.3°)	$J_{1,2} = 5.1$
			H-C2-C3-H (178.8°)	$J_{2,3} = 9.4$
			H-C3-C4-H (159.3°)	$J_{3,4} = 6.3$
			H-C4-C5-Н (-113.3°)	$J_{4,5} = 2.0$











Table A-6. DFT-optimized structures (hydrogens and protecting groups have been omitted for clarity in 3D ball and stick representations) and calculated coupling

constants of compound a-2.4



Conformation	ΔE (kcal/mol)	ΔG (kcal/mol)	Dihedral angle (degrees)	Calculated J (Hz)
⁴ C ₁ chair	0.00	0.00	H-C1-C2-H (59.7°)	$J_{1,2} = 3.8$
			H-C2-C3-H (177.4°)	$J_{2,3} = 9.6$
			H-C3-C4-H (176.6°)	$J_{3,4} = 8.8$
			H-C4-C5-H (-175.3°)	$J_{4,5} = 9.0$





ò f1 (ppm)

Figure A-2: ¹³C NMR spectrum of Ethyl 6-*O*-benzoyl-2-*O*-benzyl-1-thio-α-D-glucopyranoside (α -2.1)





Figure A-3: 2-D NMR COSY spectrum of Ethyl 6-*O*-benzoyl-2-*O*-benzyl-1-thio- α -D-glucopyranoside (α -2.1)






Figure A-5: ¹³C NMR spectrum of Ethyl 6-*O*-benzoyl-2-*O*-benzyl-3,4-di-*O*-tertbutyldimethylsilyl-1-thio- α -D-glucopyranoside (α -2.2)




Figure A-6: 2-D NMR COSY spectrum of Ethyl 6-*O*-benzoyl-2-*O*-benzyl-3,4-di-*O*-tertbutyldimethylsilyl-1-thio- α -D-glucopyranoside (α -2.2)




Figure A-7: ¹H NMR spectrum of Ethyl 6-*O*-benzoyl-2-*O*-benzyl-1-thio-3,4-di-*O*-triisopropylsilyl- α -D-glucopyranoside (α -2.3)




Figure A-8: ¹³C NMR spectrum of Ethyl 6-*O*-benzoyl-2-*O*-benzyl-1-thio-3,4-di-*O*-triisopropylsilyl- α -D-glucopyranoside (α -2.3)




Figure A-9: 2-D NMR COSY spectrum of Ethyl 6-*O*-benzoyl-2-*O*-benzyl-1-thio-3,4-di-*O*-triisopropylsilyl- α -D-glucopyranoside (α -2.3)




Figure A-10: 2-D NMR HMQC spectrum of Ethyl 6-*O*-benzoyl-2-*O*-benzyl-1-thio-3,4di-*O*-triisopropylsilyl-α-D-glucopyranoside (**α-2.3**)






Figure A-11: ¹H NMR spectrum of Ethyl 6-*O*-benzoyl-2-*O*-benzyl-3,4-di-*O*-*tert*-butyldimethylsilyl-1-thio- β -D-glucopyranoside (β -2.2)



CDCl₃ 151 MHz

Figure A-12: ¹³C NMR spectrum of Ethyl 6-*O*-benzoyl-2-*O*-benzyl-3,4-di-*O*-tert-butyldimethylsilyl-1-thio- β -D-glucopyranoside (β -2.2)



 $CDCl_{3}\ 600\ MHz$ **Figure A-13:** 2-D NMR COSY spectrum of Ethyl 6-*O*-benzoyl-2-*O*-benzyl-3,4-di-*Otert*-butyldimethylsilyl-1-thio- β -D-glucopyranoside (β -2.2)




Figure A-14: 2-D NMR HMQC spectrum of Ethyl 6-*O*-benzoyl-2-*O*-benzyl-3,4-di-*O*-*tert*-butyldimethylsilyl-1-thio-β-D-glucopyranoside (β-2.2)




Figure A-15: ¹H NMR spectrum of Ethyl 6-*O*-benzoyl-2-*O*-benzyl-1-thio-3,4-di-*O*-triisopropylsilyl-β-D-glucopyranoside (**β-2.3**)





Figure A-16: ¹³C NMR spectrum of Ethyl 6-*O*-benzoyl-2-*O*-benzyl-1-thio-3,4-di-*O*-triisopropylsilyl-β-D-glucopyranoside (β-2.3)



 $CDCl_{3} \ 600 \ MHz$ Figure A-17: 2-D NMR COSY spectrum of Ethyl 6-*O*-benzoyl-2-*O*-benzyl-1-thio-3,4-di-*O*-triisopropylsilyl- β -D-glucopyranoside (β -2.3)





Figure A-18: 2-D NMR HMQC spectrum of Ethyl 6-*O*-benzoyl-2-*O*-benzyl-1-thio-3,4di-*O*-triisopropylsilyl- β -D-glucopyranoside (β -2.3)






Figure A-20: ¹³C NMR spectrum of Methyl 6-*O*-(6-*O*-benzoyl-2-*O*-benzyl-3,4-di-*O*-*tert*-butyldimethylsilyl-α-D-glucopyranosyl)-2,3,4-tri-*O*-benzyl-α-D-glucopyranoside (**2.6**)




Figure A-21: 2-D NMR COSY spectrum of Methyl 6-*O*-(6-*O*-benzoyl-2-*O*-benzyl-3,4di-*O*-tert-butyldimethylsilyl-α-D-glucopyranosyl)-2,3,4-tri-*O*-benzyl-α-Dglucopyranoside (**2.6**)





Figure A-22: ¹H NMR spectrum of Methyl 2-*O*-(6-*O*-benzoyl-2-*O*-benzyl-3,4-di-*O*-tertbutyldimethylsilyl- α/β -D-glucopyranosyl)-3,4,6-tri-*O*-benzyl- α -D-glucopyranoside (**2.8**)



CDCl₃ 151 MHz

Figure A-23: ¹³C NMR spectrum of Methyl 2-*O*-(6-*O*-benzoyl-2-*O*-benzyl-3,4-di-*O*-tert-butyldimethylsilyl- α/β -D-glucopyranosyl)-3,4,6-tri-*O*-benzyl- α -D-glucopyranoside (**2.8**)





Figure A-24: 2-D NMR COSY spectrum of Methyl 2-*O*-(6-*O*-benzoyl-2-*O*-benzyl-3,4di-*O*-tert-butyldimethylsilyl- α/β -D-glucopyranosyl)-3,4,6-tri-*O*-benzyl- α -D-glucopyranoside (**2.8**)



CDCl₃ 300 MHz **Figure A-25**: ¹H NMR spectrum of Isopropyl 6-*O*-benzoyl-2-*O*-benzyl-3,4-di-*O*-tertbutyldimethylsilyl- α/β -D-glucopyranoside (**2.9**)




Figure A-26: ¹³C NMR spectrum of Isopropyl 6-*O*-benzoyl-2-*O*-benzyl-3,4-di-*O*-tertbutyldimethylsilyl- α/β -D-glucopyranoside (**2.9**)





Figure A-27: 2-D NMR COSY spectrum of Isopropyl 6-*O*-benzoyl-2-*O*-benzyl-3,4-di-*O*-tert-butyldimethylsilyl- α/β -D-glucopyranoside (**2.9**)



CDCl₃ 300 MHz

Figure A-28: ¹H NMR spectrum of Cyclohexyl 6-*O*-benzoyl-2-*O*-benzyl-3,4-di-*O*-tertbutyldimethylsilyl- α/β -D-glucopyranoside (**2.10**)




Figure A-29: ¹³C NMR spectrum of Cyclohexyl 6-*O*-benzoyl-2-*O*-benzyl-3,4-di-*O*-tertbutyldimethylsilyl- α/β -D-glucopyranoside (**2.10**)




Figure A-30: 2-D NMR COSY spectrum of Cyclohexyl 6-*O*-benzoyl-2-*O*-benzyl-3,4-di-*O*-tert-butyldimethylsilyl- α/β -D-glucopyranoside (**2.10**)




Figure A-31: ¹H NMR spectrum of Benzyl 6-*O*-benzoyl-2-*O*-benzyl-3,4-di-*O*-tertbutyldimethylsilyl- α/β -D-glucopyranoside (**2.11**)




Figure A-32: ¹³C NMR spectrum of Benzyl 6-*O*-benzoyl-2-*O*-benzyl-3,4-di-*O*-tert-butyldimethylsilyl- α/β -D-glucopyranoside (**2.11**)




Figure A-33: 2-D NMR COSY spectrum of Benzyl 6-*O*-benzoyl-2-*O*-benzyl-3,4-di-*O*-*tert*-butyldimethylsilyl- α/β -D-glucopyranoside (**2.11**)




Figure A-34: ¹H NMR spectrum of Methyl 6-*O*-(6-*O*-benzoyl-2-*O*-benzyl-3,4-di-*O*-triisopropylsilyl-α-D-glucopyranosyl)-2,3,4-tri-*O*-benzyl-α-D-glucopyranoside (**2.12**)




Figure A-35: ¹³C NMR spectrum of Methyl 6-*O*-(6-*O*-benzoyl-2-*O*-benzyl-3,4-di-*O*-triisopropylsilyl-α-D-glucopyranosyl)-2,3,4-tri-*O*-benzyl-α-D-glucopyranoside (**2.12**)




Figure A-36: 2-D NMR COSY spectrum of Methyl 6-*O*-(6-*O*-benzoyl-2-*O*-benzyl-3,4di-*O*-triisopropylsilyl-α-D-glucopyranosyl)-2,3,4-tri-*O*-benzyl-α-D-glucopyranoside (**2.12**)




Figure A-37: ¹H NMR spectrum of Methyl 2-*O*-(6-*O*-benzoyl-2-*O*-benzyl-3,4-di-*O*-triisopropylsilyl- α/β -D-glucopyranosyl)-3,4,6-tri-*O*-benzyl- α -D-glucopyranoside (**2.13**)





Figure A-38: ¹³C NMR spectrum of Methyl 2-*O*-(6-*O*-benzoyl-2-*O*-benzyl-3,4-di-*O*-triisopropylsilyl- α/β -D-glucopyranosyl)-3,4,6-tri-*O*-benzyl- α -D-glucopyranoside (**2.13**)



 $CDCl_{3} \ 300 \ MHz$ Figure A-39: 2-D NMR COSY spectrum of Methyl 2-*O*-(6-*O*-benzoyl-2-*O*-benzyl-3,4-di-*O*-triisopropylsilyl- α/β -D-glucopyranosyl)-3,4,6-tri-*O*-benzyl- α -D-glucopyranoside (2.13)




Figure A-40: ¹H NMR spectrum of Isopropyl 6-*O*-benzoyl-2-*O*-benzyl-3,4-di-*O*-triisopropylsilyl- α/β -D-glucopyranoside (**2.14**)




Figure A-41: ¹³C NMR spectrum of Isopropyl 6-*O*-benzoyl-2-*O*-benzyl-3,4-di-*O*-triisopropylsilyl- α/β -D-glucopyranoside (**2.14**)




Figure A-42: 2-D NMR COSY spectrum of Isopropyl 6-*O*-benzoyl-2-*O*-benzyl-3,4-di-*O*-triisopropylsilyl- α/β -D-glucopyranoside (**2.14**)




Figure A-43: ¹H NMR spectrum of Cyclohexyl 6-*O*-benzoyl-2-*O*-benzyl-3,4-di-*O*-triisopropylsilyl- α/β -D-glucopyranoside (**2.15**)






Figure A-44: ¹³C NMR spectrum of Cyclohexyl 6-*O*-benzoyl-2-*O*-benzyl-3,4-di-*O*-triisopropylsilyl- α/β -D-glucopyranoside (**2.15**)



CDCl₃ 300 MHz **Figure A-45:** 2-D NMR COSY spectrum of Cyclohexyl 6-*O*-benzoyl-2-*O*-benzyl-3,4di-*O*-triisopropylsilyl- α/β -D-glucopyranoside (**2.15**)



CDCl₃ 151 MHz **Figure A-47:** ¹³C NMR spectrum of Benzyl 6-*O*-benzoyl-2-*O*-benzyl-3,4-di-*O*triisopropylsilyl-α-D-glucopyranoside (*α*-2.16)





Figure A-48: 2-D NMR COSY spectrum of Benzyl 6-*O*-benzoyl-2-*O*-benzyl-3,4-di-*O*-triisopropylsilyl-α-D-glucopyranoside (**α-2.16**)







Figure A-50: ¹³C NMR spectrum of Benzyl 6-*O*-benzoyl-2-*O*-benzyl-3,4-di-*O*-triisopropylsilyl-β-D-glucopyranoside (**β-2.16**)



CDCl₃ 300 MHz **Figure A-51:** 2-D NMR COSY spectrum of Benzyl 6-*O*-benzoyl-2-*O*-benzyl-3,4-di-*O*triisopropylsilyl-β-D-glucopyranoside (β-2.16)




Figure A-52: ¹H NMR spectrum of 8-Acetyloxyoct-1-yl *O*-(2,3,4,6-tetra-*O*-acetyl- β -D-glucopyranosyl)-(1 \rightarrow 6)-*O*-(2,3,4-tri-*O*-acetyl- β -D-glucopyranosyl)-(1 \rightarrow 6)-*O*-(2,3,4-tri-*O*-acetyl- β -D-glucopyranosyl)-(1 \rightarrow 6)-*O*-(2,3,4-tri-*O*-acetyl- β -D-glucopyranosyl)-(1 \rightarrow 6)-2,3,4-tri-*O*-benzyl- α -D-glucopyranoside (**3.1**)





Figure A-53: ¹³C NMR spectrum of 8-Acetyloxyoct-1-yl *O*-(2,3,4,6-tetra-*O*-acetyl- β -D-glucopyranosyl)-(1 \rightarrow 6)-*O*-(2,3,4-tri-*O*-acetyl- β -D-glucopyranosyl)-(1 \rightarrow 6)-*O*-(2,3,4-tri-*O*-acetyl- β -D-glucopyranosyl)-(1 \rightarrow 6)-*O*-(2,3,4-tri-*O*-acetyl- β -D-glucopyranosyl)-(1 \rightarrow 6)-2,3,4-tri-*O*-benzyl- α -D-glucopyranoside (**3.1**)



CDCl₃ 600 MHz

Figure A-54: 2-D NMR COSY spectrum of 8-Acetyloxyoct-1-yl *O*-(2,3,4,6-tetra-*O*-acetyl- β -D-glucopyranosyl)-(1 \rightarrow 6)-*O*-(2,3,4-tri-*O*-acetyl- β -D-glucopyranosyl)-(1 \rightarrow 6)-2,3,4-tri-*O*-benzyl- α -D-glucopyranoside (**3.1**)




Figure A-55: IR spectrum of Panzagel-Chloride





Figure A-56: IR spectrum of Panzagel-NH₂








Figure A-57: IR spectrum of glycoconjugate 4.10




Figure A-59: ¹³C NMR spectrum of Di (ethylene glycol) bis (4-vinylbenzyl) ether (4.2)






Figure A-60: 2-D NMR COSY spectrum of Di (ethylene glycol) bis (4-vinylbenzyl) ether (**4.2**)



CDCl₃ 300 MHz **Figure A-61**: ¹H NMR spectrum of Acetyloxyoct-1-yl *O*-(2,3,4,6-tetra-*O*-acetyl-β-D-glucopyranosyl)-(1 \rightarrow 6)-2,3,4-tri-*O*-benzyl-α-D-glucopyranoside (**4.8**)



CDCl₃ 300 MHz

Figure A-62: 2-D NMR COSY spectrum of 8-Acetyloxyoct-1-yl O-(2,3,4,6-tetra-O-acetyl- β -D-glucopyranosyl)-(1 \rightarrow 6)-2,3,4-tri-O-benzyl- α -D-glucopyranoside (**4.8**)






Figure A-63: ¹H NMR spectrum of 8-Acetyloxyoct-1-yl *O*-(2,3,4,6-tetra-*O*-acetyl- β -D-glucopyranosyl)-(1 \rightarrow 6)-*O*-(2,3,4-tri-*O*-acetyl- β -D-glucopyranosyl)-(1 \rightarrow 6)-*O*-(2,3,4-tri-*O*-acetyl- β -D-glucopyranosyl)-(1 \rightarrow 6)-*O*-(2,3,4-tri-*O*-acetyl- β -D-glucopyranosyl)-(1 \rightarrow 6)-2,3,4-tri-*O*-benzyl- α -D-glucopyranoside (**4.9**)



CDCl₃ 600 MHz

Figure A-64: 2-D NMR COSY spectrum of 8-Acetyloxyoct-1-yl *O*-(2,3,4,6-tetra-*O*-acetyl- β -D-glucopyranosyl)-(1 \rightarrow 6)-*O*-(2,3,4-tri-*O*-acetyl- β -D-glucopyranosyl)-(1 \rightarrow 6)-(2,3,4-tri-*O*-acetyl- β -D-glucopyranosyl)-(1 \rightarrow 6)-(2,3,4-tri-*O*-acetyl- β -D-glucopyranosyl)-(1 \rightarrow 6)-(2,3,4-tri-*O*-benzyl- α -D-glucopyranosyl)-(1 \rightarrow 6)-(2,3,4-tri- α -benzyl- α -benz



Panzagel TMSOTf

Figure A-65: Thermogravimetric analysis (TGA) plots (black line) and Weight derivatives curves (red line) of Panzagel-TMSOTf




Figure A-66: SEM images of Panzagel-TMSOTf polymer at a)100x and b) 150x magnifications




Figure A-67: BET adsorption-desorption curves of the Panzagel